{"b2aa84d4ff1a34e15f3773bceaddb5bb83742a27": [["Multivariate analysis was also done to adjust for the effect of confounders.", [["Multivariate analysis", "TEST", 0, 21]]], ["An observation is said to be statistically significant if P-value is less than or equal to 0.05 (P \u2264 0.05).| RESULTSOne hundred and twelve (112) patients were evaluated of which 80 positive patients (45 males, 56.25%; 35 females, 43.75%) met the study criteria.", [["patients", "ORGANISM", 145, 153], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 145, 153], ["patients", "SPECIES", 190, 198], ["An observation", "TEST", 0, 14], ["P-value", "TEST", 58, 65], ["the study criteria", "TEST", 242, 260]]], ["Table 1 summarized the general sociodemographic characteristics, medical history, and clinical presentations of patients with SARS-CoV-2 treated with TCZ.", [["SARS", "DISEASE", 126, 130], ["TCZ", "CHEMICAL", 150, 153], ["TCZ", "CHEMICAL", 150, 153], ["patients", "ORGANISM", 112, 120], ["TCZ", "SIMPLE_CHEMICAL", 150, 153], ["patients", "SPECIES", 112, 120], ["SARS", "PROBLEM", 126, 130], ["TCZ", "TREATMENT", 150, 153]]], ["Most of the patients were within the ages 30-64 years (39, 48.75%) and \u2265 65 years (37, 46.25%), with a median (IQR) age of 63 (51, 72) years.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Patients with Hispanic ethnicity were the majority in the study (44, 57.14%), followed by White/Hispanic (25, 32.47%), which can be mainly attributed to the fact that the population of El Paso is predominately Hispanic.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Hispanic ethnicity", "PROBLEM", 14, 32], ["the study", "TEST", 54, 63], ["White/Hispanic", "TEST", 90, 104], ["predominately", "OBSERVATION_MODIFIER", 196, 209], ["Hispanic", "OBSERVATION", 210, 218]]], ["Comorbidities observed most among the patients were Hypertension (47, 65.28%), type II diabetes mellitus (37, 51.39%), and hyperlipidemia (18, 25%).", [["Hypertension", "DISEASE", 52, 64], ["type II diabetes mellitus", "DISEASE", 79, 104], ["hyperlipidemia", "DISEASE", 123, 137], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Comorbidities", "PROBLEM", 0, 13], ["Hypertension", "PROBLEM", 52, 64], ["type II diabetes mellitus", "PROBLEM", 79, 104], ["hyperlipidemia", "PROBLEM", 123, 137], ["Hypertension", "OBSERVATION", 52, 64], ["diabetes mellitus", "OBSERVATION", 87, 104], ["hyperlipidemia", "OBSERVATION", 123, 137]]], ["Other comorbidities presenting was (31, 43.05%), with the total number of presenting comorbidities on admission noted to be \u22642 symptoms on presentation in (46, 63.89%) of our patients, and those with 3 or more comorbidities (26, 36.11%), with a median of 2 comorbidities (1 -3).", [["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["Other comorbidities", "PROBLEM", 0, 19], ["presenting comorbidities", "PROBLEM", 74, 98], ["\u22642 symptoms", "PROBLEM", 124, 135]]], ["The most common presenting symptom was Shortness of breath (62, 86.11%), followed by fever (53, 73.61%), cough (49, 68.06%), and other associated symptoms (42, 58.33%), with a median (IQR) number of symptoms 3 (2-5).", [["Shortness of breath", "DISEASE", 39, 58], ["fever", "DISEASE", 85, 90], ["cough", "DISEASE", 105, 110], ["Shortness of breath", "PROBLEM", 39, 58], ["fever", "PROBLEM", 85, 90], ["cough", "PROBLEM", 105, 110], ["other associated symptoms", "PROBLEM", 129, 154], ["symptoms", "PROBLEM", 199, 207]]], ["A limited number of patients had lung bacterial coinfection (12, 15%) and multi-organ damage (10, 12.50%).", [["lung", "ANATOMY", 33, 37], ["multi-organ", "ANATOMY", 74, 85], ["lung bacterial coinfection", "DISEASE", 33, 59], ["multi-organ damage", "DISEASE", 74, 92], ["patients", "ORGANISM", 20, 28], ["lung", "ORGAN", 33, 37], ["multi-organ", "ORGAN", 74, 85], ["patients", "SPECIES", 20, 28], ["lung bacterial coinfection", "PROBLEM", 33, 59], ["multi-organ damage", "TEST", 74, 92], ["lung", "ANATOMY", 33, 37], ["bacterial coinfection", "OBSERVATION", 38, 59], ["multi-organ", "ANATOMY", 74, 85], ["damage", "OBSERVATION", 86, 92]]], ["Multi-organ damage was identified as the development of potentially reversible This article is protected by copyright.", [["Multi-organ", "ANATOMY", 0, 11], ["Multi-organ damage", "DISEASE", 0, 18], ["Multi-organ damage", "PROBLEM", 0, 18], ["damage", "OBSERVATION", 12, 18], ["reversible", "OBSERVATION_MODIFIER", 68, 78]]], ["All rights reserved.Accepted Articlephysiologic derangement involving two or more organ systems not involved in the primary admission disease.", [["organ", "ANATOMY", 82, 87], ["Articlephysiologic derangement", "DISEASE", 29, 59], ["organ", "ORGAN", 82, 87], ["Articlephysiologic derangement", "PROBLEM", 29, 59], ["derangement", "OBSERVATION", 48, 59]]], ["11 Recent travel history was reported in 11 patients (15.71%), and 34 patients had positive contact history (48.43%).", [["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 70, 78]]], ["The primary clinical outcome was mortality among SARS-CoV-2 patients, as summarized in Table 2 .", [["SARS", "DISEASE", 49, 53], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["SARS-CoV", "SPECIES", 49, 57]]], ["A total of seven patients (8.7%) were deceased during the study period.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["the study", "TEST", 54, 63], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["The duration of hospital stays ranged from five to ten days for all patients.Accepted ArticleUsing the Mann-Whitney U test, we noted statistically significant results between average IL-6 and mortality and D-dimer level with mortality.", [["patients", "ORGANISM", 68, 76], ["IL-6", "GENE_OR_GENE_PRODUCT", 183, 187], ["D-dimer", "GENE_OR_GENE_PRODUCT", 206, 213], ["IL", "PROTEIN", 183, 185], ["patients", "SPECIES", 68, 76], ["average IL", "TEST", 175, 185], ["D-dimer level", "TEST", 206, 219], ["mortality", "PROBLEM", 225, 234]]], ["An increase in mortality outcome was noted among those with higher average levels of IL-6 with P value (0.050).Accepted ArticleA similar finding was observed with D-dimer, as the higher the average D-dimer, the significant correlated increase in the risk of mortality with P value (0.024).", [["D-dimer", "CHEMICAL", 163, 170], ["IL-6", "GENE_OR_GENE_PRODUCT", 85, 89], ["D-dimer", "SIMPLE_CHEMICAL", 163, 170], ["D-dimer", "GENE_OR_GENE_PRODUCT", 198, 205], ["IL", "PROTEIN", 85, 87], ["D-dimer", "PROTEIN", 163, 170], ["D-dimer", "PROTEIN", 198, 205], ["An increase in mortality outcome", "PROBLEM", 0, 32], ["IL", "TEST", 85, 87], ["P value", "TEST", 95, 102], ["P value", "TEST", 273, 280], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["mortality outcome", "OBSERVATION", 15, 32], ["significant", "OBSERVATION_MODIFIER", 211, 222], ["correlated", "OBSERVATION_MODIFIER", 223, 233], ["increase", "OBSERVATION_MODIFIER", 234, 242]]], ["However, no statistically significant relationship with mortality was observed among CRP, procalcitonin, ferritin, and LDH levels in our study population, as illustrated in Table 3 .Accepted ArticleFrom the bivariate logistics regression model (Table 4) , there were statistically significant associations between bacterial lung infections, multi-organ damage, and mortality.", [["lung", "ANATOMY", 324, 328], ["multi-organ", "ANATOMY", 341, 352], ["lung infections", "DISEASE", 324, 339], ["multi-organ damage", "DISEASE", 341, 359], ["CRP", "GENE_OR_GENE_PRODUCT", 85, 88], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 90, 103], ["ferritin", "GENE_OR_GENE_PRODUCT", 105, 113], ["LDH", "GENE_OR_GENE_PRODUCT", 119, 122], ["lung", "ORGAN", 324, 328], ["multi-organ", "ORGAN", 341, 352], ["CRP", "PROTEIN", 85, 88], ["procalcitonin", "PROTEIN", 90, 103], ["ferritin", "PROTEIN", 105, 113], ["LDH", "PROTEIN", 119, 122], ["CRP", "TEST", 85, 88], ["procalcitonin", "TEST", 90, 103], ["ferritin", "TEST", 105, 113], ["LDH levels", "TEST", 119, 129], ["our study population", "TEST", 133, 153], ["bacterial lung infections", "PROBLEM", 314, 339], ["multi-organ damage", "PROBLEM", 341, 359], ["no", "UNCERTAINTY", 9, 11], ["LDH", "ANATOMY", 119, 122], ["significant", "OBSERVATION_MODIFIER", 281, 292], ["bacterial", "OBSERVATION_MODIFIER", 314, 323], ["lung", "ANATOMY", 324, 328], ["infections", "OBSERVATION", 329, 339], ["multi-organ damage", "OBSERVATION", 341, 359]]], ["Those with a bacterial lung infection were 10.83 times more likely to die from SARS-CoV-2 than those with no bacterial lung infection (OR: 10.83, 95% CI: 2.05 -57.40, P=0.050).", [["lung", "ANATOMY", 23, 27], ["lung", "ANATOMY", 119, 123], ["bacterial lung infection", "DISEASE", 13, 37], ["SARS", "DISEASE", 79, 83], ["bacterial lung infection", "DISEASE", 109, 133], ["lung", "ORGAN", 23, 27], ["lung", "ORGAN", 119, 123], ["a bacterial lung infection", "PROBLEM", 11, 37], ["SARS", "PROBLEM", 79, 83], ["CoV", "TEST", 84, 87], ["bacterial lung infection", "PROBLEM", 109, 133], ["CI", "TEST", 150, 152], ["P", "TEST", 167, 168], ["bacterial", "OBSERVATION_MODIFIER", 13, 22], ["lung", "ANATOMY", 23, 27], ["infection", "OBSERVATION", 28, 37], ["no", "UNCERTAINTY", 106, 108], ["bacterial", "OBSERVATION_MODIFIER", 109, 118], ["lung", "ANATOMY", 119, 123], ["infection", "OBSERVATION", 124, 133]]], ["Also, those with multi-organ damage were 103.50 times more likely to die from SARS-CoV-2 than those with no multi-organ damage (OR: 103.50, 95% CI: 9.92 -1079.55, P=0.001).Accepted ArticleAfter adjusting for possible confounders, the multivariate logistics regression model was only statistically significant for multi-organ damage, although with a slightly This article is protected by copyright.", [["multi-organ", "ANATOMY", 17, 28], ["multi-organ", "ANATOMY", 108, 119], ["multi-organ", "ANATOMY", 313, 324], ["multi-organ damage", "DISEASE", 17, 35], ["SARS", "DISEASE", 78, 82], ["multi-organ damage", "DISEASE", 108, 126], ["multi-organ damage", "DISEASE", 313, 331], ["multi-organ", "ORGAN", 17, 28], ["multi-organ", "ORGAN", 108, 119], ["multi-organ", "ORGAN", 313, 324], ["multi-organ damage", "PROBLEM", 17, 35], ["SARS", "PROBLEM", 78, 82], ["CoV", "TEST", 83, 86], ["multi-organ damage", "PROBLEM", 108, 126], ["CI", "TEST", 144, 146], ["P", "TEST", 163, 164], ["the multivariate logistics regression model", "TEST", 230, 273], ["multi-organ damage", "PROBLEM", 313, 331], ["multi-organ", "ANATOMY", 17, 28], ["damage", "OBSERVATION", 29, 35], ["no", "UNCERTAINTY", 105, 107], ["multi-organ", "ANATOMY", 108, 119], ["damage", "OBSERVATION", 120, 126], ["damage", "OBSERVATION", 325, 331]]], ["All rights reserved.| DISCUSSIONSeven patients (8.7%) of our study population (total of 80) were deceased during our study period.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["our study population", "TEST", 57, 77]]], ["All our patients have had hypoxemia with higher oxygen requirement > 3L and PSI score \u2264 130 and significant radiological changes.", [["hypoxemia", "DISEASE", 26, 35], ["oxygen", "CHEMICAL", 48, 54], ["oxygen", "CHEMICAL", 48, 54], ["patients", "ORGANISM", 8, 16], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["patients", "SPECIES", 8, 16], ["hypoxemia", "PROBLEM", 26, 35], ["higher oxygen requirement", "PROBLEM", 41, 66], ["PSI score", "TEST", 76, 85], ["significant radiological changes", "PROBLEM", 96, 128], ["hypoxemia", "OBSERVATION", 26, 35], ["higher", "OBSERVATION_MODIFIER", 41, 47], ["oxygen requirement", "OBSERVATION", 48, 66], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["radiological", "OBSERVATION", 108, 120]]], ["The majority of our patients have shown elevation in levels of CRP, ferritin, LDH, and D-dimer on initial presentation.", [["patients", "ORGANISM", 20, 28], ["CRP", "GENE_OR_GENE_PRODUCT", 63, 66], ["ferritin", "GENE_OR_GENE_PRODUCT", 68, 76], ["LDH", "GENE_OR_GENE_PRODUCT", 78, 81], ["D-dimer", "SIMPLE_CHEMICAL", 87, 94], ["CRP", "PROTEIN", 63, 66], ["ferritin", "PROTEIN", 68, 76], ["LDH", "PROTEIN", 78, 81], ["D-dimer", "PROTEIN", 87, 94], ["patients", "SPECIES", 20, 28], ["elevation in levels", "PROBLEM", 40, 59], ["CRP", "TEST", 63, 66], ["ferritin", "TEST", 68, 76], ["LDH", "TEST", 78, 81], ["D-dimer", "PROBLEM", 87, 94], ["elevation", "OBSERVATION_MODIFIER", 40, 49]]], ["After examining the association between all independent variables and mortality outcomes, we noted that mortality rates were higher among those patients with higher D-dimer and higher levels of IL-6 throughout their hospitalization period.| DISCUSSIONNevertheless, the sequential use of TCZ and methylprednisolone within 72 hours of admission and its effect on the cytokine release syndrome (CRS) as used in our study protocol was examined in our previous study by Antony et al. 12 Moreover, in this study we discovered that the occurrence of multi-organ damage in the presence of SARS-CoV-2 infection accounted for the highest risk of mortality as compared to all other examined variables.", [["multi-organ", "ANATOMY", 543, 554], ["TCZ", "CHEMICAL", 287, 290], ["methylprednisolone", "CHEMICAL", 295, 313], ["CRS", "DISEASE", 392, 395], ["multi-organ damage", "DISEASE", 543, 561], ["SARS", "DISEASE", 581, 585], ["infection", "DISEASE", 592, 601], ["TCZ", "CHEMICAL", 287, 290], ["methylprednisolone", "CHEMICAL", 295, 313], ["patients", "ORGANISM", 144, 152], ["D-dimer", "GENE_OR_GENE_PRODUCT", 165, 172], ["IL-6", "GENE_OR_GENE_PRODUCT", 194, 198], ["TCZ", "SIMPLE_CHEMICAL", 287, 290], ["methylprednisolone", "SIMPLE_CHEMICAL", 295, 313], ["multi-organ", "ORGAN", 543, 554], ["SARS-CoV-2", "ORGANISM", 581, 591], ["D-dimer", "PROTEIN", 165, 172], ["IL", "PROTEIN", 194, 196], ["cytokine", "PROTEIN", 365, 373], ["patients", "SPECIES", 144, 152], ["SARS-CoV-2", "SPECIES", 581, 591], ["mortality rates", "TEST", 104, 119], ["higher D-dimer", "PROBLEM", 158, 172], ["TCZ", "TREATMENT", 287, 290], ["methylprednisolone", "TREATMENT", 295, 313], ["the cytokine release syndrome", "TREATMENT", 361, 390], ["our study protocol", "TEST", 408, 426], ["this study", "TEST", 495, 505], ["multi-organ damage", "PROBLEM", 543, 561], ["SARS", "PROBLEM", 581, 585], ["CoV-2 infection", "PROBLEM", 586, 601], ["multi-organ", "ANATOMY", 543, 554], ["damage", "OBSERVATION", 555, 561], ["SARS", "OBSERVATION", 581, 585], ["infection", "OBSERVATION", 592, 601]]], ["Nevertheless, the coexistence of bacterial lung infection was a confounding factor in the presence of multi-organ failure.Accepted ArticleOn the molecular level, SARS-CoV-2 is considered more closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV) than the Middle East respiratory syndrome-related coronavirus (MERS-CoV) in its sequence identity.", [["lung", "ANATOMY", 43, 47], ["multi-organ", "ANATOMY", 102, 113], ["lung infection", "DISEASE", 43, 57], ["multi-organ failure", "DISEASE", 102, 121], ["acute respiratory syndrome coronavirus", "DISEASE", 222, 260], ["SARS-CoV)", "DISEASE", 262, 271], ["respiratory syndrome", "DISEASE", 293, 313], ["lung", "ORGAN", 43, 47], ["multi-organ", "ORGAN", 102, 113], ["SARS-CoV-2", "ORGANISM", 162, 172], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 215, 260], ["SARS-CoV", "ORGANISM", 262, 270], ["Middle East respiratory syndrome-related coronavirus", "ORGANISM", 281, 333], ["MERS-CoV", "ORGANISM", 335, 343], ["SARS-CoV", "SPECIES", 162, 170], ["severe acute respiratory syndrome coronavirus", "SPECIES", 215, 260], ["SARS-CoV", "SPECIES", 262, 270], ["Middle East respiratory syndrome-related coronavirus", "SPECIES", 281, 333], ["MERS-CoV", "SPECIES", 335, 343], ["bacterial lung infection", "PROBLEM", 33, 57], ["multi-organ failure", "PROBLEM", 102, 121], ["SARS", "PROBLEM", 162, 166], ["CoV", "TEST", 167, 170], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 211, 260], ["the Middle East respiratory syndrome", "PROBLEM", 277, 313], ["coronavirus", "PROBLEM", 322, 333], ["bacterial", "OBSERVATION_MODIFIER", 33, 42], ["lung", "ANATOMY", 43, 47], ["infection", "OBSERVATION", 48, 57], ["multi-organ", "ANATOMY", 102, 113], ["failure", "OBSERVATION", 114, 121], ["severe", "OBSERVATION_MODIFIER", 215, 221], ["acute", "OBSERVATION_MODIFIER", 222, 227], ["respiratory syndrome", "OBSERVATION", 228, 248], ["Middle", "ANATOMY_MODIFIER", 281, 287], ["respiratory syndrome", "OBSERVATION", 293, 313]]], ["13 Moreover, SAR-CoV-2 shares the same cellular receptor as SARS-CoV which is the ACE2 receptor 14 that commonly found in alveolar epithelial type II cells of lung tissues 15 and also seen in other extrapulmonary tissues such as the cardiac endothelium, kidneys, and intestines, 16, 17 which might play a key role in the multi-organ damage in SARS-CoV-2 infection.Accepted ArticleIn a prospective cohort study conducted by Rong-Hui et al 18 to examine mortality predictors, the presence of a secondary bacterial infection led to higher concentrations of CRP and procalcitonin.", [["cellular", "ANATOMY", 39, 47], ["alveolar epithelial type II cells", "ANATOMY", 122, 155], ["lung tissues", "ANATOMY", 159, 171], ["extrapulmonary tissues", "ANATOMY", 198, 220], ["cardiac endothelium", "ANATOMY", 233, 252], ["kidneys", "ANATOMY", 254, 261], ["intestines", "ANATOMY", 267, 277], ["multi-organ", "ANATOMY", 321, 332], ["multi-organ damage", "DISEASE", 321, 339], ["SARS-CoV-2 infection", "DISEASE", 343, 363], ["bacterial infection", "DISEASE", 502, 521], ["SAR-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 22], ["cellular", "CELL", 39, 47], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 60, 68], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["alveolar epithelial type II cells", "CELL", 122, 155], ["lung tissues", "TISSUE", 159, 171], ["extrapulmonary tissues", "TISSUE", 198, 220], ["cardiac endothelium", "TISSUE", 233, 252], ["kidneys", "ORGAN", 254, 261], ["intestines", "ORGAN", 267, 277], ["multi-organ", "ORGAN", 321, 332], ["SARS-CoV-2", "ORGANISM", 343, 353], ["CRP", "GENE_OR_GENE_PRODUCT", 554, 557], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 562, 575], ["cellular receptor", "PROTEIN", 39, 56], ["ACE2 receptor 14", "PROTEIN", 82, 98], ["alveolar epithelial type II cells", "CELL_TYPE", 122, 155], ["CRP", "PROTEIN", 554, 557], ["procalcitonin", "PROTEIN", 562, 575], ["SARS-CoV", "SPECIES", 60, 68], ["SARS-CoV-2", "SPECIES", 343, 353], ["SAR-CoV", "TEST", 13, 20], ["the ACE2 receptor", "TEST", 78, 95], ["the multi-organ damage", "PROBLEM", 317, 339], ["SARS", "PROBLEM", 343, 347], ["CoV-2 infection", "PROBLEM", 348, 363], ["a prospective cohort study", "TEST", 383, 409], ["a secondary bacterial infection", "PROBLEM", 490, 521], ["CRP", "TEST", 554, 557], ["procalcitonin", "TEST", 562, 575], ["alveolar", "ANATOMY_MODIFIER", 122, 130], ["epithelial", "ANATOMY_MODIFIER", 131, 141], ["type II cells", "OBSERVATION", 142, 155], ["lung", "ANATOMY", 159, 163], ["extrapulmonary tissues", "ANATOMY", 198, 220], ["cardiac endothelium", "ANATOMY", 233, 252], ["kidneys", "ANATOMY", 254, 261], ["intestines", "ANATOMY", 267, 277], ["multi-organ", "ANATOMY", 321, 332], ["damage", "OBSERVATION", 333, 339], ["SARS", "OBSERVATION", 343, 347], ["infection", "OBSERVATION", 354, 363], ["secondary", "OBSERVATION_MODIFIER", 492, 501], ["bacterial", "OBSERVATION_MODIFIER", 502, 511], ["infection", "OBSERVATION", 512, 521]]], ["18 Their study noted that deceased patients had higher levels of inflammatory biomarkers than those who survived the SARS-CoV-2 infection, which might go in favor of possible increased risk of mortality with a secondary bacterial infection.", [["SARS", "DISEASE", 117, 121], ["infection", "DISEASE", 128, 137], ["bacterial infection", "DISEASE", 220, 239], ["patients", "ORGANISM", 35, 43], ["SARS-CoV-2", "ORGANISM", 117, 127], ["patients", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 117, 125], ["Their study", "TEST", 3, 14], ["inflammatory biomarkers", "PROBLEM", 65, 88], ["the SARS", "PROBLEM", 113, 121], ["CoV-2 infection", "PROBLEM", 122, 137], ["a secondary bacterial infection", "PROBLEM", 208, 239], ["inflammatory", "OBSERVATION_MODIFIER", 65, 77], ["infection", "OBSERVATION", 128, 137], ["secondary", "OBSERVATION_MODIFIER", 210, 219], ["bacterial", "OBSERVATION_MODIFIER", 220, 229], ["infection", "OBSERVATION", 230, 239]]], ["Moreover, another study found that 81.7% of patients who died with SARS-CoV-2 disease were associated with bacterial infections.", [["SARS-CoV-2 disease", "DISEASE", 67, 85], ["bacterial infections", "DISEASE", 107, 127], ["patients", "ORGANISM", 44, 52], ["SARS-CoV-2", "ORGANISM", 67, 77], ["patients", "SPECIES", 44, 52], ["another study", "TEST", 10, 23], ["SARS", "PROBLEM", 67, 71], ["CoV-2 disease", "PROBLEM", 72, 85], ["bacterial infections", "PROBLEM", 107, 127], ["associated with", "UNCERTAINTY", 91, 106], ["bacterial", "OBSERVATION_MODIFIER", 107, 116], ["infections", "OBSERVATION", 117, 127]]], ["19 Also, Martins-Filho et al 20 found that sepsis was associated with a 2.5-fold increase in death risk among these patients.", [["sepsis", "DISEASE", 43, 49], ["death", "DISEASE", 93, 98], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["Martins", "TEST", 9, 16], ["sepsis", "PROBLEM", 43, 49], ["a 2.5-fold increase in death risk", "PROBLEM", 70, 103], ["sepsis", "OBSERVATION", 43, 49], ["increase", "OBSERVATION_MODIFIER", 81, 89]]], ["20 Our study examined the relationship between superimposed bacterial lung infection and mortality; however, our current result did not support the findings of previous literature.Accepted ArticleA study published earlier in the Lancet has provided further insight into the clinical course and mortality risks for severe SAR-CoV-2 infection among patients in Wuhan.", [["lung", "ANATOMY", 70, 74], ["lung infection", "DISEASE", 70, 84], ["SAR-CoV-2 infection", "DISEASE", 321, 340], ["lung", "ORGAN", 70, 74], ["CoV-2", "ORGANISM", 325, 330], ["patients", "ORGANISM", 347, 355], ["patients", "SPECIES", 347, 355], ["Our study", "TEST", 3, 12], ["superimposed bacterial lung infection", "PROBLEM", 47, 84], ["ArticleA study", "TEST", 189, 203], ["severe SAR", "PROBLEM", 314, 324], ["CoV-2 infection", "PROBLEM", 325, 340], ["superimposed", "OBSERVATION_MODIFIER", 47, 59], ["bacterial", "OBSERVATION_MODIFIER", 60, 69], ["lung", "ANATOMY", 70, 74], ["infection", "OBSERVATION", 75, 84], ["infection", "OBSERVATION", 331, 340]]], ["4 In-hospital mortality was associated with older age, a higher SOFA score, and This article is protected by copyright.", [["a higher SOFA score", "PROBLEM", 55, 74]]], ["All rights reserved.Accepted ArticleD-dimer level greater than 1 \u03bcg/mL, representing findings known to be associated with severe pneumonia.", [["pneumonia", "DISEASE", 129, 138], ["ArticleD-dimer", "GENE_OR_GENE_PRODUCT", 29, 43], ["ArticleD", "PROTEIN", 29, 37], ["ArticleD-dimer level", "TEST", 29, 49], ["severe pneumonia", "PROBLEM", 122, 138], ["known to be associated with", "UNCERTAINTY", 94, 121], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["pneumonia", "OBSERVATION", 129, 138]]], ["4 The rate of in-hospital mortality was noted to be high (28%).", [["high", "OBSERVATION_MODIFIER", 52, 56]]], ["4Accepted ArticleFurthermore, several studies have reported that pulmonary embolism and coagulopathy are frequently observed in SARS-CoV-2 patients.", [["pulmonary", "ANATOMY", 65, 74], ["pulmonary embolism", "DISEASE", 65, 83], ["coagulopathy", "DISEASE", 88, 100], ["SARS", "DISEASE", 128, 132], ["pulmonary", "ORGAN", 65, 74], ["SARS-CoV-2", "ORGANISM", 128, 138], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["SARS-CoV", "SPECIES", 128, 136], ["several studies", "TEST", 30, 45], ["pulmonary embolism", "PROBLEM", 65, 83], ["coagulopathy", "PROBLEM", 88, 100], ["pulmonary", "ANATOMY", 65, 74], ["embolism", "OBSERVATION", 75, 83], ["coagulopathy", "OBSERVATION", 88, 100]]], ["8,21-23 Zhang et al 8 reported that initial D-dimer level \u22652.0 \u00b5g/mL (equivalent to 4-fold increase) was correlated with a higher incidence of mortality, compared to those with D-dimer level of <2.0 \u00b5g/mL and therefore, could effectively predict in-hospital mortality in SARS-CoV-2 patients.", [["SARS", "DISEASE", 271, 275], ["D-dimer", "GENE_OR_GENE_PRODUCT", 44, 51], ["D-dimer", "GENE_OR_GENE_PRODUCT", 177, 184], ["SARS-CoV-2", "ORGANISM", 271, 281], ["patients", "ORGANISM", 282, 290], ["patients", "SPECIES", 282, 290], ["SARS-CoV", "SPECIES", 271, 279], ["initial D-dimer level", "TEST", 36, 57], ["D-dimer level", "TEST", 177, 190]]], ["8 In the meta-analysis study conducted by Martins-Filho et al 20 to assess for mortality risks, dyspnea at the onset of disease, decreased gas exchange, increased IL-6 levels, coagulation abnormalities including increased D-dimer levels and multi-organ damage such as cardiac injury, acute kidney disease, acute respiratory distress syndrome (ARDS), and sepsis were considered important mortality predictors among SARS-CoV-2 positive patients.", [["multi-organ", "ANATOMY", 241, 252], ["cardiac", "ANATOMY", 268, 275], ["kidney", "ANATOMY", 290, 296], ["respiratory", "ANATOMY", 312, 323], ["dyspnea", "DISEASE", 96, 103], ["coagulation abnormalities", "DISEASE", 176, 201], ["multi-organ damage", "DISEASE", 241, 259], ["cardiac injury", "DISEASE", 268, 282], ["acute kidney disease", "DISEASE", 284, 304], ["acute respiratory distress syndrome", "DISEASE", 306, 341], ["ARDS", "DISEASE", 343, 347], ["sepsis", "DISEASE", 354, 360], ["SARS", "DISEASE", 414, 418], ["IL-6", "GENE_OR_GENE_PRODUCT", 163, 167], ["D-dimer", "GENE_OR_GENE_PRODUCT", 222, 229], ["multi-organ", "ORGAN", 241, 252], ["cardiac", "ORGAN", 268, 275], ["kidney", "ORGAN", 290, 296], ["SARS-CoV-2", "ORGANISM", 414, 424], ["patients", "ORGANISM", 434, 442], ["IL-6", "PROTEIN", 163, 167], ["patients", "SPECIES", 434, 442], ["SARS-CoV", "SPECIES", 414, 422], ["the meta-analysis study", "TEST", 5, 28], ["Martins", "TEST", 42, 49], ["Filho et al", "TREATMENT", 50, 61], ["mortality risks", "PROBLEM", 79, 94], ["dyspnea", "PROBLEM", 96, 103], ["disease", "PROBLEM", 120, 127], ["decreased gas exchange", "PROBLEM", 129, 151], ["increased IL", "TREATMENT", 153, 165], ["coagulation abnormalities", "PROBLEM", 176, 201], ["increased D-dimer levels", "PROBLEM", 212, 236], ["multi-organ damage", "PROBLEM", 241, 259], ["cardiac injury", "PROBLEM", 268, 282], ["acute kidney disease", "PROBLEM", 284, 304], ["acute respiratory distress syndrome", "PROBLEM", 306, 341], ["ARDS", "PROBLEM", 343, 347], ["sepsis", "PROBLEM", 354, 360], ["CoV", "TEST", 419, 422], ["disease", "OBSERVATION", 120, 127], ["decreased", "OBSERVATION_MODIFIER", 129, 138], ["gas exchange", "OBSERVATION", 139, 151], ["increased", "OBSERVATION_MODIFIER", 153, 162], ["increased", "OBSERVATION_MODIFIER", 212, 221], ["D-dimer", "OBSERVATION_MODIFIER", 222, 229], ["multi-organ", "ANATOMY", 241, 252], ["damage", "OBSERVATION", 253, 259], ["cardiac", "ANATOMY", 268, 275], ["injury", "OBSERVATION", 276, 282], ["acute", "OBSERVATION_MODIFIER", 284, 289], ["kidney", "ANATOMY", 290, 296], ["disease", "OBSERVATION", 297, 304], ["acute", "OBSERVATION_MODIFIER", 306, 311], ["respiratory distress syndrome", "OBSERVATION", 312, 341], ["sepsis", "OBSERVATION", 354, 360]]], ["20 Their results were relatively similar to our conclusion in regard to significant laboratory markers and multi-organ damage with outcome mortality.", [["multi-organ", "ANATOMY", 107, 118], ["multi-organ damage", "DISEASE", 107, 125], ["multi-organ", "ORGAN", 107, 118], ["significant laboratory markers", "PROBLEM", 72, 102], ["multi-organ damage", "PROBLEM", 107, 125], ["outcome mortality", "PROBLEM", 131, 148]]], ["Therefore, closer attention must be paid during hospitalization to these factors to minimize the risk of multi-organ damage and possibly reverse it as soon as possible.Accepted ArticleOur study noted that the most potential risk factor for mortality that demands immediate intervention, as discussed earlier, was the multi-organ damage.", [["multi-organ", "ANATOMY", 105, 116], ["multi-organ", "ANATOMY", 317, 328], ["multi-organ damage", "DISEASE", 105, 123], ["multi-organ damage", "DISEASE", 317, 335], ["multi-organ", "ORGAN", 105, 116], ["multi-organ damage", "PROBLEM", 105, 123], ["ArticleOur study", "TEST", 177, 193], ["immediate intervention", "TREATMENT", 263, 285], ["the multi-organ damage", "PROBLEM", 313, 335], ["multi-organ", "ANATOMY", 105, 116], ["damage", "OBSERVATION", 117, 123], ["multi-organ", "ANATOMY", 317, 328], ["damage", "OBSERVATION", 329, 335]]], ["The presence of extrapulmonary organ failure was widely influencing the rapid progression of the illness and subsequent death.", [["extrapulmonary organ", "ANATOMY", 16, 36], ["extrapulmonary organ failure", "DISEASE", 16, 44], ["illness", "DISEASE", 97, 104], ["death", "DISEASE", 120, 125], ["organ", "ORGAN", 31, 36], ["extrapulmonary organ failure", "PROBLEM", 16, 44], ["the illness", "PROBLEM", 93, 104], ["subsequent death", "PROBLEM", 109, 125], ["extrapulmonary organ", "ANATOMY", 16, 36], ["failure", "OBSERVATION", 37, 44], ["rapid", "OBSERVATION_MODIFIER", 72, 77], ["progression", "OBSERVATION_MODIFIER", 78, 89]]], ["These observed injuries include ARDS, heart failure, renal failure, shock, and multi-organ failure.", [["heart", "ANATOMY", 38, 43], ["renal", "ANATOMY", 53, 58], ["multi-organ", "ANATOMY", 79, 90], ["injuries", "DISEASE", 15, 23], ["ARDS", "DISEASE", 32, 36], ["heart failure", "DISEASE", 38, 51], ["renal failure", "DISEASE", 53, 66], ["shock", "DISEASE", 68, 73], ["multi-organ failure", "DISEASE", 79, 98], ["heart", "ORGAN", 38, 43], ["renal", "ORGAN", 53, 58], ["These observed injuries", "PROBLEM", 0, 23], ["ARDS", "PROBLEM", 32, 36], ["heart failure", "PROBLEM", 38, 51], ["renal failure", "PROBLEM", 53, 66], ["shock", "PROBLEM", 68, 73], ["multi-organ failure", "PROBLEM", 79, 98], ["injuries", "OBSERVATION", 15, 23], ["ARDS", "OBSERVATION", 32, 36], ["heart", "ANATOMY", 38, 43], ["failure", "OBSERVATION", 44, 51], ["renal", "ANATOMY", 53, 58], ["failure", "OBSERVATION", 59, 66], ["shock", "OBSERVATION", 68, 73], ["multi-organ", "ANATOMY", 79, 90], ["failure", "OBSERVATION", 91, 98]]], ["Therefore, the coexistence of these findings will precipitate higher mortality rates among the SARS-CoV-2-positive population.", [["SARS", "DISEASE", 95, 99], ["SARS-CoV-2", "ORGANISM", 95, 105], ["SARS-CoV", "SPECIES", 95, 103], ["higher mortality rates", "PROBLEM", 62, 84], ["the SARS", "TEST", 91, 99], ["CoV", "TEST", 100, 103], ["positive population", "PROBLEM", 106, 125]]]], "PMC7174175": [["IntroductionOn 11 March 2020, the World Health Organization declared that the global outbreak of Covid-19 (coronavirus) had become a pandemic.", [["Covid-19", "CHEMICAL", 97, 105], ["coronavirus", "DISEASE", 107, 118], ["Covid-19", "ORGANISM", 97, 105], ["coronavirus", "ORGANISM", 107, 118], ["Covid-19", "SPECIES", 97, 105], ["Covid", "TEST", 97, 102], ["coronavirus", "PROBLEM", 107, 118], ["a pandemic", "PROBLEM", 131, 141], ["pandemic", "OBSERVATION", 133, 141]]], ["In light of the numbers infected with the virus, and the strain it was placing on health systems and societies in virtually every country in the world, many governments enacted emergency legislation as part of their response to the pandemic.", [["the virus", "PROBLEM", 38, 47], ["numbers", "OBSERVATION_MODIFIER", 16, 23], ["infected", "OBSERVATION", 24, 32]]], ["Some countries included emergency mental health legislation in their package of measures to address the unprecedented situation brought about by the virus.", [["emergency mental health legislation", "TREATMENT", 24, 59]]], ["In Ireland, the Emergency Measures in the Public Interest (Covid-19) Act, 2020 was passed with some speed through the Irish parliament and signed by the president on 27 March, with a commencement date of 30 March for the provisions relating to mental health (Section 1(2)(b)).IntroductionIreland's emergency legislation contains a broad range of measures including a nationwide freeze on rents, a ban on evictions, measures to allow the re-enlistment of former members to the defence forces and provisions to allow retired health workers to be re-hired during the emergency (Finn, 2020).", [["broad", "OBSERVATION_MODIFIER", 331, 336]]], ["There is also a large financial aid package to allow the government to contribute to wage packets during the emergency and a series of amendments to the Mental Health Act, 2001.IntroductionThis paper examines the content of this emergency legislation as it relates to mental health legislation and provides a preliminary reflection on the extent to which the measures introduced were urgent, necessary and proportionate.", [["a large financial aid package", "TREATMENT", 14, 43], ["this emergency legislation", "TREATMENT", 224, 250], ["large", "OBSERVATION_MODIFIER", 16, 21]]], ["A more detailed, definitive assessment of these matters can only be made retrospectively, after the current public health emergency is over.", [["definitive assessment", "TEST", 17, 38]]], ["For the moment, this paper (1) provides an outline of relevant sections of Ireland's Mental Health Act, 2001; (2) sets out the mental health measures introduced in the emergency legislation of March 2020 as part of the Emergency Measures in the Public Interest (Covid-19) Act, 2020; (3) discusses the new provisions and key issues that arise from them; and (4) presents some conclusions and suggestions for future work.Definitions of key terms in the Mental Health Act, 2001 ::: Ireland's Mental Health Act, 2001The Mental Health Act 2001 defines \u2018mental disorder\u2019 as \u2018mental illness, severe dementia or significant intellectual disability where (a) because of the illness, disability or dementia, there is a serious likelihood of the person concerned causing immediate and serious harm to himself or herself or to other persons, or (b) (i) because of the severity of the illness, disability or dementia, the judgment of the person concerned is so impaired that failure to admit the person to an approved centre would be likely to lead to a serious deterioration in his or her condition or would prevent the administration of appropriate treatment that could be given only by such admission, and (ii) the reception, detention and treatment of the person concerned in an approved centre would be likely to benefit or alleviate the condition of that person to a material extent\u2019 (Section 3(1)).Definitions of key terms in the Mental Health Act, 2001 ::: Ireland's Mental Health Act, 2001More specifically, a \u2018mental illness\u2019 is \u2018a state of mind of a person which affects the person's thinking, perceiving, emotion or judgment and which seriously impairs the mental function of the person to the extent that he or she requires care or medical treatment in his or her own interest or in the interest of other persons\u2019 (Section 3(2)).Definitions of key terms in the Mental Health Act, 2001 ::: Ireland's Mental Health Act, 2001\u2018Severe dementia\u2019 is \u2018a deterioration of the brain of a person which significantly impairs the intellectual function of the person thereby affecting thought, comprehension and memory and which includes severe psychiatric or behavioural symptoms such as physical aggression\u2019.", [["brain", "ANATOMY", 1967, 1972], ["\u2018mental disorder", "DISEASE", 547, 563], ["\u2018mental illness", "DISEASE", 568, 583], ["dementia", "DISEASE", 592, 600], ["intellectual disability", "DISEASE", 616, 639], ["illness", "DISEASE", 665, 672], ["disability", "DISEASE", 674, 684], ["dementia", "DISEASE", 688, 696], ["illness", "DISEASE", 872, 879], ["disability", "DISEASE", 881, 891], ["dementia", "DISEASE", 895, 903], ["illness", "DISEASE", 1514, 1521], ["dementia\u2019", "DISEASE", 1930, 1939], ["psychiatric", "DISEASE", 2131, 2142], ["physical aggression", "DISEASE", 2175, 2194], ["persons", "ORGANISM", 1805, 1812], ["brain", "ORGAN", 1967, 1972], ["person", "SPECIES", 735, 741], ["persons", "SPECIES", 821, 828], ["person", "SPECIES", 925, 931], ["person", "SPECIES", 983, 989], ["person", "SPECIES", 1247, 1253], ["person", "SPECIES", 1348, 1354], ["person", "SPECIES", 1548, 1554], ["person", "SPECIES", 1573, 1579], ["person", "SPECIES", 1679, 1685], ["persons", "SPECIES", 1805, 1812], ["person", "SPECIES", 1978, 1984], ["person", "SPECIES", 2046, 2052], ["mental disorder", "PROBLEM", 548, 563], ["mental illness", "PROBLEM", 569, 583], ["severe dementia", "PROBLEM", 585, 600], ["significant intellectual disability", "PROBLEM", 604, 639], ["the illness", "PROBLEM", 661, 672], ["disability", "PROBLEM", 674, 684], ["dementia", "PROBLEM", 688, 696], ["the illness", "PROBLEM", 868, 879], ["disability", "PROBLEM", 881, 891], ["dementia", "PROBLEM", 895, 903], ["a serious deterioration in his or her condition", "PROBLEM", 1039, 1086], ["appropriate treatment", "TREATMENT", 1126, 1147], ["treatment", "TREATMENT", 1230, 1239], ["a \u2018mental illness", "PROBLEM", 1504, 1521], ["medical treatment", "TREATMENT", 1732, 1749], ["Severe dementia\u2019", "PROBLEM", 1923, 1939], ["\u2018a deterioration of the brain", "PROBLEM", 1943, 1972], ["severe psychiatric or behavioural symptoms", "PROBLEM", 2124, 2166], ["severe", "OBSERVATION_MODIFIER", 585, 591], ["dementia", "OBSERVATION", 592, 600], ["dementia", "OBSERVATION", 688, 696], ["dementia\u2019", "OBSERVATION", 1930, 1939], ["deterioration", "OBSERVATION", 1946, 1959], ["brain", "ANATOMY", 1967, 1972]]], ["\u2018Significant intellectual disability\u2019 is \u2018a state of arrested or incomplete development of mind of a person which includes significant impairment of intelligence and social functioning and abnormally aggressive or seriously irresponsible conduct on the part of the person\u2019.Definitions of key terms in the Mental Health Act, 2001 ::: Ireland's Mental Health Act, 2001The 2001 Act states that \u2018a person may be involuntarily admitted to an approved centre [\u2026] and detained there on the grounds that he or she is suffering from a mental disorder\u2019 (Section 8(1)), but cannot be so admitted \u2018by reason only of the fact that the person (a) is suffering from a personality disorder, (b) is socially deviant, or (c) is addicted to drugs or intoxicants\u2019 (Section 8(2)).", [["intellectual disability", "DISEASE", 13, 36], ["impairment of intelligence and social functioning", "DISEASE", 135, 184], ["mental disorder", "DISEASE", 526, 541], ["personality disorder", "DISEASE", 653, 673], ["person", "SPECIES", 101, 107], ["person", "SPECIES", 265, 271], ["person", "SPECIES", 394, 400], ["person", "SPECIES", 622, 628], ["Significant intellectual disability", "PROBLEM", 1, 36], ["significant impairment of intelligence", "PROBLEM", 123, 161], ["abnormally aggressive", "PROBLEM", 189, 210], ["a mental disorder", "PROBLEM", 524, 541], ["a personality disorder", "PROBLEM", 651, 673], ["Significant", "OBSERVATION_MODIFIER", 1, 12], ["intellectual", "OBSERVATION_MODIFIER", 13, 25], ["disability", "OBSERVATION", 26, 36], ["significant", "OBSERVATION_MODIFIER", 123, 134], ["impairment", "OBSERVATION", 135, 145]]], ["The three-step involuntary admission procedure under the 2001 Act has been previously described in this journal (Feeney, Umama-Agada, Gilhooley, Asghar, & Kelly, 2019) and results, in the first instance, in a 21-day \u2018admission order\u2019, which can be followed by a \u2018renewal order\u2019 of three months and then six months duration (Section 15), if the preceding order is affirmed by a mental health tribunal (Section 18).Independent psychiatric reports under the Mental Health Act, 2001 ::: Ireland's Mental Health Act, 2001The Mental Health Act 2001 made provision for the establishment of a \u2018Mental Health Commission\u2019, one of the functions of which is to appoint mental health tribunals \u2018to determine such matter or matters as may be referred to it by the Commission\u2019 (Section 48(1)).", [["psychiatric", "DISEASE", 425, 436], ["step involuntary admission procedure", "TREATMENT", 10, 46]]], ["One of the chief functions of tribunals is to review involuntary admission and renewal orders (Section 18).Independent psychiatric reports under the Mental Health Act, 2001 ::: Ireland's Mental Health Act, 2001In order to inform the tribunal's decisions, Section 17 of the 2001 Act requires that the Mental Health Commission obtains an independent psychiatric report about each involuntary patient and supplies it to the tribunal.", [["psychiatric", "DISEASE", 119, 130], ["psychiatric", "DISEASE", 348, 359], ["patient", "ORGANISM", 390, 397], ["patient", "SPECIES", 390, 397]]], ["More specifically, the Act states that:Independent psychiatric reports under the Mental Health Act, 2001 ::: Ireland's Mental Health Act, 2001", [["psychiatric", "DISEASE", 51, 62]]]], "cc83be3b10cd50f30df8c5743fa9f78954ca443d": [["a1111111111 a1111111111 a1111111111 a1111111111 a1111111111IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus responsible for the COVID-19 pandemic, was first reported in Wuhan, China in December 2019 [1, 2] .", [["acute respiratory syndrome coronavirus", "DISEASE", 78, 116], ["coronavirus", "DISEASE", 143, 154], ["SARS-CoV-2", "ORGANISM", 120, 130], ["coronavirus", "ORGANISM", 143, 154], ["a1111111111 a1111111111 a1111111111 a1111111111 a1111111111IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 116], ["SARS-CoV-2", "SPECIES", 120, 130], ["acute respiratory syndrome coronavirus", "PROBLEM", 78, 116], ["SARS", "TEST", 120, 124], ["CoV", "TEST", 125, 128], ["the novel coronavirus", "PROBLEM", 133, 154], ["the COVID", "TEST", 171, 180], ["pandemic", "PROBLEM", 184, 192], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["respiratory syndrome", "OBSERVATION", 84, 104]]], ["In a matter of weeks, SARS-CoV-2 infections had been detected in nearly every country, and as of July 2020, reported cases continue to rapidly increase across multiple continents.", [["SARS-CoV-2 infections", "DISEASE", 22, 43], ["SARS-CoV-2", "ORGANISM", 22, 32], ["SARS-CoV", "SPECIES", 22, 30], ["SARS", "PROBLEM", 22, 26], ["2 infections", "PROBLEM", 31, 43]]], ["Powered by advances in rapid genetic sequencing, there is an expansive and growing body of data on SARS-CoV-2 sequences from individuals around the world.", [["SARS-CoV-2", "ORGANISM", 99, 109], ["SARS-CoV-2 sequences", "DNA", 99, 119], ["SARS-CoV", "SPECIES", 99, 107], ["rapid genetic sequencing", "TEST", 23, 47], ["an expansive and growing body of data", "PROBLEM", 58, 95], ["SARS", "TEST", 99, 103], ["CoV-2 sequences", "TEST", 104, 119], ["expansive", "OBSERVATION_MODIFIER", 61, 70], ["growing", "OBSERVATION_MODIFIER", 75, 82], ["body", "OBSERVATION_MODIFIER", 83, 87]]], ["During the early stage of the pandemic, a substantial degree of heterogeneity was already identified, with differences in 15% of the sites of the sequences [3] .", [["the pandemic", "PROBLEM", 26, 38], ["heterogeneity", "PROBLEM", 64, 77], ["pandemic", "OBSERVATION", 30, 38], ["substantial", "OBSERVATION_MODIFIER", 42, 53], ["degree", "OBSERVATION_MODIFIER", 54, 60], ["heterogeneity", "OBSERVATION", 64, 77]]], ["SARS-CoV-2 will mutate over time as transmissions occur and the virus spreads; although, notably, it has previously been observed that coronaviruses, which are single strand RNA viruses with a relatively large genome size (\ufffd30,000 bases), tend to have lower mutation rates than other RNA viruses [4] .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["the virus spreads", "PROBLEM", 60, 77], ["coronaviruses", "PROBLEM", 135, 148], ["single strand RNA viruses", "PROBLEM", 160, 185], ["lower mutation rates than other RNA viruses", "PROBLEM", 252, 295], ["coronaviruses", "OBSERVATION", 135, 148], ["RNA viruses", "OBSERVATION", 174, 185], ["relatively", "OBSERVATION_MODIFIER", 193, 203], ["large", "OBSERVATION_MODIFIER", 204, 209], ["genome", "OBSERVATION_MODIFIER", 210, 216], ["size", "OBSERVATION_MODIFIER", 217, 221]]], ["Central repositories are continuously accumulating SARS-CoV-2 genome data from around the world, such as the Global Initiative on Sharing all Individual Data (GISAID) [5] (available at https://www. gisaid.org/).IntroductionResearchers are presently using whole genome sequence alignment and phylogenetic tree construction to study the evolution of SARS-CoV-2 on a macro and micro scale [6] [7] [8] [9] [10] .", [["SARS", "DISEASE", 348, 352], ["[6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 386, 406], ["SARS-CoV-2 genome", "DNA", 51, 68], ["SARS-CoV", "SPECIES", 348, 356], ["continuously accumulating SARS", "PROBLEM", 25, 55], ["whole genome sequence alignment", "TEST", 255, 286], ["SARS", "PROBLEM", 348, 352], ["CoV", "TEST", 353, 356], ["a macro and micro scale", "TEST", 362, 385]]], ["For example, the Nextstrain group has created a massive phylogenetic tree incorporating sequence data and applied a model of the time-based rate of mutation to create a hypothetical map of viral distribution [6] (available at https://nextstrain.org/ncov).", [["a massive phylogenetic tree incorporating sequence data", "PROBLEM", 46, 101], ["mutation", "PROBLEM", 148, 156], ["viral distribution", "PROBLEM", 189, 207], ["massive", "OBSERVATION_MODIFIER", 48, 55], ["phylogenetic tree", "OBSERVATION", 56, 73]]], ["Similarly, the China National Center for Bioinformation has established a \"2019 Novel Coronavirus Resource\", which includes a clickable world map that links to a listing of sequences along with similarity scores based on alignment (available at https://bigd.big.ac.cn/ncov?lang=en) [11] .IntroductionIn more granular studies, early work by researchers based in China, analyzing 103 genome sequences, identified two highly linked single nucleotides, leading them to suggest that two major subtypes had emerged: one called \"L\", predominantly found in the Wuhan area, and \"S\", which derived from \"L\" and found elsewhere [12] .", [["nucleotides", "CHEMICAL", 436, 447], ["103 genome sequences", "DNA", 378, 398], ["similarity scores", "TEST", 194, 211], ["granular studies", "TEST", 308, 324]]], ["Subsequently, further diversity was recognized as the virus continued to spread, and researchers developed a consensus reference sequence for SARS-CoV-2, to which other sequences may be compared [13] .", [["consensus reference sequence", "DNA", 109, 137], ["SARS-CoV", "SPECIES", 142, 150], ["the virus", "PROBLEM", 50, 59], ["SARS", "PROBLEM", 142, 146], ["CoV", "TEST", 147, 150]]], ["Researchers have continued to publish studies of the specific variants in the context of localized outbreaks, such as the Diamond Princess cruise ship [14] , as well as regional outbreaks and their international connections [12, [15] [16] [17] [18] .IntroductionEfforts are also underway to identify potential genome sites and regions where selection pressure may result in phenotypic variation.", [["[15] [16] [17", "SIMPLE_CHEMICAL", 229, 242], ["genome sites", "DNA", 310, 322], ["potential genome sites", "PROBLEM", 300, 322], ["selection pressure", "TEST", 341, 359], ["phenotypic variation", "PROBLEM", 374, 394], ["localized", "OBSERVATION_MODIFIER", 89, 98], ["outbreaks", "OBSERVATION", 99, 108], ["phenotypic variation", "OBSERVATION", 374, 394]]], ["Particular focus has been given to the ORF (open reading frame) coding for the spike (S) receptor-binding protein, which may impact the development of vaccines and antivirals [19] .", [["spike (S) receptor", "GENE_OR_GENE_PRODUCT", 79, 97], ["ORF", "DNA", 39, 42], ["open reading frame", "DNA", 44, 62], ["spike (S) receptor", "PROTEIN", 79, 97], ["binding protein", "PROTEIN", 98, 113], ["the ORF", "PROBLEM", 35, 42], ["the spike (S) receptor-binding protein", "PROBLEM", 75, 113], ["vaccines", "TREATMENT", 151, 159], ["antivirals", "TREATMENT", 164, 174]]], ["Notably, a group studying sequence variants within patients reported limited evidence of intrahost variation, though they cautioned that the results were preliminary and could be the result of limited data [20, 21] .", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["a group studying sequence variants", "TEST", 9, 43], ["intrahost variation", "PROBLEM", 89, 108]]], ["Intrahost variation thus represents yet another layer of complexity in evaluating that viral variation which influences disease progression in an individual patient, or may be associated with events that can in turn generate sequence variation in other individuals that patient infects.IntroductionGiven the importance of tracking and modeling genetic changes in the SARS-CoV-2 virus as the outbreak expands, there is a need for an efficient methodology to quantitatively characterize groups of variation in the SARS-CoV-2 virus genome by defining genetic subtypes of the virus.", [["SARS", "DISEASE", 367, 371], ["SARS", "DISEASE", 512, 516], ["patient", "ORGANISM", 157, 164], ["patient", "ORGANISM", 270, 277], ["SARS-CoV-2 virus", "ORGANISM", 367, 383], ["SARS-CoV-2 virus", "ORGANISM", 512, 528], ["SARS-CoV-2 virus genome", "DNA", 512, 535], ["patient", "SPECIES", 157, 164], ["patient", "SPECIES", 270, 277], ["CoV-2 virus", "SPECIES", 372, 383], ["CoV-2 virus", "SPECIES", 517, 528], ["SARS-CoV-2 virus", "SPECIES", 367, 383], ["SARS-CoV-2 virus", "SPECIES", 512, 528], ["Intrahost variation", "PROBLEM", 0, 19], ["viral variation", "PROBLEM", 87, 102], ["disease progression", "PROBLEM", 120, 139], ["patient infects", "PROBLEM", 270, 285], ["tracking and modeling genetic changes", "PROBLEM", 322, 359], ["the SARS", "TEST", 363, 371], ["an efficient methodology", "TEST", 429, 453], ["the SARS", "PROBLEM", 508, 516], ["CoV", "TEST", 517, 520], ["2 virus genome", "PROBLEM", 521, 535], ["the virus", "PROBLEM", 568, 577], ["layer", "OBSERVATION_MODIFIER", 48, 53], ["viral variation", "OBSERVATION", 87, 102]]], ["Exemplary potential applications of quantitative subtyping include the following: 1) Characterizing potentially emerging variants of the virus in different regions, which may ultimately express different phenotypes.", [["the virus", "PROBLEM", 133, 142], ["different phenotypes", "PROBLEM", 194, 214], ["virus", "OBSERVATION", 137, 142]]], ["2) Monitoring variation in the viral genome that may be important for vaccine development, for example due to emerging structural differences in proteins encoded by different strains.", [["viral genome", "DNA", 31, 43], ["Monitoring variation", "TEST", 3, 23], ["the viral genome", "PROBLEM", 27, 43], ["vaccine development", "TREATMENT", 70, 89], ["emerging structural differences in proteins", "PROBLEM", 110, 153], ["viral genome", "OBSERVATION", 31, 43]]], ["3) Designing future testing methodology to contain disease transmission across countries and regions, for example developing specific tests that can characterize whether a COVID-19 patient developed symptoms due to importation or likely domestic community transmission.", [["patient", "ORGANISM", 181, 188], ["patient", "SPECIES", 181, 188], ["Designing future testing methodology", "TEST", 3, 39], ["disease transmission", "PROBLEM", 51, 71], ["specific tests", "TEST", 125, 139], ["a COVID", "TEST", 170, 177], ["symptoms", "PROBLEM", 199, 207]]], ["4) Identifying viral subtypes that may correlate with different clinical outcomes in different regions and patient subpopulations.IntroductionPhylogenetic trees obtained through sequence alignment may be utilized to map viral outbreaks geographically and trace transmission chains [22, 23] and have been applied to SARS-CoV-2 by, e.g., the Nextstrain group as discussed above.", [["SARS", "DISEASE", 315, 319], ["patient", "ORGANISM", 107, 114], ["CoV-2", "ORGANISM", 320, 325], ["patient", "SPECIES", 107, 114], ["SARS-CoV", "SPECIES", 315, 323], ["viral subtypes", "PROBLEM", 15, 29], ["different clinical outcomes in different regions and patient subpopulations", "PROBLEM", 54, 129], ["map viral outbreaks", "PROBLEM", 216, 235], ["trace transmission chains", "PROBLEM", 255, 280], ["SARS", "TEST", 315, 319], ["CoV", "TEST", 320, 323], ["viral subtypes", "OBSERVATION", 15, 29], ["may correlate with", "UNCERTAINTY", 35, 53], ["subpopulations", "OBSERVATION_MODIFIER", 115, 129]]], ["At an early stage in the pandemic, however, phylogenetic trees may be unreliable predictors of evolutionary relationships between viral strains circulating worldwide, because of insufficient information regarding the molecular clock assumption, practical limits on data collection, and sampling bias [24] .", [["viral strains circulating worldwide", "PROBLEM", 130, 165], ["data collection", "TEST", 265, 280], ["sampling bias", "TEST", 286, 299], ["early stage", "OBSERVATION_MODIFIER", 6, 17]]], ["Accordingly, subtyping based on phylogenetic models may also be unreliable and change, as the assumptions underlying the models change given more sequencing and continued variation in the viral genome.", [["viral genome", "DNA", 188, 200], ["the models change", "PROBLEM", 117, 134], ["the viral genome", "PROBLEM", 184, 200], ["may also be", "UNCERTAINTY", 52, 63], ["viral genome", "OBSERVATION", 188, 200]]], ["ISMs thus provide a robust subtype definition, which can help track the virus as the pandemic progresses.", [["ISMs", "PROBLEM", 0, 4]]], ["Therefore, it may be more efficient to focus on co-occurring patterns of only the sites of the more frequently occurring variation within the viral genome to identify subtypes, rather than utilizing whole genome sequence data to cluster viral genomes, which may contain additional confounding variation.IntroductionMoreover, the nomenclature of clades imply that the categorization of viruses in subtypes is static rather than dynamic.", [["viral genome", "DNA", 142, 154], ["viral genomes", "DNA", 237, 250], ["whole genome sequence data", "TEST", 199, 225], ["cluster viral genomes", "PROBLEM", 229, 250], ["viral genome", "OBSERVATION", 142, 154], ["viral genomes", "OBSERVATION", 237, 250], ["confounding variation", "OBSERVATION", 281, 302], ["viruses", "OBSERVATION", 385, 392]]], ["SARS-CoV-2 is a novel virus in humans that is rapidly evolving, which makes it harder to establish a stable nomenclature for genetic typing [10] .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["humans", "ORGANISM", 31, 37], ["humans", "SPECIES", 31, 37], ["SARS-CoV", "SPECIES", 0, 8], ["humans", "SPECIES", 31, 37], ["SARS", "PROBLEM", 0, 4], ["a novel virus in humans", "PROBLEM", 14, 37], ["genetic typing", "TEST", 125, 139], ["virus", "OBSERVATION", 22, 27], ["rapidly", "OBSERVATION_MODIFIER", 46, 53]]], ["The Nextstrain project has sought to address these challenges by providing their own clade definitions based on whether there are a certain number of mutations at nucleotide positions in the sequence (at least two) and naming clades based on their estimated time of emergence [25] .", [["nucleotide", "CHEMICAL", 163, 173], ["nucleotide", "CHEMICAL", 163, 173], ["mutations at nucleotide positions", "PROBLEM", 150, 183]]], ["This shows that a conventional genetic subtype relying on whole genome phylogenetic trees will be complicated by the changes in viral genome, especially early on in a pandemic before those changes are clearly governed by selection pressure.", [["viral genome", "DNA", 128, 140], ["the changes in viral genome", "PROBLEM", 113, 140], ["viral genome", "OBSERVATION", 128, 140]]], ["Lineages will likely disappear and reemerge within different geographical regions and over the course of time [10] .", [["different", "OBSERVATION_MODIFIER", 51, 60], ["geographical", "OBSERVATION_MODIFIER", 61, 73], ["regions", "OBSERVATION_MODIFIER", 74, 81]]], ["In addition, viral evolutionary analysis, such as by the Nextstrain group, relies on making assumptions solely on molecular evolution (the degree of sequence similarity and branching points in defining genetic clades and other levels of organization) and not on transmission models.IntroductionIn this paper, we propose a methodology to complement phylogenetics-based transmission and evolution models of SARS-CoV-2 that can consistently and rapidly identify subtypes without requiring an initial tree reconstruction step-and, thereby, avoid the need to make assumptions about the molecular evolution clock and clustering thresholds.", [["SARS", "DISEASE", 405, 409], ["SARS-CoV", "SPECIES", 405, 413], ["viral evolutionary analysis", "TEST", 13, 40], ["SARS", "PROBLEM", 405, 409], ["an initial tree reconstruction step", "TREATMENT", 486, 521], ["viral evolutionary", "OBSERVATION", 13, 31]]], ["To generate highly informative molecular signatures indicative of a subtype or emerging lineage, we look to methods that have been successfully employed in the microbiome field to resolve species/subspecies from 16S ribosomal RNA (16S rRNA) gene [26] .", [["16S", "GENE_OR_GENE_PRODUCT", 212, 215], ["ribosomal", "CELLULAR_COMPONENT", 216, 225], ["16S ribosomal RNA (16S rRNA) gene", "DNA", 212, 245], ["species/subspecies", "PROBLEM", 188, 206], ["16S ribosomal RNA", "PROBLEM", 212, 229]]], ["The 16S rRNA gene is a highly conserved sequence and therefore can be used for phylogenetic analysis in microbial communities [27] [28] [29] [30] [31] .", [["16S", "GENE_OR_GENE_PRODUCT", 4, 7], ["rRNA", "CELLULAR_COMPONENT", 8, 12], ["[27] [28] [29] [30] [31]", "SIMPLE_CHEMICAL", 126, 150], ["16S rRNA gene", "DNA", 4, 17], ["The 16S rRNA gene", "TEST", 0, 17], ["phylogenetic analysis", "TEST", 79, 100]]], ["One way to differentiate between closely related microbial taxa is to identify nucleotide positions in 16S rRNA data (\"oligotypes\") that represent information-rich variation [32] .", [["nucleotide", "CHEMICAL", 79, 89], ["nucleotide", "CHEMICAL", 79, 89], ["nucleotide positions in 16S rRNA data", "PROBLEM", 79, 116]]], ["This approach has also been used in the reverse direction to find conserved sites as a way to assemble viral phylogenies [33] .", [["This approach", "TREATMENT", 0, 13]]], ["Dawy et al. proposed to use Shannon's mutual information to identify multiple important loci for Gene mapping and marker clustering [34] .", [["Gene mapping", "TREATMENT", 97, 109]]], ["Shannon Entropy [35] has been applied in multiple sequence alignment data to quantify the sequence variation at different positions [32, 36] .", [["Shannon Entropy", "TREATMENT", 0, 15], ["multiple sequence alignment data", "TEST", 41, 73], ["the sequence variation", "TEST", 86, 108]]], ["Given a position of interest, entropy can be used to measure the amount of \"randomness\" at that position, as determined by whether sequences may have different bases at a specific position.", [["entropy", "TREATMENT", 30, 37]]], ["For instance, if there is an A at a given position across all aligned sequences, the entropy will be 0, i.e., there is no \"randomness\" at that position.", [["\"randomness\"", "PROBLEM", 122, 134], ["no", "UNCERTAINTY", 119, 121]]], ["On the other hand, if at a given position there is a G in 50% of the sequences and a T in the other 50%, the entropy will be 1 (i.e., essentially \"random\"), and thus a relatively high entropy.", [["a relatively high entropy", "PROBLEM", 166, 191], ["high entropy", "OBSERVATION", 179, 191]]], ["Based on this property, oligotyping [32] utilizes variable sites revealed by the entropy analysis to identify highly refined taxonomic units.", [["the entropy analysis", "TEST", 77, 97], ["taxonomic units", "OBSERVATION", 125, 140]]], ["It is important to note that while we use the term \"random\" in the foregoing, in the biological context, a position may have a different base in different sequences due to selection pressure resulting in strains with different phenotypes, rather than purely random variation.IntroductionAccordingly, we present herein a method to define a genetic signature, called an \"informative subtype marker\" or ISM, for the viral genome that can be 1) utilized to define SARS-CoV-2 subtypes that can be quantified to characterize the geographic and temporal spread of the virus, and 2) efficiently implemented for identifying strains to potentially analyze for phenotypic differences.", [["SARS-CoV-2", "ORGANISM", 460, 470], ["ISM", "DNA", 400, 403], ["viral genome", "DNA", 413, 425], ["selection pressure", "TEST", 172, 190], ["strains", "PROBLEM", 204, 211], ["different phenotypes", "PROBLEM", 217, 237], ["the viral genome", "PROBLEM", 409, 425], ["SARS", "TEST", 460, 464], ["strains", "PROBLEM", 615, 622], ["phenotypic differences", "PROBLEM", 650, 672]]], ["The method compresses the full viral genome to generate a small number of nucleotides that are highly informative of the way in which the viral genome dynamically changes.", [["nucleotides", "CHEMICAL", 74, 85], ["viral genome", "DNA", 31, 43], ["viral genome", "DNA", 138, 150], ["The method", "TREATMENT", 0, 10], ["the viral genome dynamically changes", "PROBLEM", 134, 170], ["viral genome", "OBSERVATION", 31, 43], ["small", "OBSERVATION_MODIFIER", 58, 63], ["viral genome dynamically", "OBSERVATION", 138, 162]]], ["We draw on the aforementioned oligotyping approach developed for 16S rRNA data [32] and build on its implementation of entropy and grouping patterns to address the particular challenges of viral genomes.", [["16S rRNA", "DNA", 65, 73], ["viral genomes", "DNA", 189, 202], ["16S rRNA data", "TEST", 65, 78], ["viral genomes", "PROBLEM", 189, 202], ["viral genomes", "OBSERVATION", 189, 202]]], ["On top of oligotyping, we add error correction to account for ambiguities in reported sequence data and, optionally, applied further compression by identifying patterns of base entropy correlation.", [["oligotyping", "TREATMENT", 10, 21], ["error correction", "TREATMENT", 30, 46], ["further compression", "TREATMENT", 125, 144], ["base entropy correlation", "TEST", 172, 196], ["compression", "OBSERVATION", 133, 144], ["base entropy", "OBSERVATION", 172, 184]]], ["The resulting ISM, therefore, defines a viral genetic subtype (that can be related to a phylogenetic \"lineage\", see Comparison of ISM-defined subtypes to clades identified using phylogenetic trees) in the sense that it is a compressed (reduced complexity) representation of a set of genetic features (a.k.a genotype).IntroductionThe ISM pipeline may complement a phylogenetic approach in that it can efficiently identify viral subtypes of the population through genetic hotspots and do not rely on evolutionary model assumptions.", [["ISM", "PROTEIN", 14, 17], ["ISM", "PROTEIN", 130, 133], ["a viral genetic subtype", "PROBLEM", 38, 61], ["a phylogenetic \"lineage\"", "PROBLEM", 86, 110], ["The ISM pipeline", "TREATMENT", 329, 345], ["a phylogenetic approach", "TREATMENT", 361, 384]]], ["ISMs identify subtypes with slight differences between sequences where the sequence identity is >99%, as is the case of SARS-CoV-2 with OrthoANI of 99.8% (at the end of April 2020) [37] .", [["SARS", "DISEASE", 120, 124], ["SARS-CoV", "SPECIES", 120, 128], ["the sequence identity", "TEST", 71, 92], ["SARS", "TEST", 120, 124], ["CoV", "TEST", 125, 128], ["OrthoANI", "TEST", 136, 144], ["slight", "OBSERVATION_MODIFIER", 28, 34]]], ["ISMs include the key base mutations in the marker identification itself.", [["the key base mutations", "PROBLEM", 13, 35], ["base mutations", "OBSERVATION", 21, 35]]], ["And thus, unlike phylogenetic lineages (i.e., clades and subsequent emergent subtypes), ISM-defined subtypes are expressly differentiated by mutations with high diversity (over the viral population).", [["ISM", "PROTEIN", 88, 91], ["high diversity", "PROBLEM", 156, 170], ["phylogenetic lineages", "OBSERVATION", 17, 38], ["high", "OBSERVATION_MODIFIER", 156, 160], ["diversity", "OBSERVATION_MODIFIER", 161, 170]]], ["For example, the ISM label of a subtype can include mutation in SARS-CoV-2's spike protein, which may have an important phenotypic impact.IntroductionAs a succinct and robust identifier, therefore, ISM-based subtyping can facilitate downstream analysis, such as modeling and visualizing the geographic and temporal patterns of genetic variability of SARS-CoV-2 sequences obtained from the GISAID database.", [["SARS", "DISEASE", 350, 354], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 74], ["SARS-CoV-2's spike protein", "PROTEIN", 64, 90], ["SARS-CoV-2 sequences", "DNA", 350, 370], ["SARS-CoV", "SPECIES", 350, 358], ["mutation", "PROBLEM", 52, 60], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["spike protein", "PROBLEM", 77, 90], ["downstream analysis", "TEST", 233, 252], ["SARS", "TEST", 350, 354], ["CoV-2 sequences", "TEST", 355, 370], ["the GISAID database", "TEST", 385, 404], ["important", "OBSERVATION_MODIFIER", 110, 119], ["phenotypic impact", "OBSERVATION", 120, 137]]], ["We have also developed an interactive website showing the worldwide country-specific distributions of ISM-defined subtypes, available at https:// covid19-ism.coe.drexel.edu/Data collection and preprocessingNextstrain maintains a continually-updated, pre-formatted SARS-CoV-2 (novel coronavirus) sequence dataset through GISAID (this dataset also includes sequences of other novel coronavirus sampled from other hosts such as Bat).", [["coronavirus", "ORGANISM", 282, 293], ["covid19", "DNA", 146, 153], ["pre-formatted SARS-CoV-2 (novel coronavirus) sequence dataset", "DNA", 250, 311], ["ISM", "PROBLEM", 102, 105], ["novel coronavirus)", "TREATMENT", 276, 294], ["other novel coronavirus", "PROBLEM", 368, 391]]], ["This dataset was downloaded from GISAID (http://www.gisaid.org) on June 17, 2020, which contains 47,305 sequences.", [["47,305 sequences", "DNA", 97, 113]]], ["Our preprocessing pipeline then begins by filtering out sequences that are less than 25000 base pairs (the same threshold used in Nextstrain project built for SARS-CoV-2, https://github.com/nextstrain/ ncov).", [["Our preprocessing pipeline", "TREATMENT", 0, 26], ["SARS", "PROBLEM", 159, 163], ["CoV", "TEST", 164, 167]]], ["We then performed multiple sequence alignment on all remaining sequences using MAFFT [38] with the \"FFT-NS-2\" method in XSEDE [39] .", [["multiple sequence alignment", "TEST", 18, 45], ["MAFFT", "TEST", 79, 84], ["the \"FFT", "TEST", 95, 103]]], ["After alignment, the sequence length was extended (for the present data set, up to 79716 nt) due to gaps inserted into the sequences during the multiple sequence alignment.Entropy analysis and ISM extractionFor the aligned sequences, we merged the sequence with the metadata provided by Nextstrain as of June 17, 2020, based on identification number, gisaid_epi_isl, provided by GISAID [5] .", [["the sequence length", "TEST", 17, 36], ["the multiple sequence alignment", "TEST", 140, 171], ["Entropy analysis", "TEST", 172, 188], ["ISM extraction", "TREATMENT", 193, 207], ["the aligned sequences", "TEST", 211, 232]]], ["In addition, we filtered out sequences from unknown host or non-human hosts.", [["non-human", "ORGANISM", 60, 69]]], ["The resulting final data set contained 45535 sequences excluding the reference sequence.", [["45535 sequences", "DNA", 39, 54], ["the reference sequence", "TEST", 65, 87]]], ["Then, we calculated the entropy at a given position i by Eq (1).Entropy analysis and ISM extractionwhere L is a list of unique characters in all sequences and p k (i) is a probability of observing a character k at position i.", [["the entropy", "TREATMENT", 20, 31], ["Entropy analysis", "TEST", 64, 80], ["ISM extractionwhere", "TEST", 85, 104]]], ["We refer to characters in the preceding because, in addition to the bases A, C, G, and T, the sequences include additional characters representing gaps (-) and ambiguities, which are listed in S1 File (the sequences are of cDNA derived from viral RNA, so there is a T substituting for the U that would appear in the viral RNA sequence).Entropy analysis and ISM extractionBases like N and -, which represent a fully ambiguous site and a gap respectively, are substantially less informative.", [["U", "GENE_OR_GENE_PRODUCT", 289, 290], ["cDNA", "DNA", 223, 227], ["viral RNA", "RNA", 241, 250], ["viral RNA sequence", "DNA", 316, 334], ["gaps", "TEST", 147, 151], ["viral RNA", "PROBLEM", 241, 250], ["Entropy analysis", "TEST", 336, 352], ["ISM extractionBases", "TEST", 357, 376], ["a fully ambiguous site", "PROBLEM", 407, 429], ["bases", "ANATOMY_MODIFIER", 68, 73]]], ["Therefore, we further define a masked entropy as entropy calculated without considering sequences containing N and -in a given nucleotide position in the genome.Entropy analysis and ISM extractionWith the help of this masked entropy calculation, we can focus on truly informative positions, instead of positions at the start and end of the sequence in which there is substantial uncertainty due to artifacts in the sequencing process.", [["nucleotide", "CHEMICAL", 127, 137], ["nucleotide", "CHEMICAL", 127, 137], ["genome", "CELLULAR_COMPONENT", 154, 160], ["a masked entropy", "PROBLEM", 29, 45], ["Entropy analysis", "TEST", 161, 177], ["this masked entropy calculation", "TEST", 213, 244], ["the sequence", "TEST", 336, 348], ["artifacts in the sequencing process", "PROBLEM", 398, 433], ["genome", "ANATOMY", 154, 160], ["substantial", "OBSERVATION_MODIFIER", 367, 378], ["uncertainty", "OBSERVATION", 379, 390], ["artifacts", "OBSERVATION", 398, 407]]], ["Finally, high entropy positions are selected by two criteria: 1) entropy > 0.23, and 2) the percentage of N and -is less than 25%.", [["entropy", "TEST", 65, 72]]], ["Further details about the selection of these two criteria are provided in S1 Fig. In the data set we processed for this paper, the entropy threshold yielded 20 distinct positions within the viral genome sequence.", [["viral genome sequence", "DNA", 190, 211], ["the entropy threshold", "TEST", 127, 148], ["20 distinct", "OBSERVATION_MODIFIER", 157, 168], ["viral genome", "OBSERVATION", 190, 202]]], ["We built the Informative Subtype Markers (ISMs) at these 20 nucleotide positions on each sequence.Error correction to resolve ambiguities in sequence data and remove spurious ISMsThe focus of the error correction method is to resolve an ISM that contains ambiguous symbols, i.e., a nucleotide identifier that represents an ambiguous base call (as detailed in S1 File), such as N, which represents a position that could be A, C, T, or G. Our approach uses ISMs with few or no ambiguous symbols to correct ISMs with many ambiguities.", [["nucleotide", "CHEMICAL", 60, 70], ["nucleotide", "CHEMICAL", 282, 292], ["nucleotide", "CHEMICAL", 60, 70], ["nucleotide", "CHEMICAL", 282, 292], ["N", "PROTEIN", 377, 378], ["Error correction", "TREATMENT", 98, 114], ["sequence data", "TEST", 141, 154], ["spurious ISMs", "PROBLEM", 166, 179], ["the error correction method", "PROBLEM", 192, 219], ["an ISM", "PROBLEM", 234, 240], ["a nucleotide identifier", "TEST", 280, 303], ["ambiguous symbols", "PROBLEM", 475, 492], ["ambiguous symbols", "OBSERVATION", 255, 272]]], ["Given an ISM with an error, we first find all ISMs that are identical to the subject ISM's nucleotide positions without error.", [["nucleotide", "CHEMICAL", 91, 101], ["nucleotide", "CHEMICAL", 91, 101], ["all ISMs", "PROBLEM", 42, 50]]], ["We refer here to these nearly-identical ISMs as supporting ISMs.", [["ISMs", "CANCER", 40, 44], ["ISMs", "CANCER", 59, 63]]], ["For a given nucleotide position, if all other such supporting ISMs with respect to the said erroneous position contain the same non-ambiguous base (i.e., an A, C, T, or G), then we simply correct the ambiguous base to that non-ambiguous base found in the supporting ISMs.", [["nucleotide", "CHEMICAL", 12, 22], ["nucleotide", "CHEMICAL", 12, 22], ["ISMs", "GENE_OR_GENE_PRODUCT", 62, 66], ["ISMs", "CANCER", 266, 270], ["ISMs", "DNA", 62, 66], ["a given nucleotide position", "TREATMENT", 4, 31], ["all other such supporting ISMs", "PROBLEM", 36, 66]]], ["However, when the supporting ISMs disagree at a respective nucleotide position, the method generates an ambiguous symbol which represents all the bases that occurred in the supporting ISMs and compare this artificially generated nucleotide symbol with the original position in the subject ISM.", [["nucleotide", "CHEMICAL", 59, 69], ["nucleotide", "CHEMICAL", 229, 239], ["nucleotide", "CHEMICAL", 59, 69], ["nucleotide", "CHEMICAL", 229, 239], ["ISMs", "PATHOLOGICAL_FORMATION", 29, 33], ["ISMs", "CANCER", 184, 188], ["ISMs", "DNA", 29, 33], ["ISMs", "DNA", 184, 188], ["the method", "TEST", 80, 90], ["ambiguous symbol", "OBSERVATION", 104, 120], ["bases", "ANATOMY_MODIFIER", 146, 151], ["position", "OBSERVATION_MODIFIER", 265, 273]]], ["If the generated nucleotide symbol identifies a smaller set of bases, e.g., Y representing C or T rather than N, which may be any base, then we use the generated symbol to correct the original one.Error correction to resolve ambiguities in sequence data and remove spurious ISMsWhen we applied the foregoing error correction algorithm to ISMs generated from the genome data set analyzed in this paper, we found that 90.2% of erroneous ISMs were partially corrected (meaning at least one nucleotide position with ambiguity was corrected for that ISM if not all), and 24.5% of erroneous ISMs were fully corrected (meaning all positions with ambiguity were corrected to a non-ambiguous base (i.e., an A, C, T, or G)).", [["nucleotide", "CHEMICAL", 17, 27], ["nucleotide", "CHEMICAL", 17, 27], ["N", "CHEMICAL", 110, 111], ["nucleotide", "CHEMICAL", 487, 497], ["ISMs", "CANCER", 435, 439], ["ISMs", "PATHOLOGICAL_FORMATION", 585, 589], ["ISMs", "DNA", 338, 342], ["ISMs", "DNA", 435, 439], ["Error correction", "TREATMENT", 197, 213], ["sequence data", "TEST", 240, 253], ["spurious ISMs", "PROBLEM", 265, 278], ["the foregoing error correction algorithm", "TREATMENT", 294, 334], ["erroneous ISMs", "PROBLEM", 425, 439], ["erroneous ISMs", "PROBLEM", 575, 589], ["smaller", "OBSERVATION_MODIFIER", 48, 55], ["bases", "ANATOMY_MODIFIER", 63, 68]]], ["Since one ISM may represent multiple sequences in the data set, overall the error correction algorithm was able to partially correct 96.0% of sequences identified by an erroneous ISM, and 32.4% of such sequences were fully corrected.Error correction to resolve ambiguities in sequence data and remove spurious ISMsThe error correction method necessarily results in the replacement of ISMs with an ambiguous base at a site by another ISM without an error at that site.", [["ISM", "DNA", 10, 13], ["an erroneous ISM", "TEST", 166, 182], ["such sequences", "TEST", 197, 211], ["Error correction", "TREATMENT", 233, 249], ["sequence data", "TEST", 276, 289], ["spurious ISMs", "PROBLEM", 301, 314], ["the replacement of ISMs", "TREATMENT", 365, 388], ["an ambiguous base", "PROBLEM", 394, 411], ["an error at that site", "PROBLEM", 445, 466], ["may represent", "UNCERTAINTY", 14, 27], ["multiple", "OBSERVATION_MODIFIER", 28, 36], ["error", "OBSERVATION", 448, 453]]], ["We expect, and have observed that the abundance of non-ambiguous ISMs are inflated by the error correction process.", [["ISMs", "GENE_OR_GENE_PRODUCT", 65, 69], ["non-ambiguous ISMs", "PROBLEM", 51, 69], ["abundance", "OBSERVATION_MODIFIER", 38, 47], ["error correction", "OBSERVATION", 90, 106]]], ["Here, we utilize the inflation rate of ISMs to quantify the difference in abundance of an ISM before and after error correction process.", [["the inflation rate of ISMs", "TREATMENT", 17, 43], ["error correction process", "TREATMENT", 111, 135]]], ["The inflation rate is defined by Eq (2)Error correction to resolve ambiguities in sequence data and remove spurious ISMswhere N is the abundance of an ISM of interest (typically an ISM with few or no ambiguous bases) before error correction, and N EC is the abundance of that ISM after error correction.Quantification and visualization of viral subtypesAt the country/region level, we assess the geographic distribution of SARS-CoV-2 subtypes, and, in turn, we count the frequency of unique ISMs per location and build charts and tables to visualize the ISMs, including the pie charts, graphs, and tables shown in this paper.", [["SARS", "DISEASE", 423, 427], ["N EC", "CELL_LINE", 246, 250], ["SARS-CoV", "SPECIES", 423, 431], ["The inflation rate", "TEST", 0, 18], ["sequence data", "TEST", 82, 95], ["spurious ISMswhere N", "PROBLEM", 107, 127], ["Quantification", "TEST", 303, 317], ["viral subtypes", "PROBLEM", 339, 353], ["SARS", "PROBLEM", 423, 427], ["graphs", "TEST", 586, 592], ["viral subtypes", "OBSERVATION", 339, 353], ["SARS", "OBSERVATION", 423, 427]]], ["To improve visualization, ISMs that occur with frequency of less than 5% in a given location are collapsed into \"OTHER\" category per location.", [["visualization", "TEST", 11, 24], ["ISMs", "PROBLEM", 26, 30], ["collapsed", "OBSERVATION", 97, 106]]], ["Our pipeline then creates pie charts for different locations to show the geographical distribution of subtypes.", [["subtypes", "OBSERVATION_MODIFIER", 102, 110]]], ["Novembre et al. also used Principal Components Analysis (PCA) to produce a two-dimensional visual summary of the genetic variation in human populations [43] .", [["human", "ORGANISM", 134, 139], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139]]], ["In our application, we can use the abundances of different ISMs in a country as features to quantify the genetic variation pattern of SARS-CoV-2 sequences.", [["SARS", "DISEASE", 134, 138], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 134, 144], ["SARS-CoV-2 sequences", "DNA", 134, 154], ["SARS-CoV", "SPECIES", 134, 142], ["CoV-2 sequences", "TEST", 139, 154]]], ["In our analysis, we select countries that have more than 100 viral sequences uploaded in order to have enough ISMs to viably generate such an abundance table.", [["viral sequences", "DNA", 61, 76], ["our analysis", "TEST", 3, 15], ["100 viral sequences", "TEST", 57, 76]]], ["The elements in the abundance table represent the abundance of an ISM in a country/region after down-sampling, where each column is an ISM.", [["an ISM", "PROBLEM", 63, 69], ["abundance", "OBSERVATION_MODIFIER", 50, 59], ["ISM", "OBSERVATION", 135, 138]]], ["We use Bray-Curtis dissimilarity [44] to quantify the dissimilarity of ISM compositions between a pair of regions and form a pairwise Bray-Curtis dissimilarity matrix.", [["matrix", "CELLULAR_COMPONENT", 160, 166]]], ["Finally, we employ PCA to reduce the dimensionality of the pairwise Bray-Curtis dissimilarity matrix, plotting the first two components to visualize the genetic variation patterns of those countries/regions.Quantification and visualization of viral subtypesTo study the progression of SARS-CoV-2 viral subtypes in the time domain, we group all sequences in a given location that were obtained no later than a certain date (as provided in the sequence metadata) together and compute the relative abundance (i.e., frequency) of corresponding subtypes.", [["SARS", "DISEASE", 285, 289], ["SARS-CoV-2", "ORGANISM", 285, 295], ["SARS-CoV", "SPECIES", 285, 293], ["PCA", "TREATMENT", 19, 22], ["Quantification", "TEST", 207, 221], ["viral subtypes", "PROBLEM", 243, 257], ["SARS", "PROBLEM", 285, 289], ["viral subtypes", "OBSERVATION", 243, 257]]], ["Eq (3) illustrates this calculation.Quantification and visualization of viral subtypeswhere ISM (s, c) (t) is the relative abundance of a subtype, s, in location, c, at a date t, N s, c (t) is the total number of instances of such subtype, s, in location, c, that has been sequenced no later than date t and N c (t) is the total number of sequences in location, c, that has been sequenced no later than date t.Comparison of ISM subtyping to phylogenetic analysisNextstrain [6] provides a phylogeny method to track and visualize the dynamic of SARS-CoV-2 sequences.", [["SARS", "DISEASE", 543, 547], ["SARS-CoV-2 sequences", "DNA", 543, 563], ["SARS-CoV", "SPECIES", 543, 551], ["this calculation", "TEST", 19, 35], ["Quantification", "TEST", 36, 50], ["viral subtypeswhere ISM", "PROBLEM", 72, 95], ["a phylogeny method", "TREATMENT", 486, 504], ["CoV-2 sequences", "TEST", 548, 563], ["viral", "OBSERVATION_MODIFIER", 72, 77]]], ["Since both the ISMs and the Nextstrain phylogenetic tree were generated based on the GISAID database, they may be easily compared.", [["ISMs", "DNA", 15, 19], ["Nextstrain phylogenetic tree", "DNA", 28, 56], ["GISAID database", "DNA", 85, 100], ["the GISAID database", "TEST", 81, 100]]], ["We present two comparisons in this paper: 1) ISM hamming distance and phylogenetic tree branch length; 2) ISM clusters defined at different entropy thresholds and Nextstrain defined \"clades\".", [["phylogenetic tree branch length", "PROBLEM", 70, 101], ["ISM clusters", "PROBLEM", 106, 118], ["different entropy thresholds", "TREATMENT", 130, 158], ["Nextstrain", "TREATMENT", 163, 173], ["tree", "OBSERVATION_MODIFIER", 83, 87], ["branch", "OBSERVATION_MODIFIER", 88, 94], ["length", "OBSERVATION_MODIFIER", 95, 101]]], ["The highest-abundance ISMs are involved with hundreds, if not thousands, of sequences.", [["ISMs", "GENE_OR_GENE_PRODUCT", 22, 26], ["ISMs", "PROTEIN", 22, 26], ["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["For a given ISM, we can find the lowest common ancestor (LCA) node in the phylogenetic tree of all sequences with that ISM.", [["LCA", "OBSERVATION_MODIFIER", 57, 60], ["node", "OBSERVATION", 62, 66], ["phylogenetic", "ANATOMY_MODIFIER", 74, 86], ["tree", "ANATOMY_MODIFIER", 87, 91]]], ["The branch length between the LCA and the root can be considered as the inferred evolutionary distance between the reference sequence and the LCA node.", [["root", "ANATOMY", 42, 46], ["LCA node", "ANATOMY", 142, 150], ["root", "ORGAN", 42, 46], ["LCA node", "MULTI-TISSUE_STRUCTURE", 142, 150], ["branch", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17], ["LCA", "ANATOMY_MODIFIER", 30, 33], ["root", "ANATOMY_MODIFIER", 42, 46], ["LCA", "OBSERVATION_MODIFIER", 142, 145], ["node", "OBSERVATION", 146, 150]]], ["Hamming distance between our ISMs measures the divergence between two clusters of sequences.", [["ISMs", "DNA", 29, 33], ["Hamming distance between our ISMs", "PROBLEM", 0, 33]]], ["We can compare branch length between the root and LCA with the Hamming distance between a given ISM and the reference ISM.", [["root", "ANATOMY", 41, 45], ["root", "TISSUE", 41, 45], ["branch", "OBSERVATION_MODIFIER", 15, 21], ["length", "OBSERVATION_MODIFIER", 22, 28], ["root", "OBSERVATION_MODIFIER", 41, 45], ["LCA", "OBSERVATION_MODIFIER", 50, 53]]], ["Then, we compute the Pearson correlation coefficient to measure the correlation between the evolutionary distance from the reference genome (inferred by the phylogenetic tree) and the Hamming distance between ISMs and the reference ISM.Comparison of ISM subtyping to phylogenetic analysisIn Nextstrain data, there are 5 \"clades\", namely, 19A, 19B, 20A, 20B and 20C, defined [25] .", [["reference genome", "DNA", 123, 139], ["ISM subtyping", "TEST", 250, 263]]], ["Since our ISMs are clusters of sequences with similar genetic variations, the Nextstrain \"clades\" provides us a good interface to study how our entropy threshold influences the ISM definition by comparing the overlaps between Nextstrain \"clades\" grouped sequences and ISM grouped sequences.", [["ISMs", "CANCER", 10, 14], ["ISMs", "DNA", 10, 14], ["ISM grouped sequences", "DNA", 268, 289], ["Nextstrain \"clades", "TREATMENT", 226, 244], ["ISM grouped sequences", "TEST", 268, 289]]], ["To measure the similarity between ISM labels and \"clade\" labels of sequences, we use two clustering metrics, homogeneity and completeness as proposed by Rosenberg et al [45] .", [["ISM labels", "DNA", 34, 44]]], ["We vary the entropy threshold to form different sets of ISM clusters of sequences and compare each set with Nextstrain \"clades\" using homogeneity and completeness.Results and discussionWe begin by identifying and mapping the sites that form an ISM for each genome based on sequence entropy.", [["ISM", "DNA", 244, 247], ["sequence entropy", "TREATMENT", 273, 289]]], ["Then, we analyze the properties of ISMs and validate the ISMs generated from SARS-CoV-2 data as of June 17, 2020.", [["the ISMs", "TEST", 53, 61], ["SARS", "TEST", 77, 81], ["CoV", "TEST", 82, 85]]], ["We present ISM abundance inflation introduced by error correction, demonstrate how ISMs evolve as a function of entropy threshold, and show how entropy values at different positions change over time.", [["ISMs", "PROTEIN", 83, 87], ["entropy threshold", "TEST", 112, 129], ["abundance inflation", "OBSERVATION", 15, 34], ["positions", "OBSERVATION_MODIFIER", 172, 181], ["change", "OBSERVATION_MODIFIER", 182, 188]]], ["Then, we show the visualization of spatiotemporal dynamics based on ISMs.", [["ISMs", "PROBLEM", 68, 72]]], ["We analyze the geographic distribution of SARS-CoV-2 genetic subtypes identified by ISMs, as well as the temporal dynamics of the subtypes.", [["SARS", "DISEASE", 42, 46], ["ISMs", "PROTEIN", 84, 88], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["geographic", "OBSERVATION_MODIFIER", 15, 25], ["distribution", "OBSERVATION_MODIFIER", 26, 38]]], ["We also visualize the viral genetic variation patterns of different regions based on their ISM subtype abundances.", [["viral genetic variation", "OBSERVATION", 22, 45]]], ["Then, we evaluate the results of ISM subtyping in comparison with current genetic variation studies of SARS-CoV-2.", [["SARS", "DISEASE", 103, 107], ["SARS-CoV-2", "ORGANISM", 103, 113], ["SARS-CoV", "SPECIES", 103, 111], ["ISM subtyping", "TEST", 33, 46], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111]]], ["Finally, we compare the ISM subtypes to viral \"clades\" that were determined by Nextstrain, in order to demonstrate how ISMs relate to evolutionary relationships predicted by phylogenetic methods.Identification and mapping of subtype markersIn this section, we briefly discuss the potential functional relevance of the identified ISM locations.", [["ISMs", "GENE_OR_GENE_PRODUCT", 119, 123], ["Nextstrain", "PROTEIN", 79, 89], ["ISMs", "PROTEIN", 119, 123], ["subtype markers", "PROTEIN", 225, 240], ["ISM locations", "DNA", 329, 342], ["viral \"clades", "PROBLEM", 40, 53], ["subtype markers", "TEST", 225, 240], ["subtype markers", "OBSERVATION", 225, 240]]], ["We further demonstrate that minimal artifacts are introduced by the error correction methodology, which indicates that ISM identification is stable with respect to the choice of entropy threshold within a reasonable range.", [["minimal artifacts", "PROBLEM", 28, 45], ["ISM identification", "TEST", 119, 137], ["entropy threshold", "PROBLEM", 178, 195], ["minimal", "OBSERVATION_MODIFIER", 28, 35], ["artifacts", "OBSERVATION", 36, 45], ["stable", "OBSERVATION_MODIFIER", 141, 147]]], ["Finally, we generate compressed ISM labels based on correlated entropy variation between ISM sites.Identification and mapping of subtype markersIdentification of ISM locations by whole genome sequence entropy analysis.", [["ISM sites", "DNA", 89, 98], ["ISM locations", "DNA", 162, 175], ["correlated entropy variation between ISM sites", "PROBLEM", 52, 98], ["subtype markers", "TEST", 129, 144], ["whole genome sequence entropy analysis", "TEST", 179, 217]]], ["The first step in the ISM subtyping pipeline is the determination of the entropy at each nucleotide position in the SARS-CoV-2 genome in order to identify the sites that will make up the ISM.", [["nucleotide", "CHEMICAL", 89, 99], ["nucleotide", "CHEMICAL", 89, 99], ["SARS-CoV-2 genome", "DNA", 116, 133], ["SARS-CoV", "SPECIES", 116, 124], ["the entropy", "PROBLEM", 69, 80], ["the SARS", "TEST", 112, 120], ["CoV-2 genome", "TREATMENT", 121, 133]]], ["Entropy is used to quantify the variation at different positions for sequence alignment result.", [["sequence alignment result", "TEST", 69, 94]]], ["For a given position with high entropy value, there are more than 1 nucleotides showing up frequently at this position across all the aligned sequences.", [["nucleotides", "CHEMICAL", 68, 79], ["aligned sequences", "DNA", 134, 151], ["high entropy value", "PROBLEM", 26, 44]]], ["On the other hand, if the entropy value is low at a position, it implies that this position is more conserved across all aligned sequences.", [["the entropy value", "TEST", 22, 39]]], ["Fig 1 shows the overall entropy at each nucleotide position, determined based on calculating the masked entropy for all sequences as described in the Methods section.", [["nucleotide", "CHEMICAL", 40, 50], ["overall", "OBSERVATION_MODIFIER", 16, 23], ["entropy", "OBSERVATION", 24, 31]]], ["Notably, at the beginning and end of the sequence, there is a high level of uncertainty.", [["high", "OBSERVATION_MODIFIER", 62, 66]]], ["This is because there are more N and -symbols, representing ambiguity and gaps, in these two regions (gaps are likely a result of artifacts in MAFFT's alignment of the viruses or its genomic rearrangement [21] , and both ambiguous base-calls (N's) and gaps (-'s) may result due to the difficulty of accurately sequencing the genome at the ends).", [["ambiguity and gaps", "PROBLEM", 60, 78], ["artifacts in MAFFT's alignment", "PROBLEM", 130, 160], ["the viruses", "PROBLEM", 164, 175], ["gaps", "TEST", 252, 256], ["ambiguity", "OBSERVATION_MODIFIER", 60, 69], ["gaps", "OBSERVATION_MODIFIER", 74, 78], ["likely a result of", "UNCERTAINTY", 111, 129], ["artifacts", "OBSERVATION", 130, 139], ["viruses", "OBSERVATION", 168, 175]]], ["After applying filtering to remove low entropy positions and uncertain positions, we identified 20 informative nucleotide positions in the sequence to generate informative subtype markers (see filtering details in Methods section).Identification and mapping of subtype markersImportantly, even though the combinatorial space for ISM is potentially very large due to the substantial number of characters that may present at any one nucleotide position, only certain ISMs occur in substantial quantities in the overall sequence population.", [["nucleotide", "CHEMICAL", 111, 121], ["nucleotide", "CHEMICAL", 111, 121], ["nucleotide", "CHEMICAL", 431, 441], ["ISMs", "GENE_OR_GENE_PRODUCT", 465, 469], ["subtype markers", "PROTEIN", 261, 276], ["ISMs", "PROTEIN", 465, 469], ["low entropy positions", "TREATMENT", 35, 56], ["subtype markers", "TEST", 261, 276], ["certain ISMs", "PROBLEM", 457, 469], ["subtype markers", "OBSERVATION", 261, 276], ["large", "OBSERVATION", 353, 358], ["substantial", "OBSERVATION_MODIFIER", 370, 381], ["number", "OBSERVATION_MODIFIER", 382, 388], ["position", "OBSERVATION_MODIFIER", 442, 450], ["substantial", "OBSERVATION_MODIFIER", 479, 490], ["quantities", "OBSERVATION_MODIFIER", 491, 501]]], ["In particular, the plot shows that the first three ISMs represent subtypes that have more than 4000 sequences worldwide.Identification and mapping of subtype markersSome potential reasons for the rapid drop off in the frequency relative to the diversity of ISMs may include the following: First, since the virus is transmitting and expanding so quickly, and the pandemic is still at a relatively early stage, there has not been enough time for mutations that would affect the ISM to occur and take root.", [["root", "ANATOMY", 498, 502], ["ISMs", "GENE_OR_GENE_PRODUCT", 51, 55], ["ISMs", "DNA", 51, 55], ["subtype markers", "PROTEIN", 150, 165], ["the plot", "TEST", 15, 23], ["subtype markers", "TEST", 150, 165], ["the rapid drop", "PROBLEM", 192, 206], ["the virus", "PROBLEM", 302, 311], ["mutations", "PROBLEM", 444, 453], ["subtypes", "OBSERVATION", 66, 74], ["subtype markers", "OBSERVATION", 150, 165], ["rapid", "OBSERVATION_MODIFIER", 196, 201], ["drop", "OBSERVATION", 202, 206], ["virus", "OBSERVATION", 306, 311]]], ["In that case, we would expect the number of significant ISMs to rise over time.", [["significant ISMs", "PROBLEM", 44, 60], ["significant", "OBSERVATION_MODIFIER", 44, 55]]], ["Second, the population of publicly available sequences is biased to projects in which multiple patients in a cluster are sequenced at once: e.g., a group of travelers, a family group, or a group linked to a single spreading event (there are sequences from cruise vessels in the database).", [["vessels", "ANATOMY", 263, 270], ["patients", "ORGANISM", 95, 103], ["cruise vessels", "MULTI-TISSUE_STRUCTURE", 256, 270], ["patients", "SPECIES", 95, 103], ["multiple", "OBSERVATION_MODIFIER", 86, 94]]], ["Third, ISMs may be constrained by the fact that certain mutations may result in a phenotypic change that may be selected against.", [["certain mutations", "PROBLEM", 48, 65], ["a phenotypic change", "PROBLEM", 80, 99], ["may be", "UNCERTAINTY", 12, 18]]], ["In this case, we may expect a steep change in a particular ISM or close relative in the event that there is selection pressure in favor of the corresponding variant phenotype.", [["a steep change", "PROBLEM", 28, 42], ["selection pressure", "TEST", 108, 126], ["the corresponding variant phenotype", "PROBLEM", 139, 174], ["pressure", "OBSERVATION_MODIFIER", 118, 126], ["variant phenotype", "OBSERVATION", 157, 174]]], ["However, as of yet there has been no solid evidence of mutations within SARS-CoV-2 that are associated with selection pressure, i.e., as being more transmissible or evading antibodies, though studies do suggest the possibility [19, 46, 47] .", [["SARS", "DISEASE", 72, 76], ["SARS-CoV-2", "ORGANISM", 72, 82], ["antibodies", "PROTEIN", 173, 183], ["SARS-CoV", "SPECIES", 72, 80], ["mutations within SARS", "PROBLEM", 55, 76], ["selection pressure", "TEST", 108, 126], ["studies", "TEST", 192, 199], ["no solid evidence of", "UNCERTAINTY", 34, 54], ["mutations", "OBSERVATION", 55, 64], ["selection pressure", "OBSERVATION", 108, 126]]], ["Fig 2 also shows that despite the application of the error correction method detailed in the Methods section, some symbols representing ambiguously identified nucleotides, such as S and D still remain in the ISMs.", [["nucleotides", "CHEMICAL", 159, 170], ["ISMs", "CANCER", 208, 212], ["the error correction method", "TREATMENT", 49, 76], ["the Methods section", "TREATMENT", 89, 108], ["ambiguously identified nucleotides", "PROBLEM", 136, 170]]], ["These represent instances in which there was insufficient sequence information to fully resolve ambiguities.", [["instances", "OBSERVATION", 16, 25]]], ["That said, it is possible that the ambiguity symbols in the ISMs reflect genomic regions or sites that are difficult to resolve using sequencing methods, in which case the ISMs will never fully resolve.", [["ISMs", "CANCER", 60, 64], ["ISMs", "CANCER", 172, 176], ["ISMs", "DNA", 60, 64], ["genomic regions", "DNA", 73, 88], ["the ambiguity symbols", "PROBLEM", 31, 52], ["genomic regions", "PROBLEM", 73, 88], ["sequencing methods", "TEST", 134, 152], ["ambiguity symbols", "OBSERVATION", 35, 52], ["genomic regions", "OBSERVATION", 73, 88]]], ["Importantly, however, because of the application of the error correction algorithm, there are fewer spurious subtypes which are defined due to variants arising from sequencing errors, and all remaining ISMs are still usable as subtype identifiers.Identification and mapping of subtype markersPotential functional significance of ISM locations.", [["ISMs", "CANCER", 202, 206], ["subtype markers", "PROTEIN", 277, 292], ["ISM", "PROTEIN", 329, 332], ["the error correction algorithm", "TEST", 52, 82], ["fewer spurious subtypes", "PROBLEM", 94, 117], ["sequencing errors", "TEST", 165, 182], ["subtype markers", "TEST", 277, 292], ["fewer", "OBSERVATION_MODIFIER", 94, 99], ["spurious subtypes", "OBSERVATION", 100, 117], ["subtype markers", "OBSERVATION", 277, 292]]], ["After the informative nucleotide positions were identified, we then mapped those sites back to the annotated reference sequence for functional interpretation [13] .", [["nucleotide", "CHEMICAL", 22, 32], ["nucleotide", "CHEMICAL", 22, 32]]], ["As a practical matter, because the ISM is made up of the high-diversity sites within the SARS-CoV-2 genome, it inherently includes the major loci of genetic changes that are being identified in population studies worldwide.", [["SARS", "DISEASE", 89, 93], ["ISM", "DNA", 35, 38], ["SARS-CoV-2 genome", "DNA", 89, 106], ["SARS-CoV", "SPECIES", 89, 97], ["the SARS", "PROBLEM", 85, 93], ["high", "OBSERVATION_MODIFIER", 57, 61], ["SARS", "OBSERVATION", 89, 93], ["major", "OBSERVATION_MODIFIER", 135, 140], ["loci", "OBSERVATION_MODIFIER", 141, 145], ["genetic", "OBSERVATION", 149, 156]]], ["The ISM also PLOS COMPUTATIONAL BIOLOGY excludes sites at the ends of the genome in which variation is most likely to be the result of sequencing artifacts.", [["ISM", "DNA", 4, 7], ["PLOS", "DNA", 13, 17], ["BIOLOGY", "DNA", 32, 39], ["sequencing artifacts", "PROBLEM", 135, 155], ["genome", "OBSERVATION", 74, 80], ["most likely to be", "UNCERTAINTY", 103, 120], ["artifacts", "OBSERVATION", 146, 155]]], ["As shown in Table 1 , we found that all but one of the nucleotide positions that we identified were located in coding regions of the reference sequence.", [["nucleotide", "CHEMICAL", 55, 65], ["coding regions", "DNA", 111, 125], ["reference sequence", "DNA", 133, 151]]], ["The majority of the remaining sites (12/19) were found in the ORF1ab polyprotein, which encodes a polyprotein replicase complex that is cleaved to form nonstructural proteins that are used as RNA polymerase (i.e., synthesis) machinery [48] .", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 62, 68], ["ORF1ab polyprotein", "DNA", 62, 80], ["polyprotein replicase complex", "PROTEIN", 98, 127], ["nonstructural proteins", "PROTEIN", 152, 174], ["RNA polymerase", "PROTEIN", 192, 206], ["the ORF1ab polyprotein", "PROBLEM", 58, 80], ["a polyprotein replicase complex", "PROBLEM", 96, 127], ["nonstructural proteins", "PROBLEM", 152, 174], ["RNA polymerase", "TEST", 192, 206], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["One site is located in the reading frame encoding the S surface glycoprotein, which is responsible for viral entry and antigenicity, and thus represents an important target for understanding the immune response, identifying antiviral therapeutics, and vaccine design [49, 50] .", [["reading frame", "DNA", 27, 40], ["S surface glycoprotein", "PROTEIN", 54, 76], ["One site", "PROBLEM", 0, 8], ["viral entry", "PROBLEM", 103, 114], ["antiviral therapeutics", "TREATMENT", 224, 246], ["responsible for", "UNCERTAINTY", 87, 102], ["viral entry", "OBSERVATION", 103, 114]]], ["High-entropy nucleotide positions were also found in the nucleocapsid formation protein, which is important for packaging the viral RNA [51] .", [["nucleotide", "CHEMICAL", 13, 23], ["nucleotide", "CHEMICAL", 13, 23], ["nucleocapsid", "CELLULAR_COMPONENT", 57, 69], ["nucleocapsid formation protein", "PROTEIN", 57, 87], ["viral RNA", "RNA", 126, 135], ["High-entropy nucleotide positions", "TREATMENT", 0, 33], ["the nucleocapsid formation protein", "PROBLEM", 53, 87], ["viral RNA", "OBSERVATION", 126, 135]]], ["A study has also shown that, like the spike protein, the internal nucleoprotein of the virus is significant in modulating the antibody response [52] .", [["spike protein", "PROTEIN", 38, 51], ["internal nucleoprotein", "PROTEIN", 57, 79], ["A study", "TEST", 0, 7], ["the spike protein", "PROBLEM", 34, 51], ["the internal nucleoprotein of the virus", "PROBLEM", 53, 92]]], ["Other sites were found in the ORF3a and ORF8, which, based on structural homology analysis do not have known functional domains or motifs, and have diverged substantially from other SARS-related variants which contained domains linked to increased inflammatory responses [53, 54] .Identification and mapping of subtype markersIn sum, the majority of high-entropy sites are in regions of the genome that may be significant for disease progression, as well as the design of vaccines and therapeutics.", [["SARS", "DISEASE", 182, 186], ["ORF3a", "GENE_OR_GENE_PRODUCT", 30, 35], ["ORF8", "GENE_OR_GENE_PRODUCT", 40, 44], ["genome", "CELLULAR_COMPONENT", 391, 397], ["ORF3a", "DNA", 30, 35], ["ORF8", "DNA", 40, 44], ["subtype markers", "PROTEIN", 311, 326], ["structural homology analysis", "TEST", 62, 90], ["known functional domains or motifs", "PROBLEM", 103, 137], ["other SARS-related variants", "PROBLEM", 176, 203], ["increased inflammatory responses", "PROBLEM", 238, 270], ["subtype markers", "TEST", 311, 326], ["high-entropy sites", "PROBLEM", 350, 368], ["disease progression", "PROBLEM", 426, 445], ["vaccines", "TREATMENT", 472, 480], ["therapeutics", "TREATMENT", 485, 497], ["increased", "OBSERVATION_MODIFIER", 238, 247], ["inflammatory", "OBSERVATION_MODIFIER", 248, 260], ["subtype markers", "OBSERVATION", 311, 326], ["majority", "OBSERVATION_MODIFIER", 338, 346], ["high", "OBSERVATION_MODIFIER", 350, 354], ["entropy sites", "OBSERVATION", 355, 368], ["genome", "OBSERVATION", 391, 397], ["may be significant", "UNCERTAINTY", 403, 421]]], ["Accordingly, ISMs derived from the corresponding nucleotide positions can be used for viral subtyping for clinical applications, such as identifying variants with different therapeutic responses or patient outcomes, or for tracking variation that may reduce the effectiveness of potential vaccine candidates.", [["nucleotide", "CHEMICAL", 49, 59], ["nucleotide", "CHEMICAL", 49, 59], ["patient", "ORGANISM", 198, 205], ["ISMs", "PROTEIN", 13, 17], ["patient", "SPECIES", 198, 205], ["ISMs", "PROBLEM", 13, 17], ["viral subtyping", "TEST", 86, 101], ["tracking variation", "PROBLEM", 223, 241], ["potential vaccine candidates", "TREATMENT", 279, 307]]], ["Unlike phylogenetic clusters, the ISM includes information about the single nucleotide variation (SNV) directly in the nomenclature.", [["ISM", "DNA", 34, 37], ["phylogenetic clusters", "OBSERVATION", 7, 28]]], ["The subtypes which are identified are not a function of a selected clustering algorithm or a feature that has been selected as being relevant to a cluster.PLOS COMPUTATIONAL BIOLOGYEvaluating artifacts in ISM abundance due to error correction.", [["a selected clustering algorithm", "PROBLEM", 56, 87], ["error correction", "TREATMENT", 226, 242], ["subtypes", "OBSERVATION_MODIFIER", 4, 12]]], ["Even though the SARS-CoV-2 data set appears to be large, it represents only a small sample of the full scope of cases.", [["SARS-CoV-2 data", "DNA", 16, 31], ["the SARS", "TEST", 12, 20], ["large", "OBSERVATION", 50, 55], ["small", "OBSERVATION_MODIFIER", 78, 83]]], ["Therefore, tracking the pandemic requires using as much global data as possible, which means that imperfect sequence data must be tolerated to avoid losing potentially relevant samples.", [["samples", "ANATOMY", 177, 184], ["samples", "CANCER", 177, 184], ["imperfect sequence data", "TEST", 98, 121]]], ["However, error correction will only be useful if it can maintain the integrity of the data, in particular, permit accurate identification of viral subtype abundance.", [["viral subtype", "OBSERVATION", 141, 154]]], ["In our case, we expect and do observe that the abundance of non-ambiguous ISMs will be inflated sightly by the error correction process.", [["ISMs", "GENE_OR_GENE_PRODUCT", 74, 78], ["non-ambiguous ISMs", "PROBLEM", 60, 78]]], ["S2 File shows the inflation rate of highest-abundance ISMs after error correction.PLOS COMPUTATIONAL BIOLOGYWe can see from S2 File that the error correction process only inflates the frequency of the highest-abundance ISMs in our database by less than 10%.", [["the inflation rate", "TEST", 14, 32], ["error correction", "TREATMENT", 65, 81], ["the error correction process", "PROBLEM", 137, 165], ["inflation", "OBSERVATION", 18, 27], ["highest", "OBSERVATION_MODIFIER", 36, 43]]], ["To demonstrate that the error correction is a conservative process, we further show an ISM, CCACCCGCCCACAAGGTGGG, which is inflated by 10.79% as a case study.", [["a case study", "TEST", 145, 157]]], ["Half of the inflation arises due to sequences with ISM CCACCCGCCCACNAGGTGGG with 1.0 hamming distance away from the corrected ISM (there is an N instead of an A at position 13 in the ISM).", [["the inflation", "TREATMENT", 8, 21], ["ISM CCACCCGCCCACNAGGTGGG", "TREATMENT", 51, 75], ["inflation", "OBSERVATION", 12, 21]]], ["Our error correction process corrects that N to A because all non-ambiguous ISMs with the same nucleotide configuration except for position 13 (non-ambiguous ISMs have an A at position 13 instead of N).", [["nucleotide", "CHEMICAL", 95, 105], ["nucleotide", "CHEMICAL", 95, 105], ["ISMs", "CANCER", 76, 80], ["non-ambiguous ISMs", "PROTEIN", 62, 80], ["position 13", "PROTEIN", 131, 142], ["non-ambiguous ISMs", "PROTEIN", 144, 162], ["position 13", "PROTEIN", 176, 187], ["all non-ambiguous ISMs", "PROBLEM", 58, 80]]], ["Accordingly, ISM abundance inflation due to error correction will be generally conservative, and will not confound population-level analyses of ISM subtypes based on their relative abundance.PLOS COMPUTATIONAL BIOLOGYSensitivity of ISM labels to the selection of the entropy threshold.", [["ISM abundance inflation", "PROBLEM", 13, 36], ["error correction", "PROBLEM", 44, 60], ["ISM subtypes", "PROBLEM", 144, 156]]], ["To demonstrate the influence of the entropy threshold on ISM identification, we show a Sankey diagram in The diagram tracks ISM identification according to sequences grouped by respective ISMs.", [["ISM identification", "TEST", 57, 75], ["a Sankey diagram", "PROBLEM", 85, 101]]], ["For example, ISMs defined at a higher entropy threshold each likely identify more sequences (i.e. more sequences will likely have the same given ISM).", [["ISMs", "PROBLEM", 13, 17]]], ["Correspondingly, there will be an increased number of ISMs which are more refined (each identifying smaller collections of sequences), at a lower entropy threshold.", [["an increased number of ISMs", "PROBLEM", 31, 58], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["number", "OBSERVATION_MODIFIER", 44, 50], ["more refined", "OBSERVATION_MODIFIER", 69, 81], ["smaller", "OBSERVATION_MODIFIER", 100, 107]]], ["The width of the stripe corresponds to the number of sequences with that ISM.PLOS COMPUTATIONAL BIOLOGYThe Sankey diagram further shows that ISMs defined at a lower entropy threshold can \"merge\" together as the entropy threshold moves higher.", [["ISM", "PROTEIN", 73, 76], ["ISMs", "PROTEIN", 141, 145], ["ISMs", "PROBLEM", 141, 145], ["width", "OBSERVATION_MODIFIER", 4, 9], ["stripe", "OBSERVATION_MODIFIER", 17, 23]]], ["For example, TCTTGGGGG and TCTTGTGGG are two different ISMs if we choose 0.6 as the entropy threshold.", [["TCTTGGGGG", "TREATMENT", 13, 22], ["the entropy threshold", "TEST", 80, 101]]], ["They can be differentiated by the 6th position (a G/T variation).", [["a G/T variation", "TREATMENT", 48, 63]]], ["As a result, the two ISMs are merged into TTTGGGG.", [["ISMs", "GENE_OR_GENE_PRODUCT", 21, 25], ["TTTGGGG", "GENE_OR_GENE_PRODUCT", 42, 49], ["ISMs", "PROTEIN", 21, 25], ["TTTGGGG", "PROTEIN", 42, 49]]], ["Some ISMs are stably identified throughout, while other ISMs merge together at different entropy thresholds.", [["ISMs", "GENE_OR_GENE_PRODUCT", 56, 60], ["ISMs", "PROTEIN", 5, 9], ["Some ISMs", "PROBLEM", 0, 9], ["stably", "OBSERVATION_MODIFIER", 14, 20]]], ["We can see from Fig 3 that the entropy threshold acts as a way to tune the resolution of subtype definition.", [["the entropy threshold acts", "TREATMENT", 27, 53], ["subtype definition", "OBSERVATION", 89, 107]]], ["When choosing a high entropy, positions that can differentiate relatively smaller (less abundant) subtypes are ignored.", [["a high entropy", "PROBLEM", 14, 28], ["high entropy", "OBSERVATION_MODIFIER", 16, 28], ["relatively", "OBSERVATION_MODIFIER", 63, 73], ["smaller", "OBSERVATION_MODIFIER", 74, 81]]], ["On the other hand, setting the entropy threshold lower reveals more ISM subtypes.", [["the entropy threshold", "TEST", 27, 48], ["more ISM", "OBSERVATION_MODIFIER", 63, 71]]], ["For example, TCACTCGTCCACAGGGTAAC is defined at 0.23 threshold and when set to 0.1 threshold, 5 additional less-abundant ISMs emerge.", [["ISMs", "CANCER", 121, 125], ["TCACTCGTCCACAGGGTAAC", "TEST", 13, 33]]], ["We can thus observe, based on the diagram, that some subtypes are more \"stable\" markers than others.", [["stable", "OBSERVATION_MODIFIER", 72, 78]]], ["However, there are also some ISMs that are not sensitive to the selection of entropy threshold.", [["some ISMs", "PROBLEM", 24, 33], ["entropy threshold", "TEST", 77, 94], ["some", "OBSERVATION_MODIFIER", 24, 28], ["ISMs", "OBSERVATION", 29, 33]]], ["For example, the subtype labeled as TTACTCGTCCACAGTGTGGG (particularly found in genetic sequences from New York state and some European countries, as discussed below) does not merge with other highabundance ISMs until the entropy threshold is set to 0.7.", [["TTACTCGTCCACAGTGTGGG", "GENE_OR_GENE_PRODUCT", 36, 56], ["the entropy threshold", "TEST", 218, 239]]], ["Therefore, this ISM may be considered to be a stable marker.", [["stable", "OBSERVATION_MODIFIER", 46, 52], ["marker", "OBSERVATION", 53, 59]]], ["Overall, the most abundant ISMs are generally stable for an entropy threshold between 0.", [["ISMs", "CANCER", 27, 31], ["an entropy threshold", "TEST", 57, 77], ["abundant", "OBSERVATION_MODIFIER", 18, 26], ["ISMs", "OBSERVATION", 27, 31], ["stable", "OBSERVATION_MODIFIER", 46, 52]]], ["23 That is, given a nucleotide position in the reference genome and the number of weeks since December 24, 2019, we compute the entropy of that position using all sequences collected by that time.PLOS COMPUTATIONAL BIOLOGYWe can see that at the earliest stages of the pandemic, the ISM positions corresponding to nucleotide positions 8782 and 28144 in the reference sequence had the highest entropy, i.e., high variation in these two positions were found in sequences collected by Early February.", [["nucleotide", "CHEMICAL", 20, 30], ["nucleotide", "CHEMICAL", 313, 323], ["nucleotide", "CHEMICAL", 20, 30], ["nucleotide", "CHEMICAL", 313, 323], ["reference genome", "DNA", 47, 63], ["ISM positions", "DNA", 282, 295], ["all sequences", "TEST", 159, 172], ["nucleotide positions", "TEST", 313, 333], ["high variation", "PROBLEM", 406, 420], ["high variation", "OBSERVATION", 406, 420]]], ["Subsequently, the entropy values of these two positions drop.", [["the entropy values", "TEST", 14, 32], ["two", "OBSERVATION_MODIFIER", 42, 45], ["positions", "OBSERVATION_MODIFIER", 46, 55], ["drop", "OBSERVATION_MODIFIER", 56, 60]]], ["Notably, Fig 4 shows how the highly varying spike protein mutation at position 23403 (the A to G spike protein mutation, which has been found to be abundant in Europe and US and has since spread around the world [46] , evidently became prevalent in the middle stage (in early March).", [["G spike protein", "GENE_OR_GENE_PRODUCT", 95, 110], ["Fig", "TEST", 9, 12], ["the highly varying spike protein mutation", "PROBLEM", 25, 66], ["the A to G spike protein mutation", "PROBLEM", 86, 119], ["abundant", "OBSERVATION_MODIFIER", 148, 156], ["middle stage", "OBSERVATION_MODIFIER", 253, 265]]], ["In addition, we observe that there are some ISM positions which appear to covary, as indicated by the correlation between the changes in their entropy values.", [["some ISM positions", "PROBLEM", 39, 57], ["some", "OBSERVATION_MODIFIER", 39, 43], ["ISM", "OBSERVATION", 44, 47]]], ["For example, the entropy of positions 8782PLOS COMPUTATIONAL BIOLOGYand 28144 covary, which is consistent with the correlation of the SNVs at these positions in genome sequence data available early on in the pandemic (i.e., before February 2020) [12] .PLOS COMPUTATIONAL BIOLOGYCorrelated/Covarying positions allow compression of the ISM representation.", [["the SNVs", "PROBLEM", 130, 138], ["genome sequence data", "TEST", 161, 181], ["the ISM representation", "TREATMENT", 330, 352], ["consistent with", "UNCERTAINTY", 95, 110]]], ["As indicated by Fig 4, the number of sites with sufficient entropy to be included in the ISM increases over time, as genetic changes occur and accumulate.", [["ISM", "PROTEIN", 89, 92], ["entropy", "OBSERVATION", 59, 66]]], ["This means that a representative ISM is a 20-base long identifier as of June 2020, which is unwieldy as a subtype identifier.", [["ISM", "DNA", 33, 36], ["20-base long identifier", "DNA", 42, 65]]], ["Moreover, as shown in Fig 4, there are nucleotide sites with entropy covarying over time, representing correlations in genetic changes which result in redundancy in the ISM.", [["nucleotide", "CHEMICAL", 39, 49], ["nucleotide", "CHEMICAL", 39, 49], ["nucleotide sites", "PROBLEM", 39, 55], ["entropy covarying", "PROBLEM", 61, 78], ["redundancy in the ISM", "PROBLEM", 151, 172], ["nucleotide sites", "OBSERVATION", 39, 55], ["entropy covarying", "OBSERVATION", 61, 78], ["redundancy", "OBSERVATION", 151, 161]]], ["Therefore, we may select a subset of positions to represent all the covarying positions to reduce the size of our ISMs.", [["ISMs", "CANCER", 114, 118], ["our ISMs", "PROBLEM", 110, 118], ["size", "OBSERVATION_MODIFIER", 102, 106]]], ["Table 2 shows the most abundant nucleotide configurations at certain covarying positions and how many variations can be preserved after compression.", [["nucleotide", "CHEMICAL", 32, 42], ["nucleotide", "CHEMICAL", 32, 42], ["compression", "PROBLEM", 136, 147], ["most abundant", "OBSERVATION_MODIFIER", 18, 31], ["nucleotide configurations", "OBSERVATION", 32, 57], ["compression", "OBSERVATION", 136, 147]]], ["The most abundant nucleotidePLOS COMPUTATIONAL BIOLOGYconfigurations cover at least 96% of the sequences for each covarying group (the third column in Table 2 ).", [["nucleotidePLOS", "DNA", 18, 32], ["the sequences", "TEST", 91, 104], ["most", "OBSERVATION_MODIFIER", 4, 8], ["abundant", "OBSERVATION_MODIFIER", 9, 17]]], ["We further validate the groups of covarying nucleotide sites identified by the temporal entropy curve in Fig 4 by Linkage Disequilibrium (LD) analysis, which measures the degree of nonrandom association between two loci on a genome [55] .", [["nucleotide", "CHEMICAL", 44, 54], ["nucleotide", "CHEMICAL", 44, 54], ["covarying nucleotide sites", "DNA", 34, 60], ["covarying nucleotide sites", "PROBLEM", 34, 60], ["the temporal entropy curve", "TEST", 75, 101], ["Linkage Disequilibrium (LD) analysis", "TEST", 114, 150], ["nonrandom", "OBSERVATION", 181, 190]]], ["The results, included as S3 File, show that the sites within each covarying group have significant linkage with high pairwise r 2 values (generally greater than 0.95).", [["significant linkage", "PROBLEM", 87, 106], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["linkage", "OBSERVATION", 99, 106], ["high", "OBSERVATION_MODIFIER", 112, 116]]], ["Linkage disequilibrium is a measure of the degree of nonrandom association between two loci [55] .", [["Linkage disequilibrium", "PROBLEM", 0, 22], ["disequilibrium", "OBSERVATION", 8, 22]]], ["This is in line with previous studies of LD on SARS-CoV-2 [12, 56, 57] , which found, e.g., that positions 8782 and 28144 showed high significant linkage, with an r 2 value of 0.954 [12] .", [["SARS", "DISEASE", 47, 51], ["SARS-CoV", "SPECIES", 47, 55], ["previous studies", "TEST", 21, 37], ["SARS", "TEST", 47, 51], ["CoV", "TEST", 52, 55], ["high significant linkage", "PROBLEM", 129, 153], ["high", "OBSERVATION_MODIFIER", 129, 133], ["significant", "OBSERVATION_MODIFIER", 134, 145], ["linkage", "OBSERVATION", 146, 153]]], ["We then select the representative positions with the highest entropy within each covarying group that can cover all of the most abundant nucleotide configurations.", [["nucleotide", "CHEMICAL", 137, 147], ["nucleotide", "CHEMICAL", 137, 147], ["representative", "OBSERVATION_MODIFIER", 19, 33], ["positions", "OBSERVATION_MODIFIER", 34, 43], ["highest", "OBSERVATION_MODIFIER", 53, 60], ["entropy", "OBSERVATION", 61, 68], ["nucleotide configurations", "OBSERVATION", 137, 162]]], ["Compression reduces the ISM length from 20 to 11 nucleotides.", [["nucleotides", "CHEMICAL", 49, 60], ["ISM length", "DNA", 24, 34], ["Compression", "TREATMENT", 0, 11], ["the ISM length", "TEST", 20, 34], ["reduces", "OBSERVATION_MODIFIER", 12, 19], ["ISM", "OBSERVATION_MODIFIER", 24, 27], ["length", "OBSERVATION_MODIFIER", 28, 34], ["20 to 11 nucleotides", "OBSERVATION_MODIFIER", 40, 60]]], ["Table 3 shows the mapping between the original 20-NT ISM and 11-NT compressed ISM for ISMs associated with more than 100 sequences in the database.", [["the mapping", "TEST", 14, 25], ["NT compressed ISM", "PROBLEM", 64, 81], ["ISMs", "PROBLEM", 86, 90]]], ["From the table we can see that most of the abundant 20-NT ISMs are assigned to unique 11-NT compressed ISMs.", [["ISMs", "PATHOLOGICAL_FORMATION", 103, 107], ["NT compressed ISMs", "PROBLEM", 89, 107]]], ["However, there are three 11-NT compressed ISMs that correspond to multiple 20-NT ISMs.", [["ISMs", "CANCER", 42, 46], ["three 11-NT compressed ISMs", "PROBLEM", 19, 46], ["multiple 20-NT ISMs", "PROBLEM", 66, 85], ["multiple", "OBSERVATION_MODIFIER", 66, 74]]], ["For example, 20-NT ISM TCACTCGTCCACAGGGTAAC (10,565 sequences) and TCRCTCGTCCA CAGGGTAAC (112 sequences) are merged to CCCGCCAGGGA after compression.", [["TCRCTCGTCCA CAGGGTAAC", "GENE_OR_GENE_PRODUCT", 67, 88], ["CCCGCCAGGGA", "GENE_OR_GENE_PRODUCT", 119, 130], ["10,565 sequences", "DNA", 45, 61], ["TCRCTCGTCCA CAGGGTAAC", "DNA", 67, 88], ["CCCGCCAGGGA", "DNA", 119, 130], ["example", "TEST", 4, 11], ["compression", "TEST", 137, 148], ["compression", "OBSERVATION", 137, 148]]], ["These two subtypes are differentiated by position 3 in the long ISM (A/R).", [["two", "OBSERVATION_MODIFIER", 6, 9], ["subtypes", "OBSERVATION_MODIFIER", 10, 18], ["differentiated", "OBSERVATION_MODIFIER", 23, 37], ["position", "OBSERVATION_MODIFIER", 41, 49], ["long ISM", "OBSERVATION_MODIFIER", 59, 67]]], ["As such, defining subtypes based on compressed ISM will result in the inflation of a few principal subtypes by an amountPLOS COMPUTATIONAL BIOLOGYof around 1%.", [["compressed ISM", "PROBLEM", 36, 50], ["few", "OBSERVATION_MODIFIER", 85, 88], ["principal", "OBSERVATION_MODIFIER", 89, 98], ["amount", "OBSERVATION_MODIFIER", 114, 120]]], ["Compressed ISM subtypes, therefore, conserve the distribution of major ISM subtypes.", [["Compressed ISM subtypes", "PROBLEM", 0, 23], ["major ISM subtypes", "PROBLEM", 65, 83], ["ISM subtypes", "OBSERVATION", 11, 23], ["distribution", "OBSERVATION_MODIFIER", 49, 61], ["major", "OBSERVATION_MODIFIER", 65, 70], ["ISM subtypes", "OBSERVATION", 71, 83]]], ["A more compact and easy-to-use subtype nomenclature may thus be utilized to quantitatively assess the relative subtype abundance at the population level.Geographic distribution of SARS-CoV-2 subtypesTo demonstrate that ISM subtypes can be used to analyze and visualize the spread of the SARS-CoV-2 pandemic, we describe the geographic distribution of the relative abundance of subtypes in different countries/regions worldwide, as well as in different states within the United States.", [["SARS", "DISEASE", 180, 184], ["SARS", "DISEASE", 287, 291], ["SARS-CoV-2", "ORGANISM", 180, 190], ["SARS-CoV-2", "ORGANISM", 287, 297], ["CoV-2 pandemic", "SPECIES", 292, 306], ["SARS-CoV", "SPECIES", 180, 188], ["SARS-CoV-2 pandemic", "SPECIES", 287, 306], ["SARS", "PROBLEM", 180, 184], ["ISM subtypes", "PROBLEM", 219, 231], ["the SARS", "TEST", 283, 291], ["pandemic", "PROBLEM", 298, 306], ["SARS", "OBSERVATION", 180, 184], ["geographic", "OBSERVATION_MODIFIER", 324, 334], ["distribution", "OBSERVATION_MODIFIER", 335, 347], ["abundance", "OBSERVATION_MODIFIER", 364, 373], ["subtypes", "OBSERVATION_MODIFIER", 377, 385]]], ["Not only does this provide an illustration of the method's capabilities, but it also permits comparison of the subtyping analysis with theories regarding viral spread between regions.", [["the subtyping analysis", "TEST", 107, 129], ["viral spread between regions", "PROBLEM", 154, 182]]], ["Fig 5 shows the distribution of ISMs, each indicating a different subtype, in the regions with the relatively larger amount of available sequenced genomes.", [["ISMs", "GENE_OR_GENE_PRODUCT", 32, 36], ["ISMs", "PROTEIN", 32, 36], ["ISMs", "PROBLEM", 32, 36], ["distribution", "OBSERVATION_MODIFIER", 16, 28], ["ISMs", "OBSERVATION", 32, 36], ["different", "OBSERVATION_MODIFIER", 56, 65], ["subtype", "OBSERVATION_MODIFIER", 66, 73], ["regions", "ANATOMY_MODIFIER", 82, 89], ["relatively", "OBSERVATION_MODIFIER", 99, 109], ["larger", "OBSERVATION_MODIFIER", 110, 116], ["amount", "OBSERVATION_MODIFIER", 117, 123], ["sequenced genomes", "OBSERVATION", 137, 154]]], ["As shown therein, the ISMs are able to successfully identify and label viral subtypes that produce distinct patterns of distribution in different countries/regions.", [["ISMs", "PATHOLOGICAL_FORMATION", 22, 26], ["label viral subtypes", "PROBLEM", 65, 85], ["viral subtypes", "OBSERVATION", 71, 85], ["distinct", "OBSERVATION_MODIFIER", 99, 107], ["distribution", "OBSERVATION_MODIFIER", 120, 132]]], ["Beginning with Mainland China, the source of SARS-CoV-2 reference genome [13, 58] (NCBI Accession number: NC_045512.2), we observe two dominant subtypes, as indicated by relative abundance of the ISM among available sequences: CCCGCCAAGGG (as indicated on the plot, first seen on December 24, 2019, in sequences from Mainland China in the dataset), CCTGCCAAGGG (first seen on January 5, 2020 in sequences from Mainland China in the dataset).", [["SARS", "DISEASE", 45, 49], ["SARS-CoV-2 reference genome", "DNA", 45, 72], ["ISM", "PROTEIN", 196, 199], ["SARS", "PROBLEM", 45, 49], ["CoV", "TEST", 50, 53], ["the plot", "TEST", 256, 264], ["CCTGCCAAGGG", "TEST", 349, 360]]], ["As discussed in the Results section, there are a few covarying positions that can be removed for a shorter ISM while still preserving the most of information.", [["a shorter ISM", "PROBLEM", 97, 110]]], ["Another subtype, CCCTCCAAGGG, is the most abundant, i.e., dominant subtype in other Asian countries like Japan and Singapore (first detected on January 18, 2020, in sequences from Mainland China in the dataset).", [["subtype", "OBSERVATION_MODIFIER", 8, 15], ["most abundant", "OBSERVATION_MODIFIER", 37, 50], ["dominant", "OBSERVATION_MODIFIER", 58, 66], ["subtype", "OBSERVATION_MODIFIER", 67, 74]]], ["These subtypes are found in other countries/regions, but in distinct patterns, which may likely correspond to different patterns of transmission of the virus.", [["the virus", "PROBLEM", 148, 157], ["regions", "ANATOMY_MODIFIER", 44, 51], ["distinct", "OBSERVATION_MODIFIER", 60, 68], ["may likely correspond to", "UNCERTAINTY", 85, 109], ["virus", "OBSERVATION", 152, 157]]], ["Subtype CCCGCCAGGGA (first detected in February 16, 2020, in sequences from United Kingdom in the dataset) is found abundant in many European countries and then detected in Japan and Singapore later.", [["Subtype CCCGCCAGGGA", "PROBLEM", 0, 19], ["abundant", "OBSERVATION_MODIFIER", 116, 124]]], ["This subtype has also been found in Canada and Brazil, suggesting a geographical commonality between cases in these diverse countries with the progression of the virus in Europe.", [["the virus", "PROBLEM", 158, 167], ["progression", "OBSERVATION_MODIFIER", 143, 154], ["virus", "OBSERVATION", 162, 167]]], ["This subtype then becomes the dominant subtype in Denmark, USA, and one of the major subtypes in Canada and Germany.", [["dominant", "OBSERVATION_MODIFIER", 30, 38], ["subtype", "OBSERVATION_MODIFIER", 39, 46]]], ["Both subtypes, CCCGCCAGGGA and TCCGCCAGTGG, have an A23403G mutation (corresponding to position 14 in the ISM) which has been discussed in recent studies [19, 46] .Geographic distribution of SARS-CoV-2 subtypesThe data further indicate that the United States has a distinct pattern of dominant subtypes.", [["SARS", "DISEASE", 191, 195], ["CCCGCCAGGGA", "GENE_OR_GENE_PRODUCT", 15, 26], ["TCCGCCAGTGG", "GENE_OR_GENE_PRODUCT", 31, 42], ["A23403G", "GENE_OR_GENE_PRODUCT", 52, 59], ["SARS-CoV-2", "ORGANISM", 191, 201], ["SARS-CoV", "SPECIES", 191, 199], ["TCCGCCAGTGG", "TEST", 31, 42], ["an A23403G mutation", "PROBLEM", 49, 68], ["SARS", "PROBLEM", 191, 195], ["SARS", "OBSERVATION", 191, 195], ["2 subtypes", "OBSERVATION_MODIFIER", 200, 210], ["dominant subtypes", "OBSERVATION", 285, 302]]], ["This subtype has also emerged as one of the major subtypes in Canada, with the first sequence being found on March 5, 2020.Geographic distribution of SARS-CoV-2 subtypesWe also found that some states within the United States have substantially different subtype distributions.", [["SARS", "DISEASE", 150, 154], ["SARS-CoV-2", "ORGANISM", 150, 160], ["SARS-CoV", "SPECIES", 150, 158], ["SARS", "PROBLEM", 150, 154], ["SARS", "OBSERVATION", 150, 154], ["substantially", "OBSERVATION_MODIFIER", 230, 243], ["different", "OBSERVATION_MODIFIER", 244, 253], ["subtype distributions", "OBSERVATION", 254, 275]]], ["Fig 6 shows the predominant subtype distributions in the states with the most available sequences.", [["Fig", "TEST", 0, 3], ["predominant subtype", "OBSERVATION_MODIFIER", 16, 35], ["distributions", "OBSERVATION_MODIFIER", 36, 49]]], ["The colors shown on the charts are also keyed to the colors used in Fig 5, which allows for the visualization of commonalities between the subregional subtypes in the United States and the subtypes distributed in other regions.", [["subregional", "OBSERVATION_MODIFIER", 139, 150], ["subtypes", "OBSERVATION_MODIFIER", 189, 197]]], ["It is obvious that east coast states and west coast states demonstrate different ISM distributions.Geographic distribution of SARS-CoV-2 subtypesMost prominently, New York is dominated by a subtype, TCCGCCAGTGG, which is also highly abundant among sequences from European countries, including France, Denmark, Germany, and Iceland.", [["SARS", "DISEASE", 126, 130], ["SARS-CoV-2", "ORGANISM", 126, 136], ["TCCGCCAGTGG", "GENE_OR_GENE_PRODUCT", 199, 210], ["SARS-CoV", "SPECIES", 126, 134], ["different ISM distributions", "PROBLEM", 71, 98], ["SARS", "PROBLEM", 126, 130], ["different ISM", "OBSERVATION", 71, 84], ["SARS", "OBSERVATION", 126, 130], ["2 subtypes", "OBSERVATION_MODIFIER", 135, 145], ["Most prominently", "OBSERVATION_MODIFIER", 145, 161], ["New", "OBSERVATION_MODIFIER", 163, 166]]], ["The most abundant subtype in Washington, CCTGCTAAGGG, is also a major subtype in other states in United States.", [["abundant", "OBSERVATION_MODIFIER", 9, 17], ["subtype", "OBSERVATION_MODIFIER", 18, 25]]], ["This CCTGCTAAGGG subtype is also found in substantial abundance in Canada as well.", [["CCTGCTAAGGG", "GENE_OR_GENE_PRODUCT", 5, 16], ["substantial", "OBSERVATION_MODIFIER", 42, 53], ["abundance", "OBSERVATION", 54, 63]]], ["This is consistent with the hypothesis that this subtype is endogenous to the US.Geographic distribution of SARS-CoV-2 subtypesRegions with similar genetic variant patterns are identifiable in Fig 5, but only at a qualitative level.", [["SARS", "DISEASE", 108, 112], ["SARS-CoV-2", "ORGANISM", 108, 118], ["SARS-CoV-2 subtypesRegions", "DNA", 108, 134], ["SARS-CoV", "SPECIES", 108, 116], ["the US", "TEST", 74, 80], ["SARS", "PROBLEM", 108, 112], ["CoV-2 subtypesRegions", "PROBLEM", 113, 134], ["consistent with", "UNCERTAINTY", 8, 23], ["distribution", "OBSERVATION_MODIFIER", 92, 104], ["SARS", "OBSERVATION", 108, 112], ["CoV", "OBSERVATION_MODIFIER", 113, 116], ["genetic variant", "OBSERVATION", 148, 163]]], ["As described in the Methods section, the ISM abundance table can be used to provide a quantitative analysis of the similarity between the genetic variation patterns of countries and regions.", [["a quantitative analysis", "TEST", 84, 107]]], ["Fig 7 shows a visualization of the difference in genetic subtype patterns between different countries and regions using Principle Components Analysis (PCA) as described in the Methods, projecting onto the first two principle components.", [["Principle Components Analysis (PCA)", "TREATMENT", 120, 155], ["genetic subtype", "OBSERVATION", 49, 64], ["principle", "OBSERVATION_MODIFIER", 215, 224], ["components", "OBSERVATION_MODIFIER", 225, 235]]], ["We can see that a few European countries form small clusters of similar ISM abundance, i.e., a similar subtype distribution.", [["small", "OBSERVATION_MODIFIER", 46, 51], ["clusters", "OBSERVATION_MODIFIER", 52, 60], ["similar ISM", "OBSERVATION_MODIFIER", 64, 75], ["similar", "OBSERVATION_MODIFIER", 95, 102], ["subtype distribution", "OBSERVATION", 103, 123]]], ["This implies that similar SARS-CoV-2 subtypes are shared by these countries, e.g., Austria, Netherlands, Germany, and Sweden.", [["SARS", "DISEASE", 26, 30], ["SARS-CoV-2", "ORGANISM", 26, 36], ["similar", "OBSERVATION_MODIFIER", 18, 25], ["SARS", "OBSERVATION", 26, 30]]], ["Most Asian countries are projected to the upper right part of the PCA plot, in contrast to North American countries and a few European countries clustered towards the bottom.", [["upper", "ANATOMY_MODIFIER", 42, 47], ["right", "ANATOMY_MODIFIER", 48, 53], ["PCA", "ANATOMY", 66, 69], ["few", "OBSERVATION_MODIFIER", 122, 125], ["bottom", "ANATOMY_MODIFIER", 167, 173]]], ["This indicates the difference between the dominant genetic subtypes of ISM and patterns of genetic variation between these regions of the world.", [["genetic variation", "PROBLEM", 91, 108], ["dominant", "OBSERVATION_MODIFIER", 42, 50], ["genetic", "OBSERVATION_MODIFIER", 51, 58], ["subtypes", "OBSERVATION_MODIFIER", 59, 67], ["genetic variation", "OBSERVATION", 91, 108]]], ["In particular, the separation in this ISM subtype space further supports the hypothesis that the outbreak in New York is linked to some travel cases from European countries, such as France.", [["separation", "OBSERVATION_MODIFIER", 19, 29]]], ["To further validate the utility of ISMs for subtyping, we show an analysis of the geographical distribution of the dominant subtypes in Italy in S2 Fig.Temporal dynamics of SARS-CoV-2 subtypesThe present-time geographical distributions shown in Figs 5, 6 and 7 suggest that ISM subtyping may identify the temporal trends underlying the expansion of SARS-CoV-2 virus and the COVID-19 pandemic.", [["SARS", "DISEASE", 349, 353], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 173, 183], ["SARS-CoV-2 virus", "ORGANISM", 349, 365], ["COVID-19", "ORGANISM", 374, 382], ["ISMs", "PROTEIN", 35, 39], ["CoV-2 virus", "SPECIES", 354, 365], ["SARS-CoV", "SPECIES", 173, 181], ["SARS-CoV-2 virus", "SPECIES", 349, 365], ["subtyping", "TEST", 44, 53], ["an analysis", "TEST", 63, 74], ["Temporal dynamics of SARS", "PROBLEM", 152, 177], ["CoV", "TEST", 178, 181], ["ISM subtyping", "TEST", 274, 287], ["SARS", "PROBLEM", 349, 353], ["CoV", "TEST", 354, 357], ["the COVID", "TEST", 370, 379], ["pandemic", "PROBLEM", 383, 391], ["dominant", "OBSERVATION_MODIFIER", 115, 123], ["subtypes", "OBSERVATION_MODIFIER", 124, 132], ["S2 Fig", "OBSERVATION", 145, 151], ["SARS", "OBSERVATION", 173, 177], ["2 subtypes", "OBSERVATION_MODIFIER", 182, 192], ["expansion", "OBSERVATION_MODIFIER", 336, 345]]], ["To demonstrate the feasibility of modeling the temporal dynamics of the virus, we first analyzed the temporal progression of different ISMs on a country-by-country basis.", [["the virus", "PROBLEM", 68, 77], ["temporal", "OBSERVATION_MODIFIER", 101, 109], ["progression", "OBSERVATION_MODIFIER", 110, 121], ["different", "OBSERVATION_MODIFIER", 125, 134], ["ISMs", "OBSERVATION", 135, 139]]], ["This allows examination of the complex behavior of subtypes as infections expand in each country and the potential influence on regional outbreaks by subtypes imported from other regions.Temporal dynamics of SARS-CoV-2 subtypesAs described in the Methods section, we graph how viral subtypes are emerging and growing over time, by plotting the relative abundance of viral subtypes in a country/region (via the most frequently occurring ISMs over time) in Figs 8 and 9.", [["infections", "DISEASE", 63, 73], ["SARS-CoV-2 subtypesAs", "DNA", 208, 229], ["SARS-CoV", "SPECIES", 208, 216], ["examination", "TEST", 12, 23], ["infections", "PROBLEM", 63, 73], ["SARS", "PROBLEM", 208, 212], ["CoV-2 subtypesAs", "PROBLEM", 213, 229], ["viral subtypes", "PROBLEM", 366, 380], ["infections", "OBSERVATION", 63, 73], ["SARS", "OBSERVATION", 208, 212], ["CoV", "OBSERVATION_MODIFIER", 213, 216], ["viral subtypes", "OBSERVATION", 277, 291], ["viral subtypes", "OBSERVATION", 366, 380]]], ["As discussed above, through the pipeline we have developed, these plots use a consistent set of colors to indicate different ISMs (and are also consistent with the coloring scheme in Fig 5) .Temporal dynamics of SARS-CoV-2 subtypesIn the United States, we can observe a few waves of different subtypes.", [["SARS-CoV", "SPECIES", 212, 220], ["different ISMs", "PROBLEM", 115, 129], ["SARS", "PROBLEM", 212, 216], ["consistent with", "UNCERTAINTY", 144, 159], ["SARS", "OBSERVATION", 212, 216], ["different subtypes", "OBSERVATION_MODIFIER", 283, 301]]], ["For example, in the early stage (late January and early February), the predominant subtype is the same as that of Mainland China.", [["early stage", "OBSERVATION_MODIFIER", 20, 31], ["predominant subtype", "OBSERVATION_MODIFIER", 71, 90]]], ["In contrast, the most abundantly found subtype in late February and March, CCTGCTAAGGG, is not abundant in either Asia or Europe.", [["late February", "OBSERVATION", 50, 63], ["not", "UNCERTAINTY", 91, 94], ["abundant", "OBSERVATION_MODIFIER", 95, 103]]], ["It is plausible, therefore, that the CCTGCTAAGGG subtype has become abundant as the result of community transmission in the United States, and has been exported from the United States to these other countries.", [["CCTGCTAAGGG", "GENE_OR_GENE_PRODUCT", 37, 48]]], ["Interestingly, while the CCTGCTAAGGG subtype has been found across the United States, as shown in Fig 6, it has not been found to be substantially abundant in New York.", [["CCTGCTAAGGG", "GENE_OR_GENE_PRODUCT", 25, 36], ["abundant", "OBSERVATION_MODIFIER", 147, 155]]], ["Over time, however, within the United States the dominant subtype has become TCCGCCAGTGG, which is the predominant subtype in New York state (and linked to the dominant subtype in many European countries).PLOS COMPUTATIONAL BIOLOGYAs shown in Fig 9 and additional temporal plots for the Netherlands and Spain contained in the Supplementary Material, the subtype distribution in sequences within European countries differs significantly from that of North America and Australia.", [["dominant", "OBSERVATION_MODIFIER", 49, 57], ["subtype", "OBSERVATION", 58, 65], ["predominant", "OBSERVATION_MODIFIER", 103, 114], ["subtype", "OBSERVATION_MODIFIER", 115, 122], ["subtype distribution", "OBSERVATION", 354, 374]]], ["In particular, as detailed above, the European dynamics of SARS-CoV-2 appear to reflect the theory that in many European countries, initial cases may have been due to travel exposure from Italy, rather than directly from China.", [["SARS", "DISEASE", 59, 63], ["SARS-CoV-2", "ORGANISM", 59, 69], ["SARS-CoV", "SPECIES", 59, 67]]], ["For instance, we observe that the United Kingdom data shows the same PLOS COMPUTATIONAL BIOLOGY early subtypes as those of Mainland China which were also observed in Australia and Canada, i.e., CCTGCCAAGGG and CCCGCCAAGGG.", [["the United Kingdom data", "TEST", 30, 53]]], ["This subtype was also been found with great frequency in the Netherlands and Australia, but not in Spain, suggesting additional viral genetic diversity within Europe for further study.PLOS COMPUTATIONAL BIOLOGYAll inferences drawn from observed temporal trends in subtypes based on the genome sequence dataset-whether based on ISM or phylogeny-based methods-will be limited by important caveats, including: 1) The collection date of the viral sequence is usually later than the date that the individual was actually infected by the virus.", [["viral sequence", "DNA", 437, 451], ["further study", "TEST", 170, 183], ["the genome sequence dataset", "TEST", 282, 309], ["the viral sequence", "PROBLEM", 433, 451], ["the virus", "PROBLEM", 528, 537], ["great", "OBSERVATION_MODIFIER", 38, 43], ["frequency", "OBSERVATION_MODIFIER", 44, 53]]], ["Many of those individuals will be tested after they develop symptoms, which may only begin to arise several days or even two weeks after infection according to current estimates [59] .", [["infection", "DISEASE", 137, 146], ["individuals", "ORGANISM", 14, 25], ["symptoms", "PROBLEM", 60, 68], ["infection", "PROBLEM", 137, 146]]], ["2) The depth of sequencing within different regions is highly variable.", [["depth", "OBSERVATION_MODIFIER", 7, 12], ["highly", "OBSERVATION_MODIFIER", 55, 61], ["variable", "OBSERVATION_MODIFIER", 62, 70]]], ["As an extreme case, Iceland, which has a small population, has 1.3% of all sequences in the complete data set.", [["a small population", "PROBLEM", 39, 57], ["all sequences", "TEST", 71, 84], ["small", "OBSERVATION_MODIFIER", 41, 46], ["population", "OBSERVATION_MODIFIER", 47, 57]]], ["Italy, on the other hand, had a large and early outbreak but has disproportionately less sequencing coverage (133 sequences).Evaluating the ability of ISM-defined subtypes to track significant genetic changes during the SARS-CoV-2 pandemicIn our results section, we identified a few widespread ISM subtypes, e.g., TCCGCCAGTGG that dominates New York and some ISM subtypes that are unique to a region, e.g., CCTGCTAAGGG that is mostly found in North America.", [["SARS", "DISEASE", 220, 224], ["ISM", "PROTEIN", 151, 154], ["SARS-CoV", "SPECIES", 220, 228], ["a large and early outbreak", "PROBLEM", 30, 56], ["significant genetic changes", "PROBLEM", 181, 208], ["the SARS", "TEST", 216, 224], ["a few widespread ISM subtypes", "PROBLEM", 277, 306], ["some ISM subtypes", "PROBLEM", 354, 371], ["large", "OBSERVATION_MODIFIER", 32, 37], ["early", "OBSERVATION_MODIFIER", 42, 47], ["outbreak", "OBSERVATION", 48, 56], ["few", "OBSERVATION_MODIFIER", 279, 282], ["widespread", "OBSERVATION_MODIFIER", 283, 293], ["ISM subtypes", "OBSERVATION_MODIFIER", 294, 306], ["New", "OBSERVATION_MODIFIER", 341, 344]]], ["We primarily use the original 20-nt ISM identifiers in this section, rather than the compressed ISM, in order to discuss all the positions identified by our entropy analysis and relate them to the literature.Evaluating the ability of ISM-defined subtypes to track significant genetic changes during the SARS-CoV-2 pandemicSubtype prevalent in New York and some European countries TTACTCGTCCA-CAGTGTGGG (TCCGCCAGTGG in compressed form).", [["SARS", "DISEASE", 303, 307], ["20-nt ISM identifiers", "DNA", 30, 51], ["SARS-CoV", "SPECIES", 303, 311], ["our entropy analysis", "TEST", 153, 173], ["significant genetic changes", "PROBLEM", 264, 291], ["the SARS", "TEST", 299, 307], ["CAGTGTGGG (TCCGCCAGTGG in compressed form", "TREATMENT", 392, 433]]], ["Additionally, as shown in Fig 5, this same subtype has been dominant in European countries, first observed in sequencing data in late February.", [["Fig 5", "ORGANISM", 26, 31], ["dominant", "OBSERVATION_MODIFIER", 60, 68]]], ["The first detection dates in New York (later) and Europe (earlier) align with the hypothesis of European travel exposure being the major contributor to the New York outbreak of SARS-CoV-2.", [["SARS", "DISEASE", 177, 181], ["SARS-CoV-2", "ORGANISM", 177, 187], ["SARS-CoV", "SPECIES", 177, 185]]], ["Various studies have demonstrated the SNV C14408T in ORF1b to be associated with a virus subtype found abundantly in New York as well as multiple European countries [16, 60, 61] , which is designated as an ISM hotspot site 8 in Table 1 .", [["ORF1b", "GENE_OR_GENE_PRODUCT", 53, 58], ["SNV C14408T", "DNA", 38, 49], ["ORF1b", "DNA", 53, 58], ["ISM hotspot site 8", "DNA", 206, 224], ["SNV C14408T", "SPECIES", 38, 49], ["Various studies", "TEST", 0, 15], ["the SNV", "TEST", 34, 41], ["a virus subtype", "PROBLEM", 81, 96], ["virus", "OBSERVATION", 83, 88]]], ["These studies also identified a SNV of A23403G in the S spike protein to be heavily associated with the dominant subtype of both Europe and New York, correlating to ISM hotspot site 14 from our analysis.", [["S spike protein", "PROTEIN", 54, 69], ["ISM hotspot site 14", "DNA", 165, 184], ["These studies", "TEST", 0, 13], ["a SNV", "TEST", 30, 35], ["the S spike protein", "PROBLEM", 50, 69], ["our analysis", "TEST", 190, 202]]], ["Our temporal entropy plot in Fig 4 further indicates that these two sites are covarying.", [["Our temporal entropy plot", "TEST", 0, 25], ["temporal", "OBSERVATION_MODIFIER", 4, 12], ["entropy plot", "OBSERVATION", 13, 25]]], ["Lastly, the studies also reported a SNV of G26144T, which corresponds to ISM site 16 and has been observed in the predominant subtypes found in Europe and New York.Evaluating the ability of ISM-defined subtypes to track significant genetic changes during the SARS-CoV-2 pandemicSubtype potentially endogenous to the United States CCACCTGCCTGTAAGGCGGG (CCTGCTAAGGG in short form).", [["SARS", "DISEASE", 259, 263], ["ISM site 16", "DNA", 73, 84], ["ISM", "PROTEIN", 190, 193], ["SARS-CoV", "SPECIES", 259, 267], ["the studies", "TEST", 8, 19], ["a SNV of G26144T", "PROBLEM", 34, 50], ["ISM site", "PROBLEM", 73, 81], ["significant genetic changes", "PROBLEM", 220, 247], ["the SARS", "TEST", 255, 263], ["predominant subtypes", "OBSERVATION_MODIFIER", 114, 134]]], ["This is the prevalent subtype characteristic within Washington state through the latest update of the sequencing database analyzed in this paper (June 2020).", [["the sequencing database", "TEST", 98, 121]]], ["It has been linked to the endogenous spread of the virus across the United States [18, 62] .", [["endogenous", "OBSERVATION_MODIFIER", 26, 36], ["spread", "OBSERVATION_MODIFIER", 37, 43], ["virus", "OBSERVATION", 51, 56]]], ["According to our ISM analysis, this subtype is separated by a hamming distance of 3 from one of the major subtype of the outbreak in China, CCACCTGCCCACAAGGCGGG (the differences are at ISM positions 10, 11 and 12).", [["our ISM analysis", "TEST", 13, 29], ["outbreak", "OBSERVATION", 121, 129]]], ["Viral spread is suspected to be due to primary exposure of an individual from China to Washington state, designating this case as \"WA1\" [17, 60] .", [["Viral spread", "PROBLEM", 0, 12]]], ["\"WA1\" lineage is noted to have three characteristic SNVs, namely, C17747T, A17858G, and C18060T which correspond matches with our ISM positions of 10, 11 and 12 respectively [16-18, 60, 61] .", [["WA1", "GENE_OR_GENE_PRODUCT", 1, 4], ["SNVs", "OBSERVATION", 52, 56]]], ["While \"WA1\" is suspected as the primary subtype for viral spread in Washington state, there are cases that have shown additional SNVs, which suggest mutational variation from the \"WA1\" strain.", [["WA1", "GENE_OR_GENE_PRODUCT", 7, 10], ["WA1", "GENE_OR_GENE_PRODUCT", 180, 183], ["additional SNVs", "PROBLEM", 118, 133], ["mutational variation", "PROBLEM", 149, 169], ["the \"WA1\" strain", "PROBLEM", 175, 191], ["mutational variation", "OBSERVATION", 149, 169]]], ["These SNVs include C8782T and T28144C [16, 17, 60] and correspond to hotspot sites 6 and 17 respectively.", [["hotspot sites 6 and 17", "DNA", 69, 91], ["These SNVs", "TEST", 0, 10], ["C8782T", "TEST", 19, 25], ["hotspot sites", "TEST", 69, 82]]], ["The same major subtypes seen in Washington state were also identified in positive cases in Connecticut (also detected by Fig 6 using our ISM) .", [["major", "OBSERVATION_MODIFIER", 9, 14], ["subtypes", "OBSERVATION_MODIFIER", 15, 23]]], ["It is highly probable that there was trans-coastal exposure due to domestic travel from Washington state into Connecticut, due to the various high-volume airports that are present in and around this state [18] .Evaluating the ability of ISM-defined subtypes to track significant genetic changes during the SARS-CoV-2 pandemicSubtypes including the A23403G/D614G spike protein variant.", [["SARS", "DISEASE", 306, 310], ["SARS-CoV-2", "ORGANISM", 306, 316], ["ISM", "PROTEIN", 237, 240], ["A23403G/D614G spike protein variant", "PROTEIN", 348, 383], ["SARS-CoV", "SPECIES", 306, 314], ["significant genetic changes", "PROBLEM", 267, 294], ["the SARS", "TEST", 302, 310], ["CoV", "TEST", 311, 314], ["the A23403G", "TEST", 344, 355], ["highly probable", "UNCERTAINTY", 6, 21], ["volume airports", "OBSERVATION", 147, 162]]], ["The SNV A23403G (resulting in D614G variant in spike protein) is a major viral mutation that has been observed in the major European countries of Italy, Spain, France, as well as Middle Eastern regions of Turkey and Israel [16, [63] [64] [65] .", [["SNV A23403G", "GENE_OR_GENE_PRODUCT", 4, 15], ["D614G variant in spike protein", "GENE_OR_GENE_PRODUCT", 30, 60], ["SNV A23403G", "DNA", 4, 15], ["spike protein", "PROTEIN", 47, 60], ["The SNV", "TEST", 0, 7], ["D614G variant", "PROBLEM", 30, 43], ["spike protein", "PROBLEM", 47, 60], ["a major viral mutation", "PROBLEM", 65, 87], ["viral mutation", "OBSERVATION", 73, 87], ["Middle", "ANATOMY_MODIFIER", 179, 185]]], ["Some studies suggest that this D614G variant of the S spike protein provides greater survival and transmission ability to the virus, however there need to be additional studies conducted to confirm these claims [63] .", [["D614G", "GENE_OR_GENE_PRODUCT", 31, 36], ["D614G variant", "PROTEIN", 31, 44], ["S spike protein", "PROTEIN", 52, 67], ["Some studies", "TEST", 0, 12], ["the S spike protein", "PROBLEM", 48, 67], ["the virus", "PROBLEM", 122, 131], ["additional studies", "TEST", 158, 176]]], ["This position corresponds to ISM position 14.", [["ISM position 14", "DNA", 29, 44], ["ISM", "OBSERVATION_MODIFIER", 29, 32], ["position", "OBSERVATION_MODIFIER", 33, 41]]], ["Based on our ISM table, we can quickly navigate to this position and plot the abundance of different variants at this position over time.", [["different variants", "PROBLEM", 91, 109], ["different variants", "OBSERVATION", 91, 109]]], ["Indeed, Fig 10 illustrates how, in late February, A23403G started to take off in abundance and has quickly overwhelmed the initially more prevalent subtype.Comparison of ISM-defined subtypes to clades identified using phylogenetic treesAs discussed in the foregoing, subtypes defined by ISM are differentiated based on single nucleotide variants, which may eventually be found to represent functionally significant mutations in the viral genome.", [["ISM", "PROTEIN", 170, 173], ["viral genome", "DNA", 432, 444], ["ISM", "TEST", 170, 173], ["single nucleotide variants", "PROBLEM", 319, 345], ["functionally significant mutations in the viral genome", "PROBLEM", 390, 444], ["significant", "OBSERVATION_MODIFIER", 403, 414], ["mutations", "OBSERVATION", 415, 424], ["viral genome", "OBSERVATION", 432, 444]]], ["The ISM, however, does not include phylogenetic information,PLOS COMPUTATIONAL BIOLOGYwhich sharply limits the utility of the ISM to infer patterns of viral evolution.", [["viral evolution", "PROBLEM", 151, 166], ["viral evolution", "OBSERVATION", 151, 166]]], ["Nevertheless, ISM-defined subtypes do correspond well with clusters of sequences based on phylogenic reconstruction.", [["ISM", "PROTEIN", 14, 17], ["phylogenic reconstruction", "TREATMENT", 90, 115]]], ["To identify whether the ISM may still be an effective identifier of genetic subtypes within the context of viral evolution, we compare subtype identification using the ISM and the phylogenetic tree structure.", [["viral", "OBSERVATION", 107, 112], ["phylogenetic tree structure", "OBSERVATION", 180, 207]]], ["In particular by comparing the ISM-defined groups of sequences identified by our pipeline with the phylogenetic tree-based clusters (i.e., clades) identified by the Nextstrain group [6] .", [["the ISM", "TEST", 27, 34], ["tree", "OBSERVATION_MODIFIER", 112, 116], ["clusters", "OBSERVATION_MODIFIER", 123, 131]]], ["We do so by placing an ISM of interest at the lowest common ancestor (LCA) node of sequences containing that ISM on the phylogenetic tree produced by Nextstrain.", [["Nextstrain", "PROTEIN", 150, 160], ["LCA", "OBSERVATION_MODIFIER", 70, 73], ["node", "OBSERVATION", 75, 79]]], ["Then, we compare the branch length between the root and LCA, which is considered as the evolutionary distance between a node and the reference sequence, and the Hamming distance between a given ISM and the reference ISM, CCACCCGCCCACAAGGTGGG (CCCGCCAAGGG in short form), which represents the degree of difference (by number of SNVs) between ISMs.", [["root", "ANATOMY", 47, 51], ["node", "ANATOMY", 120, 124], ["root", "TISSUE", 47, 51], ["the reference sequence", "TEST", 129, 151], ["branch", "OBSERVATION_MODIFIER", 21, 27], ["length", "OBSERVATION_MODIFIER", 28, 34], ["root", "ANATOMY_MODIFIER", 47, 51], ["LCA", "OBSERVATION_MODIFIER", 56, 59], ["node", "OBSERVATION", 120, 124], ["degree", "OBSERVATION_MODIFIER", 292, 298]]], ["Fig 11 shows that Hamming distance (dark-colored) has a high correlation with the LCA branch length (gray-colored).", [["Fig", "TEST", 0, 3], ["LCA", "OBSERVATION_MODIFIER", 82, 85], ["branch", "OBSERVATION_MODIFIER", 86, 92], ["length", "OBSERVATION_MODIFIER", 93, 99]]], ["This means that the Hamming distances between ISMs are able to consistently reflect evolutionary distance at a high level.", [["ISMs", "GENE_OR_GENE_PRODUCT", 46, 50], ["ISMs", "DNA", 46, 50], ["the Hamming distances between ISMs", "PROBLEM", 16, 50]]], ["There are a few outliers though; for example, CCACCTGCTCACAAGGCGGG (CCTGTCAAGGG in short form) has higher LCA branch length but lower ISM Hamming distance.", [["CCACCTGCTCACAAGGCGGG", "TEST", 46, 66], ["few", "OBSERVATION_MODIFIER", 12, 15], ["outliers", "OBSERVATION", 16, 24], ["higher", "OBSERVATION_MODIFIER", 99, 105], ["LCA", "OBSERVATION_MODIFIER", 106, 109], ["branch", "OBSERVATION_MODIFIER", 110, 116], ["length", "OBSERVATION_MODIFIER", 117, 123], ["lower", "OBSERVATION_MODIFIER", 128, 133], ["ISM Hamming", "OBSERVATION", 134, 145]]], ["This indicates that some evolutionary signals will be missed by grouping sequences by ISM, likely because the signals are contained in lower-entropy genomic regions which are unrepresented in the ISM.", [["some evolutionary signals", "PROBLEM", 20, 45], ["lower", "ANATOMY_MODIFIER", 135, 140], ["entropy genomic", "OBSERVATION", 141, 156]]], ["Conversely, we observe that the phylogenetic clades identified by Nextstrain are imperfect with respect to their preservation of SNV information.", [["the phylogenetic clades", "PROBLEM", 28, 51]]], ["Nextstrain identifies the clades based on whether they contain at least two prevalent SNVs.", [["Nextstrain", "TREATMENT", 0, 10]]], ["But, presumably because the clades are identified by whole genome sequence clustering, not every sequence within a clade will necessarily include those SNVs.PLOS COMPUTATIONAL BIOLOGYMoreover, not only can the ISM pipeline effectively define meaningful viral subtypes, but it can also do so with greater computational efficiency than tree reconstruction methods.", [["whole genome sequence clustering", "PROBLEM", 53, 85], ["meaningful viral subtypes", "PROBLEM", 242, 267], ["tree reconstruction methods", "TREATMENT", 334, 361]]], ["Fasttree [66] , on its fastest setting, is reportedly the fastest tree reconstruction method (orders of magnitude faster than most machine learning methods).", [["the fastest tree reconstruction method", "TREATMENT", 54, 92]]], ["Fasttree theoretically executes at \u00d7 N \u00d7 a) where L is the number of loci and N is the number of sequences, and a is the size of the alphabet.", [["size", "OBSERVATION_MODIFIER", 121, 125]]], ["Accordingly, the computational time required to enumerate subtypes using the ISM is substantially reduced, i.e., a function of the thresholded loci reduced and number of sequences instead.", [["ISM", "DNA", 77, 80], ["thresholded loci", "DNA", 131, 147], ["substantially", "OBSERVATION_MODIFIER", 84, 97], ["reduced", "OBSERVATION_MODIFIER", 98, 105]]], ["One caveat is that the ISM method requires multiple sequence alignment to identify high entropy sites, which can be a computationally intensive process.", [["multiple sequence alignment", "TEST", 43, 70], ["high entropy sites", "PROBLEM", 83, 101]]], ["However, phylogenetic tree methods based on whole genome sequences require that as well.", [["whole genome sequences", "DNA", 44, 66], ["phylogenetic tree methods", "PROBLEM", 9, 34], ["whole genome sequences", "TEST", 44, 66], ["phylogenetic tree", "OBSERVATION", 9, 26]]], ["And, ISM identification may be done on new sequences using previous positions between multiple sequence alignment updates.PLOS COMPUTATIONAL BIOLOGYIn sum, ISM can provide a compact and effective representation of a sequence as it includes the essential genetic variation information, while also including a substantial amount of molecular evolution information.PLOS COMPUTATIONAL BIOLOGYWe further assess how ISMs defined at different entropy thresholds relate to the clades identified by Nextstrain.", [["Nextstrain", "PROTEIN", 490, 500], ["ISM identification", "TEST", 5, 23], ["new sequences", "TEST", 39, 52], ["ISMs", "PROBLEM", 410, 414]]], ["We compute homogeneity and completeness scores between ISM labels and Nextstrain clades as a function of entropy threshold.", [["completeness scores between ISM labels", "PROBLEM", 27, 65], ["Nextstrain clades", "TREATMENT", 70, 87]]], ["Homogeneity measures the extent to which ISMs each identify only sequences in one clade.", [["ISMs", "DNA", 41, 45], ["extent", "OBSERVATION_MODIFIER", 25, 31]]], ["Completeness measures the extent to which sequences that are members of a given clade are identified by a common ISM.", [["a common ISM", "PROBLEM", 104, 116]]], ["Fig 12 shows the homogeneity and completeness as a function of the entropy threshold used to define ISMs.", [["ISMs", "PATHOLOGICAL_FORMATION", 100, 104], ["ISMs", "PROTEIN", 100, 104], ["the entropy threshold", "TREATMENT", 63, 84], ["ISMs", "PROBLEM", 100, 104]]], ["As shown therein, sequences with a common ISM are generally assigned to a common clade, and sequences from a given clades also often identified by a set of few ISMs.", [["ISMs", "CANCER", 160, 164], ["few ISMs", "PROBLEM", 156, 164]]], ["As the entropy threshold increases, ISMs correspondingly moving \"upwards\" through the phylogenetic tree to better represent a clade, increasing completeness while maintaining high Fig 12.", [["the entropy threshold", "TEST", 3, 24], ["ISMs", "PROBLEM", 36, 40], ["a clade", "PROBLEM", 124, 131], ["high Fig", "OBSERVATION_MODIFIER", 175, 183]]], ["The effect of the entropy threshold on ISM membership to Nextstrain clade representation.", [["the entropy threshold", "PROBLEM", 14, 35], ["Nextstrain clade representation", "TREATMENT", 57, 88]]], ["At a low entropy threshold, each ISM contains sequences that nearly all belong to the same clade (high homogeneity) but the clade contains multiple ISMs (low completeness).", [["ISM", "DNA", 33, 36], ["ISMs", "PROTEIN", 148, 152], ["a low entropy threshold", "PROBLEM", 3, 26], ["multiple ISMs", "PROBLEM", 139, 152], ["low entropy", "OBSERVATION_MODIFIER", 5, 16], ["multiple", "OBSERVATION_MODIFIER", 139, 147], ["ISMs", "OBSERVATION_MODIFIER", 148, 152], ["low completeness", "OBSERVATION_MODIFIER", 154, 170]]], ["As the entropy threshold rises, ISMs gain more sequences (some of which belong to other clades) and the clades contain fewer distinct ISMs.", [["ISMs", "PATHOLOGICAL_FORMATION", 134, 138], ["ISMs", "PROTEIN", 32, 36], ["the entropy threshold", "TEST", 3, 24], ["ISMs gain more sequences", "PROBLEM", 32, 56], ["fewer distinct ISMs", "PROBLEM", 119, 138], ["fewer", "OBSERVATION_MODIFIER", 119, 124], ["distinct", "OBSERVATION_MODIFIER", 125, 133], ["ISMs", "OBSERVATION", 134, 138]]], ["Thus, there is a trade-off with the entropy threshold, but the sweet spot is around 70-80% on both metrics, showing that ISMs capture some aspect of phylogenetics but have their own characteristics.PLOS COMPUTATIONAL BIOLOGYhttps://doi.org/10.1371/journal.pcbi.1008269.g012 PLOS COMPUTATIONAL BIOLOGY homogeneity.", [["the entropy threshold", "TEST", 32, 53], ["the sweet spot", "TEST", 59, 73]]], ["Conversely, as the entropy threshold lowers, ISMs increase in their resolution, corresponding to an increase to almost perfect homogeneity but with low completeness.ConclusionIn this paper, we present a pipeline for subtyping SARS-CoV-2 viral genomes based on short sets of highly informative nucleotide sites (ISMs).", [["SARS", "DISEASE", 226, 230], ["nucleotide", "CHEMICAL", 293, 303], ["SARS-CoV-2", "ORGANISM", 226, 236], ["SARS-CoV-2 viral genomes", "DNA", 226, 250], ["highly informative nucleotide sites", "DNA", 274, 309], ["SARS-CoV", "SPECIES", 226, 234], ["the entropy threshold lowers", "PROBLEM", 15, 43], ["ISMs", "PROBLEM", 45, 49], ["subtyping SARS", "TEST", 216, 230], ["CoV", "TEST", 231, 234], ["2 viral genomes", "PROBLEM", 235, 250], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["resolution", "OBSERVATION_MODIFIER", 68, 78]]], ["First, the ISM of a sequence preserves important nucleotide positions that can help to resolve different SARS-CoV-2 subtypes.", [["SARS", "DISEASE", 105, 109], ["nucleotide", "CHEMICAL", 49, 59], ["ISM", "PROTEIN", 11, 14], ["different SARS", "PROBLEM", 95, 109]]], ["ISMs provide a quick and easy way to track key sets of SNVs which are covarying as the SARS-CoV-2 pandemic spreads throughout the world.", [["SARS", "DISEASE", 87, 91], ["SNVs", "PROBLEM", 55, 59], ["the SARS", "PROBLEM", 83, 91]]], ["The SNVs which consistently covary with the spike protein variant has rapidly become prevalent throughout the world and may be a potential link to increased viral transmission [3, 19, 46] .", [["spike protein variant", "PROTEIN", 44, 65], ["The SNVs", "TEST", 0, 8], ["the spike protein variant", "PROBLEM", 40, 65], ["increased viral transmission", "PROBLEM", 147, 175], ["SNVs", "OBSERVATION", 4, 8], ["increased", "OBSERVATION_MODIFIER", 147, 156], ["viral", "OBSERVATION", 157, 162]]], ["Second, ISM-based subtypes are able to capture the majority of phylogenetic relationships between viral genomes that are represented in Nextstrain tree clades.", [["ISM", "PROTEIN", 8, 11], ["viral genomes", "DNA", 98, 111], ["viral genomes", "PROBLEM", 98, 111], ["phylogenetic", "OBSERVATION", 63, 75], ["viral genomes", "OBSERVATION", 98, 111], ["tree clades", "OBSERVATION", 147, 158]]], ["ISM analysis shows promise as a complement to phylogenetic classification, particularly given the limits of phylogenetics at early stages in the pandemic (e.g., due to uncertainty regarding key assumptions, such as the rate of the molecular clock and confidence in branches)-while also being more computationally efficient.", [["ISM analysis", "TEST", 0, 12], ["branches", "OBSERVATION_MODIFIER", 265, 273]]], ["Third, ISM subtyping can provide robust and informative insight regarding the geographic and temporal spread of the SARS-CoV-2 sequences, as well potentially be a way to identify phenotypic variants of the virus.", [["SARS", "DISEASE", 116, 120], ["SARS-CoV-2", "ORGANISM", 116, 126], ["SARS-CoV-2 sequences", "DNA", 116, 136], ["SARS-CoV", "SPECIES", 116, 124], ["the SARS", "TEST", 112, 120], ["CoV-2 sequences", "TEST", 121, 136], ["the virus", "PROBLEM", 202, 211]]], ["For example, in this paper, we show that the distribution of ISMs is an indicator of the geographical distribution of the virus as predicted by the flow of the virus from China, the initial European outbreak in Italy, and subsequent development of local subtypes within individual European countries as well as interregional differences in viral outbreaks in the United States.ConclusionAn important caveat of all viral analyses, including subtyping, is that they are limited by the number of viral sequences available.", [["ISMs", "GENE_OR_GENE_PRODUCT", 61, 65], ["viral sequences", "DNA", 493, 508], ["ISMs", "PROBLEM", 61, 65], ["the virus", "PROBLEM", 118, 127], ["the virus", "PROBLEM", 156, 165], ["all viral analyses", "TEST", 410, 428], ["viral sequences", "TEST", 493, 508], ["virus", "OBSERVATION", 122, 127], ["local subtypes", "OBSERVATION", 248, 262], ["viral outbreaks", "OBSERVATION", 340, 355]]], ["Small and/or non-uniform sampling of sequences within and across populations may not accurately reflect the true diversity and distribution of viral subtypes.", [["Small and/or non-uniform sampling of sequences", "PROBLEM", 0, 46], ["viral subtypes", "PROBLEM", 143, 157], ["may not accurately reflect", "UNCERTAINTY", 77, 103], ["true", "OBSERVATION_MODIFIER", 108, 112], ["diversity", "OBSERVATION", 113, 122], ["distribution", "OBSERVATION_MODIFIER", 127, 139], ["viral subtypes", "OBSERVATION", 143, 157]]], ["However, the ISM-based approach has the advantage of being scalable as sequence information grows, and with more information, it will become both more accurate and precise for different geographic regions and within subpopulations.ConclusionUsing ISM subtyping pipeline on continuously updated sequencing data, we are capable of updating subtypes as new sequences are identified and uploaded to global databases.", [["ISM", "PROTEIN", 13, 16], ["sequencing data", "TEST", 294, 309], ["new sequences", "TEST", 350, 363], ["subpopulations", "OBSERVATION_MODIFIER", 216, 230]]], ["We have made the pipeline and updated analyses available on Github at https://github.com/EESI/ISM (Jupyter notebook), https://github.com/EESI/ncov_ism (command line tool) and an interactive website at https://covid19-ism.coe.drexel.edu/.", [["github.com", "DNA", 126, 136]]], ["In the future, as more data becomes available, ISM-based subtyping can be employed on subpopulations within geographical regions, demographic groups, and groups of patients with different clinical outcomes.", [["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172]]], ["Efficient subtyping of the massive amount of SARS-CoV-2 sequence data will therefore enable quantitative modeling and machine learning methods to develop improved containment and potential therapeutic strategies against SARS-CoV-2.", [["SARS", "DISEASE", 45, 49], ["SARS", "DISEASE", 220, 224], ["SARS-CoV-2", "ORGANISM", 220, 230], ["SARS-CoV-2 sequence", "DNA", 45, 64], ["SARS-CoV", "SPECIES", 220, 228], ["SARS", "PROBLEM", 45, 49], ["CoV-2 sequence data", "TEST", 50, 69], ["machine learning methods", "TREATMENT", 118, 142], ["SARS", "PROBLEM", 220, 224], ["massive", "OBSERVATION_MODIFIER", 27, 34], ["amount", "OBSERVATION_MODIFIER", 35, 41]]], ["Moreover, the ISM-based subtyping scheme and associated downstream analyses for SARS-CoV-2 are directly applicable to other viruses, enabling efficient subtyping and real-time tracking of potential future viral pandemics.", [["viral pandemics", "DISEASE", 205, 220], ["SARS-CoV-2", "ORGANISM", 80, 90], ["ISM", "PROTEIN", 14, 17], ["SARS-CoV", "SPECIES", 80, 88], ["the ISM", "TEST", 10, 17], ["downstream analyses", "TEST", 56, 75], ["SARS", "PROBLEM", 80, 84], ["other viruses", "PROBLEM", 118, 131], ["viral pandemics", "PROBLEM", 205, 220], ["viral pandemics", "OBSERVATION", 205, 220]]], ["Based on publicly available sequence data from Italy, we found that Italy had two particularly abundant ISMs, CCCGCCAGGGA and CCCGCCAGGGG, as can be seen in the pie chart in Fig 5.", [["ISMs", "GENE_OR_GENE_PRODUCT", 104, 108], ["CCCGCCAGGGA", "GENE_OR_GENE_PRODUCT", 110, 121], ["CCCGCCAGGGG", "GENE_OR_GENE_PRODUCT", 126, 137], ["ISMs", "PROTEIN", 104, 108], ["publicly available sequence data", "TEST", 9, 41], ["abundant", "OBSERVATION_MODIFIER", 95, 103], ["ISMs", "OBSERVATION", 104, 108]]], ["The third-most abundant subtype shown in the chart (CCCTCCAAGTG) corresponds to cases that were linked to original exposure from China, which is consistent with the ISM being in common with one found in Hong Kong.", [["consistent with", "UNCERTAINTY", 145, 160]]], ["This supplementary figure shows the relative abundance (proportion of total sequences in that country/region) of each of these two dominant subtypes of Italy in other countries/regions.", [["This supplementary figure", "TEST", 0, 25], ["total sequences", "TREATMENT", 70, 85], ["abundance", "OBSERVATION_MODIFIER", 45, 54], ["two", "OBSERVATION_MODIFIER", 127, 130], ["dominant", "OBSERVATION_MODIFIER", 131, 139], ["subtypes", "OBSERVATION_MODIFIER", 140, 148], ["Italy", "OBSERVATION_MODIFIER", 152, 157]]], ["As the plot shows, the outbreak in other European countries have generally involved the same viral subtypes as those which are most abundant in Italy, as defined by ISM.", [["the plot", "TEST", 3, 11], ["abundant", "OBSERVATION_MODIFIER", 132, 140]]], ["The subtypes which are predominant in Italy are found, however, at lower yet notable abundance in countries including Japan, Canada and Australia.", [["subtypes", "OBSERVATION_MODIFIER", 4, 12], ["predominant", "OBSERVATION_MODIFIER", 23, 34], ["notable", "OBSERVATION_MODIFIER", 77, 84], ["abundance", "OBSERVATION", 85, 94]]], ["Indeed, the dominant subtype in New York (TCCGCCAGTGG) was detected in 86 sequence from Iceland and only one of them linked to travel exposure in Italy.", [["dominant", "OBSERVATION_MODIFIER", 12, 20], ["subtype", "OBSERVATION_MODIFIER", 21, 28], ["New", "OBSERVATION_MODIFIER", 32, 35]]], ["This further suggests that it was unlikely that the incidence of the TCCGCCAGTGG subtype in New York is connected to Italy but rather than elsewhere in Europe, but limited sequence coverage in Italy prevents more definitive inference.", [["the TCCGCCAGTGG subtype", "PROBLEM", 65, 88]]], ["However, one of the dominant subtypes in Italy, CCCGCCAGGGG, is not abundant in East Asian regions such as Mainland China and Japan, as indicated in this supplementary figure.Supporting information(PDF) S3 Fig. Relative abundance (%) of ISMs in DNA sequences from Australia as sampled over time.", [["DNA", "CELLULAR_COMPONENT", 245, 248], ["ISMs", "PROTEIN", 237, 241], ["DNA sequences", "DNA", 245, 258], ["Relative abundance", "PROBLEM", 211, 229], ["ISMs in DNA sequences", "PROBLEM", 237, 258], ["dominant", "OBSERVATION_MODIFIER", 20, 28], ["subtypes", "OBSERVATION_MODIFIER", 29, 37], ["not", "UNCERTAINTY", 64, 67], ["abundant", "OBSERVATION_MODIFIER", 68, 76]]], ["Australia shows growing subtype diversity as its cases increase over time.", [["growing subtype diversity", "PROBLEM", 16, 41], ["growing", "OBSERVATION_MODIFIER", 16, 23], ["subtype diversity", "OBSERVATION", 24, 41], ["increase", "OBSERVATION_MODIFIER", 55, 63]]], ["Initially, Australia's sequences were dominated by two subtypes that were also substantially abundant in Mainland China (CCCGCCAAGGG and CCTGCCAAGGG).", [["Australia's sequences", "TEST", 11, 32], ["substantially", "OBSERVATION_MODIFIER", 79, 92], ["abundant", "OBSERVATION_MODIFIER", 93, 101]]], ["This subtype was less relatively abundant in Mainland China but more highly abundant in sequences from Hong Kong and Singapore (see Fig 5) .", [["less", "OBSERVATION_MODIFIER", 17, 21], ["relatively", "OBSERVATION_MODIFIER", 22, 32], ["abundant", "OBSERVATION_MODIFIER", 33, 41]]], ["This pattern suggests a hypothesis that Australia may have had multiple independent viral transmissions from Mainland China-or, as noted in the previous discussion, potentially through transmissions from Iran-followed by potentially independent importation of the virus from Europe and North America.", [["the virus", "PROBLEM", 260, 269], ["viral", "OBSERVATION", 84, 89]]], ["(PDF) S4 Fig. Relative abundance (%) of ISMs in DNA sequences from Canada as sampled over time.", [["ISMs", "GENE_OR_GENE_PRODUCT", 40, 44], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["ISMs", "PROTEIN", 40, 44], ["DNA sequences", "DNA", 48, 61], ["Relative abundance", "PROBLEM", 14, 32], ["ISMs in DNA sequences", "PROBLEM", 40, 61]]], ["This figure shows that the earliest viral sequences in Canada included mostly subtypes found in Mainland China, with the same pattern in which there was a second, later subtype in common with Mainland China, which was also found in travel exposure from Iran (CCCTCCAAGGG).", [["the earliest viral sequences", "PROBLEM", 23, 51], ["Mainland China", "ANATOMY", 96, 110]]], ["And, like in Australia, in Canada these few initial viral sequences were followed by a diversification of subtypes that including many in common in Europe and the United States.", [["viral sequences", "DNA", 52, 67]]], ["In sum, Australia and Canada show patterns that might be expected for smaller populations in countries with diverse and extensive travel connections.", [["might be expected for", "UNCERTAINTY", 48, 69], ["smaller", "OBSERVATION_MODIFIER", 70, 77], ["populations", "OBSERVATION", 78, 89]]], ["This figure shows, in Spain, the CCCGCCAAGGG subtype was also found in an early sequence data but not thereafter.", [["CCCGCCAAGGG", "GENE_OR_GENE_PRODUCT", 33, 44], ["an early sequence data", "TEST", 71, 93]]], ["(PDF)S8 Fig. Temporal dynamics of individual viral subtypes across different regions.", [["individual viral subtypes across different regions", "PROBLEM", 34, 84], ["individual", "OBSERVATION_MODIFIER", 34, 44], ["viral subtypes", "OBSERVATION", 45, 59]]], ["In the case of Mainland China, that could be due to the substantial reduction in reported numbers of new infections and thus additional sequences being sampled.", [["infections", "DISEASE", 105, 115], ["the substantial reduction", "PROBLEM", 52, 77], ["new infections", "PROBLEM", 101, 115], ["additional sequences", "TEST", 125, 145], ["Mainland China", "ANATOMY", 15, 29], ["could be due to", "UNCERTAINTY", 36, 51], ["substantial", "OBSERVATION_MODIFIER", 56, 67], ["reduction", "OBSERVATION_MODIFIER", 68, 77], ["new", "OBSERVATION_MODIFIER", 101, 104], ["infections", "OBSERVATION", 105, 115]]], ["However, the other countries have continuing increases in reported infection as of the date of the data set, as well as substantially increasing numbers of sequences being sampled-making it less likely that the reference subtype (CCCGCCAAGGG) is simply being missed.", [["infection", "DISEASE", 67, 76], ["reported infection", "PROBLEM", 58, 76], ["substantially increasing numbers of sequences", "PROBLEM", 120, 165], ["increases", "OBSERVATION_MODIFIER", 45, 54], ["infection", "OBSERVATION", 67, 76]]], ["In those cases, it appears from Figs 8 and 9, and S6 Fig that in later times, other subtypes have emerged over time and are becoming increasingly abundant.", [["S6", "GENE_OR_GENE_PRODUCT", 50, 52], ["S6", "PROTEIN", 50, 52], ["Figs", "TEST", 32, 36], ["abundant", "OBSERVATION", 146, 154]]], ["One potential explanation is that the SARS-CoV-2 is an RNA virus and thus highly susceptible to mutation as transmissions occur [69] .", [["SARS", "DISEASE", 38, 42], ["SARS-CoV-2", "ORGANISM", 38, 48], ["SARS-CoV", "SPECIES", 38, 46], ["the SARS-CoV", "PROBLEM", 34, 46], ["an RNA virus", "PROBLEM", 52, 64]]], ["Therefore, as transmissions have continued, the ISM associated with the reference sequence has been replaced by different ISMs due to these mutations.", [["ISMs", "CANCER", 122, 126], ["ISM", "DNA", 48, 51], ["the reference sequence", "TEST", 68, 90], ["these mutations", "PROBLEM", 134, 149]]], ["The latter could plausibly explain the pattern observed in the United States, where earlier subtypes connected to Asia did not increase in abundance while a putative endogenous subtype, as well as the dominant New York subtype, have significantly increased in abundance (see Fig 8 and accompanying discussion above).", [["could plausibly explain", "UNCERTAINTY", 11, 34], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["endogenous subtype", "OBSERVATION", 166, 184], ["dominant", "OBSERVATION_MODIFIER", 201, 209], ["New", "OBSERVATION_MODIFIER", 210, 213], ["York subtype", "OBSERVATION", 214, 226], ["significantly", "OBSERVATION_MODIFIER", 233, 246], ["increased", "OBSERVATION_MODIFIER", 247, 256]]], ["Further investigation and modeling of subtype distributions, as well as additional data, will be necessary to help resolve these questions.", [["Further investigation", "TEST", 0, 21], ["subtype distributions", "OBSERVATION", 38, 59]]]], "a62a207d74138dfcda60d79ca46d96cc200a3cdc": [["Neben enteropathogenen Bakterien, die nur bei einem Teil der Erkrankungs-f~ille als Ursache gefunden werden, k6nnen nach kfirzlich ver6ffentlichten Befunden [1-4, 6, [8] [9] [10] [11] aufgrund etektronenmikroskopischer Untersuchungen von Smhlsuspensionen Viren als ~itiologisches Agens in Betracht kommen.", [["Neben enteropathogenen Bakterien, die nur bei einem Teil der Erkrankungs-f~ille als Ursache gefunden werden, k6nnen nach kfirzlich ver6ffentlichten", "SPECIES", 0, 147], ["Neben enteropathogenen Bakterien", "TREATMENT", 0, 32], ["Erkrankungs", "TEST", 61, 72], ["aufgrund etektronenmikroskopischer Untersuchungen von Smhlsuspensionen Viren als ~itiologisches", "TREATMENT", 184, 279]]], ["W/ihrend der akuten Krankheitsphase konnten von verschiedenen Untersuchergruppen zumindest 2 verschiedene Partikelformen nachgewiesen werden; eine dritte Art yon Viruspartikeln wurde dagegen bisher nur bei Erwachsenen gefunden, w/ihrend eine vierte Gruppe bislang nur bei Gastroenteritis von Sfiugetieren gefunden wurde.", [["Art yon Viruspartikeln wurde dagegen bisher nur bei Erwachsenen gefunden, w/ihrend eine vierte Gruppe bislang nur bei Gastroenteritis von Sfiugetieren gefunden wurde", "SPECIES", 154, 319], ["W/ihrend der akuten Krankheitsphase", "TREATMENT", 0, 35]]]], "9f5b434523086ca9d7bd8d553b54a50d31aff4d6": [["death based on a death certificate mentioning a COVID-19-related ICD-10 code.", [["death", "DISEASE", 0, 5], ["death", "DISEASE", 17, 22], ["COVID-19-related ICD-10 code", "DNA", 48, 76], ["death", "PROBLEM", 0, 5], ["ICD", "TREATMENT", 65, 68]]], ["The large size of the study population enabled the researchers to make well-powered conclusions about vulnerability to COVID-19 in patient subgroups.", [["patient", "ORGANISM", 131, 138], ["patient", "SPECIES", 131, 138], ["COVID", "TEST", 119, 124], ["large", "OBSERVATION_MODIFIER", 4, 9], ["size", "OBSERVATION_MODIFIER", 10, 14]]], ["Notably, in this study design COVID-19 mortality is determined not only by the risk of death for individual patients once infected with SARS-CoV-2, but also by their risk of being infected.", [["death", "DISEASE", 87, 92], ["SARS", "DISEASE", 136, 140], ["patients", "ORGANISM", 108, 116], ["SARS-CoV-2", "ORGANISM", 136, 146], ["patients", "SPECIES", 108, 116], ["SARS-CoV", "SPECIES", 136, 144], ["this study", "TEST", 12, 22], ["COVID", "TEST", 30, 35], ["death", "PROBLEM", 87, 92], ["SARS", "PROBLEM", 136, 140], ["CoV", "TEST", 141, 144], ["infected", "PROBLEM", 180, 188], ["infected", "OBSERVATION", 180, 188]]], ["Mortality rates are therefore 100-to 1,000-fold lower in this study than in previous reports that reported mortality among infected patients.", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["Mortality rates", "TEST", 0, 15], ["this study", "TEST", 57, 67], ["infected", "OBSERVATION", 123, 131]]], ["This study design may also explain, at least in part, some of the findings.", [["This study", "TEST", 0, 10], ["may also explain", "UNCERTAINTY", 18, 34]]], ["For example, people with non-white ethnicity had a 40-50% higher risk of COVID-19-related death than those with white ethnicity.", [["death", "DISEASE", 90, 95], ["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["COVID", "TEST", 73, 78], ["related death", "PROBLEM", 82, 95]]], ["A multi variable Cox proportional hazards model showed that this increased risk of death was only partially attributable to co-morbidities or other known risk factors.", [["death", "DISEASE", 83, 88], ["A multi variable Cox proportional hazards model", "PROBLEM", 0, 47], ["death", "PROBLEM", 83, 88], ["co-morbidities", "PROBLEM", 124, 138], ["other known risk factors", "PROBLEM", 142, 166]]], ["Rather than reflecting a higher risk of dying from COVID-19, the higher mortality risk among non-white ethnic groups could potentially reflect a higher risk of contracting the infection owing to differences in living conditions or occupational exposure.", [["infection", "DISEASE", 176, 185], ["COVID", "TEST", 51, 56], ["non-white ethnic groups", "PROBLEM", 93, 116], ["the infection", "PROBLEM", 172, 185], ["infection", "OBSERVATION", 176, 185]]], ["Regardless of the explanation, these new data are important from a public health perspective as they could help to identify which population subgroups should be shielded to prevent transmission of the infection.", [["infection", "DISEASE", 201, 210], ["the infection", "PROBLEM", 197, 210], ["infection", "OBSERVATION", 201, 210]]]], "19dc682cbb91c080bc58cfb2aa26ac4ab6fb8281": [["The peak of Internet searches and social media data about the coronavirus disease 2019 (COVID-19) outbreak occurred 10-14 days earlier than the peak of daily incidences in China.", [["coronavirus disease", "DISEASE", 62, 81], ["the coronavirus disease", "PROBLEM", 58, 81], ["COVID", "TEST", 88, 93], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["coronavirus disease", "OBSERVATION", 62, 81]]]], "33cb891e228c441e3307be5e057168a4076334d3": [["INTRODUCTIONAt present, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (1) is largely under control in China, but it is still spreading rapidly worldwide, seriously threatening and damaging global health (2) .", [["acute respiratory syndrome coronavirus", "DISEASE", 31, 69], ["SARS-CoV-2) infection", "DISEASE", 73, 94], ["SARS-CoV-2", "ORGANISM", 73, 83], ["severe acute respiratory syndrome coronavirus", "SPECIES", 24, 69], ["SARS-CoV-2", "SPECIES", 73, 83], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 24, 69], ["SARS", "PROBLEM", 73, 77], ["infection", "PROBLEM", 85, 94], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["respiratory syndrome", "OBSERVATION", 37, 57], ["infection", "OBSERVATION", 85, 94]]], ["The prevention and control of coronavirus disease 2019 (COVID-19) is currently the most urgent issue facing the globe.INTRODUCTIONMany studies have confirmed that inflammatory storms are the key pathological basis determining the clinical symptoms, course, and prognosis of COVID-19 (3) .", [["coronavirus disease", "DISEASE", 30, 49], ["COVID-19", "CHEMICAL", 56, 64], ["coronavirus", "ORGANISM", 30, 41], ["coronavirus disease", "PROBLEM", 30, 49], ["COVID", "TEST", 56, 61], ["INTRODUCTIONMany studies", "TEST", 118, 142], ["inflammatory storms", "PROBLEM", 163, 182], ["the clinical symptoms", "PROBLEM", 226, 247], ["COVID", "TEST", 274, 279], ["coronavirus disease", "OBSERVATION", 30, 49], ["globe", "ANATOMY", 112, 117], ["inflammatory", "OBSERVATION", 163, 175]]], ["According to the diagnosis and treatment protocol for COVID-19 (seventh edition) (4), the pathologic anatomy of patients with COVID-19 revealed that the lungs, spleen, cardiovascular system, liver, kidney, and other organs were markedly infiltrated by a large number of inflammatory cells, which resulted in functional damage and functional failure.", [["lungs", "ANATOMY", 153, 158], ["spleen", "ANATOMY", 160, 166], ["cardiovascular system", "ANATOMY", 168, 189], ["liver", "ANATOMY", 191, 196], ["kidney", "ANATOMY", 198, 204], ["organs", "ANATOMY", 216, 222], ["inflammatory cells", "ANATOMY", 270, 288], ["patients", "ORGANISM", 112, 120], ["lungs", "ORGAN", 153, 158], ["spleen", "ORGAN", 160, 166], ["cardiovascular system", "MULTI-TISSUE_STRUCTURE", 168, 189], ["liver", "ORGAN", 191, 196], ["kidney", "ORGAN", 198, 204], ["organs", "ORGAN", 216, 222], ["cells", "CELL", 283, 288], ["inflammatory cells", "CELL_TYPE", 270, 288], ["patients", "SPECIES", 112, 120], ["treatment protocol", "TREATMENT", 31, 49], ["COVID", "TEST", 54, 59], ["COVID", "TEST", 126, 131], ["the lungs, spleen, cardiovascular system, liver, kidney, and other organs", "PROBLEM", 149, 222], ["markedly infiltrated", "PROBLEM", 228, 248], ["inflammatory cells", "PROBLEM", 270, 288], ["functional damage", "PROBLEM", 308, 325], ["functional failure", "PROBLEM", 330, 348], ["lungs", "ANATOMY", 153, 158], ["spleen", "ANATOMY", 160, 166], ["cardiovascular system", "ANATOMY", 168, 189], ["liver", "ANATOMY", 191, 196], ["kidney", "ANATOMY", 198, 204], ["organs", "ANATOMY", 216, 222], ["markedly", "OBSERVATION_MODIFIER", 228, 236], ["infiltrated", "OBSERVATION", 237, 248], ["large", "OBSERVATION_MODIFIER", 254, 259], ["number", "OBSERVATION_MODIFIER", 260, 266], ["inflammatory cells", "OBSERVATION", 270, 288], ["functional damage", "OBSERVATION", 308, 325], ["functional failure", "OBSERVATION", 330, 348]]], ["Many studies have confirmed that the impairment of immune function directly affects the course and prognosis of COVID-19 (5) .", [["Many studies", "TEST", 0, 12], ["the impairment of immune function", "PROBLEM", 33, 66], ["COVID", "TEST", 112, 117]]], ["By autopsy, a decrease was observed in the numbers of CD4 + and CD8 + T cells in the spleen and lymph nodes, and denaturation and necrosis of the spleen and lymph nodes were also found, in addition to the proliferation of spleen macrophages.", [["CD4 +", "ANATOMY", 54, 59], ["CD8 + T cells", "ANATOMY", 64, 77], ["spleen", "ANATOMY", 85, 91], ["lymph nodes", "ANATOMY", 96, 107], ["spleen", "ANATOMY", 146, 152], ["lymph nodes", "ANATOMY", 157, 168], ["spleen macrophages", "ANATOMY", 222, 240], ["necrosis", "DISEASE", 130, 138], ["CD4", "GENE_OR_GENE_PRODUCT", 54, 57], ["CD8", "GENE_OR_GENE_PRODUCT", 64, 67], ["spleen", "ORGAN", 85, 91], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 96, 107], ["spleen", "ORGAN", 146, 152], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 157, 168], ["spleen macrophages", "CELL", 222, 240], ["CD4", "PROTEIN", 54, 57], ["CD8 + T cells", "CELL_TYPE", 64, 77], ["spleen macrophages", "CELL_TYPE", 222, 240], ["a decrease", "PROBLEM", 12, 22], ["CD4", "TEST", 54, 57], ["CD8 + T cells in the spleen and lymph nodes", "PROBLEM", 64, 107], ["denaturation", "PROBLEM", 113, 125], ["necrosis of the spleen and lymph nodes", "PROBLEM", 130, 168], ["the proliferation of spleen macrophages", "PROBLEM", 201, 240], ["decrease", "OBSERVATION_MODIFIER", 14, 22], ["T cells", "OBSERVATION", 70, 77], ["spleen", "ANATOMY", 85, 91], ["lymph nodes", "OBSERVATION", 96, 107], ["denaturation", "OBSERVATION_MODIFIER", 113, 125], ["necrosis", "OBSERVATION", 130, 138], ["spleen", "ANATOMY", 146, 152], ["lymph nodes", "OBSERVATION", 157, 168], ["proliferation", "OBSERVATION", 205, 218], ["spleen", "ANATOMY", 222, 228], ["macrophages", "OBSERVATION", 229, 240]]], ["It has been speculated that T lymphocytes and macrophages may also be important targets for COVID-19 (6) .INTRODUCTIONSevere pneumonia and acute respiratory distress syndrome are the worst outcomes in patients with COVID-19, resulting in cytokine release syndrome and multiorgan failure; the role of IL-6 in the pathological development of patients with COVID-19 has been a focus of research (7, 8) , but the function of IL-6 in the course of the disease is still controversial (9) (10) (11) (12) .", [["T lymphocytes", "ANATOMY", 28, 41], ["macrophages", "ANATOMY", 46, 57], ["multiorgan", "ANATOMY", 268, 278], ["pneumonia", "DISEASE", 125, 134], ["acute respiratory distress syndrome", "DISEASE", 139, 174], ["multiorgan failure", "DISEASE", 268, 286], ["COVID-19", "CHEMICAL", 354, 362], ["COVID-19", "CHEMICAL", 92, 100], ["COVID-19", "CHEMICAL", 354, 362], ["T lymphocytes", "CELL", 28, 41], ["macrophages", "CELL", 46, 57], ["patients", "ORGANISM", 201, 209], ["IL-6", "GENE_OR_GENE_PRODUCT", 300, 304], ["patients", "ORGANISM", 340, 348], ["IL-6", "GENE_OR_GENE_PRODUCT", 421, 425], ["T lymphocytes", "CELL_TYPE", 28, 41], ["macrophages", "CELL_TYPE", 46, 57], ["cytokine", "PROTEIN", 238, 246], ["IL-6", "PROTEIN", 300, 304], ["IL-6", "PROTEIN", 421, 425], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 340, 348], ["macrophages", "PROBLEM", 46, 57], ["COVID", "TEST", 92, 97], ["pneumonia", "PROBLEM", 125, 134], ["acute respiratory distress syndrome", "PROBLEM", 139, 174], ["COVID", "TEST", 215, 220], ["cytokine release syndrome", "PROBLEM", 238, 263], ["multiorgan failure", "PROBLEM", 268, 286], ["COVID", "TEST", 354, 359], ["IL", "TEST", 421, 423], ["the disease", "PROBLEM", 443, 454], ["pneumonia", "OBSERVATION", 125, 134], ["acute", "OBSERVATION_MODIFIER", 139, 144], ["respiratory distress syndrome", "OBSERVATION", 145, 174], ["cytokine release syndrome", "OBSERVATION", 238, 263], ["multiorgan failure", "OBSERVATION", 268, 286], ["disease", "OBSERVATION", 447, 454]]], ["Lymphocytopenia is a common feature of COVID-19 and may be a key factor associated with disease severity and mortality (13) .", [["Lymphocytopenia", "DISEASE", 0, 15], ["COVID-19", "CELL", 39, 47], ["Lymphocytopenia", "PROBLEM", 0, 15], ["COVID", "TEST", 39, 44], ["disease severity", "PROBLEM", 88, 104], ["common feature", "OBSERVATION_MODIFIER", 21, 35]]], ["It is critically important to identify at the early stage of the infection those patients who would be prone to developing the most adverse effects.", [["infection", "DISEASE", 65, 74], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["the infection", "PROBLEM", 61, 74], ["infection", "OBSERVATION", 65, 74]]], ["Based on clinical data from Wuhan (which had a severe outbreak of COVID-19 early in the pandemic), we conducted an in-depth analysis to clarify some of the pathological mechanisms of the disease and identify simple measures to predict its severity early on.Ethical Approval and Consent to ParticipateThis study was approved by the Research Ethics Committee of the First Affiliated Hospital of the University of Science and Technology of China (USTC) and was therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.", [["COVID", "TEST", 66, 71], ["an in-depth analysis", "TEST", 112, 132], ["the disease", "PROBLEM", 183, 194], ["simple measures", "TREATMENT", 208, 223], ["This study", "TEST", 300, 310]]], ["All participants gave their informed consent prior to their inclusion in this study.", [["participants", "SPECIES", 4, 16], ["this study", "TEST", 73, 83]]], ["Consent was obtained directly from each patient or from a family member or other legal guardian.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47]]], ["If a patient was considered incapable of giving informed consent, a family member or other legal guardian was contacted to give informed consent on behalf of the patient.", [["patient", "ORGANISM", 5, 12], ["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 5, 12], ["patient", "SPECIES", 162, 169]]], ["All patients or their close relations were informed of the purpose of the study and signed informed consent.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the study", "TEST", 70, 79]]], ["The consent procedures were approved by the ethics committee.SubjectsWe collected the clinical data of all inpatients with COVID-19 in the cancer center of Wuhan Union Hospital from February 2, 2020 to March 17, 2020.Inclusion and Exclusion CriteriaThe diagnostic criteria for suspected cases of COVID-19 pneumonia included the following (4): (1) Epidemiological history included: (i) pre-onset history of travel or residence in Wuhan or other areas where local cases continue to spread, (ii) fever or respiratory symptoms in patients who were from Wuhan City or other areas with continued local spread and were exposed 14 days before onset, and (iii) a cluster or epidemiological association with COVID-19 infection; (2) the following clinical features were present: (i) fever, (ii) imaging features indicative of pneumonia, and (iii) a normal or decreased total number of white blood cells in the early stage of the disease or a reduced lymphocyte count; or (3) if there was any epidemiological history, a suspected case could be diagnosed in the presence of any two of the listed clinical manifestations.Inclusion and Exclusion CriteriaThe inclusion criteria were as follows: (1) The case met two criteria: (i) suspected COVID-19 and (ii) detection of COVID-19 nucleic acids by real-time fluorescent RT-PCR using sputum, pharyngeal swabs, or lower respiratory tract exudate; (2) nonmild severity.Inclusion and Exclusion CriteriaThe exclusion criteria were as follows: mild cases were defined according to the National Protocol: \"the clinical symptoms were mild, and there was no sign of pneumonia on imaging\" (4) .", [["cancer", "ANATOMY", 139, 145], ["respiratory", "ANATOMY", 502, 513], ["white blood cells", "ANATOMY", 874, 891], ["lymphocyte", "ANATOMY", 939, 949], ["sputum", "ANATOMY", 1316, 1322], ["pharyngeal swabs", "ANATOMY", 1324, 1340], ["lower respiratory tract exudate", "ANATOMY", 1345, 1376], ["cancer", "DISEASE", 139, 145], ["COVID", "DISEASE", 296, 301], ["pneumonia", "DISEASE", 305, 314], ["fever", "DISEASE", 493, 498], ["respiratory symptoms", "DISEASE", 502, 522], ["infection", "DISEASE", 707, 716], ["fever", "DISEASE", 772, 777], ["pneumonia", "DISEASE", 815, 824], ["COVID-19 nucleic acids", "CHEMICAL", 1255, 1277], ["pneumonia", "DISEASE", 1590, 1599], ["COVID-19", "CHEMICAL", 1224, 1232], ["cancer", "CANCER", 139, 145], ["patients", "ORGANISM", 526, 534], ["blood cells", "CELL", 880, 891], ["lymphocyte", "CELL", 939, 949], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 1324, 1340], ["white blood cells", "CELL_TYPE", 874, 891], ["COVID", "PROTEIN", 1255, 1260], ["patients", "SPECIES", 526, 534], ["COVID-19", "SPECIES", 698, 706], ["COVID", "TEST", 296, 301], ["pneumonia", "PROBLEM", 305, 314], ["local cases", "PROBLEM", 456, 467], ["fever", "PROBLEM", 493, 498], ["respiratory symptoms", "PROBLEM", 502, 522], ["continued local spread", "PROBLEM", 580, 602], ["COVID-19 infection", "PROBLEM", 698, 716], ["fever", "PROBLEM", 772, 777], ["imaging features", "TEST", 784, 800], ["pneumonia", "PROBLEM", 815, 824], ["white blood cells", "PROBLEM", 874, 891], ["the disease", "PROBLEM", 914, 925], ["a reduced lymphocyte count", "PROBLEM", 929, 955], ["COVID", "TEST", 1224, 1229], ["COVID", "TEST", 1255, 1260], ["nucleic acids", "TEST", 1264, 1277], ["fluorescent RT-PCR", "TEST", 1291, 1309], ["sputum", "TEST", 1316, 1322], ["pharyngeal swabs", "TEST", 1324, 1340], ["lower respiratory tract exudate", "PROBLEM", 1345, 1376], ["nonmild severity", "PROBLEM", 1382, 1398], ["mild cases", "PROBLEM", 1471, 1481], ["the clinical symptoms", "PROBLEM", 1532, 1553], ["pneumonia", "PROBLEM", 1590, 1599], ["imaging", "TEST", 1603, 1610], ["cancer", "OBSERVATION", 139, 145], ["pneumonia", "OBSERVATION", 305, 314], ["infection", "OBSERVATION", 707, 716], ["indicative of", "UNCERTAINTY", 801, 814], ["pneumonia", "OBSERVATION", 815, 824], ["normal", "OBSERVATION", 838, 844], ["decreased", "OBSERVATION_MODIFIER", 848, 857], ["total", "OBSERVATION_MODIFIER", 858, 863], ["number", "OBSERVATION_MODIFIER", 864, 870], ["early stage", "OBSERVATION_MODIFIER", 899, 910], ["disease", "OBSERVATION", 918, 925], ["reduced", "OBSERVATION_MODIFIER", 931, 938], ["lymphocyte count", "OBSERVATION", 939, 955], ["pharyngeal swabs", "ANATOMY", 1324, 1340], ["lower", "ANATOMY_MODIFIER", 1345, 1350], ["respiratory tract", "ANATOMY", 1351, 1368], ["mild", "OBSERVATION_MODIFIER", 1559, 1563], ["no sign of", "UNCERTAINTY", 1579, 1589], ["pneumonia", "OBSERVATION", 1590, 1599]]], ["Given the state of emergency at the time, only patients with moderate or severe cases were admitted to the cancer center of Wuhan Union Hospital; patients with mild symptoms were admitted to the mobile cabin hospital (14) .Inclusion and Exclusion CriteriaClinical data on 230 patients with COVID-19 pneumonia in the isolation ward of the cancer center of Wuhan Union Hospital who met the above criteria were collected from February 2 to March 17, 2020.Clinical Classification of Disease SeverityAll confirmed patients were clinically classified according to the \"Novel Coronavirus Pneumonia Treatment Scheme of the National Health Commission of the People's Republic of China (version 7)\" at the time of admission (4), as follows: (1) general type: symptoms such as fever and respiratory tract complaints were present, and manifestations of pneumonia could be seen on imaging; (2) serious type: any of the following criteria were met: (1) respiratory distress, respiratory rate (RR) \u2265 30 times/min; (2) resting oxygen saturation \u2264 93%; or (3) arterial partial oxygen pressure (PaO 2 )/oxygen absorption concentration (FiO 2 ) \u2264 300 mmHg (1 mmHg = 0.133 kPa); (3) critical type: any of the following criteria were met: (1) respiratory failure and a need for mechanical ventilation, (2) shock, or (3) a combination of factors with other organ failure requiring ICU care.Course of Disease and CT GradingThe course of disease was defined as the time (days) between the onset of clinical symptoms of COVID-19 and the time of discharge from the hospital (symptoms recovery).", [["cancer", "ANATOMY", 107, 113], ["cancer", "ANATOMY", 338, 344], ["respiratory tract", "ANATOMY", 776, 793], ["respiratory", "ANATOMY", 939, 950], ["respiratory", "ANATOMY", 961, 972], ["arterial", "ANATOMY", 1043, 1051], ["respiratory", "ANATOMY", 1222, 1233], ["organ", "ANATOMY", 1335, 1340], ["cancer", "DISEASE", 107, 113], ["pneumonia", "DISEASE", 299, 308], ["cancer", "DISEASE", 338, 344], ["Pneumonia", "DISEASE", 581, 590], ["fever", "DISEASE", 766, 771], ["respiratory tract complaints", "DISEASE", 776, 804], ["pneumonia", "DISEASE", 841, 850], ["respiratory distress", "DISEASE", 939, 959], ["oxygen", "CHEMICAL", 1011, 1017], ["oxygen", "CHEMICAL", 1060, 1066], ["oxygen", "CHEMICAL", 1085, 1091], ["respiratory failure", "DISEASE", 1222, 1241], ["shock", "DISEASE", 1285, 1290], ["organ failure", "DISEASE", 1335, 1348], ["oxygen", "CHEMICAL", 1011, 1017], ["oxygen", "CHEMICAL", 1060, 1066], ["oxygen", "CHEMICAL", 1085, 1091], ["patients", "ORGANISM", 47, 55], ["cancer", "CANCER", 107, 113], ["patients", "ORGANISM", 146, 154], ["patients", "ORGANISM", 276, 284], ["cancer", "CANCER", 338, 344], ["patients", "ORGANISM", 509, 517], ["tract", "ORGANISM_SUBDIVISION", 788, 793], ["oxygen", "SIMPLE_CHEMICAL", 1011, 1017], ["arterial", "MULTI-TISSUE_STRUCTURE", 1043, 1051], ["oxygen", "SIMPLE_CHEMICAL", 1060, 1066], ["oxygen", "SIMPLE_CHEMICAL", 1085, 1091], ["organ", "ORGAN", 1335, 1340], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 276, 284], ["patients", "SPECIES", 509, 517], ["People", "SPECIES", 649, 655], ["moderate or severe cases", "PROBLEM", 61, 85], ["mild symptoms", "PROBLEM", 160, 173], ["Exclusion CriteriaClinical data", "TEST", 237, 268], ["COVID", "TEST", 290, 295], ["pneumonia", "PROBLEM", 299, 308], ["Disease Severity", "PROBLEM", 479, 495], ["symptoms", "PROBLEM", 749, 757], ["fever", "PROBLEM", 766, 771], ["respiratory tract complaints", "PROBLEM", 776, 804], ["pneumonia", "PROBLEM", 841, 850], ["imaging", "TEST", 868, 875], ["respiratory distress", "PROBLEM", 939, 959], ["respiratory rate", "TEST", 961, 977], ["RR", "TEST", 979, 981], ["resting oxygen saturation", "TEST", 1003, 1028], ["arterial partial oxygen pressure", "TEST", 1043, 1075], ["PaO", "TEST", 1077, 1080], ["oxygen absorption concentration", "TEST", 1085, 1116], ["FiO", "TEST", 1118, 1121], ["respiratory failure", "PROBLEM", 1222, 1241], ["mechanical ventilation", "TREATMENT", 1257, 1279], ["shock", "PROBLEM", 1285, 1290], ["other organ failure", "PROBLEM", 1329, 1348], ["ICU care", "TREATMENT", 1359, 1367], ["Disease", "PROBLEM", 1378, 1385], ["CT Grading", "TEST", 1390, 1400], ["disease", "PROBLEM", 1414, 1421], ["clinical symptoms", "PROBLEM", 1474, 1491], ["COVID", "TEST", 1495, 1500], ["pneumonia", "OBSERVATION", 299, 308], ["cancer", "OBSERVATION", 338, 344], ["Disease", "OBSERVATION", 479, 486], ["respiratory tract", "ANATOMY", 776, 793], ["pneumonia", "OBSERVATION", 841, 850], ["respiratory", "ANATOMY", 939, 950], ["distress", "OBSERVATION", 951, 959], ["respiratory", "ANATOMY", 1222, 1233], ["failure", "OBSERVATION", 1234, 1241], ["organ", "ANATOMY", 1335, 1340], ["failure", "OBSERVATION", 1341, 1348], ["Disease", "OBSERVATION", 1378, 1385], ["disease", "OBSERVATION", 1414, 1421]]], ["All images were independently read by three senior radiological specialists.", [["All images", "TEST", 0, 10]]], ["The location, shape, number, and size of the abnormalities on chest CTs were carefully observed and recorded.", [["chest", "ANATOMY", 62, 67], ["the abnormalities", "PROBLEM", 41, 58], ["chest CTs", "TEST", 62, 71], ["shape", "OBSERVATION_MODIFIER", 14, 19], ["number", "OBSERVATION_MODIFIER", 21, 27], ["size", "OBSERVATION_MODIFIER", 33, 37], ["abnormalities", "OBSERVATION", 45, 58], ["chest", "ANATOMY", 62, 67]]], ["CT grading was defined according to the \"Novel Coronavirus Pneumonia Treatment Scheme of the National Health Commission of the People's Republic of China (version 7)\"and Chinese expert consensus (4, 15) .Real-Time Reverse Transcription Polymerase Chain Reaction TestsThe confirmation of COVID-19 was achieved by real-time reverse transcription polymerase chain reaction (RT-PCR) testing of throat sputum, pharyngeal swabs, and lower respiratory tract exudates of suspected patients.", [["throat sputum", "ANATOMY", 390, 403], ["pharyngeal swabs", "ANATOMY", 405, 421], ["lower respiratory tract", "ANATOMY", 427, 450], ["Pneumonia", "DISEASE", 59, 68], ["respiratory tract exudates", "DISEASE", 433, 459], ["throat sputum", "MULTI-TISSUE_STRUCTURE", 390, 403], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 405, 421], ["lower", "ORGANISM_SUBDIVISION", 427, 432], ["respiratory tract", "ORGANISM_SUBDIVISION", 433, 450], ["patients", "ORGANISM", 473, 481], ["COVID-19", "DNA", 287, 295], ["People", "SPECIES", 127, 133], ["patients", "SPECIES", 473, 481], ["CT grading", "TEST", 0, 10], ["Novel Coronavirus Pneumonia", "PROBLEM", 41, 68], ["Chain Reaction", "TEST", 247, 261], ["Tests", "TEST", 262, 267], ["COVID", "TEST", 287, 292], ["chain reaction", "TEST", 355, 369], ["RT-PCR", "TEST", 371, 377], ["throat sputum", "TEST", 390, 403], ["pharyngeal swabs", "TEST", 405, 421], ["lower respiratory tract exudates", "PROBLEM", 427, 459], ["Coronavirus", "OBSERVATION_MODIFIER", 47, 58], ["Pneumonia", "OBSERVATION", 59, 68], ["throat", "ANATOMY", 390, 396], ["pharyngeal swabs", "ANATOMY", 405, 421], ["lower", "ANATOMY_MODIFIER", 427, 432], ["respiratory tract", "ANATOMY", 433, 450]]], ["Following the recommendation of the China National Centre for Disease Control, two target genes were targeted as described previously (16) , namely, open reading frame 1ab (ORF1ab) and nucleocapsid protein (N), and these genes were simultaneously amplified and tested during the real-time RT-PCR assay.", [["open reading frame 1", "GENE_OR_GENE_PRODUCT", 149, 169], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 173, 179], ["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 185, 209], ["target genes", "DNA", 83, 95], ["open reading frame 1ab", "DNA", 149, 171], ["ORF1ab", "DNA", 173, 179], ["nucleocapsid protein", "PROTEIN", 185, 205], ["N", "DNA", 207, 208], ["Disease Control", "TREATMENT", 62, 77], ["nucleocapsid protein", "TEST", 185, 205]]], ["The primers for target 1 (ORF1ab) were forward primer CCCTGTGGGTTTTACACTTAA; reverse primer ACGATTGTGCATCAGCTGA; and probe 5 -FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3 .", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 26, 32], ["target 1", "DNA", 16, 24], ["ORF1ab", "DNA", 26, 32], ["forward primer", "DNA", 39, 53], ["reverse primer", "DNA", 77, 91], ["probe 5 -FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3", "DNA", 117, 165], ["target 1 (ORF1ab)", "TREATMENT", 16, 33], ["reverse primer ACGATTGTGCATCAGCTGA", "TREATMENT", 77, 111]]], ["The primers for target 2 (N) were forward primer GGGGAACT TCTCCTGCTAGAAT; reverse primer CAGACATTTTGCT CTCAAGCTG; and probe 5 -FAMTTGCTGCTGCTTGACAG ATT-TAMRA-3 .", [["TAMRA-3", "GENE_OR_GENE_PRODUCT", 152, 159], ["forward primer", "DNA", 34, 48], ["reverse primer", "DNA", 74, 88], ["probe 5 -FAMTTGCTGCTGCTTGACAG ATT-TAMRA-3", "DNA", 118, 159], ["target 2 (N)", "TREATMENT", 16, 28], ["reverse primer CAGACATTTTGCT CTCAAGCTG", "TREATMENT", 74, 112]]], ["A cycle threshold value (Ct value) less than 37 was defined as a positive result, and a Ct value exceeding 40 was defined as a negative test.Inflammatory Cytokines and General Laboratory TestsVenous blood was taken in the emergency department at admission and sent to the laboratory for examination of routine blood parameters and inflammatory cytokines.", [["blood", "ANATOMY", 199, 204], ["blood", "ANATOMY", 310, 315], ["blood", "ORGANISM_SUBSTANCE", 199, 204], ["blood", "ORGANISM_SUBSTANCE", 310, 315], ["Inflammatory Cytokines", "PROTEIN", 141, 163], ["inflammatory cytokines", "PROTEIN", 331, 353], ["A cycle threshold value", "TEST", 0, 23], ["Ct value", "TEST", 25, 33], ["a Ct value", "TEST", 86, 96], ["a negative test", "TEST", 125, 140], ["Inflammatory Cytokines", "PROBLEM", 141, 163], ["examination", "TEST", 287, 298], ["routine blood parameters", "TEST", 302, 326], ["inflammatory cytokines", "PROBLEM", 331, 353], ["inflammatory cytokines", "OBSERVATION", 331, 353]]], ["However, T lymphocyte subsets and some biochemical indicators were obtained by testing fasting blood the morning after admission.", [["T lymphocyte", "ANATOMY", 9, 21], ["blood", "ANATOMY", 95, 100], ["T lymphocyte", "CELL", 9, 21], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["T lymphocyte subsets", "CELL_TYPE", 9, 29], ["T lymphocyte subsets", "TEST", 9, 29], ["fasting blood", "TEST", 87, 100]]], ["Serum inflammatory cytokines were detected by enzyme-linked immunosorbent assays for IL-2, IL-4, IL-6, IL-6, IL-10, and tumor necrosis factor-\u03b1 (TNF-\u03b1).", [["Serum", "ANATOMY", 0, 5], ["necrosis", "DISEASE", 126, 134], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IL-2", "GENE_OR_GENE_PRODUCT", 85, 89], ["IL-4", "GENE_OR_GENE_PRODUCT", 91, 95], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["IL-6", "GENE_OR_GENE_PRODUCT", 103, 107], ["IL-10", "GENE_OR_GENE_PRODUCT", 109, 114], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 120, 143], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 145, 150], ["Serum inflammatory cytokines", "PROTEIN", 0, 28], ["IL-10", "PROTEIN", 109, 114], ["tumor necrosis factor-\u03b1", "PROTEIN", 120, 143], ["TNF", "PROTEIN", 145, 148], ["Serum inflammatory cytokines", "TEST", 0, 28], ["enzyme", "TEST", 46, 52], ["immunosorbent assays", "TEST", 60, 80], ["IL", "TEST", 85, 87], ["IL", "TEST", 91, 93], ["IL", "TEST", 97, 99], ["IL", "TEST", 103, 105], ["IL", "TEST", 109, 111], ["tumor necrosis factor", "PROBLEM", 120, 141], ["TNF", "TEST", 145, 148], ["inflammatory", "OBSERVATION_MODIFIER", 6, 18], ["tumor", "OBSERVATION_MODIFIER", 120, 125], ["necrosis", "OBSERVATION", 126, 134]]], ["The tests were carried out strictly according to the instructions, and the test kits were purchased from eBioscience Company (EPX650-16500-901).Flow Cytometry AssayIn order to quantify T lymphocyte subsets, 100 \u00b5l of whole blood was incubated in 900 \u00b5l of Tris-NH4Cl buffer (Thermo Fisher Scientific) at room temperature for 5 min to lyse erythrocytes.", [["T lymphocyte", "ANATOMY", 185, 197], ["whole blood", "ANATOMY", 217, 228], ["erythrocytes", "ANATOMY", 339, 351], ["Tris-NH4Cl", "CHEMICAL", 256, 266], ["Tris-NH4Cl", "CHEMICAL", 256, 266], ["T lymphocyte", "CELL", 185, 197], ["blood", "ORGANISM_SUBSTANCE", 223, 228], ["Tris-NH4Cl", "SIMPLE_CHEMICAL", 256, 266], ["erythrocytes", "CELL", 339, 351], ["T lymphocyte subsets", "CELL_TYPE", 185, 205], ["lyse erythrocytes", "CELL_TYPE", 334, 351], ["The tests", "TEST", 0, 9], ["the test kits", "TEST", 71, 84], ["Flow Cytometry", "TEST", 144, 158], ["T lymphocyte subsets", "TEST", 185, 205], ["whole blood", "TEST", 217, 228], ["Tris", "TREATMENT", 256, 260], ["lyse erythrocytes", "TEST", 334, 351]]], ["After two washes with phosphate-buffered saline (PBS), cells were incubated with CD3-APC, CD4-PerCP, and CD8-FITC antibodies (5 \u00b5g/ml each, all from BD Biosciences) for 15 min on ice.", [["cells", "ANATOMY", 55, 60], ["phosphate", "CHEMICAL", 22, 31], ["phosphate", "CHEMICAL", 22, 31], ["FITC", "CHEMICAL", 109, 113], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 22, 47], ["cells", "CELL", 55, 60], ["CD3", "GENE_OR_GENE_PRODUCT", 81, 84], ["APC", "GENE_OR_GENE_PRODUCT", 85, 88], ["CD4", "GENE_OR_GENE_PRODUCT", 90, 93], ["PerCP", "SIMPLE_CHEMICAL", 94, 99], ["CD8-FITC antibodies", "GENE_OR_GENE_PRODUCT", 105, 124], ["CD3", "PROTEIN", 81, 84], ["APC", "PROTEIN", 85, 88], ["CD4", "PROTEIN", 90, 93], ["PerCP", "PROTEIN", 94, 99], ["CD8", "PROTEIN", 105, 108], ["FITC antibodies", "PROTEIN", 109, 124], ["phosphate-buffered saline (PBS", "TREATMENT", 22, 52], ["cells", "TEST", 55, 60], ["CD3", "TEST", 81, 84], ["APC", "TEST", 85, 88], ["CD4", "TEST", 90, 93], ["PerCP", "TEST", 94, 99], ["CD8", "TEST", 105, 108], ["FITC antibodies", "TEST", 109, 124]]], ["After another two washes with PBS, cells were resuspended in 500 \u00b5l of PBS.", [["cells", "ANATOMY", 35, 40], ["cells", "CELL", 35, 40], ["PBS", "TREATMENT", 30, 33], ["cells", "TREATMENT", 35, 40], ["PBS", "TREATMENT", 71, 74]]], ["Samples were analyzed on a BD FACS Canto Plus flow cytometer.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["flow cytometer", "TEST", 46, 60]]], ["Among all collected events, single events were gated between forward scatter (FSC)-A and FSC-H.", [["single events", "PROBLEM", 28, 41], ["FSC", "TEST", 78, 81]]], ["Cell debris was excluded, and intact cells were then gated from single events based on FSC-A and side scatter (SSC).", [["Cell", "ANATOMY", 0, 4], ["cells", "ANATOMY", 37, 42], ["Cell", "CELL", 0, 4], ["cells", "CELL", 37, 42], ["intact cells", "CELL_TYPE", 30, 42], ["Cell debris", "PROBLEM", 0, 11], ["FSC", "TEST", 87, 90], ["debris", "OBSERVATION", 5, 11]]], ["Each cell population was then detected based on antibody staining.Statistical AnalysisAll statistical analyses were conducted with Statistical Package for the Social Sciences version 16.0 (SPSS, Company, Chicago, IL, United States).", [["cell", "ANATOMY", 5, 9], ["cell", "CELL", 5, 9], ["Each cell population", "PROBLEM", 0, 20], ["antibody staining", "TEST", 48, 65], ["Statistical Analysis", "TEST", 66, 86], ["All statistical analyses", "TEST", 86, 110]]], ["All continuous data were tested for normal distributions using the Kolmogorov-Smirnov test.", [["All continuous data", "TEST", 0, 19], ["the Kolmogorov-Smirnov test", "TEST", 63, 90]]], ["Categorical variables were expressed as constituent ratios and percentages in each category.", [["Categorical variables", "TEST", 0, 21], ["constituent ratios", "TEST", 40, 58]]], ["One-way ANOVA or Kruskal-Wallis analysis was applied to continuous variables, and the chi-square test or Fisher's exact test was applied to categorical variables.", [["Kruskal-Wallis analysis", "TEST", 17, 40], ["the chi-square test", "TEST", 82, 101], ["Fisher's exact test", "TEST", 105, 124]]], ["Differences in cytokine and T lymphocyte subsets tested twice for each patient were assessed by paired t-test or Wilcoxon signed rank test.", [["T lymphocyte", "ANATOMY", 28, 40], ["T lymphocyte", "CELL", 28, 40], ["patient", "ORGANISM", 71, 78], ["cytokine", "PROTEIN", 15, 23], ["T lymphocyte subsets", "CELL_TYPE", 28, 48], ["patient", "SPECIES", 71, 78], ["cytokine and T lymphocyte subsets", "TEST", 15, 48], ["paired t-test", "TEST", 96, 109], ["Wilcoxon signed rank test", "TEST", 113, 138]]], ["Correlation analysis was used to determine the relationship between N/LRs and inflammatory cytokines, T lymphocyte subsets, severity of illness, course of disease, or CT grading.", [["T lymphocyte", "ANATOMY", 102, 114], ["T lymphocyte", "CELL", 102, 114], ["inflammatory cytokines", "PROTEIN", 78, 100], ["T lymphocyte subsets", "CELL_TYPE", 102, 122], ["Correlation analysis", "TEST", 0, 20], ["N/LRs", "TREATMENT", 68, 73], ["inflammatory cytokines", "PROBLEM", 78, 100], ["illness", "PROBLEM", 136, 143], ["disease", "PROBLEM", 155, 162], ["CT grading", "TEST", 167, 177], ["inflammatory", "OBSERVATION_MODIFIER", 78, 90]]], ["N/LRs in different patient condition groups were tested by Kruskal-Wallis analysis and the Jonckheere-Terpstra trend test.", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["Kruskal-Wallis analysis", "TEST", 59, 82], ["the Jonckheere", "TEST", 87, 101]]], ["Binary logistic regression analysis was used to test the risk factors for the severity level of patients with COVID-19.", [["COVID-19", "CHEMICAL", 110, 118], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["Binary logistic regression analysis", "TEST", 0, 35], ["COVID", "TEST", 110, 115]]], ["A P value < 0.05 was considered statistically significant.RESULTS(1) Clinical characteristics of patients with COVID-19.RESULTSWe collected 230 patients with COVID-19; 99 (43%) patients were male, the average age was 62 (16) years, and the total course of disease was 27 (18) days.", [["COVID-19", "CHEMICAL", 111, 119], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 144, 152], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 177, 185], ["A P value", "TEST", 0, 9], ["COVID", "TEST", 111, 116], ["COVID", "TEST", 158, 163], ["disease", "PROBLEM", 256, 263]]], ["The distribution of severity categories was as follows: 190 (82.6%) patients had the general type, 35 (15.2%) patients had the serious type, and five (2.2%) patients had the critical type.", [["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 157, 165], ["severity categories", "TEST", 20, 39], ["the general type", "TEST", 81, 97], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["According to CT grading, 99 (43.0%) patients were in the early stage, nearly half (106 patients, 46.1%) were in the progressive stage, and 25 (10.9%) were in the critical stage.", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 87, 95], ["CT grading", "TEST", 13, 23], ["progressive", "OBSERVATION_MODIFIER", 116, 127]]], ["The underlying (comorbid) diseases of the patients were as follows: 10 (4.3%) patients had respiratory system diseases, 51 (22.2%) patients had immune-related diseases, 79 (34.3%) patients had cardiovascular system diseases, 15 (6.5%) patients had liver or kidney diseases, and 127 (55.2%) patients had other comorbidities.", [["respiratory system", "ANATOMY", 91, 109], ["cardiovascular system", "ANATOMY", 193, 214], ["liver", "ANATOMY", 248, 253], ["kidney", "ANATOMY", 257, 263], ["respiratory system diseases", "DISEASE", 91, 118], ["immune-related diseases", "DISEASE", 144, 167], ["cardiovascular system diseases", "DISEASE", 193, 223], ["liver or kidney diseases", "DISEASE", 248, 272], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 180, 188], ["patients", "ORGANISM", 235, 243], ["liver", "ORGAN", 248, 253], ["kidney", "ORGAN", 257, 263], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 235, 243], ["patients", "SPECIES", 290, 298], ["The underlying (comorbid) diseases", "PROBLEM", 0, 34], ["respiratory system diseases", "PROBLEM", 91, 118], ["immune-related diseases", "PROBLEM", 144, 167], ["cardiovascular system diseases", "PROBLEM", 193, 223], ["liver or kidney diseases", "PROBLEM", 248, 272], ["other comorbidities", "PROBLEM", 303, 322], ["respiratory system", "ANATOMY", 91, 109], ["cardiovascular system", "ANATOMY", 193, 214], ["diseases", "OBSERVATION", 215, 223], ["liver", "ANATOMY", 248, 253], ["kidney", "ANATOMY", 257, 263], ["diseases", "OBSERVATION", 264, 272]]], ["The patients' initial symptoms were as follows: 154 (67.0%) patients had fever, 109 (47.4%) patients had respiratory system symptoms, 45 (19.6%) patients had general symptoms, nine (3.9%) patients had cardiovascular system symptoms, 21 (9.1%) patients had digestive system symptoms, 16 (7.0%) patients had nervous system symptoms, and five (2.2%) patients were asymptomatic.", [["respiratory system", "ANATOMY", 105, 123], ["cardiovascular system", "ANATOMY", 201, 222], ["digestive system", "ANATOMY", 256, 272], ["nervous system", "ANATOMY", 306, 320], ["fever", "DISEASE", 73, 78], ["respiratory system symptoms", "DISEASE", 105, 132], ["cardiovascular system symptoms", "DISEASE", 201, 231], ["digestive system symptoms", "DISEASE", 256, 281], ["nervous system symptoms", "DISEASE", 306, 329], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 92, 100], ["patients", "ORGANISM", 145, 153], ["patients", "ORGANISM", 188, 196], ["patients", "ORGANISM", 243, 251], ["patients", "ORGANISM", 293, 301], ["nervous", "ANATOMICAL_SYSTEM", 306, 313], ["system", "ANATOMICAL_SYSTEM", 314, 320], ["patients", "ORGANISM", 347, 355], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 145, 153], ["patients", "SPECIES", 188, 196], ["patients", "SPECIES", 243, 251], ["patients", "SPECIES", 293, 301], ["patients", "SPECIES", 347, 355], ["The patients' initial symptoms", "PROBLEM", 0, 30], ["fever", "PROBLEM", 73, 78], ["respiratory system symptoms", "PROBLEM", 105, 132], ["general symptoms", "PROBLEM", 158, 174], ["cardiovascular system symptoms", "PROBLEM", 201, 231], ["digestive system symptoms", "PROBLEM", 256, 281], ["nervous system symptoms", "PROBLEM", 306, 329], ["asymptomatic", "PROBLEM", 361, 373], ["respiratory system", "ANATOMY", 105, 123], ["cardiovascular system", "ANATOMY", 201, 222]]], ["The damage to physiological systems was as follows (Multiple system damage were directly caused by COVID-19): 111 (48.3%) patients had respiratory system damage, 14 (6.1%) patients had cardiovascular system damage, 20 (8.7%) patients had liver function damage, 22 (9.6%) patients had renal function damage, 21 (9.1%) patients had digestive system damage, 16 (7.0%) patients had nervous system damage, and 14 (6.1%) patients had muscle damage.", [["respiratory system", "ANATOMY", 135, 153], ["cardiovascular system", "ANATOMY", 185, 206], ["liver", "ANATOMY", 238, 243], ["renal", "ANATOMY", 284, 289], ["digestive system", "ANATOMY", 330, 346], ["nervous system", "ANATOMY", 378, 392], ["muscle", "ANATOMY", 428, 434], ["respiratory system damage", "DISEASE", 135, 160], ["cardiovascular system damage", "DISEASE", 185, 213], ["liver function damage", "DISEASE", 238, 259], ["renal function damage", "DISEASE", 284, 305], ["digestive system damage", "DISEASE", 330, 353], ["nervous system damage", "DISEASE", 378, 399], ["muscle damage", "DISEASE", 428, 441], ["COVID-19", "CHEMICAL", 99, 107], ["patients", "ORGANISM", 122, 130], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 225, 233], ["liver", "ORGAN", 238, 243], ["patients", "ORGANISM", 271, 279], ["renal", "ORGAN", 284, 289], ["patients", "ORGANISM", 317, 325], ["digestive system", "MULTI-TISSUE_STRUCTURE", 330, 346], ["patients", "ORGANISM", 365, 373], ["nervous system", "ANATOMICAL_SYSTEM", 378, 392], ["patients", "ORGANISM", 415, 423], ["muscle", "ORGAN", 428, 434], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 225, 233], ["patients", "SPECIES", 271, 279], ["patients", "SPECIES", 317, 325], ["patients", "SPECIES", 365, 373], ["patients", "SPECIES", 415, 423], ["The damage to physiological systems", "PROBLEM", 0, 35], ["Multiple system damage", "PROBLEM", 52, 74], ["COVID", "TEST", 99, 104], ["respiratory system damage", "PROBLEM", 135, 160], ["cardiovascular system damage", "TEST", 185, 213], ["liver function damage", "TEST", 238, 259], ["renal function damage", "TEST", 284, 305], ["digestive system damage", "PROBLEM", 330, 353], ["nervous system damage", "PROBLEM", 378, 399], ["muscle damage", "PROBLEM", 428, 441], ["respiratory system", "ANATOMY", 135, 153], ["cardiovascular system", "ANATOMY", 185, 206], ["liver", "ANATOMY", 238, 243], ["renal", "ANATOMY", 284, 289], ["digestive system", "ANATOMY", 330, 346], ["nervous system", "ANATOMY", 378, 392], ["muscle", "ANATOMY", 428, 434], ["damage", "OBSERVATION", 435, 441]]], ["A total of 175 (76.1%) patients had general symptoms.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["general symptoms", "PROBLEM", 36, 52]]], ["Of the patients, three (1.3%) were asymptomatic.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["asymptomatic", "PROBLEM", 35, 47]]], ["The variables with statistical significance were identified by univariate analysis.", [["univariate analysis", "TEST", 63, 82]]], ["These variables were sex (male) (P = 0.005), underlying disease (cardiovascular system diseases) (P = 0.019), multisystem damage (muscle) (P = 0.047), course of disease (P = 0.007), pulse (P = 0.049), systolic pressure (P = 0.044), L (P = 0.", [["cardiovascular system", "ANATOMY", 65, 86], ["muscle", "ANATOMY", 130, 136], ["cardiovascular system diseases", "DISEASE", 65, 95], ["multisystem damage", "DISEASE", 110, 128], ["muscle", "ORGAN", 130, 136], ["underlying disease (cardiovascular system diseases", "PROBLEM", 45, 95], ["multisystem damage (muscle)", "PROBLEM", 110, 137], ["disease", "PROBLEM", 161, 168], ["pulse", "TEST", 182, 187], ["P", "TEST", 189, 190], ["systolic pressure", "TEST", 201, 218], ["P", "TEST", 220, 221], ["disease", "OBSERVATION", 56, 63], ["cardiovascular system", "ANATOMY", 65, 86], ["multisystem", "OBSERVATION_MODIFIER", 110, 121], ["damage", "OBSERVATION", 122, 128], ["muscle", "ANATOMY", 130, 136]]], ["029) (see Table 1 ).RESULTS(2) There were significant differences between the first test and last test regarding the cytokines and classification of leukocytes.RESULTSWe collected the data regarding the cytokines and T lymphocyte subsets and classification of leukocytes at the time of admission (first test) and the time of discharge (last test), and there were statistically significant differences in cytokine levels between admission and discharge.", [["leukocytes", "ANATOMY", 149, 159], ["T lymphocyte", "ANATOMY", 217, 229], ["leukocytes", "ANATOMY", 260, 270], ["leukocytes", "CELL", 149, 159], ["T lymphocyte", "CELL", 217, 229], ["leukocytes", "CELL", 260, 270], ["cytokines", "PROTEIN", 117, 126], ["leukocytes", "CELL_TYPE", 149, 159], ["cytokines", "PROTEIN", 203, 212], ["T lymphocyte subsets", "CELL_TYPE", 217, 237], ["leukocytes", "CELL_TYPE", 260, 270], ["cytokine", "PROTEIN", 404, 412], ["the first test", "TEST", 74, 88], ["last test", "TEST", 93, 102], ["the cytokines", "TEST", 113, 126], ["leukocytes", "PROBLEM", 149, 159], ["the data", "TEST", 180, 188], ["the cytokines", "TEST", 199, 212], ["T lymphocyte subsets", "TEST", 217, 237], ["leukocytes", "PROBLEM", 260, 270], ["cytokine levels", "TEST", 404, 419], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["leukocytes", "ANATOMY", 149, 159], ["significant", "OBSERVATION_MODIFIER", 377, 388], ["differences", "OBSERVATION_MODIFIER", 389, 400]]], ["For example, IL-6 and IL-10 were significantly decreased and increased, respectively (P = 0.006, P < 0.001).", [["IL-6", "GENE_OR_GENE_PRODUCT", 13, 17], ["IL-10", "GENE_OR_GENE_PRODUCT", 22, 27], ["IL-6", "PROTEIN", 13, 17], ["IL", "PROTEIN", 22, 24], ["IL", "TEST", 13, 15], ["IL", "TEST", 22, 24], ["P", "TEST", 86, 87], ["decreased", "OBSERVATION_MODIFIER", 47, 56], ["increased", "OBSERVATION_MODIFIER", 61, 70]]], ["The IL-6/IL-10 ratio was also significantly different (P < 0.001).", [["IL-6", "GENE_OR_GENE_PRODUCT", 4, 8], ["IL-10", "GENE_OR_GENE_PRODUCT", 9, 14], ["The IL", "TEST", 0, 6]]], ["Additionally, there were statistically significant differences in lymphocytes and N/LRs between admission and discharge (P = 0.002, P < 0.001).", [["lymphocytes", "ANATOMY", 66, 77], ["lymphocytes", "CELL", 66, 77], ["lymphocytes", "CELL_TYPE", 66, 77], ["lymphocytes", "TEST", 66, 77], ["P", "TEST", 121, 122], ["statistically", "OBSERVATION_MODIFIER", 25, 38], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["differences", "OBSERVATION_MODIFIER", 51, 62]]], ["However, there were no statistically significant differences in T lymphocyte subsets between admission and discharge ( Table 2) .RESULTS(3) Risk factors for the severity of COVID-19.", [["T lymphocyte", "ANATOMY", 64, 76], ["COVID-19", "CHEMICAL", 173, 181], ["T lymphocyte", "CELL", 64, 76], ["T lymphocyte subsets", "CELL_TYPE", 64, 84], ["COVID", "TEST", 173, 178], ["no", "UNCERTAINTY", 20, 22], ["statistically", "OBSERVATION_MODIFIER", 23, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["differences", "OBSERVATION_MODIFIER", 49, 60]]], ["The risk factors for the severity of COVID-19 were analyzed by binary logistic regression.", [["The risk factors", "PROBLEM", 0, 16], ["COVID", "TEST", 37, 42]]], ["Due to the small number of critical-type samples, the critical type and the serious type were grouped together.", [["samples", "ANATOMY", 41, 48], ["samples", "CANCER", 41, 48], ["small", "OBSERVATION_MODIFIER", 11, 16], ["number", "OBSERVATION_MODIFIER", 17, 23], ["critical", "OBSERVATION_MODIFIER", 27, 35], ["-type", "OBSERVATION_MODIFIER", 35, 40], ["critical type", "OBSERVATION_MODIFIER", 54, 67]]], ["Variables with statistically significant differences among different groups of diseases by univariate analysis were substituted into the regression equation, and finally, four variables with statistical significance were selected: male sex, underlying disease (cardiovascular disease), pulse, and N/LRs were all closely related to the severity of the disease (P = 0.004, P = 0.012, P = 0.013, P = 0.028) ( Table 3) .RESULTS(4) N/LRs are closely related to severity level and disease course.RESULTSWe found that N/LRs were closely related to the severity level and disease course of COVID-19 according to the Kruskal-Wallis test, P = 0.021 and P < 0.001, respectively ( Table 1) .", [["cardiovascular", "ANATOMY", 261, 275], ["cardiovascular disease", "DISEASE", 261, 283], ["cardiovascular", "ANATOMICAL_SYSTEM", 261, 275], ["univariate analysis", "TEST", 91, 110], ["the regression equation", "TEST", 133, 156], ["underlying disease (cardiovascular disease)", "PROBLEM", 241, 284], ["pulse", "TEST", 286, 291], ["N/LRs", "TEST", 297, 302], ["the disease", "PROBLEM", 347, 358], ["P", "TEST", 360, 361], ["P", "TEST", 371, 372], ["P", "TEST", 382, 383], ["P", "TEST", 393, 394], ["/LRs", "TEST", 428, 432], ["severity level", "PROBLEM", 456, 470], ["disease course", "PROBLEM", 475, 489], ["N/LRs", "TEST", 511, 516], ["the severity level", "PROBLEM", 541, 559], ["COVID", "TEST", 582, 587], ["P", "TEST", 629, 630], ["P", "TEST", 643, 644], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["disease", "OBSERVATION", 252, 259], ["disease", "OBSERVATION", 351, 358], ["disease", "OBSERVATION", 475, 482]]], ["The difference between each pair of groups was statistically significant.", [["significant", "OBSERVATION_MODIFIER", 61, 72]]], ["Patients with higher N/LRs had more severe disease.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["higher N/LRs", "PROBLEM", 14, 26], ["more severe disease", "PROBLEM", 31, 50], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["disease", "OBSERVATION", 43, 50]]], ["A Jonckheere-Terpstra trend test was performed and showed a statistically significant difference between each group; the more severe the disease, the higher the N/LR (Figure 1) .", [["A Jonckheere-Terpstra trend test", "TEST", 0, 32], ["the more severe the disease", "PROBLEM", 117, 144], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["difference", "OBSERVATION", 86, 96], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["disease", "OBSERVATION", 137, 144]]], ["Patients with higher N/LRs had longer disease courses (Figure 2 ) (P < 0.001).RESULTS(6) N/LRs were closely related to IL-6 and IL-10.", [["Patients", "ORGANISM", 0, 8], ["IL-6", "GENE_OR_GENE_PRODUCT", 119, 123], ["IL-10", "GENE_OR_GENE_PRODUCT", 128, 133], ["IL-6", "PROTEIN", 119, 123], ["IL", "PROTEIN", 128, 130], ["Patients", "SPECIES", 0, 8], ["higher N/LRs", "PROBLEM", 14, 26], ["longer disease courses", "PROBLEM", 31, 53], ["N/LRs", "TEST", 89, 94], ["IL", "TEST", 119, 121]]], ["We found that N/LRs were positively related to IL-6 and IL-10, P < 0.001 and P = 0.024, respectively.", [["IL-6", "GENE_OR_GENE_PRODUCT", 47, 51], ["IL-10", "GENE_OR_GENE_PRODUCT", 56, 61], ["IL", "PROTEIN", 47, 49], ["IL", "PROTEIN", 56, 58], ["N/LRs", "TEST", 14, 19], ["IL", "TEST", 47, 49], ["IL", "TEST", 56, 58], ["P", "TEST", 63, 64], ["P", "TEST", 77, 78]]], ["However, there was no significant correlation with other cytokines (Figure 3) .", [["cytokines", "PROTEIN", 57, 66], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33]]], ["The trend of the relationship between N/LRs and different inflammatory cytokines is shown in Figure 3 .RESULTS(7) N/LRs are closely related to CD3 + and CD8 + cells (T lymphocyte subsets).RESULTSWe found that N/LRs were negatively related to CD3 + and CD8 + T lymphocytes (P < 0.001 and P = 0.046, respectively; Figure 4 ).", [["CD3 + and CD8 + cells", "ANATOMY", 143, 164], ["T lymphocyte", "ANATOMY", 166, 178], ["CD3 +", "ANATOMY", 242, 247], ["CD8 + T lymphocytes", "ANATOMY", 252, 271], ["CD3", "GENE_OR_GENE_PRODUCT", 143, 146], ["CD8", "GENE_OR_GENE_PRODUCT", 153, 156], ["T lymphocyte", "CELL", 166, 178], ["CD3", "GENE_OR_GENE_PRODUCT", 242, 245], ["CD8", "GENE_OR_GENE_PRODUCT", 252, 255], ["N/LRs", "PROTEIN", 38, 43], ["inflammatory cytokines", "PROTEIN", 58, 80], ["CD3", "PROTEIN", 143, 146], ["CD8", "PROTEIN", 153, 156], ["T lymphocyte subsets", "CELL_TYPE", 166, 186], ["CD3", "PROTEIN", 242, 245], ["CD8", "PROTEIN", 252, 255], ["T lymphocytes", "CELL_TYPE", 258, 271], ["N/LRs", "TREATMENT", 38, 43], ["different inflammatory cytokines", "PROBLEM", 48, 80], ["N/LRs", "TEST", 114, 119], ["CD3", "TEST", 143, 146], ["CD8 + cells", "PROBLEM", 153, 164], ["N/LRs", "TEST", 209, 214], ["CD3", "TEST", 242, 245], ["CD8", "TEST", 252, 255], ["lymphocytes", "TEST", 260, 271], ["P", "TEST", 273, 274], ["P", "TEST", 287, 288], ["inflammatory cytokines", "OBSERVATION", 58, 80]]], ["The trend of the relationship between N/LRs and different T lymphocyte subsets is shown in Figure 4 .DISCUSSIONIn this study, we analyzed the clinical data of 230 patients diagnosed with non-mild COVID-19 in the cancer center of Wuhan Union Hospital and summarized the clinical characteristics of this disease.", [["T lymphocyte", "ANATOMY", 58, 70], ["cancer", "ANATOMY", 212, 218], ["COVID-19", "CHEMICAL", 196, 204], ["cancer", "DISEASE", 212, 218], ["T lymphocyte", "CELL", 58, 70], ["patients", "ORGANISM", 163, 171], ["cancer", "CANCER", 212, 218], ["T lymphocyte subsets", "CELL_TYPE", 58, 78], ["patients", "SPECIES", 163, 171], ["N/LRs", "TREATMENT", 38, 43], ["different T lymphocyte subsets", "TREATMENT", 48, 78], ["this study", "TEST", 114, 124], ["this disease", "PROBLEM", 297, 309], ["lymphocyte subsets", "OBSERVATION", 60, 78]]], ["We found the following: (1) N/LRs, male sex, underlying disease (cardiovascular disease), and pulse were all closely related to the severity of the disease; (2) N/LRs were positively correlated with the levels of cytokines (IL-6, IL-10); (3) N/LRs were negatively correlated with the proportion of CD3 + and CD8 + T lymphocyte subsets; (4) N/LRs were positively correlated with the severity of the disease, as the higher N/LRs were, the more serious the disease; (5) N/LRs were related to the course of disease, as the higher N/LRs were, the longer the course of disease; and (6) most patients had multisystem symptoms and injury and had underlying multisystem comorbidities.DISCUSSIONAs the COVID-19 epidemic continues to spread across the globe, effective treatment is urgent, and it is particularly crucial to explore the pathogenesis of the disease.", [["cardiovascular", "ANATOMY", 65, 79], ["CD3 + and CD8 + T lymphocyte", "ANATOMY", 298, 326], ["cardiovascular disease", "DISEASE", 65, 87], ["multisystem symptoms", "DISEASE", 598, 618], ["cardiovascular", "ANATOMICAL_SYSTEM", 65, 79], ["IL-6", "GENE_OR_GENE_PRODUCT", 224, 228], ["IL-10", "GENE_OR_GENE_PRODUCT", 230, 235], ["CD3", "GENE_OR_GENE_PRODUCT", 298, 301], ["CD8", "GENE_OR_GENE_PRODUCT", 308, 311], ["patients", "ORGANISM", 585, 593], ["cytokines", "PROTEIN", 213, 222], ["IL-6", "PROTEIN", 224, 228], ["IL", "PROTEIN", 230, 232], ["CD3", "PROTEIN", 298, 301], ["CD8", "PROTEIN", 308, 311], ["T lymphocyte subsets", "CELL_TYPE", 314, 334], ["patients", "SPECIES", 585, 593], ["underlying disease (cardiovascular disease)", "PROBLEM", 45, 88], ["the disease", "PROBLEM", 144, 155], ["N/LRs", "TEST", 161, 166], ["cytokines", "TEST", 213, 222], ["IL", "TEST", 224, 226], ["IL", "TEST", 230, 232], ["N/LRs", "TEST", 242, 247], ["CD3", "TEST", 298, 301], ["CD8", "TEST", 308, 311], ["N/LRs", "TEST", 340, 345], ["the disease", "PROBLEM", 394, 405], ["the higher N/LRs", "PROBLEM", 410, 426], ["the more serious the disease", "PROBLEM", 433, 461], ["N/LRs", "TEST", 467, 472], ["disease", "PROBLEM", 503, 510], ["the higher N/LRs", "PROBLEM", 515, 531], ["disease", "PROBLEM", 563, 570], ["multisystem symptoms", "PROBLEM", 598, 618], ["injury", "PROBLEM", 623, 629], ["underlying multisystem comorbidities", "PROBLEM", 638, 674], ["the COVID", "TEST", 688, 697], ["epidemic", "PROBLEM", 701, 709], ["the disease", "PROBLEM", 841, 852], ["disease", "OBSERVATION", 56, 63], ["disease", "OBSERVATION", 148, 155], ["disease", "OBSERVATION", 398, 405], ["disease", "OBSERVATION", 454, 461], ["disease", "OBSERVATION", 503, 510], ["disease", "OBSERVATION", 563, 570], ["multisystem", "OBSERVATION_MODIFIER", 649, 660], ["comorbidities", "OBSERVATION", 661, 674], ["globe", "ANATOMY", 741, 746], ["disease", "OBSERVATION", 845, 852]]], ["COVID-19 infection activates innate and adaptive immune responses.", [["COVID-19", "CHEMICAL", 0, 8], ["infection", "DISEASE", 9, 18], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["COVID-19", "SPECIES", 0, 8], ["COVID", "TEST", 0, 5], ["infection", "PROBLEM", 9, 18], ["infection", "OBSERVATION", 9, 18]]], ["However, uncontrolled damage from the natural inflammatory response and adaptive immune response may lead to local and systemic tissue damage.", [["tissue", "ANATOMY", 128, 134], ["tissue", "TISSUE", 128, 134], ["uncontrolled damage", "PROBLEM", 9, 28], ["the natural inflammatory response", "PROBLEM", 34, 67], ["adaptive immune response", "PROBLEM", 72, 96], ["local and systemic tissue damage", "PROBLEM", 109, 141], ["uncontrolled", "OBSERVATION_MODIFIER", 9, 21], ["damage", "OBSERVATION", 22, 28], ["natural", "OBSERVATION_MODIFIER", 38, 45], ["inflammatory response", "OBSERVATION", 46, 67], ["systemic tissue", "OBSERVATION", 119, 134], ["damage", "OBSERVATION", 135, 141]]], ["Lymphocytopenia is a common feature in patients with severe COVID-19, with a dramatic decrease in the number of CD4 + and CD8 + T cells, B cells, and natural killer (NK) cells (5, (17) (18) (19) and lower proportions of monocytes, eosinophils, and basophils among leukocytes (18, 20) ; in particular, patients with higher N/LRs have poorer outcomes (20) .", [["CD4 + and CD8 + T cells", "ANATOMY", 112, 135], ["B cells", "ANATOMY", 137, 144], ["natural killer (NK) cells", "ANATOMY", 150, 175], ["monocytes", "ANATOMY", 220, 229], ["eosinophils", "ANATOMY", 231, 242], ["basophils", "ANATOMY", 248, 257], ["leukocytes", "ANATOMY", 264, 274], ["Lymphocytopenia", "DISEASE", 0, 15], ["patients", "ORGANISM", 39, 47], ["CD4", "GENE_OR_GENE_PRODUCT", 112, 115], ["CD8", "GENE_OR_GENE_PRODUCT", 122, 125], ["B cells", "CELL", 137, 144], ["natural killer", "CELL", 150, 164], ["NK) cells", "CELL", 166, 175], ["monocytes", "CELL", 220, 229], ["eosinophils", "CELL", 231, 242], ["basophils", "CELL", 248, 257], ["leukocytes", "CELL", 264, 274], ["patients", "ORGANISM", 301, 309], ["CD4", "PROTEIN", 112, 115], ["CD8 + T cells", "CELL_TYPE", 122, 135], ["B cells", "CELL_TYPE", 137, 144], ["natural killer (NK) cells", "CELL_TYPE", 150, 175], ["monocytes", "CELL_TYPE", 220, 229], ["eosinophils", "CELL_TYPE", 231, 242], ["basophils", "CELL_TYPE", 248, 257], ["leukocytes", "CELL_TYPE", 264, 274], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 301, 309], ["Lymphocytopenia", "PROBLEM", 0, 15], ["severe COVID", "PROBLEM", 53, 65], ["a dramatic decrease", "PROBLEM", 75, 94], ["CD4", "TEST", 112, 115], ["CD8 + T cells", "PROBLEM", 122, 135], ["B cells", "TEST", 137, 144], ["natural killer (NK) cells", "TEST", 150, 175], ["monocytes", "TEST", 220, 229], ["eosinophils", "TEST", 231, 242], ["basophils", "TEST", 248, 257], ["leukocytes", "TEST", 264, 274], ["higher N/LRs", "PROBLEM", 315, 327], ["common feature", "OBSERVATION_MODIFIER", 21, 35], ["dramatic", "OBSERVATION_MODIFIER", 77, 85], ["decrease", "OBSERVATION_MODIFIER", 86, 94], ["natural killer", "ANATOMY", 150, 164], ["lower", "ANATOMY_MODIFIER", 199, 204], ["monocytes", "ANATOMY", 220, 229]]], ["Yang et al. found that NLRs can be considered independent biomarkers for indicating poor clinical outcomes (21) .", [["NLRs", "GENE_OR_GENE_PRODUCT", 23, 27], ["NLRs", "PROTEIN", 23, 27]]], ["Consistent with the above data, our research found that the NLRs were closely related to the severity and course of patients with non-mild COVID-19 and that higher N/LRs were related to longer courses and more severe non-mild COVID-19.DISCUSSIONCurrently, N/LRs are a well-known marker of systemic inflammation and infection, and they have been studied as predictors of bacterial infection, showing superior predictive value over conventional inflammatory markers (22) (23) (24) .", [["inflammation", "DISEASE", 298, 310], ["infection", "DISEASE", 315, 324], ["bacterial infection", "DISEASE", 370, 389], ["COVID-19", "CHEMICAL", 226, 234], ["NLRs", "GENE_OR_GENE_PRODUCT", 60, 64], ["patients", "ORGANISM", 116, 124], ["N/LRs", "GENE_OR_GENE_PRODUCT", 256, 261], ["NLRs", "PROTEIN", 60, 64], ["patients", "SPECIES", 116, 124], ["the NLRs", "TEST", 56, 64], ["non-mild COVID", "TEST", 130, 144], ["higher N/LRs", "PROBLEM", 157, 169], ["more severe non-mild COVID", "PROBLEM", 205, 231], ["systemic inflammation", "PROBLEM", 289, 310], ["infection", "PROBLEM", 315, 324], ["bacterial infection", "PROBLEM", 370, 389], ["conventional inflammatory markers", "TEST", 430, 463], ["severe", "OBSERVATION_MODIFIER", 210, 216], ["systemic", "OBSERVATION_MODIFIER", 289, 297], ["inflammation", "OBSERVATION", 298, 310], ["infection", "OBSERVATION", 315, 324], ["bacterial", "OBSERVATION_MODIFIER", 370, 379], ["infection", "OBSERVATION", 380, 389], ["inflammatory", "OBSERVATION_MODIFIER", 443, 455]]], ["In addition, the N/LRs have displayed good predictive power for pneumonia, as well as dose-response information relating to the burden of community-acquired pneumonia, such as pneumonia severity or mortality (25, 26) .", [["pneumonia", "DISEASE", 64, 73], ["pneumonia", "DISEASE", 157, 166], ["pneumonia", "DISEASE", 176, 185], ["the N/LRs", "TREATMENT", 13, 22], ["pneumonia", "PROBLEM", 64, 73], ["community-acquired pneumonia", "PROBLEM", 138, 166], ["pneumonia severity", "PROBLEM", 176, 194], ["pneumonia", "OBSERVATION", 64, 73], ["pneumonia", "OBSERVATION", 157, 166], ["pneumonia", "OBSERVATION", 176, 185]]], ["Neutrophilia and lymphocytopenia are physiological responses of the innate immune system to systemic inflammation.", [["Neutrophilia", "DISEASE", 0, 12], ["lymphocytopenia", "DISEASE", 17, 32], ["inflammation", "DISEASE", 101, 113], ["immune system", "ANATOMICAL_SYSTEM", 75, 88], ["Neutrophilia", "PROBLEM", 0, 12], ["lymphocytopenia", "PROBLEM", 17, 32], ["systemic inflammation", "PROBLEM", 92, 113], ["lymphocytopenia", "OBSERVATION", 17, 32], ["systemic", "OBSERVATION_MODIFIER", 92, 100], ["inflammation", "OBSERVATION", 101, 113]]], ["Lymphocytopenia consists of accelerated apoptosis and margination of lymphocytes within the reticuloendothelial system, liver, and splanchnic lymphatic system and of the redistribution of lymphocytes within the lymphatic system (27) (28) (29) .", [["lymphocytes", "ANATOMY", 69, 80], ["reticuloendothelial system", "ANATOMY", 92, 118], ["liver", "ANATOMY", 120, 125], ["splanchnic lymphatic system", "ANATOMY", 131, 158], ["lymphocytes", "ANATOMY", 188, 199], ["lymphatic system", "ANATOMY", 211, 227], ["Lymphocytopenia", "DISEASE", 0, 15], ["lymphocytes", "CELL", 69, 80], ["reticuloendothelial system", "ANATOMICAL_SYSTEM", 92, 118], ["liver", "ORGAN", 120, 125], ["splanchnic lymphatic system", "ANATOMICAL_SYSTEM", 131, 158], ["lymphocytes", "CELL", 188, 199], ["lymphatic system", "MULTI-TISSUE_STRUCTURE", 211, 227], ["lymphocytes", "CELL_TYPE", 69, 80], ["lymphocytes", "CELL_TYPE", 188, 199], ["Lymphocytopenia", "PROBLEM", 0, 15], ["accelerated apoptosis", "PROBLEM", 28, 49], ["margination of lymphocytes within the reticuloendothelial system, liver, and splanchnic lymphatic system", "PROBLEM", 54, 158], ["accelerated", "OBSERVATION_MODIFIER", 28, 39], ["apoptosis", "OBSERVATION", 40, 49], ["margination", "OBSERVATION_MODIFIER", 54, 65], ["lymphocytes", "OBSERVATION", 69, 80], ["reticuloendothelial system", "ANATOMY", 92, 118], ["liver", "ANATOMY", 120, 125], ["splanchnic", "ANATOMY_MODIFIER", 131, 141], ["lymphatic system", "ANATOMY", 142, 158], ["redistribution", "OBSERVATION_MODIFIER", 170, 184], ["lymphocytes", "OBSERVATION", 188, 199], ["lymphatic system", "ANATOMY", 211, 227]]], ["As immune changes and inflammation are the core pathological basis of COVID-19, compared with imaging and biochemical examination, N/LRs may be a simpler and more specific way to determine the prognosis of COVID-19.DISCUSSIONMost patients with severe COVID-19 show significantly elevated serum levels of inflammatory cytokines, such as IL-6 and IL-1, as well as IL-2, IL-17, G-GSF, GM-GSF, IP-10, MCP1, MIP-1a (also known as CCL3), and TNF, known as a cytokine storm (5, (17) (18) (19) .", [["serum", "ANATOMY", 288, 293], ["inflammation", "DISEASE", 22, 34], ["COVID-19", "CHEMICAL", 251, 259], ["patients", "ORGANISM", 230, 238], ["serum", "ORGANISM_SUBSTANCE", 288, 293], ["IL-6", "GENE_OR_GENE_PRODUCT", 336, 340], ["IL-1", "GENE_OR_GENE_PRODUCT", 345, 349], ["IL-2", "GENE_OR_GENE_PRODUCT", 362, 366], ["IL-17", "GENE_OR_GENE_PRODUCT", 368, 373], ["G-GSF", "GENE_OR_GENE_PRODUCT", 375, 380], ["GM-GSF", "GENE_OR_GENE_PRODUCT", 382, 388], ["IP-10", "GENE_OR_GENE_PRODUCT", 390, 395], ["MCP1", "GENE_OR_GENE_PRODUCT", 397, 401], ["MIP-1a", "GENE_OR_GENE_PRODUCT", 403, 409], ["CCL3", "GENE_OR_GENE_PRODUCT", 425, 429], ["TNF", "GENE_OR_GENE_PRODUCT", 436, 439], ["inflammatory cytokines", "PROTEIN", 304, 326], ["IL-6", "PROTEIN", 336, 340], ["IL", "PROTEIN", 345, 347], ["GSF", "PROTEIN", 377, 380], ["GM", "PROTEIN", 382, 384], ["GSF", "PROTEIN", 385, 388], ["IP-10", "PROTEIN", 390, 395], ["MCP1", "PROTEIN", 397, 401], ["MIP-1a", "PROTEIN", 403, 409], ["CCL3", "PROTEIN", 425, 429], ["TNF", "PROTEIN", 436, 439], ["cytokine", "PROTEIN", 452, 460], ["patients", "SPECIES", 230, 238], ["immune changes", "PROBLEM", 3, 17], ["inflammation", "PROBLEM", 22, 34], ["COVID", "TEST", 70, 75], ["imaging", "TEST", 94, 101], ["biochemical examination", "TEST", 106, 129], ["LRs", "TEST", 133, 136], ["COVID", "TEST", 206, 211], ["severe COVID", "TEST", 244, 256], ["significantly elevated serum levels", "PROBLEM", 265, 300], ["inflammatory cytokines", "PROBLEM", 304, 326], ["IL", "TEST", 336, 338], ["IL", "TEST", 345, 347], ["IL", "TEST", 362, 364], ["IL", "TEST", 368, 370], ["G", "TEST", 375, 376], ["GM", "TEST", 382, 384], ["IP", "TEST", 390, 392], ["MCP1", "TEST", 397, 401], ["MIP", "TEST", 403, 406], ["TNF", "PROBLEM", 436, 439], ["a cytokine storm", "TEST", 450, 466], ["inflammation", "OBSERVATION", 22, 34], ["inflammatory cytokines", "OBSERVATION", 304, 326], ["TNF", "ANATOMY", 436, 439]]], ["In our research, we found that cytokines, such as serum IL-2, IL-4, IL-6, IL-10, TNF-\u03b1, and INF\u03b3, were significantly elevated at admission, and in some patients, these inflammatory cytokines were reviewed before discharge.", [["serum", "ANATOMY", 50, 55], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["IL-2", "GENE_OR_GENE_PRODUCT", 56, 60], ["IL-4", "GENE_OR_GENE_PRODUCT", 62, 66], ["IL-6", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL-10", "GENE_OR_GENE_PRODUCT", 74, 79], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 81, 86], ["INF\u03b3", "GENE_OR_GENE_PRODUCT", 92, 96], ["patients", "ORGANISM", 152, 160], ["cytokines", "PROTEIN", 31, 40], ["TNF", "PROTEIN", 81, 84], ["INF\u03b3", "PROTEIN", 92, 96], ["inflammatory cytokines", "PROTEIN", 168, 190], ["patients", "SPECIES", 152, 160], ["cytokines", "TEST", 31, 40], ["serum IL", "TEST", 50, 58], ["IL", "TEST", 62, 64], ["IL", "TEST", 68, 70], ["IL", "TEST", 74, 76], ["TNF", "TEST", 81, 84], ["significantly elevated", "PROBLEM", 103, 125], ["these inflammatory cytokines", "PROBLEM", 162, 190], ["cytokines", "OBSERVATION", 31, 40], ["INF", "ANATOMY", 92, 95], ["inflammatory", "OBSERVATION_MODIFIER", 168, 180]]], ["There were statistically significant differences in cytokine levels at admission and discharge.", [["cytokine", "PROTEIN", 52, 60], ["statistically significant differences in cytokine levels", "PROBLEM", 11, 67], ["statistically", "OBSERVATION_MODIFIER", 11, 24], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["differences", "OBSERVATION_MODIFIER", 37, 48]]], ["Interestingly, we found that in the process of treatment, the levels of some inflammatory cytokines were decreased, while others were increased.", [["inflammatory cytokines", "PROTEIN", 77, 99], ["treatment", "TREATMENT", 47, 56], ["the levels", "TEST", 58, 68], ["some inflammatory cytokines", "PROBLEM", 72, 99], ["some", "OBSERVATION_MODIFIER", 72, 76], ["inflammatory", "OBSERVATION_MODIFIER", 77, 89], ["cytokines", "OBSERVATION", 90, 99], ["decreased", "OBSERVATION_MODIFIER", 105, 114], ["increased", "OBSERVATION_MODIFIER", 134, 143]]], ["This phenomenon may be because some inflammatory cytokines are pro-inflammatory and others are anti-inflammatory; these changes may reflect the dynamic transformation process of inflammation from damage to repair during homeostasis and inflammation (30) .", [["inflammation", "DISEASE", 178, 190], ["inflammation", "DISEASE", 236, 248], ["inflammatory cytokines", "PROTEIN", 36, 58], ["some inflammatory cytokines", "PROBLEM", 31, 58], ["the dynamic transformation process", "PROBLEM", 140, 174], ["inflammation", "PROBLEM", 178, 190], ["repair", "TREATMENT", 206, 212], ["inflammation", "PROBLEM", 236, 248], ["may be because", "UNCERTAINTY", 16, 30], ["inflammatory", "OBSERVATION_MODIFIER", 36, 48], ["pro-inflammatory", "OBSERVATION_MODIFIER", 63, 79], ["anti-inflammatory", "OBSERVATION_MODIFIER", 95, 112], ["dynamic transformation", "OBSERVATION", 144, 166], ["inflammation", "OBSERVATION", 178, 190], ["repair", "OBSERVATION", 206, 212], ["inflammation", "OBSERVATION_MODIFIER", 236, 248]]], ["More importantly, correlation analysis indicated that N/LRs were closely related to IL-6 and IL-10.DISCUSSIONA recent study showed that M1 macrophages produce proinflammatory cytokines, such as IL-6, and that M2 macrophages produce anti-inflammatory cytokines, such as IL-10 (30).", [["M1 macrophages", "ANATOMY", 136, 150], ["M2 macrophages", "ANATOMY", 209, 223], ["N/LRs", "GENE_OR_GENE_PRODUCT", 54, 59], ["IL-6", "GENE_OR_GENE_PRODUCT", 84, 88], ["IL-10", "GENE_OR_GENE_PRODUCT", 93, 98], ["M1 macrophages", "CELL", 136, 150], ["IL-6", "GENE_OR_GENE_PRODUCT", 194, 198], ["M2 macrophages", "CELL", 209, 223], ["IL-10", "GENE_OR_GENE_PRODUCT", 269, 274], ["IL-6", "PROTEIN", 84, 88], ["IL", "PROTEIN", 93, 95], ["M1 macrophages", "CELL_TYPE", 136, 150], ["proinflammatory cytokines", "PROTEIN", 159, 184], ["IL-6", "PROTEIN", 194, 198], ["M2 macrophages", "CELL_TYPE", 209, 223], ["anti-inflammatory cytokines", "PROTEIN", 232, 259], ["IL", "PROTEIN", 269, 271], ["correlation analysis", "TEST", 18, 38], ["N/LRs", "TEST", 54, 59], ["IL", "TEST", 84, 86], ["recent study", "TEST", 111, 123], ["proinflammatory cytokines", "PROBLEM", 159, 184], ["anti-inflammatory cytokines", "TREATMENT", 232, 259], ["IL", "TEST", 269, 271], ["proinflammatory cytokines", "OBSERVATION", 159, 184], ["anti-inflammatory cytokines", "OBSERVATION", 232, 259]]], ["Our research found that, compared to those at the first test, IL-10 significantly increased and IL-6 significantly decreased at the last test (P < 0.001), which described the patient's transition from the acute phase to the convalescent phase, and these phenomena may indicate that N/LRs were closely related to injury in the acute stage and repair in the recovery stage in patients with COVID-19.", [["COVID-19", "CHEMICAL", 388, 396], ["IL-10", "GENE_OR_GENE_PRODUCT", 62, 67], ["IL-6", "GENE_OR_GENE_PRODUCT", 96, 100], ["patient", "ORGANISM", 175, 182], ["patients", "ORGANISM", 374, 382], ["IL", "PROTEIN", 62, 64], ["IL-6", "PROTEIN", 96, 100], ["patient", "SPECIES", 175, 182], ["patients", "SPECIES", 374, 382], ["IL", "TEST", 62, 64], ["IL", "TEST", 96, 98], ["N/LRs", "PROBLEM", 282, 287], ["injury", "PROBLEM", 312, 318], ["the acute stage", "PROBLEM", 322, 337], ["repair", "TREATMENT", 342, 348], ["COVID", "TEST", 388, 393], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["convalescent phase", "OBSERVATION_MODIFIER", 224, 242], ["acute", "OBSERVATION_MODIFIER", 326, 331], ["repair", "OBSERVATION", 342, 348]]], ["The source, function, and interaction of various inflammatory cytokines are complex.", [["inflammatory cytokines", "PROTEIN", 49, 71], ["various inflammatory cytokines", "PROBLEM", 41, 71], ["various", "OBSERVATION_MODIFIER", 41, 48], ["inflammatory cytokines", "OBSERVATION", 49, 71]]], ["Severe acute respiratory syndrome coronavirus 2-infected macrophages demonstrate upregulation of IL-6 production and low expression of interferons (31, 32) .", [["macrophages", "ANATOMY", 57, 68], ["acute respiratory syndrome", "DISEASE", 7, 33], ["Severe acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 47], ["macrophages", "CELL", 57, 68], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["interferons", "GENE_OR_GENE_PRODUCT", 135, 146], ["infected macrophages", "CELL_TYPE", 48, 68], ["IL-6", "PROTEIN", 97, 101], ["interferons", "PROTEIN", 135, 146], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["infected macrophages", "PROBLEM", 48, 68], ["upregulation of IL", "TREATMENT", 81, 99], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome coronavirus", "OBSERVATION", 13, 45], ["infected", "OBSERVATION_MODIFIER", 48, 56], ["macrophages", "OBSERVATION", 57, 68], ["upregulation", "OBSERVATION_MODIFIER", 81, 93], ["IL", "OBSERVATION_MODIFIER", 97, 99], ["low expression", "OBSERVATION_MODIFIER", 117, 131]]], ["Th1 cell-derived IFN-\u03b3 is essential for an effective antiviral immune response.", [["Th1 cell", "ANATOMY", 0, 8], ["Th1 cell", "CELL", 0, 8], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 17, 22], ["Th1 cell", "CELL_TYPE", 0, 8], ["IFN-\u03b3", "PROTEIN", 17, 22], ["Th1 cell", "TEST", 0, 8], ["IFN", "TEST", 17, 20], ["an effective antiviral immune response", "PROBLEM", 40, 78]]], ["However, IL-6 may inhibit Th1 polarization by stimulating CD4 + cells to differentiate into Th2 cells or by suppressing IFN-\u03b3 expression (33, 34) .", [["CD4 + cells", "ANATOMY", 58, 69], ["Th2 cells", "ANATOMY", 92, 101], ["IL-6", "GENE_OR_GENE_PRODUCT", 9, 13], ["Th1", "CELL", 26, 29], ["CD4", "GENE_OR_GENE_PRODUCT", 58, 61], ["Th2 cells", "CELL", 92, 101], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 120, 125], ["IL-6", "PROTEIN", 9, 13], ["CD4", "PROTEIN", 58, 61], ["Th2 cells", "CELL_TYPE", 92, 101], ["IFN", "PROTEIN", 120, 123], ["\u03b3", "PROTEIN", 124, 125], ["Th1 polarization", "TREATMENT", 26, 42], ["stimulating CD4 + cells", "PROBLEM", 46, 69], ["Th2 cells", "OBSERVATION", 92, 101]]], ["However, IL-6 can cooperate with transforming growth factor (TGF)-\u03b2 to induce IL-10 production in Th17 cells (35) ; IL-10 is also produced by regulatory T cells (Tregs), and TGF-\u03b2 is critical to enable human Tregs to express IL-10 (36).", [["Th17 cells", "ANATOMY", 98, 108], ["regulatory T cells", "ANATOMY", 142, 160], ["Tregs", "ANATOMY", 162, 167], ["Tregs", "ANATOMY", 208, 213], ["IL-6", "GENE_OR_GENE_PRODUCT", 9, 13], ["transforming growth factor (TGF)-\u03b2", "GENE_OR_GENE_PRODUCT", 33, 67], ["IL-10", "GENE_OR_GENE_PRODUCT", 78, 83], ["Th17 cells", "CELL", 98, 108], ["IL-10", "GENE_OR_GENE_PRODUCT", 116, 121], ["regulatory T cells", "CELL", 142, 160], ["Tregs", "CELL", 162, 167], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 174, 179], ["human", "ORGANISM", 202, 207], ["Tregs", "CELL", 208, 213], ["IL-10", "GENE_OR_GENE_PRODUCT", 225, 230], ["IL-6", "PROTEIN", 9, 13], ["transforming growth factor (TGF)-\u03b2", "PROTEIN", 33, 67], ["Th17 cells", "CELL_TYPE", 98, 108], ["IL-10", "PROTEIN", 116, 121], ["regulatory T cells", "CELL_TYPE", 142, 160], ["Tregs", "CELL_TYPE", 162, 167], ["TGF-\u03b2", "PROTEIN", 174, 179], ["human Tregs", "CELL_TYPE", 202, 213], ["IL", "PROTEIN", 225, 227], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 202, 207], ["transforming growth factor", "PROBLEM", 33, 59], ["TGF", "TEST", 61, 64], ["IL", "TEST", 78, 80], ["IL", "TEST", 116, 118], ["TGF", "TEST", 174, 177], ["IL", "TEST", 225, 227]]], ["IL-10 can stimulate lymphocytes, leading to a decrease in the secretion of IL-2 and IFN-\u03b3 by T cells (37) .", [["lymphocytes", "ANATOMY", 20, 31], ["T cells", "ANATOMY", 93, 100], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["lymphocytes", "CELL", 20, 31], ["IL-2", "GENE_OR_GENE_PRODUCT", 75, 79], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 84, 89], ["T cells", "CELL", 93, 100], ["IL-10", "PROTEIN", 0, 5], ["lymphocytes", "CELL_TYPE", 20, 31], ["IL-2", "PROTEIN", 75, 79], ["IFN", "PROTEIN", 84, 87], ["T cells", "CELL_TYPE", 93, 100], ["IL", "TREATMENT", 0, 2], ["lymphocytes", "PROBLEM", 20, 31], ["a decrease in the secretion of IL", "PROBLEM", 44, 77], ["decrease", "OBSERVATION_MODIFIER", 46, 54]]], ["Studying the complex inflammatory cytokine network after COVID-19 infection is of great significance for the treatment and prediction of the disease.", [["COVID-19", "CHEMICAL", 57, 65], ["infection", "DISEASE", 66, 75], ["the complex inflammatory cytokine network", "PROBLEM", 9, 50], ["COVID", "TEST", 57, 62], ["19 infection", "PROBLEM", 63, 75], ["the treatment", "TREATMENT", 105, 118], ["the disease", "PROBLEM", 137, 148], ["complex", "OBSERVATION_MODIFIER", 13, 20], ["inflammatory", "OBSERVATION_MODIFIER", 21, 33], ["infection", "OBSERVATION", 66, 75], ["disease", "OBSERVATION", 141, 148]]], ["Most patients with COVID-19 exhibit mild to moderate symptoms, but approximately 15% progress to severe pneumonia, and approximately 5% eventually develop acute respiratory distress syndrome (ARDS), septic shock, and/or multiple organ failure (5, 17) .", [["respiratory", "ANATOMY", 161, 172], ["organ", "ANATOMY", 229, 234], ["pneumonia", "DISEASE", 104, 113], ["acute respiratory distress syndrome", "DISEASE", 155, 190], ["ARDS", "DISEASE", 192, 196], ["septic shock", "DISEASE", 199, 211], ["multiple organ failure", "DISEASE", 220, 242], ["patients", "ORGANISM", 5, 13], ["organ", "ORGAN", 229, 234], ["patients", "SPECIES", 5, 13], ["COVID", "TEST", 19, 24], ["mild to moderate symptoms", "PROBLEM", 36, 61], ["severe pneumonia", "PROBLEM", 97, 113], ["acute respiratory distress syndrome", "PROBLEM", 155, 190], ["ARDS)", "PROBLEM", 192, 197], ["septic shock", "PROBLEM", 199, 211], ["multiple organ failure", "PROBLEM", 220, 242], ["mild", "OBSERVATION_MODIFIER", 36, 40], ["moderate", "OBSERVATION_MODIFIER", 44, 52], ["symptoms", "OBSERVATION", 53, 61], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["pneumonia", "OBSERVATION", 104, 113], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["respiratory distress syndrome", "OBSERVATION", 161, 190], ["ARDS", "OBSERVATION", 192, 196], ["septic shock", "OBSERVATION", 199, 211], ["multiple", "OBSERVATION_MODIFIER", 220, 228], ["organ", "ANATOMY", 229, 234], ["failure", "OBSERVATION", 235, 242]]], ["Wei's group study showed that after COVID-19 infection, CD4 + T lymphocytes are rapidly activated to become pathogenic T helper (Th)1 cells and generate GM-CSF.", [["CD4 + T lymphocytes", "ANATOMY", 56, 75], ["T helper (Th)1 cells", "ANATOMY", 119, 139], ["infection", "DISEASE", 45, 54], ["GM", "CHEMICAL", 153, 155], ["CD4", "GENE_OR_GENE_PRODUCT", 56, 59], ["T helper (Th)1 cells", "CELL", 119, 139], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 153, 159], ["CD4", "PROTEIN", 56, 59], ["T lymphocytes", "CELL_TYPE", 62, 75], ["T helper (Th)1 cells", "CELL_TYPE", 119, 139], ["GM-CSF", "PROTEIN", 153, 159], ["Wei's group study", "TEST", 0, 17], ["COVID", "TEST", 36, 41], ["infection", "PROBLEM", 45, 54], ["CD4", "TEST", 56, 59], ["T lymphocytes", "PROBLEM", 62, 75], ["GM", "TEST", 153, 155], ["infection", "OBSERVATION", 45, 54], ["CSF", "ANATOMY", 156, 159]]], ["The cytokine environment induces inflammatory CD14 + CD16 + monocytes with high expression of IL-6 and accelerates inflammation (3).", [["inflammatory CD14 + CD16 + monocytes", "ANATOMY", 33, 69], ["inflammation", "DISEASE", 115, 127], ["CD14", "GENE_OR_GENE_PRODUCT", 46, 50], ["CD16", "GENE_OR_GENE_PRODUCT", 53, 57], ["IL-6", "GENE_OR_GENE_PRODUCT", 94, 98], ["cytokine", "PROTEIN", 4, 12], ["CD14", "PROTEIN", 46, 50], ["CD16", "PROTEIN", 53, 57], ["IL-6", "PROTEIN", 94, 98], ["The cytokine environment", "TEST", 0, 24], ["inflammatory CD14", "TEST", 33, 50], ["CD16", "TEST", 53, 57], ["monocytes", "TEST", 60, 69], ["IL", "TEST", 94, 96], ["accelerates inflammation", "PROBLEM", 103, 127], ["inflammatory", "OBSERVATION_MODIFIER", 33, 45], ["high expression", "OBSERVATION_MODIFIER", 75, 90], ["inflammation", "OBSERVATION", 115, 127]]], ["These aberrant pathogenic Th1 cells and inflammatory monocytes may enter the pulmonary circulation in large numbers and play an immune damaging role to cause lung functional disability and quick mortality (5, 38) .", [["Th1 cells", "ANATOMY", 26, 35], ["monocytes", "ANATOMY", 53, 62], ["pulmonary", "ANATOMY", 77, 86], ["lung", "ANATOMY", 158, 162], ["lung functional disability", "DISEASE", 158, 184], ["Th1 cells", "CELL", 26, 35], ["inflammatory monocytes", "CELL", 40, 62], ["pulmonary", "ORGAN", 77, 86], ["lung", "ORGAN", 158, 162], ["Th1 cells", "CELL_TYPE", 26, 35], ["inflammatory monocytes", "CELL_TYPE", 40, 62], ["These aberrant pathogenic Th1 cells", "PROBLEM", 0, 35], ["inflammatory monocytes", "PROBLEM", 40, 62], ["an immune damaging role", "TREATMENT", 125, 148], ["lung functional disability", "PROBLEM", 158, 184], ["aberrant", "OBSERVATION_MODIFIER", 6, 14], ["pathogenic", "OBSERVATION_MODIFIER", 15, 25], ["Th1 cells", "OBSERVATION", 26, 35], ["inflammatory monocytes", "OBSERVATION", 40, 62], ["pulmonary", "ANATOMY", 77, 86], ["circulation", "ANATOMY_MODIFIER", 87, 98], ["large", "OBSERVATION_MODIFIER", 102, 107], ["numbers", "OBSERVATION_MODIFIER", 108, 115], ["lung", "ANATOMY", 158, 162]]], ["Their team launched a clinical trial using tocilizumab to block inflammatory storms (IL-6 receptor inhibitor) in severely ill patients and achieved some results (3) .", [["severely ill", "DISEASE", 113, 125], ["tocilizumab", "SIMPLE_CHEMICAL", 43, 54], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 85, 98], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["a clinical trial", "TREATMENT", 20, 36], ["tocilizumab to block inflammatory storms", "TREATMENT", 43, 83], ["IL-6 receptor inhibitor", "TREATMENT", 85, 108]]], ["Partly corresponding to Wei's team (3), our clinical study found that the serum level of IL-6 decreased significantly before discharge, which may reflect the pro-inflammatory role of IL-6 in the course of COVID-19 from another perspective.", [["serum", "ANATOMY", 74, 79], ["COVID-19", "CHEMICAL", 205, 213], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["IL-6", "GENE_OR_GENE_PRODUCT", 89, 93], ["IL-6", "GENE_OR_GENE_PRODUCT", 183, 187], ["IL-6", "PROTEIN", 89, 93], ["IL-6", "PROTEIN", 183, 187], ["our clinical study", "TEST", 40, 58], ["the serum level", "TEST", 70, 85], ["IL", "TEST", 89, 91], ["IL", "TEST", 183, 185], ["COVID", "TEST", 205, 210], ["may reflect", "UNCERTAINTY", 142, 153], ["pro-inflammatory", "OBSERVATION_MODIFIER", 158, 174]]], ["However, our team did not find that inflammatory cytokines (such as IL-6) were significantly different among different severity level groups.", [["IL-6", "GENE_OR_GENE_PRODUCT", 68, 72], ["inflammatory cytokines", "PROTEIN", 36, 58], ["IL", "PROTEIN", 68, 70], ["inflammatory cytokines", "PROBLEM", 36, 58], ["IL", "TEST", 68, 70], ["inflammatory", "OBSERVATION_MODIFIER", 36, 48]]], ["Part of the explanation is that there are no mild cases in this study (see section \"Materials and Methods\").", [["mild cases", "PROBLEM", 45, 55], ["this study", "TEST", 59, 69], ["no", "UNCERTAINTY", 42, 44], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["cases", "OBSERVATION", 50, 55]]], ["More importantly, although the role of IL-6 in the pathological development of COVID-19 has attracted much attention (3), its specific role remains controversial (9) (10) (11) (12) , and several experimental models of viral lung infections suggest that IL-6 demonstrates either pathogenic (39)or protective (40) effects in vivo; the consequences of IL-6 induction in COVID-19 may vary depending on the stage of infection and the immune status of the host.", [["lung", "ANATOMY", 224, 228], ["COVID-19", "CHEMICAL", 79, 87], ["viral lung infections", "DISEASE", 218, 239], ["COVID-19", "CHEMICAL", 367, 375], ["infection", "DISEASE", 411, 420], ["COVID-19", "CHEMICAL", 79, 87], ["IL-6", "GENE_OR_GENE_PRODUCT", 39, 43], ["COVID-19", "GENE_OR_GENE_PRODUCT", 79, 87], ["lung", "ORGAN", 224, 228], ["IL-6", "GENE_OR_GENE_PRODUCT", 253, 257], ["IL-6", "GENE_OR_GENE_PRODUCT", 349, 353], ["COVID-19", "CELL", 367, 375], ["IL-6", "PROTEIN", 39, 43], ["IL-6", "PROTEIN", 253, 257], ["IL-6", "PROTEIN", 349, 353], ["COVID", "TEST", 79, 84], ["viral lung infections", "PROBLEM", 218, 239], ["pathogenic", "PROBLEM", 278, 288], ["IL-6 induction in COVID", "TREATMENT", 349, 372], ["infection", "PROBLEM", 411, 420], ["viral", "OBSERVATION_MODIFIER", 218, 223], ["lung", "ANATOMY", 224, 228], ["infections", "OBSERVATION", 229, 239], ["pathogenic", "OBSERVATION_MODIFIER", 278, 288], ["infection", "OBSERVATION", 411, 420]]], ["The role of these cytokines in SARS-CoV-2 infection should be carefully evaluated.DISCUSSIONSevere acute respiratory syndrome coronavirus 2 might act mainly on lymphocytes, especially T lymphocytes (18) , and decreases in the levels of CD3 + and CD4 + T lymphocytes are associated with immunosuppression (41).", [["lymphocytes", "ANATOMY", 160, 171], ["T lymphocytes", "ANATOMY", 184, 197], ["CD3 + and CD4 + T lymphocytes", "ANATOMY", 236, 265], ["SARS", "DISEASE", 31, 35], ["infection", "DISEASE", 42, 51], ["acute respiratory syndrome coronavirus", "DISEASE", 99, 137], ["SARS-CoV-2", "ORGANISM", 31, 41], ["lymphocytes", "CELL", 160, 171], ["T lymphocytes", "CELL", 184, 197], ["CD3", "GENE_OR_GENE_PRODUCT", 236, 239], ["CD4", "GENE_OR_GENE_PRODUCT", 246, 249], ["cytokines", "PROTEIN", 18, 27], ["lymphocytes", "CELL_TYPE", 160, 171], ["T lymphocytes", "CELL_TYPE", 184, 197], ["CD3", "PROTEIN", 236, 239], ["CD4", "PROTEIN", 246, 249], ["T lymphocytes", "CELL_TYPE", 252, 265], ["SARS-CoV", "SPECIES", 31, 39], ["DISCUSSIONSevere acute respiratory syndrome coronavirus", "SPECIES", 82, 137], ["these cytokines", "TEST", 12, 27], ["SARS", "PROBLEM", 31, 35], ["CoV-2 infection", "PROBLEM", 36, 51], ["acute respiratory syndrome coronavirus", "PROBLEM", 99, 137], ["lymphocytes", "TEST", 160, 171], ["T lymphocytes", "TEST", 184, 197], ["the levels", "TEST", 222, 232], ["CD3", "TEST", 236, 239], ["CD4 + T lymphocytes", "PROBLEM", 246, 265], ["immunosuppression", "TREATMENT", 286, 303], ["infection", "OBSERVATION", 42, 51], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["respiratory syndrome", "OBSERVATION", 105, 125], ["decreases", "OBSERVATION_MODIFIER", 209, 218]]], ["Our research found that N/LRs were negatively related to CD3 + and CD8 + T lymphocyte levels, suggesting that the elevated N/LRs reflect the degree of lymphatic impairment, which may support the hypothesis that N/LRs are a sensitive and simple biomarker of immune function in patients with COVID-19.DISCUSSIONAdditionally, our results suggest that male sex, underlying disease (cardiovascular disease), and pulse are risk factors for COVID-19.", [["CD3 +", "ANATOMY", 57, 62], ["CD8 + T lymphocyte", "ANATOMY", 67, 85], ["lymphatic", "ANATOMY", 151, 160], ["cardiovascular", "ANATOMY", 378, 392], ["lymphatic impairment", "DISEASE", 151, 171], ["cardiovascular disease", "DISEASE", 378, 400], ["COVID-19", "CHEMICAL", 434, 442], ["CD3", "GENE_OR_GENE_PRODUCT", 57, 60], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["lymphatic", "ORGAN", 151, 160], ["patients", "ORGANISM", 276, 284], ["cardiovascular", "ANATOMICAL_SYSTEM", 378, 392], ["CD3", "PROTEIN", 57, 60], ["CD8", "PROTEIN", 67, 70], ["patients", "SPECIES", 276, 284], ["Our research", "TEST", 0, 12], ["N/LRs", "TEST", 24, 29], ["CD3", "TEST", 57, 60], ["CD8", "TEST", 67, 70], ["T lymphocyte levels", "TEST", 73, 92], ["the elevated N/LRs", "PROBLEM", 110, 128], ["lymphatic impairment", "PROBLEM", 151, 171], ["the hypothesis", "PROBLEM", 191, 205], ["N/LRs", "TEST", 211, 216], ["COVID", "TEST", 290, 295], ["underlying disease (cardiovascular disease)", "PROBLEM", 358, 401], ["COVID", "TEST", 434, 439], ["lymphatic", "ANATOMY", 151, 160], ["impairment", "OBSERVATION", 161, 171]]], ["The risk associated with male sex raises a topic of great interest: the effects of estrogens on IL-6 and on COVID-19 progression.", [["estrogens", "CHEMICAL", 83, 92], ["estrogens", "CHEMICAL", 83, 92], ["estrogens", "SIMPLE_CHEMICAL", 83, 92], ["IL-6", "GENE_OR_GENE_PRODUCT", 96, 100], ["IL-6", "PROTEIN", 96, 100], ["estrogens on IL", "TREATMENT", 83, 98]]], ["Estrogens can suppress lipopolysaccharide (LPS)-mediated IL-6 expression in mouse macrophages by both blocking nuclear factor kappa B (NF-kB) activation (42, 43) and inhibiting p38 mitogen-activated protein kinase (MAPK) phosphorylation (43) by acting on estrogen receptors to decrease the production of pro-inflammatory cytokines (42) .", [["macrophages", "ANATOMY", 82, 93], ["lipopolysaccharide", "CHEMICAL", 23, 41], ["LPS", "CHEMICAL", 43, 46], ["estrogen", "CHEMICAL", 255, 263], ["Estrogens", "CHEMICAL", 0, 9], ["estrogen", "CHEMICAL", 255, 263], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 23, 41], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["IL-6", "GENE_OR_GENE_PRODUCT", 57, 61], ["mouse", "ORGANISM", 76, 81], ["macrophages", "CELL", 82, 93], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 111, 133], ["NF-kB", "GENE_OR_GENE_PRODUCT", 135, 140], ["p38 mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 177, 213], ["MAPK", "GENE_OR_GENE_PRODUCT", 215, 219], ["estrogen receptors", "GENE_OR_GENE_PRODUCT", 255, 273], ["IL-6", "PROTEIN", 57, 61], ["mouse macrophages", "CELL_TYPE", 76, 93], ["nuclear factor kappa B (NF-kB", "PROTEIN", 111, 140], ["p38 mitogen-activated protein kinase", "PROTEIN", 177, 213], ["MAPK", "PROTEIN", 215, 219], ["estrogen receptors", "PROTEIN", 255, 273], ["pro-inflammatory cytokines", "PROTEIN", 304, 330], ["mouse", "SPECIES", 76, 81], ["mouse", "SPECIES", 76, 81], ["Estrogens", "TREATMENT", 0, 9], ["lipopolysaccharide (LPS", "TREATMENT", 23, 46], ["mediated IL", "TREATMENT", 48, 59], ["p38 mitogen", "TEST", 177, 188], ["activated protein kinase", "TEST", 189, 213], ["phosphorylation", "TEST", 221, 236], ["estrogen receptors", "TREATMENT", 255, 273], ["pro-inflammatory cytokines", "TEST", 304, 330]]], ["However, the immunomodulatory effects of estrogens in COVID-19 require further study.", [["estrogens", "CHEMICAL", 41, 50], ["estrogens", "CHEMICAL", 41, 50], ["COVID-19", "CHEMICAL", 54, 62], ["estrogens", "SIMPLE_CHEMICAL", 41, 50], ["estrogens", "TREATMENT", 41, 50], ["COVID", "TEST", 54, 59], ["further study", "TEST", 71, 84]]], ["Cardiovascular disease and pulse are risk factors for COVID-19, which may suggest that cardiovascular disease has a critical impact on COVID-19 patient mortality (44) and requires more attention as a comorbidity.", [["Cardiovascular", "ANATOMY", 0, 14], ["cardiovascular", "ANATOMY", 87, 101], ["Cardiovascular disease", "DISEASE", 0, 22], ["cardiovascular disease", "DISEASE", 87, 109], ["cardiovascular", "ANATOMICAL_SYSTEM", 87, 101], ["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 144, 151], ["Cardiovascular disease", "PROBLEM", 0, 22], ["risk factors", "PROBLEM", 37, 49], ["COVID", "TEST", 54, 59], ["cardiovascular disease", "PROBLEM", 87, 109], ["COVID", "TEST", 135, 140], ["disease", "OBSERVATION", 15, 22], ["cardiovascular disease", "OBSERVATION", 87, 109]]], ["We found that there were statistically significant differences in cytokines and N/LRs at admission and discharge, while there were no differences in T lymphocyte subsets (CD3 + /CD4 + /CD8 + ) in the research.", [["T lymphocyte", "ANATOMY", 149, 161], ["CD3 + /CD4 + /CD8 +", "ANATOMY", 171, 190], ["T lymphocyte", "CELL", 149, 161], ["CD3", "GENE_OR_GENE_PRODUCT", 171, 174], ["CD4", "GENE_OR_GENE_PRODUCT", 178, 181], ["CD8", "GENE_OR_GENE_PRODUCT", 185, 188], ["cytokines", "PROTEIN", 66, 75], ["T lymphocyte subsets", "CELL_TYPE", 149, 169], ["CD3", "PROTEIN", 171, 174], ["CD4", "PROTEIN", 178, 181], ["CD8", "PROTEIN", 185, 188], ["cytokines", "TREATMENT", 66, 75], ["N/LRs", "TREATMENT", 80, 85], ["T lymphocyte subsets", "TEST", 149, 169], ["CD3", "TEST", 171, 174], ["CD4", "TEST", 178, 181], ["CD8", "PROBLEM", 185, 188], ["statistically", "OBSERVATION_MODIFIER", 25, 38], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["differences", "OBSERVATION_MODIFIER", 51, 62]]], ["We wanted to know whether the indicators of lymphocyte subset recovery lagged relatively over time and what their significance was.", [["lymphocyte", "ANATOMY", 44, 54], ["lymphocyte", "CELL", 44, 54]]], ["Further work is needed to understand the specific characteristics of the various inflammatory cytokines and T cell subsets in COVID-19, the specific relationship between N/LRs and different inflammatory cytokines and T cell subsets in COVID-19, and the prognostic value for the disease, especially during immunotherapy.CONCLUSIONPost-COVID-19 inflammation is a very complex network system that has a decisive influence on the prognosis of patients.", [["T cell", "ANATOMY", 108, 114], ["T cell", "ANATOMY", 217, 223], ["inflammation", "DISEASE", 343, 355], ["T cell", "CELL", 108, 114], ["COVID-19", "CELL", 126, 134], ["T cell", "CELL", 217, 223], ["COVID-19", "CELL", 235, 243], ["patients", "ORGANISM", 439, 447], ["inflammatory cytokines", "PROTEIN", 81, 103], ["T cell subsets", "CELL_TYPE", 108, 122], ["N/LRs", "PROTEIN", 170, 175], ["inflammatory cytokines", "PROTEIN", 190, 212], ["T cell subsets", "CELL_TYPE", 217, 231], ["patients", "SPECIES", 439, 447], ["the various inflammatory cytokines", "PROBLEM", 69, 103], ["COVID", "TEST", 126, 131], ["N/LRs", "TREATMENT", 170, 175], ["different inflammatory cytokines", "TREATMENT", 180, 212], ["T cell subsets", "TREATMENT", 217, 231], ["COVID", "TEST", 235, 240], ["the disease", "PROBLEM", 274, 285], ["immunotherapy", "TREATMENT", 305, 318], ["CONCLUSIONPost-COVID", "TEST", 319, 339], ["inflammation", "PROBLEM", 343, 355], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93], ["inflammatory", "OBSERVATION_MODIFIER", 190, 202], ["disease", "OBSERVATION", 278, 285], ["inflammation", "OBSERVATION", 343, 355]]], ["Some inflammatory cytokines (such as IL-6), whose mechanisms and effects are still controversial, need further study.", [["IL-6", "GENE_OR_GENE_PRODUCT", 37, 41], ["inflammatory cytokines", "PROTEIN", 5, 27], ["IL-6", "PROTEIN", 37, 41], ["Some inflammatory cytokines", "PROBLEM", 0, 27], ["further study", "TEST", 103, 116], ["inflammatory", "OBSERVATION_MODIFIER", 5, 17], ["cytokines", "OBSERVATION", 18, 27]]], ["As a quick and convenient marker of inflammation, N/LRs may predict the disease course and severity level of non-mild COVID-19; male sex, cardiovascular disease, and pulse are also risk factors for the severity of non-mild COVID-19.LIMITATIONSFirst, the sample size of critical type patients was relatively small, which may have influenced the results.", [["cardiovascular", "ANATOMY", 138, 152], ["inflammation", "DISEASE", 36, 48], ["cardiovascular disease", "DISEASE", 138, 160], ["cardiovascular", "ANATOMICAL_SYSTEM", 138, 152], ["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 283, 291], ["inflammation", "PROBLEM", 36, 48], ["N/LRs", "TREATMENT", 50, 55], ["the disease course", "PROBLEM", 68, 86], ["severity level", "TEST", 91, 105], ["non-mild COVID", "TEST", 109, 123], ["cardiovascular disease", "PROBLEM", 138, 160], ["non-mild COVID", "PROBLEM", 214, 228], ["inflammation", "OBSERVATION", 36, 48], ["cardiovascular", "ANATOMY", 138, 152], ["disease", "OBSERVATION", 153, 160], ["size", "OBSERVATION_MODIFIER", 261, 265], ["critical type", "OBSERVATION_MODIFIER", 269, 282], ["small", "OBSERVATION_MODIFIER", 307, 312]]], ["Second, due to the emergency situation of the epidemic outbreak, there is a certain lack of clinical data, including inflammatory cytokines.", [["inflammatory cytokines", "PROTEIN", 117, 139], ["the epidemic outbreak", "PROBLEM", 42, 63], ["inflammatory cytokines", "PROBLEM", 117, 139], ["inflammatory cytokines", "OBSERVATION", 117, 139]]], ["We are also collating clinical data from other centers and investigating the mechanisms of inflammatory factors in animal models.DATA AVAILABILITY STATEMENTThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.", [["inflammatory factors", "PROTEIN", 91, 111], ["inflammatory factors", "PROBLEM", 91, 111], ["inflammatory", "OBSERVATION", 91, 103]]]], "PMC7418755": [["INTRODUCTIONInterstitial lung disease (ILD) is a heterogeneous group of disorders characterized by dyspnea and bilateral infiltrations of the lung.", [["lung", "ANATOMY", 25, 29], ["lung", "ANATOMY", 142, 146], ["INTRODUCTIONInterstitial lung disease", "DISEASE", 0, 37], ["ILD", "DISEASE", 39, 42], ["dyspnea", "DISEASE", 99, 106], ["lung", "ORGAN", 25, 29], ["lung", "ORGAN", 142, 146], ["INTRODUCTIONInterstitial lung disease (ILD", "PROBLEM", 0, 42], ["a heterogeneous group of disorders", "PROBLEM", 47, 81], ["dyspnea", "PROBLEM", 99, 106], ["bilateral infiltrations of the lung", "PROBLEM", 111, 146], ["lung", "ANATOMY", 25, 29], ["disease", "OBSERVATION", 30, 37], ["heterogeneous", "OBSERVATION_MODIFIER", 49, 62], ["dyspnea", "OBSERVATION", 99, 106], ["bilateral", "ANATOMY_MODIFIER", 111, 120], ["infiltrations", "OBSERVATION", 121, 134], ["lung", "ANATOMY", 142, 146]]], ["While some cases are idiopathic (e.g., idiopathic pulmonary fibrosis), others are associated with systemic illnesses (e.g., autoimmune disorders), environmental exposures (e.g., asbestosis, hypersensitivity pneumonitis), or drug-induced, among other causes.1 In general, ILD results from inflammation and excessive accumulation of connective tissue matrices in the interstitium of the lung.2 Exacerbations with rapid progression resulting in increased dyspnea, increased oxygen supplementation requirements, and respiratory failure have been described in idiopathic pulmonary fibrosis and other types of ILDs.3 Surgery, aspiration of gastric contents, infection, and other factors have been proposed to contribute to ILD exacerbation.", [["pulmonary", "ANATOMY", 50, 59], ["connective tissue matrices", "ANATOMY", 331, 357], ["interstitium", "ANATOMY", 365, 377], ["lung", "ANATOMY", 385, 389], ["respiratory", "ANATOMY", 512, 523], ["pulmonary", "ANATOMY", 566, 575], ["gastric", "ANATOMY", 634, 641], ["idiopathic", "DISEASE", 21, 31], ["idiopathic pulmonary fibrosis", "DISEASE", 39, 68], ["systemic illnesses", "DISEASE", 98, 116], ["autoimmune disorders", "DISEASE", 124, 144], ["asbestosis", "DISEASE", 178, 188], ["hypersensitivity pneumonitis", "DISEASE", 190, 218], ["ILD", "DISEASE", 271, 274], ["inflammation", "DISEASE", 288, 300], ["dyspnea", "DISEASE", 452, 459], ["oxygen", "CHEMICAL", 471, 477], ["respiratory failure", "DISEASE", 512, 531], ["idiopathic pulmonary fibrosis", "DISEASE", 555, 584], ["ILDs", "DISEASE", 604, 608], ["aspiration of gastric contents", "DISEASE", 620, 650], ["infection", "DISEASE", 652, 661], ["ILD", "DISEASE", 717, 720], ["oxygen", "CHEMICAL", 471, 477], ["pulmonary", "ORGAN", 50, 59], ["connective tissue matrices", "TISSUE", 331, 357], ["interstitium", "MULTI-TISSUE_STRUCTURE", 365, 377], ["lung", "ORGAN", 385, 389], ["oxygen", "SIMPLE_CHEMICAL", 471, 477], ["pulmonary", "ORGAN", 566, 575], ["gastric", "ORGAN", 634, 641], ["idiopathic", "PROBLEM", 21, 31], ["idiopathic pulmonary fibrosis", "PROBLEM", 39, 68], ["systemic illnesses", "PROBLEM", 98, 116], ["autoimmune disorders", "PROBLEM", 124, 144], ["environmental exposures", "PROBLEM", 147, 170], ["asbestosis", "PROBLEM", 178, 188], ["hypersensitivity pneumonitis", "PROBLEM", 190, 218], ["inflammation", "PROBLEM", 288, 300], ["excessive accumulation of connective tissue matrices", "PROBLEM", 305, 357], ["2 Exacerbations", "PROBLEM", 390, 405], ["rapid progression", "PROBLEM", 411, 428], ["increased dyspnea", "PROBLEM", 442, 459], ["increased oxygen supplementation requirements", "TREATMENT", 461, 506], ["respiratory failure", "PROBLEM", 512, 531], ["idiopathic pulmonary fibrosis", "PROBLEM", 555, 584], ["ILDs", "PROBLEM", 604, 608], ["Surgery", "TREATMENT", 611, 618], ["aspiration of gastric contents", "PROBLEM", 620, 650], ["infection", "PROBLEM", 652, 661], ["ILD exacerbation", "PROBLEM", 717, 733], ["idiopathic", "OBSERVATION", 21, 31], ["idiopathic", "OBSERVATION_MODIFIER", 39, 49], ["pulmonary", "ANATOMY", 50, 59], ["fibrosis", "OBSERVATION", 60, 68], ["asbestosis", "OBSERVATION", 178, 188], ["hypersensitivity pneumonitis", "OBSERVATION", 190, 218], ["ILD", "OBSERVATION", 271, 274], ["inflammation", "OBSERVATION", 288, 300], ["excessive accumulation", "OBSERVATION", 305, 327], ["connective tissue matrices", "OBSERVATION", 331, 357], ["interstitium", "ANATOMY_MODIFIER", 365, 377], ["lung", "ANATOMY", 385, 389], ["rapid", "OBSERVATION_MODIFIER", 411, 416], ["progression", "OBSERVATION_MODIFIER", 417, 428], ["increased", "OBSERVATION_MODIFIER", 442, 451], ["dyspnea", "OBSERVATION", 452, 459], ["increased", "OBSERVATION_MODIFIER", 461, 470], ["oxygen supplementation", "OBSERVATION", 471, 493], ["respiratory failure", "OBSERVATION", 512, 531], ["idiopathic", "OBSERVATION_MODIFIER", 555, 565], ["pulmonary", "ANATOMY", 566, 575], ["fibrosis", "OBSERVATION", 576, 584], ["gastric", "ANATOMY", 634, 641], ["contents", "OBSERVATION", 642, 650], ["infection", "OBSERVATION", 652, 661], ["ILD", "OBSERVATION_MODIFIER", 717, 720], ["exacerbation", "OBSERVATION", 721, 733]]], ["Viral infection has been implicated as an important cause of ILD and of ILD exacerbation, but the viruses involved and the mechanisms triggered during an exacerbation remain poorly elucidated.4 Recent concerns have been raised by the potential impact of the COVID-19 pandemic on ILD, mainly because of its propensity to cause severe lung injury in older individuals and in individuals with pre-existing lung disease.", [["lung", "ANATOMY", 333, 337], ["lung", "ANATOMY", 403, 407], ["Viral infection", "DISEASE", 0, 15], ["ILD", "DISEASE", 61, 64], ["ILD", "DISEASE", 72, 75], ["ILD", "DISEASE", 279, 282], ["lung injury", "DISEASE", 333, 344], ["lung disease", "DISEASE", 403, 415], ["Viral", "ORGANISM", 0, 5], ["lung", "ORGAN", 333, 337], ["lung", "ORGAN", 403, 407], ["Viral infection", "PROBLEM", 0, 15], ["ILD", "PROBLEM", 61, 64], ["ILD exacerbation", "PROBLEM", 72, 88], ["the viruses", "PROBLEM", 94, 105], ["an exacerbation", "PROBLEM", 151, 166], ["the COVID", "TEST", 254, 263], ["ILD", "PROBLEM", 279, 282], ["severe lung injury", "PROBLEM", 326, 344], ["pre-existing lung disease", "PROBLEM", 390, 415], ["infection", "OBSERVATION", 6, 15], ["ILD", "OBSERVATION", 61, 64], ["ILD", "OBSERVATION_MODIFIER", 72, 75], ["exacerbation", "OBSERVATION", 76, 88], ["viruses", "OBSERVATION", 98, 105], ["severe", "OBSERVATION_MODIFIER", 326, 332], ["lung", "ANATOMY", 333, 337], ["injury", "OBSERVATION", 338, 344], ["lung", "ANATOMY", 403, 407], ["disease", "OBSERVATION", 408, 415]]], ["COVID-19 is caused by the novel \u03b2 coronavirus SARS-CoV-2.5 Here, we present a case of a patient with Rheumatoid Arthritis (RA) associated ILD (RA-ILD) recently hospitalized due to COVID-19.", [["Rheumatoid Arthritis", "DISEASE", 101, 121], ["RA", "DISEASE", 123, 125], ["ILD", "DISEASE", 138, 141], ["RA", "DISEASE", 143, 145], ["ILD", "DISEASE", 146, 149], ["\u03b2 coronavirus", "ORGANISM", 32, 45], ["SARS-CoV", "ORGANISM", 46, 54], ["patient", "ORGANISM", 88, 95], ["coronavirus", "SPECIES", 34, 45], ["patient", "SPECIES", 88, 95], ["\u03b2 coronavirus", "SPECIES", 32, 45], ["COVID", "TEST", 0, 5], ["the novel \u03b2 coronavirus SARS", "PROBLEM", 22, 50], ["CoV", "TEST", 51, 54], ["Rheumatoid Arthritis", "PROBLEM", 101, 121], ["ILD (RA-ILD)", "PROBLEM", 138, 150], ["COVID", "TEST", 180, 185], ["Rheumatoid", "OBSERVATION_MODIFIER", 101, 111], ["Arthritis", "OBSERVATION", 112, 121], ["RA", "ANATOMY", 123, 125], ["ILD", "OBSERVATION", 138, 141], ["RA", "ANATOMY", 143, 145]]], ["We first summarize the case and discuss the literature followed by a discussion of gaps in knowledge in need of further investigation.CASEA 60-year-old woman with RA presented with six days of dyspnea on exertion associated with a dry cough.", [["RA", "DISEASE", 163, 165], ["dyspnea", "DISEASE", 193, 200], ["dry cough", "DISEASE", 231, 240], ["woman", "ORGANISM", 152, 157], ["woman", "SPECIES", 152, 157], ["further investigation", "TEST", 112, 133], ["dyspnea", "PROBLEM", 193, 200], ["a dry cough", "PROBLEM", 229, 240], ["RA", "ANATOMY", 163, 165], ["dyspnea", "OBSERVATION", 193, 200], ["cough", "OBSERVATION", 235, 240]]], ["In the weeks prior, the patient noted malaise, subjective fevers, and upper respiratory symptoms.", [["respiratory", "ANATOMY", 76, 87], ["fevers", "DISEASE", 58, 64], ["upper respiratory symptoms", "DISEASE", 70, 96], ["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31], ["malaise", "PROBLEM", 38, 45], ["subjective fevers", "PROBLEM", 47, 64], ["upper respiratory symptoms", "PROBLEM", 70, 96], ["fevers", "OBSERVATION", 58, 64], ["upper", "ANATOMY_MODIFIER", 70, 75], ["respiratory", "ANATOMY", 76, 87], ["symptoms", "OBSERVATION", 88, 96]]], ["In the two days prior to presenting to the hospital, the patient became severely limited in her ability to ambulate within her home resulting in prompt medical evaluation.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["severely limited", "PROBLEM", 72, 88], ["prompt medical evaluation", "TEST", 145, 170]]], ["A review of the patient's history revealed that she was a remote smoker (20 pack-year) and carried diagnoses of type II diabetes mellitus, obstructive sleep apnea (not compliant with treatment), and heart failure with preserved ejection fraction.", [["heart", "ANATOMY", 199, 204], ["type II diabetes mellitus", "DISEASE", 112, 137], ["obstructive sleep apnea", "DISEASE", 139, 162], ["heart failure", "DISEASE", 199, 212], ["patient", "ORGANISM", 16, 23], ["heart", "ORGAN", 199, 204], ["patient", "SPECIES", 16, 23], ["type II diabetes mellitus", "PROBLEM", 112, 137], ["obstructive sleep apnea", "PROBLEM", 139, 162], ["treatment", "TREATMENT", 183, 192], ["heart failure", "PROBLEM", 199, 212], ["type II", "OBSERVATION_MODIFIER", 112, 119], ["diabetes mellitus", "OBSERVATION", 120, 137], ["obstructive", "OBSERVATION_MODIFIER", 139, 150], ["sleep apnea", "OBSERVATION", 151, 162], ["heart", "ANATOMY", 199, 204], ["failure", "OBSERVATION", 205, 212], ["preserved", "OBSERVATION", 218, 227], ["ejection fraction", "OBSERVATION", 228, 245]]], ["The patient had also been diagnosed with RA-ILD with Computed Tomography (CT) scan images showing infiltrates with peripheral and basilar predominance and some honey combing, which was interpreted as consistent with a usual interstitial pneumonitis or UIP pattern (Figure 1A).", [["basilar", "ANATOMY", 130, 137], ["interstitial", "ANATOMY", 224, 236], ["RA", "DISEASE", 41, 43], ["ILD", "DISEASE", 44, 47], ["peripheral and basilar predominance", "DISEASE", 115, 150], ["pneumonitis", "DISEASE", 237, 248], ["patient", "ORGANISM", 4, 11], ["basilar", "MULTI-TISSUE_STRUCTURE", 130, 137], ["patient", "SPECIES", 4, 11], ["RA", "PROBLEM", 41, 43], ["ILD", "PROBLEM", 44, 47], ["Computed Tomography (CT) scan images", "TEST", 53, 89], ["infiltrates", "PROBLEM", 98, 109], ["peripheral and basilar predominance", "PROBLEM", 115, 150], ["a usual interstitial pneumonitis", "PROBLEM", 216, 248], ["UIP pattern", "PROBLEM", 252, 263], ["RA", "ANATOMY", 41, 43], ["infiltrates", "OBSERVATION", 98, 109], ["peripheral", "ANATOMY_MODIFIER", 115, 125], ["basilar", "ANATOMY_MODIFIER", 130, 137], ["predominance", "OBSERVATION", 138, 150], ["some", "OBSERVATION_MODIFIER", 155, 159], ["honey combing", "OBSERVATION", 160, 173], ["consistent with", "UNCERTAINTY", 200, 215], ["interstitial", "ANATOMY_MODIFIER", 224, 236], ["pneumonitis", "OBSERVATION", 237, 248], ["UIP pattern", "OBSERVATION", 252, 263]]], ["She was being treated with azathioprine; however, she had recently discontinued the medication prior to the hospitalization due to subjectively stable disease.", [["azathioprine", "CHEMICAL", 27, 39], ["azathioprine", "CHEMICAL", 27, 39], ["azathioprine", "SIMPLE_CHEMICAL", 27, 39], ["azathioprine", "TREATMENT", 27, 39], ["the medication", "TREATMENT", 80, 94], ["subjectively stable disease", "PROBLEM", 131, 158], ["stable", "OBSERVATION_MODIFIER", 144, 150], ["disease", "OBSERVATION", 151, 158]]], ["Most recent pulmonary function tests from 9 months prior showed normal forced vital capacity (2.25 liters; 83% predicted) and forced expired volume in first second (1.74 liters, 81% predicted), reduced total lung capacity (3.34 liters, 67% predicted), and significant reduction in DLCO (10.1 mL/min/mmHg; 47% of expected) consistent with moderate restriction and impaired gas exchange.CASEUpon arrival to the emergency department, the patient was afebrile, had a heart rate of 97, a respiratory rate of 26 breaths per minute, and a low hemoglobin oxygen saturation of 79% on room air.", [["pulmonary", "ANATOMY", 12, 21], ["lung", "ANATOMY", 208, 212], ["heart", "ANATOMY", 463, 468], ["respiratory", "ANATOMY", 483, 494], ["oxygen", "CHEMICAL", 547, 553], ["oxygen", "CHEMICAL", 547, 553], ["pulmonary", "ORGAN", 12, 21], ["lung", "ORGAN", 208, 212], ["patient", "ORGANISM", 435, 442], ["heart", "ORGAN", 463, 468], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 536, 546], ["oxygen", "SIMPLE_CHEMICAL", 547, 553], ["hemoglobin", "PROTEIN", 536, 546], ["patient", "SPECIES", 435, 442], ["Most recent pulmonary function tests", "TEST", 0, 36], ["forced expired volume", "TEST", 126, 147], ["reduced total lung capacity", "PROBLEM", 194, 221], ["significant reduction in DLCO", "PROBLEM", 256, 285], ["moderate restriction", "PROBLEM", 338, 358], ["impaired gas exchange", "PROBLEM", 363, 384], ["afebrile", "PROBLEM", 447, 455], ["a heart rate", "TEST", 461, 473], ["a respiratory rate", "TEST", 481, 499], ["a low hemoglobin oxygen saturation", "PROBLEM", 530, 564], ["pulmonary", "ANATOMY", 12, 21], ["reduced", "OBSERVATION_MODIFIER", 194, 201], ["total", "OBSERVATION_MODIFIER", 202, 207], ["lung", "ANATOMY", 208, 212], ["capacity", "OBSERVATION_MODIFIER", 213, 221], ["significant", "OBSERVATION_MODIFIER", 256, 267], ["reduction", "OBSERVATION_MODIFIER", 268, 277], ["consistent with", "UNCERTAINTY", 322, 337], ["moderate", "OBSERVATION_MODIFIER", 338, 346], ["restriction", "OBSERVATION", 347, 358], ["impaired", "OBSERVATION_MODIFIER", 363, 371], ["gas exchange", "OBSERVATION", 372, 384], ["low hemoglobin", "OBSERVATION_MODIFIER", 532, 546]]], ["She was speaking in full sentences and physical examination revealed digital clubbing and velcro-like crackles in both lung bases.", [["lung", "ANATOMY", 119, 123], ["clubbing", "DISEASE", 77, 85], ["lung", "ORGAN", 119, 123], ["physical examination", "TEST", 39, 59], ["digital clubbing", "PROBLEM", 69, 85], ["velcro", "TEST", 90, 96], ["crackles in both lung bases", "PROBLEM", 102, 129], ["clubbing", "OBSERVATION", 77, 85], ["crackles", "OBSERVATION", 102, 110], ["both", "ANATOMY_MODIFIER", 114, 118], ["lung", "ANATOMY", 119, 123], ["bases", "ANATOMY_MODIFIER", 124, 129]]], ["Hemoglobin oxygen saturation improved to 97% on 12 L/min of oxygen supplementation via nasal cannula.", [["nasal", "ANATOMY", 87, 92], ["oxygen", "CHEMICAL", 11, 17], ["oxygen", "CHEMICAL", 60, 66], ["oxygen", "CHEMICAL", 11, 17], ["oxygen", "CHEMICAL", 60, 66], ["Hemoglobin", "SIMPLE_CHEMICAL", 0, 10], ["oxygen", "SIMPLE_CHEMICAL", 11, 17], ["oxygen", "SIMPLE_CHEMICAL", 60, 66], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 87, 100], ["Hemoglobin oxygen saturation", "TEST", 0, 28], ["oxygen supplementation", "TREATMENT", 60, 82], ["nasal cannula", "TREATMENT", 87, 100], ["nasal cannula", "OBSERVATION", 87, 100]]], ["CT of the chest was notable for progression of ILD compared to prior CT ten months prior in addition to superimposed ground glass opacities in a peripheral and basilar distribution (Figure 1B).", [["chest", "ANATOMY", 10, 15], ["basilar", "ANATOMY", 160, 167], ["ILD", "DISEASE", 47, 50], ["chest", "ORGAN", 10, 15], ["peripheral", "TISSUE", 145, 155], ["basilar", "MULTI-TISSUE_STRUCTURE", 160, 167], ["CT of the chest", "TEST", 0, 15], ["ILD", "PROBLEM", 47, 50], ["prior CT", "TEST", 63, 71], ["superimposed ground glass opacities", "PROBLEM", 104, 139], ["a peripheral and basilar distribution", "PROBLEM", 143, 180], ["chest", "ANATOMY", 10, 15], ["progression", "OBSERVATION_MODIFIER", 32, 43], ["ILD", "OBSERVATION", 47, 50], ["superimposed", "OBSERVATION_MODIFIER", 104, 116], ["ground glass opacities", "OBSERVATION", 117, 139], ["peripheral", "ANATOMY_MODIFIER", 145, 155], ["basilar", "ANATOMY_MODIFIER", 160, 167]]], ["Laboratory data were notable for a lack of leukocytosis, elevated ESR and CRP, and SARS-CoV-2 RNA positive nucleic acid amplification test (NAAT).CASEPatient was treated for community-acquired pneumonia with ceftriaxone.", [["leukocytosis", "DISEASE", 43, 55], ["nucleic acid", "CHEMICAL", 107, 119], ["pneumonia", "DISEASE", 193, 202], ["ceftriaxone", "CHEMICAL", 208, 219], ["ceftriaxone", "CHEMICAL", 208, 219], ["CRP", "GENE_OR_GENE_PRODUCT", 74, 77], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 83, 93], ["ceftriaxone", "SIMPLE_CHEMICAL", 208, 219], ["ESR", "PROTEIN", 66, 69], ["CRP", "PROTEIN", 74, 77], ["SARS-CoV", "SPECIES", 83, 91], ["Laboratory data", "TEST", 0, 15], ["leukocytosis", "PROBLEM", 43, 55], ["elevated ESR", "PROBLEM", 57, 69], ["CRP", "TEST", 74, 77], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91], ["nucleic acid amplification test", "TEST", 107, 138], ["community-acquired pneumonia", "PROBLEM", 174, 202], ["ceftriaxone", "TREATMENT", 208, 219], ["leukocytosis", "OBSERVATION", 43, 55], ["pneumonia", "OBSERVATION", 193, 202]]], ["Because she presented during the early part of the pandemic, she was treated with hydroxychloroquine for COVID-19.", [["hydroxychloroquine", "CHEMICAL", 82, 100], ["COVID-19", "CHEMICAL", 105, 113], ["hydroxychloroquine", "CHEMICAL", 82, 100], ["COVID-19", "CHEMICAL", 105, 113], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 82, 100], ["hydroxychloroquine", "TREATMENT", 82, 100], ["COVID", "TEST", 105, 110]]], ["Due to concerns for ILD exacerbation, she was also administered methylprednisolone 40 mg IV every 8 hours with a quick taper.", [["ILD", "DISEASE", 20, 23], ["methylprednisolone", "CHEMICAL", 64, 82], ["methylprednisolone", "CHEMICAL", 64, 82], ["methylprednisolone", "SIMPLE_CHEMICAL", 64, 82], ["ILD exacerbation", "PROBLEM", 20, 36], ["methylprednisolone", "TREATMENT", 64, 82], ["a quick taper", "TREATMENT", 111, 124]]], ["The patient showed improvement over the next few days and was discharged home requiring 4 L/min of oxygen supplementation.", [["oxygen", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 99, 105], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 99, 105], ["patient", "SPECIES", 4, 11], ["oxygen supplementation", "TREATMENT", 99, 121], ["improvement", "OBSERVATION_MODIFIER", 19, 30]]], ["She was also re-started on azathioprine, although dose was lowered due to concern of co-existing infection.CASEOne-week after discharge, the patient was re-hospitalized because of several days of worsening dyspnea on exertion, sputum production, and a home pulse oximetry showing hemoglobin oxygen desaturation down to 82% despite oxygen supplementation.", [["sputum", "ANATOMY", 227, 233], ["azathioprine", "CHEMICAL", 27, 39], ["infection", "DISEASE", 97, 106], ["dyspnea", "DISEASE", 206, 213], ["oxygen", "CHEMICAL", 291, 297], ["oxygen", "CHEMICAL", 331, 337], ["azathioprine", "CHEMICAL", 27, 39], ["oxygen", "CHEMICAL", 291, 297], ["oxygen", "CHEMICAL", 331, 337], ["azathioprine", "SIMPLE_CHEMICAL", 27, 39], ["patient", "ORGANISM", 141, 148], ["hemoglobin", "SIMPLE_CHEMICAL", 280, 290], ["oxygen", "SIMPLE_CHEMICAL", 291, 297], ["oxygen", "SIMPLE_CHEMICAL", 331, 337], ["hemoglobin", "PROTEIN", 280, 290], ["patient", "SPECIES", 141, 148], ["azathioprine", "TREATMENT", 27, 39], ["co-existing infection", "PROBLEM", 85, 106], ["worsening dyspnea", "PROBLEM", 196, 213], ["sputum production", "PROBLEM", 227, 244], ["a home pulse oximetry", "TEST", 250, 271], ["hemoglobin oxygen desaturation", "PROBLEM", 280, 310], ["oxygen supplementation", "TREATMENT", 331, 353], ["co-existing", "OBSERVATION_MODIFIER", 85, 96], ["infection", "OBSERVATION", 97, 106], ["worsening", "OBSERVATION_MODIFIER", 196, 205], ["dyspnea", "OBSERVATION", 206, 213], ["hemoglobin", "OBSERVATION", 280, 290], ["oxygen desaturation", "OBSERVATION", 291, 310]]], ["Oxygenation improved to 98% on 50 L/min at 70% FiO2.", [["FiO2", "CHEMICAL", 47, 51], ["Oxygenation", "TEST", 0, 11], ["FiO2", "TREATMENT", 47, 51]]], ["A repeat chest CT was notable for interval progression of patchy airspace opacities and consolidations, with no thromboembolism (Figure 1C).", [["chest", "ANATOMY", 9, 14], ["airspace", "ANATOMY", 65, 73], ["opacities", "DISEASE", 74, 83], ["thromboembolism", "DISEASE", 112, 127], ["chest", "ORGAN", 9, 14], ["A repeat chest CT", "TEST", 0, 17], ["patchy airspace opacities", "PROBLEM", 58, 83], ["consolidations", "PROBLEM", 88, 102], ["thromboembolism", "PROBLEM", 112, 127], ["chest", "ANATOMY", 9, 14], ["progression", "OBSERVATION_MODIFIER", 43, 54], ["patchy", "OBSERVATION_MODIFIER", 58, 64], ["airspace", "ANATOMY_MODIFIER", 65, 73], ["opacities", "OBSERVATION", 74, 83], ["consolidations", "OBSERVATION", 88, 102], ["no", "UNCERTAINTY", 109, 111], ["thromboembolism", "OBSERVATION", 112, 127]]], ["Most inflammatory markers, except CRP, were reduced when compared to the prior hospitalization suggesting her deterioration was not related to COVD-19.", [["COVD-19", "CHEMICAL", 143, 150], ["CRP", "GENE_OR_GENE_PRODUCT", 34, 37], ["inflammatory markers", "PROTEIN", 5, 25], ["CRP", "PROTEIN", 34, 37], ["Most inflammatory markers", "PROBLEM", 0, 25], ["CRP", "TEST", 34, 37], ["her deterioration", "PROBLEM", 106, 123], ["COVD", "TEST", 143, 147], ["inflammatory", "OBSERVATION_MODIFIER", 5, 17], ["CRP", "OBSERVATION_MODIFIER", 34, 37], ["reduced", "OBSERVATION_MODIFIER", 44, 51]]], ["She was treated for hospital-acquired pneumonia and given methylprednisolone 40 mg IV every 12 hours for possible ILD flare.", [["pneumonia", "DISEASE", 38, 47], ["methylprednisolone", "CHEMICAL", 58, 76], ["ILD", "DISEASE", 114, 117], ["methylprednisolone", "CHEMICAL", 58, 76], ["methylprednisolone", "SIMPLE_CHEMICAL", 58, 76], ["hospital-acquired pneumonia", "PROBLEM", 20, 47], ["methylprednisolone", "TREATMENT", 58, 76], ["ILD flare", "PROBLEM", 114, 123], ["pneumonia", "OBSERVATION", 38, 47], ["possible", "UNCERTAINTY", 105, 113], ["ILD", "OBSERVATION_MODIFIER", 114, 117], ["flare", "OBSERVATION", 118, 123]]], ["She was continued with azathioprine.", [["azathioprine", "CHEMICAL", 23, 35], ["azathioprine", "CHEMICAL", 23, 35], ["azathioprine", "SIMPLE_CHEMICAL", 23, 35], ["azathioprine", "TREATMENT", 23, 35]]], ["Despite the above, her condition deteriorated, ultimately requiring non-invasive ventilation and transfer to the intensive care unit for surveillance.", [["non-invasive ventilation", "TREATMENT", 68, 92], ["surveillance", "TEST", 137, 149]]], ["With continuing antibiotics and corticosteroids followed by taper, the patient improved without requiring intubation and mechanical ventilation.", [["corticosteroids", "CHEMICAL", 32, 47], ["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["continuing antibiotics", "TREATMENT", 5, 27], ["corticosteroids", "TREATMENT", 32, 47], ["taper", "TREATMENT", 60, 65], ["intubation", "TREATMENT", 106, 116], ["mechanical ventilation", "TREATMENT", 121, 143], ["mechanical ventilation", "OBSERVATION", 121, 143]]], ["She returned to using 4 L/min of supplemental oxygen and was discharged home with supplemental oxygen.", [["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 95, 101], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 95, 101], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["oxygen", "SIMPLE_CHEMICAL", 95, 101], ["supplemental oxygen", "TREATMENT", 33, 52], ["supplemental oxygen", "TREATMENT", 82, 101]]], ["A repeat transthoracic echocardiogram performed after discharge showed mildly decreased left ventricular systolic function with global hypokinesis and estimated ejection fraction of 45-50%.", [["left ventricular", "ANATOMY", 88, 104], ["hypokinesis", "DISEASE", 135, 146], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 88, 104], ["A repeat transthoracic echocardiogram", "TEST", 0, 37], ["mildly decreased left ventricular systolic function", "PROBLEM", 71, 122], ["global hypokinesis", "PROBLEM", 128, 146], ["estimated ejection fraction", "TEST", 151, 178], ["mildly", "OBSERVATION_MODIFIER", 71, 77], ["decreased", "OBSERVATION", 78, 87], ["left ventricular", "ANATOMY", 88, 104], ["systolic function", "OBSERVATION", 105, 122], ["global", "OBSERVATION_MODIFIER", 128, 134], ["hypokinesis", "OBSERVATION", 135, 146], ["ejection fraction", "OBSERVATION", 161, 178]]], ["One month after the hospitalization, the patient was still requiring oxygen supplementation and her pulmonary function tests showed deterioration when compared to the prior year (FVC 1.98L, FEV1 1.65L, TLC 3.79L, DLCO 8.2 mL/min/mmHg).DISCUSSIONWe report the case of a woman with RA-ILD who was admitted with acute hypoxemic respiratory failure in the setting of COVID-19.", [["pulmonary", "ANATOMY", 100, 109], ["respiratory", "ANATOMY", 325, 336], ["oxygen", "CHEMICAL", 69, 75], ["RA", "DISEASE", 280, 282], ["ILD", "DISEASE", 283, 286], ["hypoxemic respiratory failure", "DISEASE", 315, 344], ["oxygen", "CHEMICAL", 69, 75], ["COVID-19", "CHEMICAL", 363, 371], ["patient", "ORGANISM", 41, 48], ["oxygen", "SIMPLE_CHEMICAL", 69, 75], ["pulmonary", "ORGAN", 100, 109], ["woman", "ORGANISM", 269, 274], ["patient", "SPECIES", 41, 48], ["woman", "SPECIES", 269, 274], ["oxygen supplementation", "TREATMENT", 69, 91], ["her pulmonary function tests", "TEST", 96, 124], ["FVC", "TEST", 179, 182], ["FEV1", "TEST", 190, 194], ["TLC", "TEST", 202, 205], ["DLCO", "TEST", 213, 217], ["ILD", "PROBLEM", 283, 286], ["acute hypoxemic respiratory failure", "PROBLEM", 309, 344], ["COVID", "TEST", 363, 368], ["pulmonary", "ANATOMY", 100, 109], ["acute", "OBSERVATION_MODIFIER", 309, 314], ["hypoxemic", "OBSERVATION_MODIFIER", 315, 324], ["respiratory failure", "OBSERVATION", 325, 344]]], ["ILD is increasingly being recognized as a manifestation of RA and is associated with significant morbidity and mortality.6 However, one third of patients are believed to have subclinical disease, which delays diagnosis and intervention.", [["ILD", "DISEASE", 0, 3], ["RA", "DISEASE", 59, 61], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["ILD", "PROBLEM", 0, 3], ["significant morbidity", "PROBLEM", 85, 106], ["subclinical disease", "PROBLEM", 175, 194], ["intervention", "TREATMENT", 223, 235], ["RA", "ANATOMY", 59, 61], ["significant", "OBSERVATION_MODIFIER", 85, 96], ["morbidity", "OBSERVATION", 97, 106], ["subclinical", "OBSERVATION_MODIFIER", 175, 186], ["disease", "OBSERVATION", 187, 194]]], ["Interestingly, connective tissue disorders like RA are well known to affect women predominantly.7 However, the development of ILD in the setting of RA is more common in men.8 Hormonal differences have been suggested, but this requires further investigation.7", [["connective tissue", "ANATOMY", 15, 32], ["connective tissue disorders", "DISEASE", 15, 42], ["RA", "DISEASE", 48, 50], ["ILD", "DISEASE", 126, 129], ["RA", "DISEASE", 148, 150], ["connective tissue", "TISSUE", 15, 32], ["women", "ORGANISM", 76, 81], ["men", "ORGANISM", 169, 172], ["women", "SPECIES", 76, 81], ["men", "SPECIES", 169, 172], ["connective tissue disorders", "PROBLEM", 15, 42], ["ILD", "PROBLEM", 126, 129], ["further investigation", "TEST", 235, 256], ["connective tissue", "OBSERVATION", 15, 32], ["RA", "ANATOMY", 48, 50], ["ILD", "OBSERVATION", 126, 129], ["RA", "ANATOMY", 148, 150]]]], "PMC7432482": [["IntroductionCoronaviruses (CoVs) are a group of large enveloped non-segmented positive-sense RNA viruses, causing respiratory and enteric diseases in animals and humans [1].", [["respiratory", "ANATOMY", 114, 125], ["respiratory and enteric diseases", "DISEASE", 114, 146], ["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["humans", "ORGANISM", 162, 168], ["humans", "SPECIES", 162, 168], ["humans", "SPECIES", 162, 168], ["IntroductionCoronaviruses (CoVs", "PROBLEM", 0, 31], ["large enveloped non-segmented positive-sense RNA viruses", "PROBLEM", 48, 104], ["respiratory and enteric diseases", "PROBLEM", 114, 146], ["enteric diseases", "OBSERVATION", 130, 146]]], ["A highly pathogenic CoV, named Severe Acute Respiratory Syndrome (SARS)-CoV-2 (formerly known as 2019-nCoV), emerged in December 2019 in the Hubei region of China, and in the city of Wuhan in particular.", [["Acute Respiratory Syndrome", "DISEASE", 38, 64], ["SARS", "DISEASE", 66, 70], ["CoV", "ORGANISM", 20, 23], ["CoV-2", "ORGANISM", 72, 77], ["Severe Acute Respiratory Syndrome (SARS)-CoV-2", "SPECIES", 31, 77], ["A highly pathogenic CoV", "PROBLEM", 0, 23], ["Severe Acute Respiratory Syndrome", "PROBLEM", 31, 64], ["CoV", "TEST", 72, 75], ["pathogenic CoV", "OBSERVATION", 9, 23], ["Severe", "OBSERVATION_MODIFIER", 31, 37], ["Acute", "OBSERVATION_MODIFIER", 38, 43], ["Respiratory Syndrome", "OBSERVATION", 44, 64]]], ["The initial cases, presenting with a dry cough, sore throat, fever, dyspnea, and bilateral lung infiltrates on chest imaging, were all linked to the Wuhan\u2019s Huanan Seafood Wholesale Market, which trades fish and a variety of live animals, including bats, poultry, marmots, and snakes [2].", [["lung", "ANATOMY", 91, 95], ["chest", "ANATOMY", 111, 116], ["marmots", "ANATOMY", 264, 271], ["dry cough", "DISEASE", 37, 46], ["sore throat", "DISEASE", 48, 59], ["fever", "DISEASE", 61, 66], ["dyspnea", "DISEASE", 68, 75], ["lung", "ORGAN", 91, 95], ["chest", "ORGAN", 111, 116], ["a dry cough", "PROBLEM", 35, 46], ["sore throat", "PROBLEM", 48, 59], ["fever", "PROBLEM", 61, 66], ["dyspnea", "PROBLEM", 68, 75], ["bilateral lung infiltrates", "PROBLEM", 81, 107], ["chest imaging", "TEST", 111, 124], ["cough", "OBSERVATION", 41, 46], ["sore throat", "ANATOMY", 48, 59], ["fever", "OBSERVATION", 61, 66], ["dyspnea", "OBSERVATION", 68, 75], ["bilateral", "ANATOMY_MODIFIER", 81, 90], ["lung", "ANATOMY", 91, 95], ["infiltrates", "OBSERVATION", 96, 107], ["chest", "ANATOMY", 111, 116]]], ["This novel CoV has caused an outbreak of severe pneumonia (called COVID-19) in China, that has rapidly spread around the world [3].", [["pneumonia", "DISEASE", 48, 57], ["COVID-19", "CHEMICAL", 66, 74], ["CoV", "ORGANISM", 11, 14], ["severe pneumonia", "PROBLEM", 41, 57], ["COVID", "TEST", 66, 71], ["outbreak", "OBSERVATION_MODIFIER", 29, 37], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["pneumonia", "OBSERVATION", 48, 57]]], ["IntroductionPerson-to-person transmission occurs primarily through direct contact or droplets spread by coughing or sneezing from infected individuals [5].", [["coughing", "DISEASE", 104, 112], ["person", "SPECIES", 22, 28], ["coughing", "PROBLEM", 104, 112], ["sneezing", "PROBLEM", 116, 124]]], ["In closed rooms, larger aerosols with a greater contagion capacity can form, in which the virus lasts for several hours.", [["larger", "OBSERVATION_MODIFIER", 17, 23], ["aerosols", "OBSERVATION", 24, 32]]], ["Transmission by fomites is also possible as SARS-CoV-2 persists on smooth surfaces (such as cardboard, stainless steel, and plastic surfaces) from 24 to 72 h.", [["smooth surfaces", "ANATOMY", 67, 82], ["smooth surfaces", "TISSUE", 67, 82], ["SARS", "PROBLEM", 44, 48], ["cardboard, stainless steel", "TREATMENT", 92, 118], ["smooth surfaces", "OBSERVATION_MODIFIER", 67, 82]]], ["Additionally, SARS-CoV-2 has been detected not only in lung secretions but also in blood, feces, saliva, and urine of infected people [6].1.1.", [["lung secretions", "ANATOMY", 55, 70], ["blood", "ANATOMY", 83, 88], ["feces", "ANATOMY", 90, 95], ["saliva", "ANATOMY", 97, 103], ["urine", "ANATOMY", 109, 114], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["lung", "ORGAN", 55, 59], ["secretions", "ORGANISM_SUBSTANCE", 60, 70], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["feces", "ORGANISM_SUBSTANCE", 90, 95], ["saliva", "ORGANISM_SUBSTANCE", 97, 103], ["urine", "ORGANISM_SUBSTANCE", 109, 114], ["people", "ORGANISM", 127, 133], ["people", "SPECIES", 127, 133], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 14, 18], ["lung secretions", "PROBLEM", 55, 70], ["blood", "TEST", 83, 88], ["lung", "ANATOMY", 55, 59], ["secretions", "OBSERVATION", 60, 70]]], ["IntroductionThe symptoms of COVID-19 infection usually appear after an incubation period of approximately 5 days (from 3 to 14 days) [7] and, in deceased patients, the interval from the symptom onset to death ranges from 6 to 41 days, with a median of 14 days [8].", [["COVID-19", "CHEMICAL", 28, 36], ["infection", "DISEASE", 37, 46], ["death", "DISEASE", 203, 208], ["COVID-19", "ORGANISM", 28, 36], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["The symptoms", "PROBLEM", 12, 24], ["COVID-19 infection", "PROBLEM", 28, 46], ["infection", "OBSERVATION", 37, 46]]], ["Most SARS-CoV-2 infected patients have mild symptoms that spontaneously resolve, whereas others, especially comorbid adults and elderly subjects, develop various complications, including severe pneumonia, septic shock, pulmonary edema, and acute respiratory distress syndrome, despite invasive ventilation in some cases.", [["pulmonary", "ANATOMY", 219, 228], ["respiratory", "ANATOMY", 246, 257], ["SARS-CoV-2 infected", "DISEASE", 5, 24], ["pneumonia", "DISEASE", 194, 203], ["septic shock", "DISEASE", 205, 217], ["pulmonary edema", "DISEASE", 219, 234], ["acute respiratory distress syndrome", "DISEASE", 240, 275], ["SARS-CoV-2", "ORGANISM", 5, 15], ["patients", "ORGANISM", 25, 33], ["pulmonary", "ORGAN", 219, 228], ["CoV-", "SPECIES", 10, 14], ["patients", "SPECIES", 25, 33], ["Most SARS", "PROBLEM", 0, 9], ["mild symptoms", "PROBLEM", 39, 52], ["various complications", "PROBLEM", 154, 175], ["severe pneumonia", "PROBLEM", 187, 203], ["septic shock", "PROBLEM", 205, 217], ["pulmonary edema", "PROBLEM", 219, 234], ["acute respiratory distress syndrome", "PROBLEM", 240, 275], ["invasive ventilation", "TREATMENT", 285, 305], ["mild", "OBSERVATION_MODIFIER", 39, 43], ["symptoms", "OBSERVATION", 44, 52], ["complications", "OBSERVATION", 162, 175], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["pneumonia", "OBSERVATION", 194, 203], ["septic shock", "OBSERVATION", 205, 217], ["pulmonary", "ANATOMY", 219, 228], ["edema", "OBSERVATION", 229, 234], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["respiratory distress syndrome", "OBSERVATION", 246, 275], ["invasive ventilation", "OBSERVATION", 285, 305]]], ["The overall mortality is estimated to be 8% and is due to respiratory failure or multiple organ failure [9,10].1.2.", [["respiratory", "ANATOMY", 58, 69], ["organ", "ANATOMY", 90, 95], ["respiratory failure", "DISEASE", 58, 77], ["organ failure", "DISEASE", 90, 103], ["organ", "ORGAN", 90, 95], ["respiratory failure", "PROBLEM", 58, 77], ["multiple organ failure", "PROBLEM", 81, 103], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["mortality", "OBSERVATION", 12, 21], ["due to", "UNCERTAINTY", 51, 57], ["respiratory failure", "OBSERVATION", 58, 77], ["multiple", "OBSERVATION_MODIFIER", 81, 89], ["organ", "ANATOMY", 90, 95], ["failure", "OBSERVATION", 96, 103]]], ["Basic SARS-CoV-2 Virology ::: 1.", [["Basic SARS-CoV", "TEST", 0, 14], ["SARS-CoV", "OBSERVATION", 6, 14]]], ["IntroductionThe term \u201ccoronavirus\u201d refers to the peculiar crown-shaped appearance of its envelope at electron microscopy, further surrounded by spike-shaped membrane glycoproteins.", [["membrane", "ANATOMY", 157, 165], ["coronavirus", "DISEASE", 22, 33], ["coronavirus", "ORGANISM", 22, 33], ["membrane glycoproteins", "CELLULAR_COMPONENT", 157, 179], ["spike-shaped membrane glycoproteins", "PROTEIN", 144, 179], ["coronavirus", "SPECIES", 22, 33], ["electron microscopy", "TEST", 101, 120], ["spike-shaped membrane glycoproteins", "PROBLEM", 144, 179], ["shaped", "OBSERVATION_MODIFIER", 150, 156], ["membrane glycoproteins", "OBSERVATION", 157, 179]]], ["In particular, the glycoprotein S, located on the outer surface, forms a three-dimensional structure in the receptor-binding domain of the host cell that facilitates the viral anchorage [11].", [["outer surface", "ANATOMY", 50, 63], ["cell", "ANATOMY", 144, 148], ["glycoprotein S", "GENE_OR_GENE_PRODUCT", 19, 33], ["outer surface", "CELLULAR_COMPONENT", 50, 63], ["host cell", "CELL", 139, 148], ["glycoprotein S", "PROTEIN", 19, 33], ["receptor-binding domain", "PROTEIN", 108, 131], ["the glycoprotein S", "PROBLEM", 15, 33], ["outer", "OBSERVATION_MODIFIER", 50, 55], ["surface", "OBSERVATION_MODIFIER", 56, 63], ["three-dimensional", "OBSERVATION_MODIFIER", 73, 90], ["host cell", "OBSERVATION", 139, 148], ["viral anchorage", "OBSERVATION", 170, 185]]], ["Phylogenetically, the Coronaviridae family encompasses four genera, i.e., alpha-, beta-, gamma-, and delta-coronavirus.", [["alpha-", "GENE_OR_GENE_PRODUCT", 74, 80], ["beta-", "GENE_OR_GENE_PRODUCT", 82, 87], ["gamma-", "GENE_OR_GENE_PRODUCT", 89, 95], ["Coronaviridae family", "PROTEIN", 22, 42], ["alpha-, beta-, gamma-, and delta-coronavirus", "PROTEIN", 74, 118], ["alpha-", "TEST", 74, 80], ["delta-coronavirus", "PROBLEM", 101, 118]]], ["SARS-CoV-2 is a beta-coronavirus with a 29,903-base single-stranded RNA genome that belongs to the Orthocoronavirinae subfamily, which is part of the Coronaviridae family [12].1.2.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["beta-coronavirus", "ORGANISM", 16, 32], ["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 99, 117], ["29,903-base single-stranded RNA genome", "DNA", 40, 78], ["Orthocoronavirinae subfamily", "PROTEIN", 99, 127], ["SARS-CoV", "SPECIES", 0, 8], ["beta-coronavirus", "SPECIES", 16, 32], ["a beta-coronavirus", "PROBLEM", 14, 32]]], ["Basic SARS-CoV-2 Virology ::: 1.", [["Basic SARS-CoV", "TEST", 0, 14], ["SARS-CoV", "OBSERVATION", 6, 14]]], ["IntroductionCoVs have remarkable genetic diversity and a high ability to recombine, thus explaining the interspecies leap of some CoVs that have affected humans in recent decades [13].", [["CoVs", "GENE_OR_GENE_PRODUCT", 130, 134], ["humans", "ORGANISM", 154, 160], ["humans", "SPECIES", 154, 160], ["humans", "SPECIES", 154, 160], ["IntroductionCoVs", "TREATMENT", 0, 16], ["some CoVs", "PROBLEM", 125, 134], ["diversity", "OBSERVATION_MODIFIER", 41, 50]]], ["The genome of SARS-CoV-2 is closely related to two beta-coronaviruses isolated in bats, and phylogenetic studies suggest that bats are the original host and reservoir [14,15].", [["SARS-CoV-2", "ORGANISM", 14, 24], ["beta-coronaviruses", "ORGANISM", 51, 69], ["bats", "ORGANISM", 126, 130], ["SARS-CoV-2", "SPECIES", 14, 24], ["SARS", "PROBLEM", 14, 18], ["two beta-coronaviruses", "PROBLEM", 47, 69], ["phylogenetic studies", "TEST", 92, 112]]], ["Then, it is likely that SARS-CoV-2 jumped into humans through an intermediate host, probably the pangolin [16].", [["SARS", "DISEASE", 24, 28], ["pangolin", "CHEMICAL", 97, 105], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["humans", "ORGANISM", 47, 53], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["SARS", "PROBLEM", 24, 28], ["CoV", "TEST", 29, 32], ["is likely", "UNCERTAINTY", 9, 18]]], ["Sequence analysis of SARS-CoV-2 has shown the typical structure of other CoVs [3], in particular, it shares highly homolog sequences with the SARS-CoV [17] and clinically causes pneumonia similar to that previously induced by the SARS-CoV and the Middle East Respiratory Syndrome (MERS)-CoV [18].1.2.", [["pneumonia", "DISEASE", 178, 187], ["SARS-CoV-2", "ORGANISM", 21, 31], ["CoVs [3", "GENE_OR_GENE_PRODUCT", 73, 80], ["SARS-CoV", "ORGANISM", 142, 150], ["SARS-CoV", "ORGANISM", 230, 238], ["SARS-CoV-2", "DNA", 21, 31], ["SARS-CoV", "SPECIES", 21, 29], ["SARS-CoV", "SPECIES", 142, 150], ["SARS-CoV", "SPECIES", 230, 238], ["Middle East Respiratory Syndrome (MERS)-CoV", "SPECIES", 247, 290], ["Sequence analysis", "TEST", 0, 17], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["other CoVs", "PROBLEM", 67, 77], ["the SARS", "TEST", 138, 146], ["pneumonia", "PROBLEM", 178, 187], ["the SARS", "PROBLEM", 226, 234], ["CoV", "PROBLEM", 235, 238], ["the Middle East Respiratory Syndrome", "PROBLEM", 243, 279], ["pneumonia", "OBSERVATION", 178, 187], ["Middle", "ANATOMY_MODIFIER", 247, 253], ["Respiratory Syndrome", "OBSERVATION", 259, 279]]], ["Basic SARS-CoV-2 Virology ::: 1.", [["Basic SARS-CoV", "TEST", 0, 14], ["SARS-CoV", "OBSERVATION", 6, 14]]], ["IntroductionStructurally, SARS-CoV has a well-defined composition comprising of 14 binding residues that directly interact with the human angiotensin-converting enzyme-2 (ACE2) receptor.", [["SARS", "DISEASE", 26, 30], ["angiotensin", "CHEMICAL", 138, 149], ["human", "ORGANISM", 132, 137], ["angiotensin-converting enzyme-2 (ACE2) receptor", "GENE_OR_GENE_PRODUCT", 138, 185], ["human angiotensin-converting enzyme-2 (ACE2) receptor", "PROTEIN", 132, 185], ["human", "SPECIES", 132, 137], ["SARS-CoV", "SPECIES", 26, 34], ["human", "SPECIES", 132, 137], ["SARS", "PROBLEM", 26, 30], ["14 binding residues", "PROBLEM", 80, 99], ["the human angiotensin", "TREATMENT", 128, 149], ["converting enzyme-2 (ACE2) receptor", "TREATMENT", 150, 185]]], ["Given the similarity between SARS-CoV and SARS-CoV-2, the pathogenesis underlying these infections may be the same [19,20,21], although the exact pathogenic mechanism of SARS-CoV-2 is not yet completely understood.1.3.", [["SARS-CoV", "DISEASE", 29, 37], ["infections", "DISEASE", 88, 98], ["SARS", "DISEASE", 170, 174], ["SARS-CoV", "ORGANISM", 29, 37], ["SARS-CoV-2", "ORGANISM", 42, 52], ["SARS-CoV-2", "ORGANISM", 170, 180], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 42, 50], ["SARS-CoV", "SPECIES", 170, 178], ["SARS", "TEST", 29, 33], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["these infections", "PROBLEM", 82, 98], ["infections", "OBSERVATION", 88, 98]]], ["IntroductionThe WHO issued guidelines for the diagnosis and management of COVID-19 [22].", [["COVID-19", "CHEMICAL", 74, 82], ["COVID", "TEST", 74, 79]]], ["Clinical diagnosis is based on a history of exposure and clinical manifestations, supported by laboratory confirmation.", [["clinical manifestations", "PROBLEM", 57, 80], ["laboratory confirmation", "TEST", 95, 118]]], ["The antibody response to SARS-CoV-2 follows a typical pattern, with the IgM antibodies disappearing 12 weeks after initial infection and the IgG antibodies (specifically directed against viral protein S and N) persisting for a longer time, thus likely exerting a protective role [23].1.3.", [["SARS", "DISEASE", 25, 29], ["infection", "DISEASE", 123, 132], ["SARS-CoV-2", "ORGANISM", 25, 35], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 141, 155], ["IgM antibodies", "PROTEIN", 72, 86], ["IgG antibodies", "PROTEIN", 141, 155], ["viral protein S and N", "PROTEIN", 187, 208], ["SARS-CoV", "SPECIES", 25, 33], ["The antibody response", "TEST", 0, 21], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["the IgM antibodies", "TEST", 68, 86], ["initial infection", "PROBLEM", 115, 132], ["the IgG antibodies", "TEST", 137, 155], ["viral protein S", "TEST", 187, 202], ["infection", "OBSERVATION", 123, 132]]], ["IntroductionThe real-time reverse polymerase-transcriptase chain reaction (RT-PCR) technique and genomic sequencing techniques are valid tests currently used to confirm the diagnosis from the nasopharynx and respiratory secretions.", [["nasopharynx", "ANATOMY", 192, 203], ["respiratory secretions", "ANATOMY", 208, 230], ["nasopharynx", "ORGAN", 192, 203], ["secretions", "ORGANISM_SUBSTANCE", 220, 230], ["The real-time reverse polymerase-transcriptase chain reaction", "TREATMENT", 12, 73], ["RT-PCR) technique", "TREATMENT", 75, 92], ["genomic sequencing techniques", "TEST", 97, 126], ["valid tests", "TEST", 131, 142], ["the nasopharynx and respiratory secretions", "PROBLEM", 188, 230], ["nasopharynx", "ANATOMY", 192, 203], ["respiratory", "ANATOMY", 208, 219], ["secretions", "OBSERVATION", 220, 230]]], ["Conversely, the isolation and cultivation of the virus in the blood and the sequencing of its entire genome are limited in the clinical practice due to the high costs involved [24].", [["blood", "ANATOMY", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["the isolation", "TREATMENT", 12, 25], ["the virus", "PROBLEM", 45, 54], ["the blood", "TEST", 58, 67]]], ["Viral antigen and more rapid antibody detection systems (such as the enzyme-linked immunosorbent assay) are currently being developed, although their accuracy is still limited by the relatively high rate of false-negative cases and, therefore, needs to be improved [25].", [["Viral antigen", "PROTEIN", 0, 13], ["Viral antigen", "TEST", 0, 13], ["more rapid antibody detection systems", "PROBLEM", 18, 55], ["the enzyme", "TEST", 65, 75], ["immunosorbent assay", "TEST", 83, 102], ["negative cases", "OBSERVATION_MODIFIER", 213, 227]]], ["More recently, other studies are trying to propose droplet digital PCR-based methods as more effective diagnostic strategies for the identification of SARS-CoV-2 positive patients with low viral load [26].1.3.", [["SARS", "DISEASE", 151, 155], ["SARS-CoV-2", "ORGANISM", 151, 161], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["SARS-CoV", "SPECIES", 151, 159], ["other studies", "TEST", 15, 28], ["droplet digital PCR", "TREATMENT", 51, 70], ["SARS", "PROBLEM", 151, 155], ["CoV", "TEST", 156, 159], ["low viral load", "PROBLEM", 185, 199]]], ["IntroductionTo date, there is no effective treatment for patients with COVID-19.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["effective treatment", "TREATMENT", 33, 52], ["COVID", "TEST", 71, 76], ["no", "UNCERTAINTY", 30, 32]]], ["Adenosine analogs (e.g., remdesivir, favipiravir, ribavirin, and galidesivir) acting on the RNA-dependent polymerase and blocking the viral RNA synthesis are promising.", [["Adenosine", "CHEMICAL", 0, 9], ["remdesivir", "CHEMICAL", 25, 35], ["favipiravir", "CHEMICAL", 37, 48], ["ribavirin", "CHEMICAL", 50, 59], ["galidesivir", "CHEMICAL", 65, 76], ["Adenosine", "CHEMICAL", 0, 9], ["remdesivir", "CHEMICAL", 25, 35], ["favipiravir", "CHEMICAL", 37, 48], ["ribavirin", "CHEMICAL", 50, 59], ["galidesivir", "CHEMICAL", 65, 76], ["Adenosine analogs", "SIMPLE_CHEMICAL", 0, 17], ["remdesivir", "SIMPLE_CHEMICAL", 25, 35], ["favipiravir", "SIMPLE_CHEMICAL", 37, 48], ["ribavirin", "SIMPLE_CHEMICAL", 50, 59], ["galidesivir", "SIMPLE_CHEMICAL", 65, 76], ["RNA-dependent polymerase", "PROTEIN", 92, 116], ["Adenosine analogs", "TREATMENT", 0, 17], ["remdesivir", "TREATMENT", 25, 35], ["favipiravir", "TREATMENT", 37, 48], ["ribavirin", "TREATMENT", 50, 59], ["galidesivir", "TREATMENT", 65, 76], ["dependent polymerase", "PROBLEM", 96, 116], ["blocking the viral RNA synthesis", "TREATMENT", 121, 153], ["viral RNA", "OBSERVATION", 134, 143]]], ["Chloroquine (CQ) and hydroxychloroquine (HCQ) can effectively inhibit SARS-CoV-2 in vitro, but their efficacy in vivo is under evaluation, as well as the effect of serum rich in anti-SARS-CoV-2 antibodies obtained from convalescent subjects [23].", [["serum", "ANATOMY", 164, 169], ["Chloroquine", "CHEMICAL", 0, 11], ["CQ", "CHEMICAL", 13, 15], ["hydroxychloroquine", "CHEMICAL", 21, 39], ["HCQ", "CHEMICAL", 41, 44], ["Chloroquine", "CHEMICAL", 0, 11], ["CQ", "CHEMICAL", 13, 15], ["hydroxychloroquine", "CHEMICAL", 21, 39], ["HCQ", "CHEMICAL", 41, 44], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["CQ", "SIMPLE_CHEMICAL", 13, 15], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 21, 39], ["HCQ", "SIMPLE_CHEMICAL", 41, 44], ["CoV-2", "GENE_OR_GENE_PRODUCT", 75, 80], ["serum", "ORGANISM_SUBSTANCE", 164, 169], ["anti-SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 178, 204], ["anti-SARS-CoV-2 antibodies", "PROTEIN", 178, 204], ["SARS-CoV", "SPECIES", 70, 78], ["Chloroquine (CQ)", "TREATMENT", 0, 16], ["hydroxychloroquine (HCQ)", "TREATMENT", 21, 45], ["CoV", "TEST", 75, 78], ["evaluation", "TEST", 127, 137], ["serum rich", "TEST", 164, 174], ["anti-SARS", "TEST", 178, 187], ["CoV-2 antibodies", "TEST", 188, 204]]], ["Very recently, a systematic review assessed the efficacy and safety of CQ/HCQ for treatment or prophylaxis of adult patients with COVID-19 [27].", [["CQ", "CHEMICAL", 71, 73], ["HCQ", "CHEMICAL", 74, 77], ["CQ", "CHEMICAL", 71, 73], ["HCQ", "CHEMICAL", 74, 77], ["COVID-19", "CHEMICAL", 130, 138], ["CQ", "SIMPLE_CHEMICAL", 71, 73], ["HCQ", "SIMPLE_CHEMICAL", 74, 77], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["CQ/HCQ", "TREATMENT", 71, 77], ["treatment", "TREATMENT", 82, 91], ["prophylaxis", "TREATMENT", 95, 106], ["COVID", "TEST", 130, 135]]], ["Thirty-two studies were included, of which 6 randomized clinical trials (RCTs) and 26 non-randomized, with a total of 29,192 participants.", [["participants", "SPECIES", 125, 137], ["RCTs", "TEST", 73, 77]]], ["Overall, studies suggest that the treatment of hospitalized patients with CQ/HCQ may not reduce the risk of death compared to standard care.", [["CQ", "CHEMICAL", 74, 76], ["HCQ", "CHEMICAL", 77, 80], ["death", "DISEASE", 108, 113], ["CQ", "CHEMICAL", 74, 76], ["HCQ", "CHEMICAL", 77, 80], ["patients", "ORGANISM", 60, 68], ["CQ", "SIMPLE_CHEMICAL", 74, 76], ["HCQ", "SIMPLE_CHEMICAL", 77, 80], ["patients", "SPECIES", 60, 68], ["CQ/HCQ", "TREATMENT", 74, 80], ["death", "PROBLEM", 108, 113]]], ["High dose regimens or combination with macrolides may be associated with harm, particularly QTc prolongation and cardiac arrhythmias [28].", [["cardiac", "ANATOMY", 113, 120], ["macrolides", "CHEMICAL", 39, 49], ["QTc prolongation", "DISEASE", 92, 108], ["cardiac arrhythmias", "DISEASE", 113, 132], ["macrolides", "CHEMICAL", 39, 49], ["macrolides", "SIMPLE_CHEMICAL", 39, 49], ["High dose regimens", "TREATMENT", 0, 18], ["macrolides", "TREATMENT", 39, 49], ["harm", "PROBLEM", 73, 77], ["QTc prolongation", "PROBLEM", 92, 108], ["cardiac arrhythmias", "PROBLEM", 113, 132]]], ["Post-exposure prophylaxis may not reduce the rate of infection, although the quality of the evidence is low.", [["infection", "DISEASE", 53, 62], ["Post-exposure prophylaxis", "TREATMENT", 0, 25], ["infection", "PROBLEM", 53, 62], ["infection", "OBSERVATION", 53, 62], ["low", "OBSERVATION_MODIFIER", 104, 107]]], ["The authors concluded that patients should be treated with CQ/HCQ only if monitored and in the context of high-quality RCTs [27].", [["CQ", "CHEMICAL", 59, 61], ["HCQ", "CHEMICAL", 62, 65], ["CQ", "CHEMICAL", 59, 61], ["HCQ", "CHEMICAL", 62, 65], ["patients", "ORGANISM", 27, 35], ["CQ", "SIMPLE_CHEMICAL", 59, 61], ["HCQ", "SIMPLE_CHEMICAL", 62, 65], ["patients", "SPECIES", 27, 35], ["CQ/HCQ", "TREATMENT", 59, 65]]], ["Therefore, rationalization of the use of these drugs is also advised [29].1.3.", [["these drugs", "TREATMENT", 41, 52]]], ["IntroductionOther non-specific immune modulators include human immunoglobulin and corticosteroids, such as dexamethasone, a glucocorticoid that has proved to be the first life-saving drug in these patients.", [["dexamethasone", "CHEMICAL", 107, 120], ["dexamethasone", "CHEMICAL", 107, 120], ["human", "ORGANISM", 57, 62], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 63, 77], ["corticosteroids", "SIMPLE_CHEMICAL", 82, 97], ["dexamethasone", "SIMPLE_CHEMICAL", 107, 120], ["glucocorticoid", "SIMPLE_CHEMICAL", 124, 138], ["patients", "ORGANISM", 197, 205], ["human immunoglobulin", "PROTEIN", 57, 77], ["human", "SPECIES", 57, 62], ["patients", "SPECIES", 197, 205], ["human", "SPECIES", 57, 62], ["IntroductionOther non-specific immune modulators", "TREATMENT", 0, 48], ["human immunoglobulin", "TREATMENT", 57, 77], ["corticosteroids", "TREATMENT", 82, 97], ["dexamethasone", "TREATMENT", 107, 120], ["a glucocorticoid", "TREATMENT", 122, 138]]], ["In particular, dexamethasone 6 mg once daily (either per os or by intravenous injection) for 10 days may result in a reduction in mortality by 1/3 in patients on ventilators and by 1/5 in those receiving oxygen [30].", [["intravenous", "ANATOMY", 66, 77], ["dexamethasone", "CHEMICAL", 15, 28], ["oxygen", "CHEMICAL", 204, 210], ["dexamethasone", "CHEMICAL", 15, 28], ["oxygen", "CHEMICAL", 204, 210], ["dexamethasone", "SIMPLE_CHEMICAL", 15, 28], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 77], ["patients", "ORGANISM", 150, 158], ["oxygen", "SIMPLE_CHEMICAL", 204, 210], ["patients", "SPECIES", 150, 158], ["dexamethasone", "TREATMENT", 15, 28], ["ventilators", "TREATMENT", 162, 173], ["reduction", "OBSERVATION_MODIFIER", 117, 126]]], ["Other treatment options include specific monoclonal antibodies that bind the receptor-receptor domain of SARS-CoV-2 and antibodies that block inflammatory interleukins (IL), such as tocilizumab.", [["tocilizumab", "CHEMICAL", 182, 193], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 105, 115], ["interleukins", "GENE_OR_GENE_PRODUCT", 155, 167], ["IL", "GENE_OR_GENE_PRODUCT", 169, 171], ["tocilizumab", "SIMPLE_CHEMICAL", 182, 193], ["monoclonal antibodies", "PROTEIN", 41, 62], ["receptor-receptor domain", "PROTEIN", 77, 101], ["SARS-CoV-2", "PROTEIN", 105, 115], ["antibodies", "PROTEIN", 120, 130], ["inflammatory interleukins", "PROTEIN", 142, 167], ["IL", "PROTEIN", 169, 171], ["Other treatment options", "TREATMENT", 0, 23], ["specific monoclonal antibodies", "TREATMENT", 32, 62], ["SARS", "TEST", 105, 109], ["CoV", "TEST", 110, 113], ["antibodies", "TREATMENT", 120, 130], ["block inflammatory interleukins (IL)", "TREATMENT", 136, 172], ["tocilizumab", "TREATMENT", 182, 193]]], ["Finally, several vaccines are under analysis and include live attenuated viruses, inactivated viruses, use of recombinant DNA, and vaccines based on SARS-CoV-2 specific proteins and subunits [31].", [["DNA", "CELLULAR_COMPONENT", 122, 125], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 149, 159], ["SARS-CoV-2 specific proteins", "PROTEIN", 149, 177], ["SARS-CoV", "SPECIES", 149, 157], ["several vaccines", "TREATMENT", 9, 25], ["analysis", "TEST", 36, 44], ["live attenuated viruses", "PROBLEM", 57, 80], ["recombinant DNA", "TREATMENT", 110, 125], ["vaccines", "TREATMENT", 131, 139], ["SARS", "TEST", 149, 153], ["CoV", "TEST", 154, 157]]], ["Until these therapeutic options are confirmed, the main measures are prevention, isolation, social distancing, frequent hand washing, and the use of personal protective equipment.2.1.", [["hand", "ANATOMY", 120, 124], ["hand", "ORGANISM_SUBDIVISION", 120, 124], ["isolation", "TREATMENT", 81, 90], ["frequent hand washing", "TREATMENT", 111, 132], ["personal protective equipment", "TREATMENT", 149, 178], ["main", "OBSERVATION_MODIFIER", 51, 55]]], ["CNS Infection From Respiratory Viruses ::: 2.", [["CNS", "ANATOMY", 0, 3], ["Respiratory Viruses", "DISEASE", 19, 38], ["CNS", "ANATOMICAL_SYSTEM", 0, 3], ["CNS Infection", "PROBLEM", 0, 13], ["Infection", "OBSERVATION", 4, 13], ["Respiratory Viruses", "OBSERVATION", 19, 38]]], ["Background on SARS-CoV-2 and Nervous SystemAll the common respiratory viruses affecting humans, such as influenza, CoVs, and respiratory syncytial virus (RSV), can be associated with various neurological manifestations, particularly in subjects experiencing severe pulmonary symptoms [34].", [["neurological", "ANATOMY", 191, 203], ["pulmonary", "ANATOMY", 265, 274], ["respiratory viruses", "DISEASE", 58, 77], ["influenza, CoVs", "DISEASE", 104, 119], ["respiratory syncytial virus", "DISEASE", 125, 152], ["RSV", "DISEASE", 154, 157], ["SARS-CoV-2", "ORGANISM", 14, 24], ["Nervous SystemAll", "ORGANISM", 29, 46], ["humans", "ORGANISM", 88, 94], ["CoVs", "GENE_OR_GENE_PRODUCT", 115, 119], ["respiratory syncytial virus", "ORGANISM", 125, 152], ["RSV", "ORGANISM", 154, 157], ["pulmonary", "ORGAN", 265, 274], ["humans", "SPECIES", 88, 94], ["respiratory syncytial virus", "SPECIES", 125, 152], ["SARS-CoV", "SPECIES", 14, 22], ["humans", "SPECIES", 88, 94], ["respiratory syncytial virus", "SPECIES", 125, 152], ["RSV", "SPECIES", 154, 157], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["influenza", "PROBLEM", 104, 113], ["CoVs", "PROBLEM", 115, 119], ["respiratory syncytial virus", "PROBLEM", 125, 152], ["various neurological manifestations", "PROBLEM", 183, 218], ["severe pulmonary symptoms", "PROBLEM", 258, 283], ["SARS", "OBSERVATION", 14, 18], ["common", "ANATOMY", 51, 57], ["respiratory viruses", "OBSERVATION", 58, 77], ["respiratory", "ANATOMY", 125, 136], ["syncytial virus", "OBSERVATION", 137, 152], ["pulmonary", "ANATOMY", 265, 274]]], ["For instance, the effects that RSV may cause include seizures, encephalitis, ataxia, and cerebellitis, and the virus has been detected in the cerebrospinal fluid (CSF).", [["cerebrospinal fluid", "ANATOMY", 142, 161], ["RSV", "DISEASE", 31, 34], ["seizures", "DISEASE", 53, 61], ["encephalitis", "DISEASE", 63, 75], ["ataxia", "DISEASE", 77, 83], ["cerebellitis", "DISEASE", 89, 101], ["RSV", "ORGANISM", 31, 34], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 142, 161], ["CSF", "ORGANISM_SUBSTANCE", 163, 166], ["RSV", "SPECIES", 31, 34], ["RSV", "PROBLEM", 31, 34], ["seizures", "PROBLEM", 53, 61], ["encephalitis", "PROBLEM", 63, 75], ["ataxia", "PROBLEM", 77, 83], ["cerebellitis", "PROBLEM", 89, 101], ["the virus", "PROBLEM", 107, 116], ["the cerebrospinal fluid", "TEST", 138, 161], ["may cause include", "UNCERTAINTY", 35, 52], ["seizures", "OBSERVATION", 53, 61], ["encephalitis", "OBSERVATION", 63, 75], ["cerebrospinal", "ANATOMY", 142, 155], ["fluid", "OBSERVATION", 156, 161]]], ["Influenza is known to cause neurological complications, such as encephalitis, myelitis, meningitis, and Guillain-Barr\u00e9 syndrome (GBS) [34].2.2.", [["neurological", "ANATOMY", 28, 40], ["Influenza", "DISEASE", 0, 9], ["neurological complications", "DISEASE", 28, 54], ["encephalitis", "DISEASE", 64, 76], ["myelitis", "DISEASE", 78, 86], ["meningitis", "DISEASE", 88, 98], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 104, 127], ["GBS", "DISEASE", 129, 132], ["Guillain-Barr\u00e9", "ORGANISM", 104, 118], ["Guillain-Barr\u00e9 syndrome (GBS)", "SPECIES", 104, 133], ["Influenza", "PROBLEM", 0, 9], ["neurological complications", "PROBLEM", 28, 54], ["encephalitis", "PROBLEM", 64, 76], ["myelitis", "PROBLEM", 78, 86], ["meningitis", "PROBLEM", 88, 98], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 104, 127], ["GBS", "TEST", 129, 132], ["known to cause", "UNCERTAINTY", 13, 27], ["encephalitis", "OBSERVATION", 64, 76], ["myelitis", "OBSERVATION", 78, 86], ["meningitis", "OBSERVATION", 88, 98], ["Barr\u00e9 syndrome", "OBSERVATION", 113, 127]]], ["Coronaviruses Affecting the CNS of Other Species ::: 2.", [["CNS", "ANATOMY", 28, 31], ["Coronaviruses", "PROBLEM", 0, 13]]], ["Background on SARS-CoV-2 and Nervous SystemRespiratory viruses, including the CoV family, affect the CNS of other species, such as birds, felines, and livestock [35].", [["CNS", "ANATOMY", 101, 104], ["SARS-CoV-2", "ORGANISM", 14, 24], ["Nervous SystemRespiratory viruses", "ORGANISM", 29, 62], ["CoV", "GENE_OR_GENE_PRODUCT", 78, 81], ["CNS", "ANATOMICAL_SYSTEM", 101, 104], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["Nervous SystemRespiratory viruses", "PROBLEM", 29, 62], ["viruses", "OBSERVATION", 55, 62]]], ["Meningitis and spinal cord inflammation have been reported in cats affected by a pathogenic feline CoV [36].", [["spinal cord", "ANATOMY", 15, 26], ["Meningitis", "DISEASE", 0, 10], ["cord inflammation", "DISEASE", 22, 39], ["spinal cord", "ORGAN", 15, 26], ["cats", "ORGANISM", 62, 66], ["feline CoV", "ORGANISM", 92, 102], ["cats", "SPECIES", 62, 66], ["feline CoV", "SPECIES", 92, 102], ["feline CoV", "SPECIES", 92, 102], ["Meningitis", "PROBLEM", 0, 10], ["spinal cord inflammation", "PROBLEM", 15, 39], ["spinal cord", "ANATOMY", 15, 26], ["inflammation", "OBSERVATION", 27, 39]]], ["A 91% homology resemblance has been assessed between the human OC43 CoV and the swine hemagglutinating encephalomyelitis virus (HEV), which can invade the porcine brain by retrograde neuronal propagation through the peripheral nerves [37].", [["brain", "ANATOMY", 163, 168], ["neuronal", "ANATOMY", 183, 191], ["peripheral nerves", "ANATOMY", 216, 233], ["hemagglutinating encephalomyelitis", "DISEASE", 86, 120], ["human", "ORGANISM", 57, 62], ["OC43 CoV", "ORGANISM", 63, 71], ["swine hemagglutinating encephalomyelitis virus", "ORGANISM", 80, 126], ["HEV", "ORGANISM", 128, 131], ["porcine", "ORGANISM", 155, 162], ["brain", "ORGAN", 163, 168], ["neuronal", "CELL", 183, 191], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 216, 233], ["human", "SPECIES", 57, 62], ["swine hemagglutinating encephalomyelitis virus", "SPECIES", 80, 126], ["porcine", "SPECIES", 155, 162], ["human OC43 CoV", "SPECIES", 57, 71], ["swine hemagglutinating encephalomyelitis virus", "SPECIES", 80, 126], ["HEV", "SPECIES", 128, 131], ["porcine", "SPECIES", 155, 162], ["the human OC43 CoV", "PROBLEM", 53, 71], ["the swine hemagglutinating encephalomyelitis virus", "PROBLEM", 76, 126], ["hemagglutinating", "OBSERVATION_MODIFIER", 86, 102], ["encephalomyelitis", "OBSERVATION", 103, 120], ["porcine", "ANATOMY_MODIFIER", 155, 162], ["brain", "ANATOMY", 163, 168], ["neuronal propagation", "OBSERVATION", 183, 203], ["peripheral nerves", "ANATOMY", 216, 233]]], ["A subspecies of murine CoVs, called mouse hepatitis virus, induces a demyelinating disease resembling Multiple Sclerosis (MS) [35].2.3.", [["mouse hepatitis virus", "DISEASE", 36, 57], ["demyelinating disease", "DISEASE", 69, 90], ["Multiple Sclerosis", "DISEASE", 102, 120], ["MS", "DISEASE", 122, 124], ["murine", "ORGANISM", 16, 22], ["CoVs", "GENE_OR_GENE_PRODUCT", 23, 27], ["mouse hepatitis virus", "ORGANISM", 36, 57], ["murine", "SPECIES", 16, 22], ["mouse", "SPECIES", 36, 41], ["hepatitis virus", "SPECIES", 42, 57], ["mouse hepatitis virus", "SPECIES", 36, 57], ["murine CoVs", "PROBLEM", 16, 27], ["mouse hepatitis virus", "PROBLEM", 36, 57], ["a demyelinating disease", "PROBLEM", 67, 90], ["Multiple Sclerosis (MS)", "PROBLEM", 102, 125], ["murine CoVs", "OBSERVATION", 16, 27], ["demyelinating", "OBSERVATION_MODIFIER", 69, 82], ["Multiple", "OBSERVATION_MODIFIER", 102, 110], ["Sclerosis", "OBSERVATION", 111, 120]]], ["Animal and In Vitro Models of CNS Infection by Human Coronaviruses ::: 2.", [["Infection", "DISEASE", 34, 43], ["Human", "ORGANISM", 47, 52], ["Human", "SPECIES", 47, 52], ["Human", "SPECIES", 47, 52], ["CNS Infection", "PROBLEM", 30, 43], ["CNS", "ANATOMY", 30, 33], ["Infection", "OBSERVATION", 34, 43]]], ["Background on SARS-CoV-2 and Nervous SystemHuman CoVs can induce acute or persistent infections in neuronal cell lineages, neuroglia, and oligodendrocytes [38,39,40].", [["neuronal cell", "ANATOMY", 99, 112], ["neuroglia", "ANATOMY", 123, 132], ["oligodendrocytes", "ANATOMY", 138, 154], ["infections", "DISEASE", 85, 95], ["SARS-CoV-2", "ORGANISM", 14, 24], ["Nervous SystemHuman CoVs", "SIMPLE_CHEMICAL", 29, 53], ["neuronal cell lineages", "CELL", 99, 121], ["neuroglia", "CELL", 123, 132], ["oligodendrocytes", "CELL", 138, 154], ["neuronal cell lineages", "CELL_TYPE", 99, 121], ["neuroglia", "CELL_TYPE", 123, 132], ["oligodendrocytes", "CELL_TYPE", 138, 154], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["Nervous SystemHuman CoVs", "PROBLEM", 29, 53], ["persistent infections in neuronal cell lineages", "PROBLEM", 74, 121], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["persistent", "OBSERVATION_MODIFIER", 74, 84], ["infections", "OBSERVATION", 85, 95], ["neuronal cell lineages", "OBSERVATION", 99, 121]]], ["Moreover, flaccid paralysis and demyelination in animal models can be caused by the human OC43 CoV [41].", [["flaccid", "ANATOMY", 10, 17], ["flaccid paralysis", "DISEASE", 10, 27], ["demyelination", "DISEASE", 32, 45], ["human", "ORGANISM", 84, 89], ["OC43 CoV", "ORGANISM", 90, 98], ["human", "SPECIES", 84, 89], ["human OC43 CoV", "SPECIES", 84, 98], ["flaccid paralysis", "PROBLEM", 10, 27], ["demyelination", "PROBLEM", 32, 45], ["flaccid", "OBSERVATION_MODIFIER", 10, 17], ["paralysis", "OBSERVATION", 18, 27], ["demyelination", "OBSERVATION", 32, 45]]], ["In particular, it has been shown that the spread of the OC43 in susceptible mice runs from the olfactory bulb to the brainstem and spinal cord, and uses the axonal transport system as the avenue for the neuron-to-neuron spread [33].", [["olfactory bulb", "ANATOMY", 95, 109], ["brainstem", "ANATOMY", 117, 126], ["spinal cord", "ANATOMY", 131, 142], ["axonal", "ANATOMY", 157, 163], ["neuron", "ANATOMY", 203, 209], ["neuron", "ANATOMY", 213, 219], ["OC43", "CHEMICAL", 56, 60], ["OC43", "GENE_OR_GENE_PRODUCT", 56, 60], ["mice", "ORGANISM", 76, 80], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 95, 109], ["brainstem", "ORGAN", 117, 126], ["spinal cord", "ORGAN", 131, 142], ["neuron", "CELL", 213, 219], ["OC43", "DNA", 56, 60], ["mice", "SPECIES", 76, 80], ["mice", "SPECIES", 76, 80], ["the OC43", "PROBLEM", 52, 60], ["spread", "OBSERVATION_MODIFIER", 42, 48], ["olfactory", "ANATOMY_MODIFIER", 95, 104], ["bulb", "ANATOMY_MODIFIER", 105, 109], ["brainstem", "ANATOMY", 117, 126], ["spinal cord", "ANATOMY", 131, 142]]], ["Further, neuron-to-neuron propagation strategies observed in cell cultures include both passive viral particle diffusion and axonal transport [42].", [["neuron", "ANATOMY", 9, 15], ["neuron", "ANATOMY", 19, 25], ["cell cultures", "ANATOMY", 61, 74], ["axonal", "ANATOMY", 125, 131], ["neuron", "CELL", 9, 15], ["neuron", "CELL", 19, 25], ["cell cultures", "CELL", 61, 74], ["cell cultures", "CELL_LINE", 61, 74], ["cell cultures", "TEST", 61, 74], ["passive viral particle diffusion", "PROBLEM", 88, 120]]], ["SARS-CoV, which may enter the CNS through the olfactory bulb and transneuronally spread to other brain regions, can cause neuronal death in the human ACE2 receptor transgenic mouse [43].2.4.", [["CNS", "ANATOMY", 30, 33], ["olfactory bulb", "ANATOMY", 46, 60], ["brain", "ANATOMY", 97, 102], ["neuronal", "ANATOMY", 122, 130], ["SARS", "DISEASE", 0, 4], ["neuronal death", "DISEASE", 122, 136], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["CNS", "ANATOMICAL_SYSTEM", 30, 33], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 46, 60], ["brain", "ORGAN", 97, 102], ["neuronal", "CELL", 122, 130], ["human", "ORGANISM", 144, 149], ["ACE2", "GENE_OR_GENE_PRODUCT", 150, 154], ["mouse", "ORGANISM", 175, 180], ["human ACE2 receptor", "PROTEIN", 144, 163], ["human", "SPECIES", 144, 149], ["mouse", "SPECIES", 175, 180], ["SARS-CoV", "SPECIES", 0, 8], ["human", "SPECIES", 144, 149], ["mouse", "SPECIES", 175, 180], ["SARS", "PROBLEM", 0, 4], ["neuronal death", "PROBLEM", 122, 136], ["olfactory bulb", "ANATOMY", 46, 60], ["brain", "ANATOMY", 97, 102]]], ["Neurological Complications by Other Human Coronaviruses ::: 2.", [["Human", "ORGANISM", 36, 41], ["Human", "SPECIES", 36, 41]]], ["Background on SARS-CoV-2 and Nervous SystemAt least four types of human CoVs have shown neuroinvasive capacity based on the detection of viral RNA or other nucleic acids in the human brain [35].2.4.", [["brain", "ANATOMY", 183, 188], ["nucleic acids", "CHEMICAL", 156, 169], ["SARS-CoV-2", "ORGANISM", 14, 24], ["human", "ORGANISM", 66, 71], ["CoVs", "GENE_OR_GENE_PRODUCT", 72, 76], ["human", "ORGANISM", 177, 182], ["brain", "ORGAN", 183, 188], ["viral RNA", "RNA", 137, 146], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 177, 182], ["SARS-CoV", "SPECIES", 14, 22], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 177, 182], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["human CoVs", "PROBLEM", 66, 76], ["neuroinvasive capacity", "PROBLEM", 88, 110], ["viral RNA", "PROBLEM", 137, 146], ["other nucleic acids in the human brain", "PROBLEM", 150, 188], ["viral RNA", "OBSERVATION", 137, 146], ["nucleic acids", "OBSERVATION", 156, 169], ["human brain", "ANATOMY", 177, 188]]], ["Neurological Complications by Other Human Coronaviruses ::: 2.", [["Human", "ORGANISM", 36, 41], ["Human", "SPECIES", 36, 41]]], ["Background on SARS-CoV-2 and Nervous SystemIn a 12-month-old infant with severe immunodeficiency, a case of fatal OC43 CoV-related encephalitis was confirmed through RNA sequencing techniques and RT-PCR in samples of brain biopsy [44].", [["samples", "ANATOMY", 206, 213], ["brain", "ANATOMY", 217, 222], ["immunodeficiency", "DISEASE", 80, 96], ["encephalitis", "DISEASE", 131, 143], ["SARS-CoV-2", "ORGANISM", 14, 24], ["infant", "ORGANISM", 61, 67], ["OC43 CoV", "ORGANISM", 114, 122], ["brain biopsy", "MULTI-TISSUE_STRUCTURE", 217, 229], ["infant", "SPECIES", 61, 67], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["severe immunodeficiency", "PROBLEM", 73, 96], ["fatal OC43 CoV", "PROBLEM", 108, 122], ["related encephalitis", "PROBLEM", 123, 143], ["RNA sequencing techniques", "TEST", 166, 191], ["RT-PCR", "TEST", 196, 202], ["brain biopsy", "TEST", 217, 229], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["immunodeficiency", "OBSERVATION", 80, 96], ["encephalitis", "OBSERVATION", 131, 143], ["brain", "ANATOMY", 217, 222]]], ["Immunohistochemical study of the brain showed a microglial reaction, T lymphocyte infiltrates, and presence of the OC43 CoV nucleocapsid in neurons.", [["brain", "ANATOMY", 33, 38], ["microglial", "ANATOMY", 48, 58], ["T lymphocyte", "ANATOMY", 69, 81], ["neurons", "ANATOMY", 140, 147], ["brain", "ORGAN", 33, 38], ["microglial", "CELL", 48, 58], ["T lymphocyte", "CELL", 69, 81], ["OC43", "GENE_OR_GENE_PRODUCT", 115, 119], ["neurons", "CELL", 140, 147], ["T lymphocyte infiltrates", "CELL_TYPE", 69, 93], ["OC43 CoV nucleocapsid", "PROTEIN", 115, 136], ["neurons", "CELL_TYPE", 140, 147], ["OC43 CoV", "SPECIES", 115, 123], ["Immunohistochemical study of the brain", "TEST", 0, 38], ["a microglial reaction", "PROBLEM", 46, 67], ["T lymphocyte infiltrates", "PROBLEM", 69, 93], ["the OC43 CoV nucleocapsid in neurons", "PROBLEM", 111, 147], ["brain", "ANATOMY", 33, 38], ["microglial reaction", "OBSERVATION", 48, 67], ["lymphocyte infiltrates", "OBSERVATION", 71, 93], ["OC43 CoV", "OBSERVATION", 115, 123], ["nucleocapsid", "OBSERVATION_MODIFIER", 124, 136], ["neurons", "ANATOMY", 140, 147]]], ["In a 15-year-old adolescent with disseminated acute encephalomyelitis associated with OC43 CoV infection, magnetic resonance imaging (MRI) disclosed demyelination in the subcortical white matter, cerebellum, and spinal cord [45].", [["subcortical white matter", "ANATOMY", 170, 194], ["cerebellum", "ANATOMY", 196, 206], ["spinal cord", "ANATOMY", 212, 223], ["disseminated acute encephalomyelitis", "DISEASE", 33, 69], ["CoV infection", "DISEASE", 91, 104], ["demyelination", "DISEASE", 149, 162], ["OC43 CoV", "ORGANISM", 86, 94], ["subcortical white matter", "CANCER", 170, 194], ["cerebellum", "ORGAN", 196, 206], ["spinal cord", "ORGAN", 212, 223], ["OC43 CoV", "SPECIES", 86, 94], ["disseminated acute encephalomyelitis", "PROBLEM", 33, 69], ["OC43 CoV infection", "PROBLEM", 86, 104], ["magnetic resonance imaging", "TEST", 106, 132], ["MRI", "TEST", 134, 137], ["demyelination in the subcortical white matter, cerebellum, and spinal cord", "PROBLEM", 149, 223], ["disseminated", "OBSERVATION_MODIFIER", 33, 45], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["encephalomyelitis", "OBSERVATION", 52, 69], ["OC43 CoV infection", "OBSERVATION", 86, 104], ["demyelination", "OBSERVATION", 149, 162], ["subcortical", "ANATOMY_MODIFIER", 170, 181], ["white matter", "ANATOMY", 182, 194], ["cerebellum", "ANATOMY", 196, 206], ["spinal cord", "ANATOMY", 212, 223]]], ["The OC43 CoV was detected in the CSF and nasopharynx secretions by using the PCR.", [["CSF", "ANATOMY", 33, 36], ["nasopharynx secretions", "ANATOMY", 41, 63], ["OC43 CoV", "ORGANISM", 4, 12], ["CSF", "ORGANISM_SUBSTANCE", 33, 36], ["nasopharynx secretions", "ORGAN", 41, 63], ["OC43 CoV", "PROTEIN", 4, 12], ["OC43 CoV", "SPECIES", 4, 12], ["The OC43 CoV", "TEST", 0, 12], ["the CSF and nasopharynx secretions", "TEST", 29, 63], ["the PCR", "TEST", 73, 80], ["OC43 CoV", "OBSERVATION", 4, 12], ["CSF", "ANATOMY", 33, 36], ["nasopharynx", "ANATOMY", 41, 52], ["secretions", "OBSERVATION", 53, 63]]], ["There has also been a report of GBS associated with 229E and OC43 CoV co-infection in a pediatric patient [46].2.4.", [["GBS", "DISEASE", 32, 35], ["co-infection", "DISEASE", 70, 82], ["OC43 CoV", "ORGANISM", 61, 69], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["OC43 CoV", "SPECIES", 61, 69], ["GBS", "PROBLEM", 32, 35], ["OC43 CoV co-infection", "PROBLEM", 61, 82], ["GBS", "OBSERVATION", 32, 35]]], ["Neurological Complications by Other Human Coronaviruses ::: 2.", [["Human", "ORGANISM", 36, 41], ["Human", "SPECIES", 36, 41]]], ["Background on SARS-CoV-2 and Nervous SystemEncephalitis, ischemic stroke, and polyneuropathy can result from SARS-CoV exposure, with viral RNA detectable in the CSF [47,48].", [["Nervous SystemEncephalitis", "DISEASE", 29, 55], ["ischemic stroke", "DISEASE", 57, 72], ["polyneuropathy", "DISEASE", 78, 92], ["SARS", "DISEASE", 109, 113], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 109, 117], ["CSF", "GENE_OR_GENE_PRODUCT", 161, 164], ["viral RNA", "RNA", 133, 142], ["SARS-CoV", "SPECIES", 14, 22], ["SARS-CoV", "SPECIES", 109, 117], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["Nervous SystemEncephalitis", "PROBLEM", 29, 55], ["ischemic stroke", "PROBLEM", 57, 72], ["polyneuropathy", "PROBLEM", 78, 92], ["SARS", "PROBLEM", 109, 113], ["CoV exposure", "PROBLEM", 114, 126], ["viral RNA", "PROBLEM", 133, 142], ["the CSF", "TEST", 157, 164], ["SARS", "OBSERVATION", 14, 18], ["Nervous SystemEncephalitis", "ANATOMY", 29, 55], ["ischemic", "OBSERVATION_MODIFIER", 57, 65], ["stroke", "OBSERVATION", 66, 72], ["polyneuropathy", "OBSERVATION", 78, 92]]], ["In a necropsy study carried out on 8 victims of SARS-CoV, infected neurons were found in the cortex and hypothalamus, and genomic sequences of SARS-CoV were detected in all cases by using the RT-PCR [49].2.4.", [["neurons", "ANATOMY", 67, 74], ["cortex", "ANATOMY", 93, 99], ["hypothalamus", "ANATOMY", 104, 116], ["SARS", "DISEASE", 48, 52], ["SARS-CoV", "ORGANISM", 48, 56], ["neurons", "CELL", 67, 74], ["cortex", "CANCER", 93, 99], ["hypothalamus", "ORGAN", 104, 116], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 143, 151], ["genomic sequences", "DNA", 122, 139], ["SARS-CoV", "SPECIES", 48, 56], ["SARS-CoV", "SPECIES", 143, 151], ["a necropsy study", "TEST", 3, 19], ["SARS", "PROBLEM", 48, 52], ["CoV", "PROBLEM", 53, 56], ["infected neurons", "PROBLEM", 58, 74], ["hypothalamus", "PROBLEM", 104, 116], ["SARS", "PROBLEM", 143, 147], ["CoV", "PROBLEM", 148, 151], ["the RT-PCR", "TEST", 188, 198], ["cortex", "ANATOMY", 93, 99], ["hypothalamus", "ANATOMY", 104, 116]]], ["Neurological Complications by Other Human Coronaviruses ::: 2.", [["Human", "ORGANISM", 36, 41], ["Human", "SPECIES", 36, 41]]], ["Background on SARS-CoV-2 and Nervous SystemEncephalomyelitis and vasculitis may result also from MERS-CoV infection.", [["Nervous SystemEncephalomyelitis", "DISEASE", 29, 60], ["vasculitis", "DISEASE", 65, 75], ["MERS-CoV infection", "DISEASE", 97, 115], ["SARS-CoV-2", "ORGANISM", 14, 24], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 97, 105], ["SARS-CoV", "SPECIES", 14, 22], ["MERS-CoV", "SPECIES", 97, 105], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["Nervous SystemEncephalomyelitis", "PROBLEM", 29, 60], ["vasculitis", "PROBLEM", 65, 75], ["MERS", "PROBLEM", 97, 101], ["CoV infection", "PROBLEM", 102, 115], ["SARS", "OBSERVATION", 14, 18], ["Nervous", "ANATOMY", 29, 36], ["vasculitis", "OBSERVATION", 65, 75], ["CoV", "OBSERVATION_MODIFIER", 102, 105], ["infection", "OBSERVATION", 106, 115]]], ["A series of three patients showed that they all suffered from an altered level of consciousness, ranging from confusion to coma, along with ataxia and motor deficit [50].", [["confusion", "DISEASE", 110, 119], ["coma", "DISEASE", 123, 127], ["ataxia", "DISEASE", 140, 146], ["motor deficit", "DISEASE", 151, 164], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["an altered level of consciousness", "PROBLEM", 62, 95], ["confusion", "PROBLEM", 110, 119], ["coma", "PROBLEM", 123, 127], ["ataxia", "PROBLEM", 140, 146], ["motor deficit", "PROBLEM", 151, 164]]], ["At brain MRI, bilateral lesions were evident in the white matter of the frontal, parietal, and temporal lobes, as well as in the basal ganglia and corpus callosum.", [["brain", "ANATOMY", 3, 8], ["lesions", "ANATOMY", 24, 31], ["white matter", "ANATOMY", 52, 64], ["frontal", "ANATOMY", 72, 79], ["parietal", "ANATOMY", 81, 89], ["temporal lobes", "ANATOMY", 95, 109], ["basal ganglia", "ANATOMY", 129, 142], ["corpus callosum", "ANATOMY", 147, 162], ["brain", "ORGAN", 3, 8], ["bilateral lesions", "CANCER", 14, 31], ["frontal", "MULTI-TISSUE_STRUCTURE", 72, 79], ["parietal", "MULTI-TISSUE_STRUCTURE", 81, 89], ["temporal lobes", "MULTI-TISSUE_STRUCTURE", 95, 109], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 129, 142], ["corpus callosum", "ORGAN", 147, 162], ["brain MRI", "TEST", 3, 12], ["bilateral lesions", "PROBLEM", 14, 31], ["bilateral", "ANATOMY_MODIFIER", 14, 23], ["lesions", "OBSERVATION", 24, 31], ["white", "ANATOMY_MODIFIER", 52, 57], ["matter", "ANATOMY_MODIFIER", 58, 64], ["frontal", "ANATOMY_MODIFIER", 72, 79], ["parietal", "ANATOMY_MODIFIER", 81, 89], ["temporal lobes", "ANATOMY", 95, 109], ["basal", "ANATOMY_MODIFIER", 129, 134], ["ganglia", "ANATOMY", 135, 142], ["corpus callosum", "ANATOMY", 147, 162]]], ["Two of these patients showed an increased protein level in the CSF, while all had lymphocytopenia and severe multiple organ involvement, including kidney, liver, and the cardiovascular system [50].", [["CSF", "ANATOMY", 63, 66], ["organ", "ANATOMY", 118, 123], ["kidney", "ANATOMY", 147, 153], ["liver", "ANATOMY", 155, 160], ["cardiovascular", "ANATOMY", 170, 184], ["lymphocytopenia", "DISEASE", 82, 97], ["patients", "ORGANISM", 13, 21], ["CSF", "ORGANISM_SUBSTANCE", 63, 66], ["organ", "ORGAN", 118, 123], ["kidney", "ORGAN", 147, 153], ["liver", "ORGAN", 155, 160], ["cardiovascular", "ANATOMICAL_SYSTEM", 170, 184], ["system", "ANATOMICAL_SYSTEM", 185, 191], ["patients", "SPECIES", 13, 21], ["an increased protein level in the CSF", "PROBLEM", 29, 66], ["lymphocytopenia", "PROBLEM", 82, 97], ["severe multiple organ involvement", "PROBLEM", 102, 135], ["kidney, liver, and the cardiovascular system", "PROBLEM", 147, 191], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["protein level", "OBSERVATION", 42, 55], ["CSF", "ANATOMY", 63, 66], ["lymphocytopenia", "OBSERVATION", 82, 97], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["multiple", "OBSERVATION_MODIFIER", 109, 117], ["organ", "ANATOMY", 118, 123], ["involvement", "OBSERVATION", 124, 135], ["kidney", "ANATOMY", 147, 153], ["liver", "ANATOMY", 155, 160], ["cardiovascular system", "ANATOMY", 170, 191]]], ["During the MERS-CoV infection, other neurological complications were reported: brainstem encephalitis, GBS [51], and cerebral hemorrhage in the context of thrombocytopenia and disseminated intravascular coagulation [52].", [["neurological", "ANATOMY", 37, 49], ["brainstem", "ANATOMY", 79, 88], ["cerebral", "ANATOMY", 117, 125], ["intravascular", "ANATOMY", 189, 202], ["MERS-CoV infection", "DISEASE", 11, 29], ["neurological complications", "DISEASE", 37, 63], ["brainstem encephalitis", "DISEASE", 79, 101], ["GBS", "DISEASE", 103, 106], ["cerebral hemorrhage", "DISEASE", 117, 136], ["thrombocytopenia", "DISEASE", 155, 171], ["disseminated intravascular coagulation", "DISEASE", 176, 214], ["MERS-CoV", "ORGANISM", 11, 19], ["cerebral", "ORGAN", 117, 125], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 202], ["MERS-CoV", "SPECIES", 11, 19], ["CoV infection", "PROBLEM", 16, 29], ["other neurological complications", "PROBLEM", 31, 63], ["brainstem encephalitis", "PROBLEM", 79, 101], ["GBS", "PROBLEM", 103, 106], ["cerebral hemorrhage", "PROBLEM", 117, 136], ["thrombocytopenia", "PROBLEM", 155, 171], ["disseminated intravascular coagulation", "PROBLEM", 176, 214], ["infection", "OBSERVATION", 20, 29], ["brainstem", "ANATOMY", 79, 88], ["encephalitis", "OBSERVATION", 89, 101], ["cerebral", "ANATOMY", 117, 125], ["hemorrhage", "OBSERVATION", 126, 136], ["thrombocytopenia", "OBSERVATION", 155, 171], ["disseminated", "OBSERVATION_MODIFIER", 176, 188], ["intravascular coagulation", "OBSERVATION", 189, 214]]], ["A retrospective study involving 70 MERS patients reported that 8.6% had seizures, while four had GBS in a series of 23 cases.", [["seizures", "DISEASE", 72, 80], ["GBS", "DISEASE", 97, 100], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["A retrospective study", "TEST", 0, 21], ["seizures", "PROBLEM", 72, 80], ["GBS", "PROBLEM", 97, 100], ["a series", "TEST", 104, 112]]], ["The latency of the neurological symptoms ranged from 7 and 26 days after the onset of the pulmonary disease [53].3.", [["neurological", "ANATOMY", 19, 31], ["pulmonary", "ANATOMY", 90, 99], ["pulmonary disease", "DISEASE", 90, 107], ["pulmonary", "ORGAN", 90, 99], ["the neurological symptoms", "PROBLEM", 15, 40], ["the pulmonary disease", "PROBLEM", 86, 107], ["latency", "OBSERVATION_MODIFIER", 4, 11], ["pulmonary", "ANATOMY", 90, 99], ["disease", "OBSERVATION", 100, 107]]], ["The search queries were \u201cCOVID-19 AND nervous system\u201d, \u201cbrain\u201d, \u201cneurology\u201d, \u201cneurological\u201d, \u201cencephalopathy\u201d, \u201cencephalitis\u201d, \u201cstroke\u201d, \u201cseizures\u201d, \u201cneuropathy\u201d.", [["nervous system", "ANATOMY", 38, 52], ["brain", "ANATOMY", 56, 61], ["neurological", "ANATOMY", 78, 90], ["neurological\u201d", "DISEASE", 78, 91], ["encephalopathy", "DISEASE", 94, 108], ["encephalitis", "DISEASE", 112, 124], ["stroke", "DISEASE", 128, 134], ["seizures", "DISEASE", 138, 146], ["neuropathy", "DISEASE", 150, 160], ["nervous system\u201d", "CANCER", 38, 53], ["brain", "ORGAN", 56, 61], ["COVID", "TEST", 25, 30], ["encephalopathy", "PROBLEM", 94, 108], ["encephalitis", "PROBLEM", 112, 124], ["stroke", "PROBLEM", 128, 134], ["seizures", "PROBLEM", 138, 146], ["neuropathy", "PROBLEM", 150, 160], ["brain", "ANATOMY", 56, 61], ["encephalopathy", "OBSERVATION", 94, 108], ["encephalitis", "OBSERVATION", 112, 124], ["stroke", "OBSERVATION", 128, 134], ["neuropathy", "OBSERVATION", 150, 160]]], ["The search was also repeated by using the above-mentioned keywords and the term \u201cSARS-CoV-2\u201d instead of \u201cCOVID-19\u201d.3.", [["SARS", "DISEASE", 81, 85], ["CoV", "TEST", 86, 89], ["COVID", "TEST", 105, 110]]], ["Search Strategy and ResultsThe authors selected all the articles based on the abstract and full-text examination and without a priori appraisal of inclusion/exclusion criteria.", [["full-text examination", "TEST", 91, 112]]], ["Indeed, the number of studies reporting neurological complications of COVID-19 is still limited and the majority include case reports/case series or retrospective samples, without a systematic specific assessment of the neurological complications.", [["neurological", "ANATOMY", 40, 52], ["samples", "ANATOMY", 163, 170], ["neurological", "ANATOMY", 220, 232], ["COVID-19", "CHEMICAL", 70, 78], ["neurological complications", "PROBLEM", 40, 66], ["COVID", "TEST", 70, 75], ["retrospective samples", "TEST", 149, 170], ["a systematic specific assessment", "TEST", 180, 212], ["the neurological complications", "PROBLEM", 216, 246]]], ["After this process, a total of 23 studies [54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76] were included.3.", [["23 studies", "TEST", 31, 41]]], ["Search Strategy and ResultsFigure 1 summarizes the main neurological manifestations of COVID-19 and proposed mechanisms.4.1.", [["neurological", "ANATOMY", 56, 68], ["COVID-19", "CHEMICAL", 87, 95], ["COVID", "TEST", 87, 92]]], ["Encephalopathy ::: 4.", [["Encephalopathy", "DISEASE", 0, 14], ["Encephalopathy", "PROBLEM", 0, 14]]], ["Main Neurological Manifestations of COVID-19Elderly patients and those with previous cognitive decline, multiple comorbidities, other infections, severe medical illness, poor premorbid functional status, malnutrition, and vascular risk factors (especially hypertension) have a higher risk to show an altered level of consciousness related to COVID-19 [55,68,79].", [["vascular", "ANATOMY", 222, 230], ["cognitive decline", "DISEASE", 85, 102], ["infections", "DISEASE", 134, 144], ["malnutrition", "DISEASE", 204, 216], ["hypertension", "DISEASE", 256, 268], ["COVID-19", "CHEMICAL", 342, 350], ["patients", "ORGANISM", 52, 60], ["vascular", "MULTI-TISSUE_STRUCTURE", 222, 230], ["patients", "SPECIES", 52, 60], ["previous cognitive decline", "PROBLEM", 76, 102], ["multiple comorbidities", "PROBLEM", 104, 126], ["other infections", "PROBLEM", 128, 144], ["severe medical illness", "PROBLEM", 146, 168], ["poor premorbid functional status", "PROBLEM", 170, 202], ["malnutrition", "PROBLEM", 204, 216], ["vascular risk factors", "PROBLEM", 222, 243], ["hypertension", "PROBLEM", 256, 268], ["an altered level of consciousness", "PROBLEM", 297, 330], ["COVID", "TEST", 342, 347], ["multiple", "OBSERVATION_MODIFIER", 104, 112], ["comorbidities", "OBSERVATION", 113, 126], ["infections", "OBSERVATION", 134, 144], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["malnutrition", "OBSERVATION", 204, 216], ["vascular", "ANATOMY", 222, 230]]], ["Moreover, metabolic or endocrine derangements, including hypo- or hypernatremia, hypo- or hypercalcemia, hypo- or hyperglycemia, renal and/or liver dysfunction, among others, put patients at further risk for encephalopathy.", [["endocrine", "ANATOMY", 23, 32], ["renal", "ANATOMY", 129, 134], ["liver", "ANATOMY", 142, 147], ["hypernatremia", "DISEASE", 66, 79], ["hypercalcemia", "DISEASE", 90, 103], ["hyperglycemia", "DISEASE", 114, 127], ["renal and/or liver dysfunction", "DISEASE", 129, 159], ["encephalopathy", "DISEASE", 208, 222], ["renal", "ORGAN", 129, 134], ["liver", "ORGAN", 142, 147], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["endocrine derangements", "PROBLEM", 23, 45], ["hypo", "TEST", 57, 61], ["hypernatremia", "PROBLEM", 66, 79], ["hypo", "PROBLEM", 81, 85], ["hypercalcemia", "PROBLEM", 90, 103], ["hypo", "PROBLEM", 105, 109], ["hyperglycemia", "PROBLEM", 114, 127], ["renal and/or liver dysfunction", "PROBLEM", 129, 159], ["encephalopathy", "PROBLEM", 208, 222], ["hypernatremia", "OBSERVATION", 66, 79], ["hypercalcemia", "OBSERVATION", 90, 103], ["hyperglycemia", "OBSERVATION", 114, 127], ["renal", "ANATOMY", 129, 134], ["liver", "ANATOMY", 142, 147], ["dysfunction", "OBSERVATION", 148, 159], ["encephalopathy", "OBSERVATION", 208, 222]]], ["Sepsis and the subsequent inflammatory and the so-called \u201ccytokine storm\u201d may also contribute to encephalopathy with IL-6, IL-8, IL-10, and tumor necrosis factor \u03b1 (TNF\u03b1) being implicated in confusional states [80].", [["Sepsis", "DISEASE", 0, 6], ["encephalopathy", "DISEASE", 97, 111], ["tumor necrosis", "DISEASE", 140, 154], ["confusional", "DISEASE", 191, 202], ["IL-6", "GENE_OR_GENE_PRODUCT", 117, 121], ["IL-8", "GENE_OR_GENE_PRODUCT", 123, 127], ["IL-10", "GENE_OR_GENE_PRODUCT", 129, 134], ["tumor necrosis factor \u03b1", "GENE_OR_GENE_PRODUCT", 140, 163], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 165, 169], ["cytokine", "PROTEIN", 58, 66], ["IL-10", "PROTEIN", 129, 134], ["tumor necrosis factor \u03b1", "PROTEIN", 140, 163], ["TNF\u03b1", "PROTEIN", 165, 169], ["Sepsis", "PROBLEM", 0, 6], ["the subsequent inflammatory", "PROBLEM", 11, 38], ["encephalopathy", "PROBLEM", 97, 111], ["IL", "TEST", 117, 119], ["IL", "TEST", 123, 125], ["IL", "TEST", 129, 131], ["tumor necrosis factor", "PROBLEM", 140, 161], ["inflammatory", "OBSERVATION_MODIFIER", 26, 38], ["encephalopathy", "OBSERVATION", 97, 111], ["tumor", "OBSERVATION_MODIFIER", 140, 145], ["necrosis", "OBSERVATION", 146, 154]]], ["Finally, patients with previous neurological disorders and acute respiratory symptoms seem to be at increased risk for encephalopathy as the initial symptom of COVID-19.", [["neurological", "ANATOMY", 32, 44], ["respiratory", "ANATOMY", 65, 76], ["neurological disorders", "DISEASE", 32, 54], ["acute respiratory symptoms", "DISEASE", 59, 85], ["encephalopathy", "DISEASE", 119, 133], ["COVID-19", "CHEMICAL", 160, 168], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["previous neurological disorders", "PROBLEM", 23, 54], ["acute respiratory symptoms", "PROBLEM", 59, 85], ["encephalopathy", "PROBLEM", 119, 133], ["COVID", "TEST", 160, 165], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["respiratory", "ANATOMY", 65, 76], ["encephalopathy", "OBSERVATION", 119, 133]]], ["Coherently, in the study by Mao et al. [68], 15% of patients with a severe form of the disease presented an altered level of consciousness.4.1.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["the study", "TEST", 15, 24], ["the disease", "PROBLEM", 83, 94], ["an altered level of consciousness", "PROBLEM", 105, 138], ["disease", "OBSERVATION", 87, 94]]], ["Encephalopathy ::: 4.", [["Encephalopathy", "DISEASE", 0, 14], ["Encephalopathy", "PROBLEM", 0, 14]]], ["Main Neurological Manifestations of COVID-19Toxic and metabolic causes, as well as the effects of drugs or hypoxia, may result in COVID-19-associated encephalopathy [57].", [["hypoxia", "DISEASE", 107, 114], ["COVID-19", "CHEMICAL", 130, 138], ["encephalopathy", "DISEASE", 150, 164], ["COVID-19", "CHEMICAL", 130, 138], ["COVID-19", "GENE_OR_GENE_PRODUCT", 130, 138], ["COVID", "TEST", 36, 41], ["drugs", "TREATMENT", 98, 103], ["hypoxia", "PROBLEM", 107, 114], ["COVID", "TEST", 130, 135], ["encephalopathy", "PROBLEM", 150, 164], ["metabolic causes", "OBSERVATION", 54, 70], ["encephalopathy", "OBSERVATION", 150, 164]]], ["Interestingly, an electroencephalography (EEG) report on a patient with altered mental status who was unable to follow verbal orders as the presenting symptom of COVID-19 showed diffuse slow waves, particularly in the left temporal region, whereas pathological findings demonstrated cerebral edema without inflammatory signs [55].", [["left temporal region", "ANATOMY", 218, 238], ["cerebral", "ANATOMY", 283, 291], ["cerebral edema", "DISEASE", 283, 297], ["patient", "ORGANISM", 59, 66], ["cerebral edema", "PATHOLOGICAL_FORMATION", 283, 297], ["patient", "SPECIES", 59, 66], ["an electroencephalography", "TEST", 15, 40], ["altered mental status", "PROBLEM", 72, 93], ["COVID", "TEST", 162, 167], ["diffuse slow waves", "PROBLEM", 178, 196], ["cerebral edema", "PROBLEM", 283, 297], ["inflammatory signs", "PROBLEM", 306, 324], ["diffuse", "OBSERVATION_MODIFIER", 178, 185], ["slow waves", "OBSERVATION", 186, 196], ["left", "ANATOMY_MODIFIER", 218, 222], ["temporal", "ANATOMY_MODIFIER", 223, 231], ["region", "ANATOMY_MODIFIER", 232, 238], ["cerebral", "ANATOMY", 283, 291], ["edema", "OBSERVATION", 292, 297], ["without", "UNCERTAINTY", 298, 305], ["inflammatory", "OBSERVATION_MODIFIER", 306, 318]]], ["In these cases, treatment is symptomatic and includes fever control, treatment of hypoxia, and antiepileptic medications [77].4.1.", [["fever", "DISEASE", 54, 59], ["hypoxia", "DISEASE", 82, 89], ["treatment", "TREATMENT", 16, 25], ["symptomatic", "PROBLEM", 29, 40], ["fever control", "TREATMENT", 54, 67], ["hypoxia", "PROBLEM", 82, 89], ["antiepileptic medications", "TREATMENT", 95, 120], ["symptomatic", "OBSERVATION_MODIFIER", 29, 40], ["hypoxia", "OBSERVATION", 82, 89]]], ["Encephalopathy ::: 4.", [["Encephalopathy", "DISEASE", 0, 14], ["Encephalopathy", "PROBLEM", 0, 14]]], ["Main Neurological Manifestations of COVID-19A case of COVID-19-associated (confirmed by RT-PCR in a nasopharyngeal sample) acute hemorrhagic necrotizing encephalopathy has also been described [71].", [["Neurological", "ANATOMY", 5, 17], ["nasopharyngeal sample", "ANATOMY", 100, 121], ["COVID-19", "CHEMICAL", 54, 62], ["hemorrhagic", "DISEASE", 129, 140], ["encephalopathy", "DISEASE", 153, 167], ["COVID-19", "CELL", 54, 62], ["COVID", "TEST", 36, 41], ["COVID", "TEST", 54, 59], ["RT-PCR", "TEST", 88, 94], ["a nasopharyngeal sample", "TEST", 98, 121], ["acute hemorrhagic necrotizing encephalopathy", "PROBLEM", 123, 167], ["nasopharyngeal", "ANATOMY", 100, 114], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["hemorrhagic", "OBSERVATION_MODIFIER", 129, 140], ["necrotizing", "OBSERVATION_MODIFIER", 141, 152], ["encephalopathy", "OBSERVATION", 153, 167]]], ["Brain computed tomography (CT) detected a symmetrical bilateral hypodense area in the medial thalamic nucleus, whereas MRI showed contrast-enhanced hemorrhagic lesions, with multifocal and symmetrical disposition, in both thalami, insula, and the mesial region of temporal lobes [71].", [["Brain", "ANATOMY", 0, 5], ["hypodense area", "ANATOMY", 64, 78], ["medial thalamic nucleus", "ANATOMY", 86, 109], ["hemorrhagic lesions", "ANATOMY", 148, 167], ["thalami", "ANATOMY", 222, 229], ["insula", "ANATOMY", 231, 237], ["mesial region", "ANATOMY", 247, 260], ["temporal lobes", "ANATOMY", 264, 278], ["hemorrhagic", "DISEASE", 148, 159], ["thalamic nucleus", "MULTI-TISSUE_STRUCTURE", 93, 109], ["hemorrhagic lesions", "PATHOLOGICAL_FORMATION", 148, 167], ["thalami", "CANCER", 222, 229], ["insula", "CANCER", 231, 237], ["temporal lobes", "MULTI-TISSUE_STRUCTURE", 264, 278], ["Brain computed tomography (CT)", "TEST", 0, 30], ["a symmetrical bilateral hypodense area in the medial thalamic nucleus", "PROBLEM", 40, 109], ["MRI", "TEST", 119, 122], ["contrast-enhanced hemorrhagic lesions", "PROBLEM", 130, 167], ["multifocal and symmetrical disposition, in both thalami, insula, and the mesial region of temporal lobes", "PROBLEM", 174, 278], ["symmetrical", "OBSERVATION_MODIFIER", 42, 53], ["bilateral", "ANATOMY_MODIFIER", 54, 63], ["hypodense", "OBSERVATION", 64, 73], ["medial", "ANATOMY_MODIFIER", 86, 92], ["thalamic nucleus", "ANATOMY", 93, 109], ["enhanced", "OBSERVATION_MODIFIER", 139, 147], ["hemorrhagic", "OBSERVATION_MODIFIER", 148, 159], ["lesions", "OBSERVATION", 160, 167], ["multifocal", "OBSERVATION_MODIFIER", 174, 184], ["symmetrical", "OBSERVATION_MODIFIER", 189, 200], ["disposition", "OBSERVATION_MODIFIER", 201, 212], ["both", "ANATOMY_MODIFIER", 217, 221], ["thalami", "ANATOMY", 222, 229], ["insula", "ANATOMY_MODIFIER", 231, 237], ["mesial", "ANATOMY_MODIFIER", 247, 253], ["region", "ANATOMY_MODIFIER", 254, 260], ["temporal lobes", "ANATOMY", 264, 278]]], ["Although relatively rare, acute necrotizing encephalopathy can be a severe complication of some viral infections, including the influenza virus.", [["encephalopathy", "DISEASE", 44, 58], ["viral infections", "DISEASE", 96, 112], ["influenza virus", "DISEASE", 128, 143], ["influenza virus", "ORGANISM", 128, 143], ["influenza virus", "SPECIES", 128, 143], ["acute necrotizing encephalopathy", "PROBLEM", 26, 58], ["a severe complication", "PROBLEM", 66, 87], ["some viral infections", "PROBLEM", 91, 112], ["the influenza virus", "PROBLEM", 124, 143], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["necrotizing", "OBSERVATION_MODIFIER", 32, 43], ["encephalopathy", "OBSERVATION", 44, 58], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["complication", "OBSERVATION", 75, 87], ["some", "OBSERVATION_MODIFIER", 91, 95], ["viral", "OBSERVATION_MODIFIER", 96, 101], ["infections", "OBSERVATION", 102, 112], ["influenza virus", "OBSERVATION", 128, 143]]], ["The authors postulated that the pathogenesis might be related to the \u201ccytokine storm\u201d induced by COVID-19 [81].", [["COVID-19", "CHEMICAL", 97, 105], ["COVID-19", "CHEMICAL", 97, 105], ["cytokine", "PROTEIN", 70, 78]]], ["A posterior reversible encephalopathy-like syndrome, associated with transient cortical blindness, was also reported [64].4.2.", [["cortical", "ANATOMY", 79, 87], ["encephalopathy", "DISEASE", 23, 37], ["cortical blindness", "DISEASE", 79, 97], ["cortical", "MULTI-TISSUE_STRUCTURE", 79, 87], ["A posterior reversible encephalopathy", "PROBLEM", 0, 37], ["like syndrome", "PROBLEM", 38, 51], ["transient cortical blindness", "PROBLEM", 69, 97], ["posterior", "ANATOMY_MODIFIER", 2, 11], ["reversible", "OBSERVATION_MODIFIER", 12, 22], ["encephalopathy", "OBSERVATION", 23, 37], ["transient", "OBSERVATION_MODIFIER", 69, 78], ["cortical blindness", "OBSERVATION", 79, 97]]], ["Encephalitis ::: 4.", [["Encephalitis", "DISEASE", 0, 12], ["Encephalitis", "PROBLEM", 0, 12]]], ["Main Neurological Manifestations of COVID-19Based on the available evidence, SARS-CoV-2 should be included in the differential diagnosis algorithm of viral encephalitis.", [["viral encephalitis", "DISEASE", 150, 168], ["SARS-CoV", "SPECIES", 77, 85], ["COVID", "TEST", 36, 41], ["SARS", "PROBLEM", 77, 81], ["viral encephalitis", "PROBLEM", 150, 168], ["viral encephalitis", "OBSERVATION", 150, 168]]], ["Typical symptoms are fever, headache, seizures, behavioral disorders, and altered level of consciousness.", [["fever", "DISEASE", 21, 26], ["headache", "DISEASE", 28, 36], ["seizures", "DISEASE", 38, 46], ["behavioral disorders", "DISEASE", 48, 68], ["Typical symptoms", "PROBLEM", 0, 16], ["fever", "PROBLEM", 21, 26], ["headache", "PROBLEM", 28, 36], ["seizures", "PROBLEM", 38, 46], ["behavioral disorders", "PROBLEM", 48, 68], ["altered level of consciousness", "PROBLEM", 74, 104]]], ["In these patients, an early diagnosis is of crucial importance to increase the survival rate, especially in those with severe pneumonia and hypoxia [23].", [["pneumonia", "DISEASE", 126, 135], ["hypoxia", "DISEASE", 140, 147], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["the survival rate", "TREATMENT", 75, 92], ["severe pneumonia", "PROBLEM", 119, 135], ["hypoxia", "PROBLEM", 140, 147], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["pneumonia", "OBSERVATION", 126, 135], ["hypoxia", "OBSERVATION", 140, 147]]], ["In a report of a 56-year-old woman from Wuhan with COVID-19, the brain CT remained normal but the diagnosis of encephalitis was confirmed through the isolation of SARS-CoV-2 in the CSF using genomic sequencing techniques [75].4.2.", [["brain", "ANATOMY", 65, 70], ["encephalitis", "DISEASE", 111, 123], ["SARS", "DISEASE", 163, 167], ["woman", "ORGANISM", 29, 34], ["brain", "ORGAN", 65, 70], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 163, 173], ["CSF", "ORGANISM_SUBSTANCE", 181, 184], ["woman", "SPECIES", 29, 34], ["SARS-CoV", "SPECIES", 163, 171], ["COVID", "TEST", 51, 56], ["the brain CT", "TEST", 61, 73], ["encephalitis", "PROBLEM", 111, 123], ["SARS", "PROBLEM", 163, 167], ["CoV", "TEST", 168, 171], ["genomic sequencing techniques", "TEST", 191, 220], ["brain", "ANATOMY", 65, 70], ["normal", "OBSERVATION", 83, 89], ["encephalitis", "OBSERVATION", 111, 123]]], ["Encephalitis ::: 4.", [["Encephalitis", "DISEASE", 0, 12], ["Encephalitis", "PROBLEM", 0, 12]]], ["Main Neurological Manifestations of COVID-19The case of a 24-year-old Japanese man presenting with multiple generalized epileptic seizures and decreased level of consciousness led to a diagnosis of meningoencephalitis [69].", [["COVID-19", "CHEMICAL", 36, 44], ["epileptic seizures", "DISEASE", 120, 138], ["decreased level of consciousness", "DISEASE", 143, 175], ["meningoencephalitis", "DISEASE", 198, 217], ["COVID-19", "CHEMICAL", 36, 44], ["Japanese", "ORGANISM", 70, 78], ["man", "ORGANISM", 79, 82], ["man", "SPECIES", 79, 82], ["COVID", "TEST", 36, 41], ["multiple generalized epileptic seizures", "PROBLEM", 99, 138], ["decreased level of consciousness", "PROBLEM", 143, 175], ["meningoencephalitis", "PROBLEM", 198, 217], ["multiple", "OBSERVATION_MODIFIER", 99, 107], ["generalized", "OBSERVATION_MODIFIER", 108, 119], ["epileptic seizures", "OBSERVATION", 120, 138], ["meningoencephalitis", "OBSERVATION", 198, 217]]], ["Brain MRI showed hyperintense areas in the right mesial region of the temporal lobe and hippocampus.", [["Brain", "ANATOMY", 0, 5], ["right mesial region", "ANATOMY", 43, 62], ["temporal lobe", "ANATOMY", 70, 83], ["hippocampus", "ANATOMY", 88, 99], ["temporal lobe", "MULTI-TISSUE_STRUCTURE", 70, 83], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 88, 99], ["Brain MRI", "TEST", 0, 9], ["hyperintense areas", "PROBLEM", 17, 35], ["hyperintense", "OBSERVATION", 17, 29], ["right", "ANATOMY_MODIFIER", 43, 48], ["mesial", "ANATOMY_MODIFIER", 49, 55], ["region", "ANATOMY_MODIFIER", 56, 62], ["temporal lobe", "ANATOMY", 70, 83], ["hippocampus", "ANATOMY", 88, 99]]], ["While the SARS-CoV-2 RNA was not detected in the nasopharynx, it was identified in the CSF by using RT-PCR, although it was unclear if some of the patient features were present in the context of seizures due to other causes [69].", [["nasopharynx", "ANATOMY", 49, 60], ["seizures", "DISEASE", 195, 203], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 10, 20], ["nasopharynx", "ORGAN", 49, 60], ["CSF", "GENE_OR_GENE_PRODUCT", 87, 90], ["patient", "ORGANISM", 147, 154], ["SARS-CoV-2 RNA", "RNA", 10, 24], ["patient", "SPECIES", 147, 154], ["SARS-CoV", "SPECIES", 10, 18], ["the SARS", "TEST", 6, 14], ["RT-PCR", "TEST", 100, 106], ["seizures", "PROBLEM", 195, 203], ["SARS", "OBSERVATION", 10, 14], ["nasopharynx", "ANATOMY", 49, 60], ["CSF", "ANATOMY", 87, 90]]], ["Anyhow, high levels of proinflammatory cytokines in the CSF can cause breakdown and increased permeability of the blood-brain barrier (BBB) which may, in turn, lead to viral invasion and clinical manifestation [71].4.3.", [["blood-brain barrier", "ANATOMY", 114, 133], ["BBB", "ANATOMY", 135, 138], ["CSF", "GENE_OR_GENE_PRODUCT", 56, 59], ["blood", "MULTI-TISSUE_STRUCTURE", 114, 119], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 120, 133], ["BBB", "MULTI-TISSUE_STRUCTURE", 135, 138], ["proinflammatory cytokines", "PROTEIN", 23, 48], ["CSF", "PROTEIN", 56, 59], ["high levels of proinflammatory cytokines in the CSF", "PROBLEM", 8, 59], ["breakdown", "PROBLEM", 70, 79], ["increased permeability", "PROBLEM", 84, 106], ["the blood", "TEST", 110, 119], ["viral invasion", "PROBLEM", 168, 182], ["proinflammatory cytokines", "OBSERVATION", 23, 48], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["permeability", "OBSERVATION_MODIFIER", 94, 106], ["brain", "ANATOMY", 120, 125], ["viral", "OBSERVATION_MODIFIER", 168, 173], ["invasion", "OBSERVATION", 174, 182]]], ["Seizures ::: 4.", [["Seizures", "DISEASE", 0, 8], ["Seizures", "PROBLEM", 0, 8]]], ["Main Neurological Manifestations of COVID-19Seizures have already been reported in CoV infections, and there has been a high proportion of breakthrough seizures in patients with epilepsy who developed COVID-19 [78].", [["CoV infections", "DISEASE", 83, 97], ["seizures", "DISEASE", 152, 160], ["epilepsy", "DISEASE", 178, 186], ["COVID-19", "CHEMICAL", 201, 209], ["CoV", "ORGANISM", 83, 86], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["COVID-19Seizures", "PROBLEM", 36, 52], ["CoV infections", "PROBLEM", 83, 97], ["breakthrough seizures", "PROBLEM", 139, 160], ["epilepsy", "PROBLEM", 178, 186], ["COVID", "TEST", 201, 206], ["infections", "OBSERVATION", 87, 97]]], ["Nevertheless, a recent analysis of 304 patients with COVID-19 [67] reported two seizure-like events only, with no confirmed cases of new-onset seizures.", [["seizure", "DISEASE", 80, 87], ["seizures", "DISEASE", 143, 151], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["a recent analysis", "TEST", 14, 31], ["COVID", "TEST", 53, 58], ["two seizure-like events", "PROBLEM", 76, 99], ["new-onset seizures", "PROBLEM", 133, 151], ["seizures", "OBSERVATION", 143, 151]]], ["However, the study was limited by a lack of instrumental investigation (e.g., EEG, neuroimaging) and by its retrospective approach.4.3.", [["the study", "TEST", 9, 18], ["instrumental investigation", "TEST", 44, 70], ["EEG", "TEST", 78, 81], ["neuroimaging", "TEST", 83, 95]]], ["Seizures ::: 4.", [["Seizures", "DISEASE", 0, 8], ["Seizures", "PROBLEM", 0, 8]]], ["Main Neurological Manifestations of COVID-19A case report of a patient with no history of epilepsy who had multiple apparent tonic-clonic seizures in the context of COVID-19 might be interpreted as an unmasked seizure disorder or a direct effect of COVID-19 on the brain, although further confirmations are needed [63].4.4.", [["brain", "ANATOMY", 265, 270], ["epilepsy", "DISEASE", 90, 98], ["tonic-clonic seizures", "DISEASE", 125, 146], ["seizure disorder", "DISEASE", 210, 226], ["COVID-19", "CHEMICAL", 249, 257], ["COVID-19", "CHEMICAL", 165, 173], ["COVID-19", "CHEMICAL", 249, 257], ["patient", "ORGANISM", 63, 70], ["COVID-19", "GENE_OR_GENE_PRODUCT", 249, 257], ["brain", "ORGAN", 265, 270], ["patient", "SPECIES", 63, 70], ["epilepsy", "PROBLEM", 90, 98], ["multiple apparent tonic-clonic seizures", "PROBLEM", 107, 146], ["COVID", "TEST", 165, 170], ["an unmasked seizure disorder", "PROBLEM", 198, 226], ["COVID", "TEST", 249, 254], ["epilepsy", "OBSERVATION", 90, 98], ["seizure", "OBSERVATION", 210, 217], ["brain", "ANATOMY", 265, 270]]], ["Cerebrovascular Events ::: 4.", [["Cerebrovascular", "ANATOMY", 0, 15], ["Cerebrovascular", "MULTI-TISSUE_STRUCTURE", 0, 15]]], ["Main Neurological Manifestations of COVID-19When compared to younger subjects without comorbidities, elderly patients with COVID-19 and vascular risk factors appear to be at greater risk for developing cerebrovascular complications [23].", [["vascular", "ANATOMY", 136, 144], ["cerebrovascular", "ANATOMY", 202, 217], ["cerebrovascular complications", "DISEASE", 202, 231], ["patients", "ORGANISM", 109, 117], ["vascular", "MULTI-TISSUE_STRUCTURE", 136, 144], ["cerebrovascular", "ANATOMICAL_SYSTEM", 202, 217], ["patients", "SPECIES", 109, 117], ["COVID", "TEST", 36, 41], ["comorbidities", "PROBLEM", 86, 99], ["COVID", "TEST", 123, 128], ["vascular risk factors", "PROBLEM", 136, 157], ["developing cerebrovascular complications", "PROBLEM", 191, 231], ["vascular", "ANATOMY", 136, 144], ["cerebrovascular", "ANATOMY", 202, 217], ["complications", "OBSERVATION", 218, 231]]], ["In a retrospective study of 221 patients [66], 11 (5%) presented with ischemic stroke, one (0.5%) with cerebral venous thrombosis, and one (0.5%) with a cerebral hemorrhage.4.4.", [["cerebral venous", "ANATOMY", 103, 118], ["cerebral", "ANATOMY", 153, 161], ["ischemic stroke", "DISEASE", 70, 85], ["cerebral venous thrombosis", "DISEASE", 103, 129], ["cerebral hemorrhage", "DISEASE", 153, 172], ["patients", "ORGANISM", 32, 40], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 103, 118], ["cerebral", "ORGAN", 153, 161], ["patients", "SPECIES", 32, 40], ["a retrospective study", "TEST", 3, 24], ["ischemic stroke", "PROBLEM", 70, 85], ["cerebral venous thrombosis", "PROBLEM", 103, 129], ["a cerebral hemorrhage", "PROBLEM", 151, 172], ["ischemic", "OBSERVATION_MODIFIER", 70, 78], ["stroke", "OBSERVATION", 79, 85], ["cerebral venous", "ANATOMY", 103, 118], ["thrombosis", "OBSERVATION", 119, 129], ["cerebral", "ANATOMY", 153, 161], ["hemorrhage", "OBSERVATION", 162, 172]]], ["Cerebrovascular Events ::: 4.", [["Cerebrovascular", "ANATOMY", 0, 15], ["Cerebrovascular", "MULTI-TISSUE_STRUCTURE", 0, 15]]], ["Main Neurological Manifestations of COVID-19The risk factors for stroke in this population were: advanced age (mean age: 71.6 years), severe pulmonary disease, hypertension, diabetes, marked inflammatory or procoagulant response (e.g., increased C-reactive protein and D-dimer), and previous cerebrovascular events [66].", [["pulmonary", "ANATOMY", 141, 150], ["cerebrovascular", "ANATOMY", 292, 307], ["stroke", "DISEASE", 65, 71], ["pulmonary disease", "DISEASE", 141, 158], ["hypertension", "DISEASE", 160, 172], ["diabetes", "DISEASE", 174, 182], ["cerebrovascular events", "DISEASE", 292, 314], ["pulmonary", "ORGAN", 141, 150], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 246, 264], ["D-dimer", "GENE_OR_GENE_PRODUCT", 269, 276], ["C-reactive protein", "PROTEIN", 246, 264], ["D-dimer", "PROTEIN", 269, 276], ["COVID", "TEST", 36, 41], ["The risk factors", "PROBLEM", 44, 60], ["stroke", "PROBLEM", 65, 71], ["severe pulmonary disease", "PROBLEM", 134, 158], ["hypertension", "PROBLEM", 160, 172], ["diabetes", "PROBLEM", 174, 182], ["marked inflammatory or procoagulant response", "PROBLEM", 184, 228], ["increased C-reactive protein and D-dimer", "PROBLEM", 236, 276], ["previous cerebrovascular events", "PROBLEM", 283, 314], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["pulmonary", "ANATOMY", 141, 150], ["disease", "OBSERVATION", 151, 158], ["hypertension", "OBSERVATION", 160, 172], ["diabetes", "OBSERVATION", 174, 182], ["marked", "OBSERVATION_MODIFIER", 184, 190], ["inflammatory", "OBSERVATION_MODIFIER", 191, 203], ["procoagulant response", "OBSERVATION", 207, 228], ["cerebrovascular", "ANATOMY", 292, 307]]], ["Other researchers described five patients with stroke (80% ischemic), who had severe forms of COVID-19, increased D-dimer, thrombocytopenia, and multiple organ failure [68].", [["organ", "ANATOMY", 154, 159], ["stroke", "DISEASE", 47, 53], ["thrombocytopenia", "DISEASE", 123, 139], ["multiple organ failure", "DISEASE", 145, 167], ["COVID-19", "CHEMICAL", 94, 102], ["patients", "ORGANISM", 33, 41], ["D-dimer", "GENE_OR_GENE_PRODUCT", 114, 121], ["organ", "ORGAN", 154, 159], ["patients", "SPECIES", 33, 41], ["stroke", "PROBLEM", 47, 53], ["COVID", "TEST", 94, 99], ["increased D-dimer", "PROBLEM", 104, 121], ["thrombocytopenia", "PROBLEM", 123, 139], ["multiple organ failure", "PROBLEM", 145, 167], ["thrombocytopenia", "OBSERVATION", 123, 139], ["multiple", "OBSERVATION_MODIFIER", 145, 153], ["organ", "ANATOMY", 154, 159], ["failure", "OBSERVATION", 160, 167]]], ["Notably, a study in the USA demonstrated that young patients (aged < 50 years) more likely developed large-vessel strokes in the context of COVID-19, suggesting that all ages are vulnerable [70].4.4.", [["vessel", "ANATOMY", 107, 113], ["strokes", "DISEASE", 114, 121], ["patients", "ORGANISM", 52, 60], ["vessel", "MULTI-TISSUE_STRUCTURE", 107, 113], ["patients", "SPECIES", 52, 60], ["a study", "TEST", 9, 16], ["large-vessel strokes", "PROBLEM", 101, 121], ["COVID", "TEST", 140, 145], ["large", "OBSERVATION_MODIFIER", 101, 106], ["-", "OBSERVATION_MODIFIER", 106, 107], ["vessel", "ANATOMY", 107, 113], ["strokes", "OBSERVATION", 114, 121]]], ["Cerebrovascular Events ::: 4.", [["Cerebrovascular", "ANATOMY", 0, 15], ["Cerebrovascular", "MULTI-TISSUE_STRUCTURE", 0, 15]]], ["Main Neurological Manifestations of COVID-19Regarding pathomechanisms, the increased risk of cerebrovascular disease during the COVID-19 infection is likely multifactorial.", [["cerebrovascular", "ANATOMY", 93, 108], ["cerebrovascular disease", "DISEASE", 93, 116], ["infection", "DISEASE", 137, 146], ["cerebrovascular", "ANATOMICAL_SYSTEM", 93, 108], ["COVID-19", "SPECIES", 128, 136], ["COVID", "TEST", 36, 41], ["pathomechanisms", "PROBLEM", 54, 69], ["cerebrovascular disease", "PROBLEM", 93, 116], ["the COVID-19 infection", "PROBLEM", 124, 146], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["cerebrovascular disease", "OBSERVATION", 93, 116], ["infection", "OBSERVATION", 137, 146], ["likely", "UNCERTAINTY", 150, 156], ["multifactorial", "OBSERVATION_MODIFIER", 157, 171]]], ["It has been shown that SARS-CoV-2 can bind to the ACE2 receptor on endothelial cells, which might result in increased blood pressure.", [["endothelial cells", "ANATOMY", 67, 84], ["blood", "ANATOMY", 118, 123], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 50, 63], ["endothelial cells", "CELL", 67, 84], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["ACE2 receptor", "PROTEIN", 50, 63], ["endothelial cells", "CELL_TYPE", 67, 84], ["SARS", "PROBLEM", 23, 27], ["endothelial cells", "TEST", 67, 84], ["increased blood pressure", "PROBLEM", 108, 132], ["endothelial cells", "OBSERVATION", 67, 84], ["increased", "OBSERVATION_MODIFIER", 108, 117], ["blood pressure", "OBSERVATION", 118, 132]]], ["Both ischemic and hemorrhagic strokes can be secondary to the increase in blood pressure, together with the presence of thrombocytopenia and coagulation disorders.4.4.", [["blood", "ANATOMY", 74, 79], ["ischemic and hemorrhagic strokes", "DISEASE", 5, 37], ["increase in blood pressure", "DISEASE", 62, 88], ["thrombocytopenia", "DISEASE", 120, 136], ["coagulation disorders", "DISEASE", 141, 162], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["Both ischemic and hemorrhagic strokes", "PROBLEM", 0, 37], ["the increase in blood pressure", "PROBLEM", 58, 88], ["thrombocytopenia", "PROBLEM", 120, 136], ["coagulation disorders", "PROBLEM", 141, 162], ["ischemic", "OBSERVATION_MODIFIER", 5, 13], ["hemorrhagic", "OBSERVATION_MODIFIER", 18, 29], ["strokes", "OBSERVATION", 30, 37], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["blood pressure", "OBSERVATION", 74, 88], ["thrombocytopenia", "OBSERVATION", 120, 136]]], ["Cerebrovascular Events ::: 4.", [["Cerebrovascular", "ANATOMY", 0, 15], ["Cerebrovascular", "MULTI-TISSUE_STRUCTURE", 0, 15]]], ["Main Neurological Manifestations of COVID-19The \u201ccytokine storm\u201d may act as another pathogenic mechanism [23].", [["cytokine", "PROTEIN", 49, 57], ["COVID", "TEST", 36, 41], ["The \u201ccytokine storm", "TREATMENT", 44, 63]]], ["The levels of C-reactive protein, ferritin, D-dimer, lactate dehydrogenase, and the leukocyte count have often been found to be elevated in these patients [82].", [["leukocyte", "ANATOMY", 84, 93], ["lactate", "CHEMICAL", 53, 60], ["lactate", "CHEMICAL", 53, 60], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 14, 32], ["ferritin", "GENE_OR_GENE_PRODUCT", 34, 42], ["D-dimer", "GENE_OR_GENE_PRODUCT", 44, 51], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 53, 74], ["leukocyte", "CELL", 84, 93], ["patients", "ORGANISM", 146, 154], ["C-reactive protein", "PROTEIN", 14, 32], ["ferritin", "PROTEIN", 34, 42], ["D-dimer", "PROTEIN", 44, 51], ["lactate dehydrogenase", "PROTEIN", 53, 74], ["patients", "SPECIES", 146, 154], ["The levels", "TEST", 0, 10], ["C-reactive protein", "TEST", 14, 32], ["ferritin", "TEST", 34, 42], ["D-dimer", "TEST", 44, 51], ["lactate dehydrogenase", "TEST", 53, 74], ["the leukocyte count", "TEST", 80, 99]]], ["Moreover, increased inflammatory markers and hypercoagulability state seem to characterize severe cases, along with a substantially enhanced risk of stroke [68].", [["hypercoagulability", "DISEASE", 45, 63], ["stroke", "DISEASE", 149, 155], ["inflammatory markers", "PROTEIN", 20, 40], ["increased inflammatory markers", "PROBLEM", 10, 40], ["hypercoagulability state", "PROBLEM", 45, 69], ["severe cases", "PROBLEM", 91, 103], ["stroke", "PROBLEM", 149, 155], ["increased", "OBSERVATION_MODIFIER", 10, 19], ["inflammatory", "OBSERVATION_MODIFIER", 20, 32], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["cases", "OBSERVATION", 98, 103], ["substantially", "OBSERVATION_MODIFIER", 118, 131], ["enhanced", "OBSERVATION_MODIFIER", 132, 140], ["stroke", "OBSERVATION", 149, 155]]], ["The likelihood of ischemic or hemorrhagic stroke may be also increased by some viral-related mechanisms, including vascular endothelial cell infection and consequent vessel damage.", [["vascular endothelial cell", "ANATOMY", 115, 140], ["vessel", "ANATOMY", 166, 172], ["hemorrhagic stroke", "DISEASE", 30, 48], ["vascular endothelial cell infection", "DISEASE", 115, 150], ["vessel damage", "DISEASE", 166, 179], ["vascular endothelial cell", "CELL", 115, 140], ["vessel", "MULTI-TISSUE_STRUCTURE", 166, 172], ["ischemic", "PROBLEM", 18, 26], ["hemorrhagic stroke", "PROBLEM", 30, 48], ["some viral-related mechanisms", "PROBLEM", 74, 103], ["vascular endothelial cell infection", "PROBLEM", 115, 150], ["consequent vessel damage", "PROBLEM", 155, 179], ["likelihood of", "UNCERTAINTY", 4, 17], ["ischemic", "OBSERVATION_MODIFIER", 18, 26], ["hemorrhagic", "OBSERVATION_MODIFIER", 30, 41], ["stroke", "OBSERVATION", 42, 48], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["viral", "OBSERVATION", 79, 84], ["vascular", "ANATOMY", 115, 123], ["endothelial cell infection", "OBSERVATION", 124, 150], ["vessel", "ANATOMY", 166, 172], ["damage", "OBSERVATION", 173, 179]]], ["On the other hand, it is well known that infection-associated systemic inflammation, thrombosis, or vasculitis increase the risk of stroke [83].", [["infection", "DISEASE", 41, 50], ["systemic inflammation", "DISEASE", 62, 83], ["thrombosis", "DISEASE", 85, 95], ["vasculitis", "DISEASE", 100, 110], ["stroke", "DISEASE", 132, 138], ["infection", "PROBLEM", 41, 50], ["systemic inflammation", "PROBLEM", 62, 83], ["thrombosis", "PROBLEM", 85, 95], ["vasculitis", "PROBLEM", 100, 110], ["stroke", "PROBLEM", 132, 138], ["infection", "OBSERVATION", 41, 50], ["systemic", "OBSERVATION_MODIFIER", 62, 70], ["inflammation", "OBSERVATION", 71, 83], ["thrombosis", "OBSERVATION", 85, 95], ["vasculitis", "OBSERVATION", 100, 110], ["stroke", "OBSERVATION", 132, 138]]], ["Finally, systemic vasculitis and CNS vasculitis have been demonstrated at autopsy in patients with SARS-CoV [84].4.5.", [["CNS", "ANATOMY", 33, 36], ["vasculitis", "DISEASE", 18, 28], ["vasculitis", "DISEASE", 37, 47], ["SARS", "DISEASE", 99, 103], ["CNS vasculitis", "PATHOLOGICAL_FORMATION", 33, 47], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 99, 107], ["systemic vasculitis", "PROBLEM", 9, 28], ["CNS vasculitis", "PROBLEM", 33, 47], ["SARS", "PROBLEM", 99, 103], ["systemic", "OBSERVATION_MODIFIER", 9, 17], ["vasculitis", "OBSERVATION", 18, 28], ["CNS", "ANATOMY", 33, 36], ["vasculitis", "OBSERVATION", 37, 47]]], ["Headache ::: 4.", [["Headache", "DISEASE", 0, 8], ["Headache", "PROBLEM", 0, 8]]], ["Main Neurological Manifestations of COVID-19Most patients with COVID-19 complain of headaches.", [["headaches", "DISEASE", 84, 93], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["COVID", "TEST", 36, 41], ["COVID", "TEST", 63, 68], ["headaches", "PROBLEM", 84, 93], ["headaches", "OBSERVATION", 84, 93]]], ["Guan et al. [57] found that 13.6% of a series of more than 1000 patients reported headache, and in 15% of those with severe forms.", [["headache", "DISEASE", 82, 90], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["headache", "PROBLEM", 82, 90], ["headache", "OBSERVATION", 82, 90]]], ["The intensity of headache was generally referred to be mild, although the study did not mention whether a prior history of headache or any meningeal sign was present.", [["meningeal", "ANATOMY", 139, 148], ["headache", "DISEASE", 17, 25], ["headache", "DISEASE", 123, 131], ["headache", "PROBLEM", 17, 25], ["the study", "TEST", 70, 79], ["headache", "PROBLEM", 123, 131], ["any meningeal sign", "PROBLEM", 135, 153], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["headache", "OBSERVATION", 17, 25], ["mild", "OBSERVATION_MODIFIER", 55, 59], ["meningeal", "ANATOMY", 139, 148]]], ["In a recent case series [58], headaches were a predominant complaint, along with fever, cough, sore throat, and breathlessness.", [["headaches", "DISEASE", 30, 39], ["fever", "DISEASE", 81, 86], ["cough", "DISEASE", 88, 93], ["sore throat", "DISEASE", 95, 106], ["breathlessness", "DISEASE", 112, 126], ["headaches", "PROBLEM", 30, 39], ["fever", "PROBLEM", 81, 86], ["cough", "PROBLEM", 88, 93], ["sore throat", "PROBLEM", 95, 106], ["breathlessness", "PROBLEM", 112, 126], ["cough", "OBSERVATION", 88, 93], ["sore throat", "ANATOMY", 95, 106]]], ["The prevalence varies in different reports, but headache may affect up to 1/3 of patients [54,62].4.5.", [["headache", "DISEASE", 48, 56], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["headache", "PROBLEM", 48, 56]]], ["Headache ::: 4.", [["Headache", "DISEASE", 0, 8], ["Headache", "PROBLEM", 0, 8]]], ["Main Neurological Manifestations of COVID-19Headache is a well-known clinical feature of meningitis, encephalitis, intracranial hypertension, cerebrovascular diseases, and vasculitis, whereas scarce pathophysiological data link it to COVID-19.", [["Neurological", "ANATOMY", 5, 17], ["intracranial", "ANATOMY", 115, 127], ["cerebrovascular", "ANATOMY", 142, 157], ["COVID-19Headache", "DISEASE", 36, 52], ["meningitis", "DISEASE", 89, 99], ["encephalitis", "DISEASE", 101, 113], ["intracranial hypertension", "DISEASE", 115, 140], ["cerebrovascular diseases", "DISEASE", 142, 166], ["vasculitis", "DISEASE", 172, 182], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 142, 157], ["COVID", "PROBLEM", 36, 41], ["meningitis", "PROBLEM", 89, 99], ["encephalitis", "PROBLEM", 101, 113], ["intracranial hypertension", "PROBLEM", 115, 140], ["cerebrovascular diseases", "PROBLEM", 142, 166], ["vasculitis", "PROBLEM", 172, 182], ["COVID", "TEST", 234, 239], ["meningitis", "OBSERVATION", 89, 99], ["encephalitis", "OBSERVATION", 101, 113], ["intracranial", "ANATOMY", 115, 127], ["hypertension", "OBSERVATION", 128, 140], ["cerebrovascular", "ANATOMY", 142, 157], ["diseases", "OBSERVATION", 158, 166], ["vasculitis", "OBSERVATION", 172, 182]]], ["In some cases, cytokines and chemokines released by macrophages may activate nociceptive sensory neurons [85], with a neuroinflammatory mechanism similar to that involved in pain [86].", [["macrophages", "ANATOMY", 52, 63], ["nociceptive sensory neurons", "ANATOMY", 77, 104], ["pain", "DISEASE", 174, 178], ["macrophages", "CELL", 52, 63], ["nociceptive sensory neurons", "CELL", 77, 104], ["cytokines", "PROTEIN", 15, 24], ["chemokines", "PROTEIN", 29, 39], ["macrophages", "CELL_TYPE", 52, 63], ["nociceptive sensory neurons", "CELL_TYPE", 77, 104], ["cytokines and chemokines", "TREATMENT", 15, 39], ["a neuroinflammatory mechanism", "PROBLEM", 116, 145], ["pain", "PROBLEM", 174, 178]]], ["In this scenario, screening patients for secondary causes of headache, including COVID-19, is mandatory, especially for patients in whom frequency or severity of headache change, or present with systemic symptoms, or do not respond to first-line or habitual treatments.4.6.", [["headache", "DISEASE", 61, 69], ["headache", "DISEASE", 162, 170], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 120, 128], ["screening", "TEST", 18, 27], ["headache", "PROBLEM", 61, 69], ["COVID", "TEST", 81, 86], ["headache change", "PROBLEM", 162, 177], ["systemic symptoms", "PROBLEM", 195, 212], ["first-line", "TREATMENT", 235, 245], ["habitual treatments", "TREATMENT", 249, 268]]], ["Smell and Taste Disorders ::: 4.", [["Taste Disorders", "DISEASE", 10, 25]]], ["Main Neurological Manifestations of COVID-19Anosmia and secondarily taste disorders are commonly reported in patients with COVID-19 and may appear suddenly [56].", [["COVID-19Anosmia", "CHEMICAL", 36, 51], ["taste disorders", "DISEASE", 68, 83], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["COVID", "TEST", 36, 41], ["19Anosmia", "PROBLEM", 42, 51], ["secondarily taste disorders", "PROBLEM", 56, 83], ["COVID", "TEST", 123, 128]]], ["In Italy, 19.4% of patients had some form of chemosensory dysfunction [74], whereas in a case register of twelve European hospitals, the prevalence of olfactory and gustatory dysfunction in 417 patients with COVID-19 with mild-to-moderate symptoms [65] was 85.6% and 88%, respectively.", [["olfactory", "ANATOMY", 151, 160], ["gustatory", "ANATOMY", 165, 174], ["chemosensory dysfunction", "DISEASE", 45, 69], ["olfactory and gustatory dysfunction", "DISEASE", 151, 186], ["patients", "ORGANISM", 19, 27], ["olfactory", "ORGAN", 151, 160], ["gustatory", "ANATOMICAL_SYSTEM", 165, 174], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 194, 202], ["chemosensory dysfunction", "PROBLEM", 45, 69], ["gustatory dysfunction", "PROBLEM", 165, 186], ["COVID", "TEST", 208, 213], ["mild-to-moderate symptoms", "PROBLEM", 222, 247], ["chemosensory dysfunction", "OBSERVATION", 45, 69]]], ["Notably, 12% of them declared the olfactory dysfunction as the initial symptom and 18% had no runny nose or nasal obstruction [65].", [["olfactory", "ANATOMY", 34, 43], ["nose", "ANATOMY", 100, 104], ["nasal", "ANATOMY", 108, 113], ["olfactory dysfunction", "DISEASE", 34, 55], ["nasal obstruction", "DISEASE", 108, 125], ["olfactory", "ORGAN", 34, 43], ["nose", "ORGANISM_SUBDIVISION", 100, 104], ["the olfactory dysfunction", "PROBLEM", 30, 55], ["runny nose", "PROBLEM", 94, 104], ["nasal obstruction", "PROBLEM", 108, 125], ["nasal", "ANATOMY", 108, 113], ["obstruction", "OBSERVATION", 114, 125]]], ["Indeed, although anosmia is noted in many other respiratory infections, such as cold and influenza, in COVID-19 it is typically not accompanied by nasal swelling or rhinitis [65,74,87].4.6.", [["respiratory", "ANATOMY", 48, 59], ["nasal", "ANATOMY", 147, 152], ["anosmia", "DISEASE", 17, 24], ["respiratory infections", "DISEASE", 48, 70], ["influenza", "DISEASE", 89, 98], ["nasal swelling", "DISEASE", 147, 161], ["rhinitis", "DISEASE", 165, 173], ["nasal", "ORGANISM_SUBDIVISION", 147, 152], ["anosmia", "PROBLEM", 17, 24], ["many other respiratory infections", "PROBLEM", 37, 70], ["cold", "PROBLEM", 80, 84], ["influenza", "PROBLEM", 89, 98], ["COVID", "TEST", 103, 108], ["nasal swelling", "PROBLEM", 147, 161], ["rhinitis", "PROBLEM", 165, 173], ["anosmia", "OBSERVATION", 17, 24], ["respiratory", "ANATOMY", 48, 59], ["infections", "OBSERVATION", 60, 70], ["nasal", "ANATOMY", 147, 152], ["swelling", "OBSERVATION", 153, 161], ["rhinitis", "OBSERVATION", 165, 173]]], ["Smell and Taste Disorders ::: 4.", [["Taste Disorders", "DISEASE", 10, 25]]], ["Main Neurological Manifestations of COVID-19Given the reports of anosmia presenting as an early symptom of COVID-19, dedicated testing may offer the potential for early detection of SARS-CoV-2 infection.", [["anosmia", "DISEASE", 65, 72], ["SARS-CoV-2 infection", "DISEASE", 182, 202], ["SARS-CoV-2", "ORGANISM", 182, 192], ["SARS-CoV-2", "SPECIES", 182, 192], ["COVID", "TEST", 36, 41], ["anosmia", "PROBLEM", 65, 72], ["COVID", "TEST", 107, 112], ["dedicated testing", "TEST", 117, 134], ["SARS", "PROBLEM", 182, 186], ["CoV", "PROBLEM", 187, 190], ["2 infection", "PROBLEM", 191, 202], ["SARS", "OBSERVATION", 182, 186], ["infection", "OBSERVATION", 193, 202]]], ["Nevertheless, the chemosensory deficit in COVID-19 has not yet been systematically investigated, although it is a current research \u201chot topic\u201d, both at the clinical-epidemiological and cellular level.", [["cellular", "ANATOMY", 185, 193], ["chemosensory deficit", "DISEASE", 18, 38], ["COVID-19", "CHEMICAL", 42, 50], ["COVID-19", "CHEMICAL", 42, 50], ["COVID-19", "CELL", 42, 50], ["cellular", "CELL", 185, 193], ["the chemosensory deficit", "PROBLEM", 14, 38], ["COVID", "TEST", 42, 47]]], ["Initial observations and early studies suggested as possible mechanisms for anosmia in COVID-19 the cleft syndrome, nasal obstruction and rhinorrhea, \u201ccytokine storm\u201d, direct damage to olfactory receptor neurons (ORNs), and impairment of the brain olfactory centers.", [["nasal", "ANATOMY", 116, 121], ["olfactory receptor neurons", "ANATOMY", 185, 211], ["ORNs", "ANATOMY", 213, 217], ["brain olfactory centers", "ANATOMY", 242, 265], ["anosmia", "DISEASE", 76, 83], ["cleft syndrome", "DISEASE", 100, 114], ["nasal obstruction", "DISEASE", 116, 133], ["rhinorrhea", "DISEASE", 138, 148], ["impairment of the brain", "DISEASE", 224, 247], ["cleft", "ORGAN", 100, 105], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 116, 133], ["olfactory receptor neurons", "GENE_OR_GENE_PRODUCT", 185, 211], ["ORNs", "MULTI-TISSUE_STRUCTURE", 213, 217], ["brain olfactory centers", "MULTI-TISSUE_STRUCTURE", 242, 265], ["cytokine", "PROTEIN", 151, 159], ["olfactory receptor neurons", "CELL_TYPE", 185, 211], ["ORNs", "CELL_TYPE", 213, 217], ["early studies", "TEST", 25, 38], ["anosmia", "PROBLEM", 76, 83], ["COVID", "TEST", 87, 92], ["the cleft syndrome", "PROBLEM", 96, 114], ["nasal obstruction", "PROBLEM", 116, 133], ["rhinorrhea", "PROBLEM", 138, 148], ["cytokine storm", "PROBLEM", 151, 165], ["direct damage to olfactory receptor neurons", "PROBLEM", 168, 211], ["impairment of the brain olfactory centers", "PROBLEM", 224, 265], ["cleft syndrome", "OBSERVATION", 100, 114], ["nasal", "ANATOMY", 116, 121], ["obstruction", "OBSERVATION", 122, 133], ["rhinorrhea", "OBSERVATION", 138, 148], ["impairment", "OBSERVATION", 224, 234], ["brain olfactory", "ANATOMY", 242, 257]]], ["The most obvious cause would be a direct damage to ORNs, since other human CoVs (e.g., OC43) have shown to directly bind to ORNs.", [["human", "ORGANISM", 69, 74], ["CoVs", "GENE_OR_GENE_PRODUCT", 75, 79], ["OC43", "GENE_OR_GENE_PRODUCT", 87, 91], ["ORNs", "CELL", 124, 128], ["human CoVs", "PROTEIN", 69, 79], ["OC43", "PROTEIN", 87, 91], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74], ["a direct damage to ORNs", "PROBLEM", 32, 55]]], ["However, although anosmia is linked with human viruses causing the common cold, such as influenza and other CoVs (respiratory or not), the exact mechanism has not yet been clearly established.4.6.", [["anosmia", "DISEASE", 18, 25], ["influenza", "DISEASE", 88, 97], ["human", "ORGANISM", 41, 46], ["CoVs", "GENE_OR_GENE_PRODUCT", 108, 112], ["human", "SPECIES", 41, 46], ["human viruses", "SPECIES", 41, 54], ["anosmia", "PROBLEM", 18, 25], ["human viruses", "PROBLEM", 41, 54], ["the common cold", "PROBLEM", 63, 78], ["influenza", "PROBLEM", 88, 97], ["other CoVs", "PROBLEM", 102, 112], ["anosmia", "OBSERVATION", 18, 25]]], ["Smell and Taste Disorders ::: 4.", [["Taste Disorders", "DISEASE", 10, 25]]], ["Main Neurological Manifestations of COVID-19A new model of olfactory dysfunction in COVID-19 has been recently drawn from the observation that sustentacular cells (SUSs) are the primary target of the virus and that SUSs infection triggers a cascade of events leading to anosmia [88].", [["olfactory", "ANATOMY", 59, 68], ["sustentacular cells", "ANATOMY", 143, 162], ["SUSs", "ANATOMY", 164, 168], ["olfactory dysfunction", "DISEASE", 59, 80], ["infection", "DISEASE", 220, 229], ["anosmia", "DISEASE", 270, 277], ["olfactory", "ORGAN", 59, 68], ["COVID-19", "CELL", 84, 92], ["sustentacular cells", "CELL", 143, 162], ["SUSs", "CELL", 164, 168], ["SUSs", "GENE_OR_GENE_PRODUCT", 215, 219], ["sustentacular cells", "CELL_TYPE", 143, 162], ["SUSs", "CELL_TYPE", 164, 168], ["COVID", "TEST", 36, 41], ["olfactory dysfunction", "PROBLEM", 59, 80], ["COVID", "TEST", 84, 89], ["sustentacular cells", "PROBLEM", 143, 162], ["the virus", "PROBLEM", 196, 205], ["SUSs infection", "PROBLEM", 215, 229], ["anosmia", "PROBLEM", 270, 277], ["olfactory dysfunction", "OBSERVATION", 59, 80], ["sustentacular cells", "OBSERVATION", 143, 162]]], ["SUSs express ACE2 and would be infected first.", [["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["ACE2", "PROTEIN", 13, 17], ["infected", "OBSERVATION", 31, 39]]], ["Impairment of SUS would negatively affect ORNs, leading to the inhibition of the odor perception.", [["ORNs", "ANATOMY", 42, 46], ["ORNs", "MULTI-TISSUE_STRUCTURE", 42, 46], ["Impairment of SUS would negatively affect ORNs", "PROBLEM", 0, 46], ["the odor perception", "PROBLEM", 77, 96]]], ["Simultaneously, rapid immune response would be induced in a subset of ORNs and microvillar cells, which would lead to activation of lymphocytes and macrophages and their infiltration into the olfactory epithelium, as well as secretion of proinflammatory cytokines.", [["ORNs", "ANATOMY", 70, 74], ["microvillar cells", "ANATOMY", 79, 96], ["lymphocytes", "ANATOMY", 132, 143], ["macrophages", "ANATOMY", 148, 159], ["olfactory epithelium", "ANATOMY", 192, 212], ["ORNs", "CELL", 70, 74], ["microvillar cells", "CELL", 79, 96], ["lymphocytes", "CELL", 132, 143], ["macrophages", "CELL", 148, 159], ["olfactory epithelium", "TISSUE", 192, 212], ["ORNs", "CELL_TYPE", 70, 74], ["microvillar cells", "CELL_TYPE", 79, 96], ["lymphocytes", "CELL_TYPE", 132, 143], ["macrophages", "CELL_TYPE", 148, 159], ["proinflammatory cytokines", "PROTEIN", 238, 263], ["microvillar cells", "PROBLEM", 79, 96], ["lymphocytes", "PROBLEM", 132, 143], ["macrophages", "PROBLEM", 148, 159], ["their infiltration into the olfactory epithelium", "PROBLEM", 164, 212], ["proinflammatory cytokines", "PROBLEM", 238, 263], ["microvillar cells", "OBSERVATION", 79, 96], ["infiltration", "OBSERVATION", 170, 182], ["olfactory epithelium", "ANATOMY", 192, 212], ["proinflammatory cytokines", "OBSERVATION", 238, 263]]], ["Stem cell infection may potentially explain why a small fraction of patients with COVID-19 experience long-term dysosmia [88].4.6.", [["Stem cell", "ANATOMY", 0, 9], ["Stem cell infection", "DISEASE", 0, 19], ["dysosmia", "DISEASE", 112, 120], ["Stem cell", "CELL", 0, 9], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Stem cell infection", "PROBLEM", 0, 19], ["COVID", "TEST", 82, 87], ["long-term dysosmia", "PROBLEM", 102, 120], ["cell infection", "OBSERVATION", 5, 19], ["may potentially explain", "UNCERTAINTY", 20, 43], ["small", "OBSERVATION_MODIFIER", 50, 55]]], ["Smell and Taste Disorders ::: 4.", [["Taste Disorders", "DISEASE", 10, 25]]], ["Main Neurological Manifestations of COVID-19Of note, such a model does not imply that SARS-CoV-2 travels from the olfactory epithelium to the brain along the olfactory axons.", [["olfactory epithelium", "ANATOMY", 114, 134], ["brain", "ANATOMY", 142, 147], ["olfactory axons", "ANATOMY", 158, 173], ["SARS", "DISEASE", 86, 90], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 86, 96], ["olfactory epithelium", "TISSUE", 114, 134], ["brain", "ORGAN", 142, 147], ["olfactory axons", "MULTI-TISSUE_STRUCTURE", 158, 173], ["COVID", "TEST", 36, 41], ["olfactory", "ANATOMY_MODIFIER", 114, 123], ["epithelium", "ANATOMY_MODIFIER", 124, 134], ["brain", "ANATOMY", 142, 147], ["olfactory axons", "ANATOMY", 158, 173]]], ["Indeed, no axonal transport of SARS-CoV-2 to the brain has been demonstrated in the hamster model during the first two weeks after infection [89], and no viral accumulation or persistence has been reported in cerebral olfactory regions of autopsy material from patients with COVID-19 [90].", [["axonal", "ANATOMY", 11, 17], ["brain", "ANATOMY", 49, 54], ["hamster", "ANATOMY", 84, 91], ["cerebral olfactory regions", "ANATOMY", 209, 235], ["SARS", "DISEASE", 31, 35], ["infection", "DISEASE", 131, 140], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 31, 41], ["brain", "ORGAN", 49, 54], ["hamster", "ORGANISM", 84, 91], ["cerebral olfactory", "MULTI-TISSUE_STRUCTURE", 209, 227], ["autopsy material", "MULTI-TISSUE_STRUCTURE", 239, 255], ["patients", "ORGANISM", 261, 269], ["hamster", "SPECIES", 84, 91], ["patients", "SPECIES", 261, 269], ["hamster", "SPECIES", 84, 91], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["infection", "PROBLEM", 131, 140], ["viral accumulation", "PROBLEM", 154, 172], ["COVID", "TEST", 275, 280], ["no", "UNCERTAINTY", 8, 10], ["axonal", "OBSERVATION_MODIFIER", 11, 17], ["brain", "ANATOMY", 49, 54], ["no", "UNCERTAINTY", 151, 153], ["viral accumulation", "OBSERVATION", 154, 172], ["cerebral olfactory", "ANATOMY", 209, 227]]], ["On the other hand, rapid SARS-CoV-2 accumulation in the brain after intranasal injection was recently shown using the new humanized ACE2 knock-in mouse [91].", [["brain", "ANATOMY", 56, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["brain", "ORGAN", 56, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 132, 136], ["mouse", "ORGANISM", 146, 151], ["ACE2", "PROTEIN", 132, 136], ["mouse", "SPECIES", 146, 151], ["mouse", "SPECIES", 146, 151], ["rapid SARS-CoV-2 accumulation in the brain", "PROBLEM", 19, 61], ["intranasal injection", "TREATMENT", 68, 88], ["the new humanized ACE2 knock", "TREATMENT", 114, 142], ["rapid", "OBSERVATION_MODIFIER", 19, 24], ["SARS", "OBSERVATION", 25, 29], ["brain", "ANATOMY", 56, 61]]], ["Yet, this is not synonymous with transport along olfactory axons, as other routes are also possible.", [["olfactory axons", "ANATOMY", 49, 64], ["olfactory axons", "MULTI-TISSUE_STRUCTURE", 49, 64], ["synonymous", "OBSERVATION", 17, 27]]], ["If SARS-CoV-2 travels within the olfactory axons, this would require an ACE2-independent passage of the virus from SUSs to ORNs within the olfactory epithelium.", [["olfactory axons", "ANATOMY", 33, 48], ["SUSs", "ANATOMY", 115, 119], ["ORNs", "ANATOMY", 123, 127], ["olfactory epithelium", "ANATOMY", 139, 159], ["SARS", "DISEASE", 3, 7], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 3, 13], ["olfactory axons", "MULTI-TISSUE_STRUCTURE", 33, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["SUSs", "GENE_OR_GENE_PRODUCT", 115, 119], ["ORNs", "CELL", 123, 127], ["olfactory epithelium", "TISSUE", 139, 159], ["ACE2", "PROTEIN", 72, 76], ["SARS", "PROBLEM", 3, 7], ["an ACE2", "TEST", 69, 76], ["olfactory epithelium", "ANATOMY", 139, 159]]], ["In addition, it would be relevant to examine progenitor or stem cell infection, as these olfactory epithelium cells also express significant levels of ACE2.", [["progenitor", "ANATOMY", 45, 55], ["stem cell", "ANATOMY", 59, 68], ["olfactory epithelium cells", "ANATOMY", 89, 115], ["infection", "DISEASE", 69, 78], ["progenitor", "CELL", 45, 55], ["stem cell", "CELL", 59, 68], ["olfactory epithelium cells", "CELL", 89, 115], ["ACE2", "GENE_OR_GENE_PRODUCT", 151, 155], ["olfactory epithelium cells", "CELL_TYPE", 89, 115], ["ACE2", "PROTEIN", 151, 155], ["stem cell infection", "PROBLEM", 59, 78], ["these olfactory epithelium cells", "TEST", 83, 115], ["significant levels of ACE2", "PROBLEM", 129, 155], ["stem cell infection", "OBSERVATION", 59, 78], ["significant", "OBSERVATION_MODIFIER", 129, 140]]], ["Probably, also host genetic factors play a role in individual susceptibility to anosmia in COVID-19 and the characterization of these factors is of particular interest [92].4.6.", [["anosmia", "DISEASE", 80, 87], ["anosmia", "PROBLEM", 80, 87], ["COVID", "TEST", 91, 96]]], ["Smell and Taste Disorders ::: 4.", [["Taste Disorders", "DISEASE", 10, 25]]], ["Main Neurological Manifestations of COVID-19Regarding gustatory dysfunction in COVID-19, it is known that the ability to separate flavors depends on the retronasal stimulation pathway.", [["retronasal", "ANATOMY", 153, 163], ["gustatory dysfunction", "DISEASE", 54, 75], ["COVID-19", "CHEMICAL", 79, 87], ["COVID", "TEST", 36, 41], ["gustatory dysfunction", "PROBLEM", 54, 75], ["COVID", "TEST", 79, 84], ["the retronasal stimulation pathway", "TREATMENT", 149, 183]]], ["Therefore, in patients with ageusia, retronasal olfactory dysfunction is commonly suggested, although some studies reported high ACE2 expression on the oral cavity mucosa and epithelial cells of the tongue [93].", [["retronasal olfactory", "ANATOMY", 37, 57], ["oral cavity mucosa", "ANATOMY", 152, 170], ["epithelial cells", "ANATOMY", 175, 191], ["tongue", "ANATOMY", 199, 205], ["ageusia", "DISEASE", 28, 35], ["olfactory dysfunction", "DISEASE", 48, 69], ["patients", "ORGANISM", 14, 22], ["retronasal olfactory", "MULTI-TISSUE_STRUCTURE", 37, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 129, 133], ["oral cavity mucosa", "MULTI-TISSUE_STRUCTURE", 152, 170], ["epithelial cells", "CELL", 175, 191], ["tongue", "ORGAN", 199, 205], ["ACE2", "PROTEIN", 129, 133], ["epithelial cells", "CELL_TYPE", 175, 191], ["patients", "SPECIES", 14, 22], ["ageusia", "TREATMENT", 28, 35], ["retronasal olfactory dysfunction", "PROBLEM", 37, 69], ["some studies", "TEST", 102, 114], ["high ACE2 expression on the oral cavity mucosa", "PROBLEM", 124, 170], ["epithelial cells of the tongue", "PROBLEM", 175, 205], ["olfactory dysfunction", "OBSERVATION", 48, 69], ["cavity mucosa", "ANATOMY", 157, 170], ["epithelial cells", "OBSERVATION", 175, 191], ["tongue", "ANATOMY", 199, 205]]], ["Another possibility is that SARS-CoV-2 may have a direct effect on the taste buds or receptors [94].4.7.", [["taste buds", "ANATOMY", 71, 81], ["SARS", "DISEASE", 28, 32], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["taste buds", "MULTI-TISSUE_STRUCTURE", 71, 81], ["SARS", "PROBLEM", 28, 32]]], ["Guillain-Barre Syndrome ::: 4.", [["Guillain-Barre Syndrome", "DISEASE", 0, 23], ["Barre Syndrome", "PROBLEM", 9, 23], ["Barre Syndrome", "OBSERVATION", 9, 23]]], ["Main Neurological Manifestations of COVID-19GBS (i.e., acute inflammatory demyelinating polyneuropathy) can follow a gastrointestinal or respiratory infection.", [["Neurological", "ANATOMY", 5, 17], ["gastrointestinal", "ANATOMY", 117, 133], ["respiratory", "ANATOMY", 137, 148], ["COVID-19GBS", "CHEMICAL", 36, 47], ["polyneuropathy", "DISEASE", 88, 102], ["gastrointestinal or respiratory infection", "DISEASE", 117, 158], ["gastrointestinal", "ORGAN", 117, 133], ["COVID", "TEST", 36, 41], ["acute inflammatory demyelinating polyneuropathy", "PROBLEM", 55, 102], ["a gastrointestinal or respiratory infection", "PROBLEM", 115, 158], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["inflammatory", "OBSERVATION_MODIFIER", 61, 73], ["gastrointestinal", "ANATOMY", 117, 133], ["respiratory", "ANATOMY", 137, 148], ["infection", "OBSERVATION", 149, 158]]], ["A molecular mimicry mechanism, in which infecting viruses likely share epitopes similar to some peripheral nerve components, is believed to occur and to stimulate autoreactive T or B lymphocytes.", [["peripheral nerve components", "ANATOMY", 96, 123], ["autoreactive T", "ANATOMY", 163, 177], ["B lymphocytes", "ANATOMY", 181, 194], ["peripheral nerve", "MULTI-TISSUE_STRUCTURE", 96, 112], ["T", "CELL", 176, 177], ["B lymphocytes", "CELL", 181, 194], ["epitopes", "PROTEIN", 71, 79], ["autoreactive T or B lymphocytes", "CELL_TYPE", 163, 194], ["A molecular mimicry mechanism", "PROBLEM", 0, 29], ["infecting viruses", "PROBLEM", 40, 57], ["some peripheral nerve components", "PROBLEM", 91, 123], ["mimicry mechanism", "OBSERVATION", 12, 29], ["viruses", "OBSERVATION", 50, 57], ["peripheral", "ANATOMY_MODIFIER", 96, 106], ["nerve", "ANATOMY", 107, 112], ["lymphocytes", "ANATOMY", 183, 194]]], ["Antibodies against the virus cross-react and bind to peripheral nerve components, thus causing neuronal dysfunction and clinical manifestations.", [["peripheral nerve components", "ANATOMY", 53, 80], ["neuronal", "ANATOMY", 95, 103], ["neuronal dysfunction", "DISEASE", 95, 115], ["peripheral nerve", "MULTI-TISSUE_STRUCTURE", 53, 69], ["neuronal", "CELL", 95, 103], ["Antibodies", "TEST", 0, 10], ["the virus cross-react", "PROBLEM", 19, 40], ["peripheral nerve components", "PROBLEM", 53, 80], ["neuronal dysfunction", "PROBLEM", 95, 115], ["clinical manifestations", "PROBLEM", 120, 143], ["peripheral", "ANATOMY_MODIFIER", 53, 63], ["nerve", "ANATOMY", 64, 69], ["thus causing", "UNCERTAINTY", 82, 94], ["neuronal dysfunction", "OBSERVATION", 95, 115]]], ["After SARS- and MERS-CoV infections, both GBS and acute motor axonal neuropathy have been described [32,51].4.7.", [["SARS- and MERS-CoV infections", "DISEASE", 6, 35], ["GBS", "DISEASE", 42, 45], ["acute motor axonal neuropathy", "DISEASE", 50, 79], ["MERS-CoV", "ORGANISM", 16, 24], ["MERS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 6, 10], ["MERS", "PROBLEM", 16, 20], ["CoV infections", "PROBLEM", 21, 35], ["both GBS", "PROBLEM", 37, 45], ["acute motor axonal neuropathy", "PROBLEM", 50, 79], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["motor axonal neuropathy", "OBSERVATION", 56, 79]]], ["Guillain-Barre Syndrome ::: 4.", [["Guillain-Barre Syndrome", "DISEASE", 0, 23], ["Barre Syndrome", "PROBLEM", 9, 23], ["Barre Syndrome", "OBSERVATION", 9, 23]]], ["Main Neurological Manifestations of COVID-19Reports of GBS in patients with COVID-19 are emerging.", [["GBS", "DISEASE", 55, 58], ["COVID-19", "CHEMICAL", 76, 84], ["COVID-19", "CHEMICAL", 76, 84], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["COVID", "TEST", 36, 41], ["GBS", "PROBLEM", 55, 58], ["COVID", "TEST", 76, 81]]], ["A case series [73] reported five cases of GBS in Italy, and four of them presented with lower-extremity weakness and paresthesia.", [["GBS", "DISEASE", 42, 45], ["lower-extremity weakness", "DISEASE", 88, 112], ["paresthesia", "DISEASE", 117, 128], ["A case series", "TEST", 0, 13], ["GBS", "PROBLEM", 42, 45], ["lower-extremity weakness", "PROBLEM", 88, 112], ["paresthesia", "PROBLEM", 117, 128], ["GBS", "OBSERVATION", 42, 45], ["lower", "ANATOMY_MODIFIER", 88, 93], ["extremity", "ANATOMY", 94, 103], ["weakness", "OBSERVATION", 104, 112], ["paresthesia", "OBSERVATION", 117, 128]]], ["Patients developed symptoms five to 10 days after the onset of the viral infection.", [["viral infection", "DISEASE", 67, 82], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 19, 27], ["the viral infection", "PROBLEM", 63, 82], ["viral", "OBSERVATION_MODIFIER", 67, 72], ["infection", "OBSERVATION", 73, 82]]], ["At electromyography, two patients had GBS and three acute motor axonal neuropathy [73].", [["GBS", "DISEASE", 38, 41], ["axonal neuropathy", "DISEASE", 64, 81], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["electromyography", "TEST", 3, 19], ["GBS", "PROBLEM", 38, 41], ["three acute motor axonal neuropathy", "PROBLEM", 46, 81], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["motor axonal neuropathy", "OBSERVATION", 58, 81]]], ["Another patient in Iran [72] and an Italian patient with the Miller-Fisher GBS variant [59] were also reported.4.7.", [["patient", "ORGANISM", 8, 15], ["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 8, 15], ["patient", "SPECIES", 44, 51]]], ["Guillain-Barre Syndrome ::: 4.", [["Guillain-Barre Syndrome", "DISEASE", 0, 23], ["Barre Syndrome", "PROBLEM", 9, 23], ["Barre Syndrome", "OBSERVATION", 9, 23]]], ["Main Neurological Manifestations of COVID-19In a 62-year-old patient presenting with motor weakness of the lower extremities and COVID-19 symptoms, GBS associated with SARS-CoV-2 infection was observed a week later [76].", [["Neurological", "ANATOMY", 5, 17], ["lower extremities", "ANATOMY", 107, 124], ["motor weakness of the lower extremities", "DISEASE", 85, 124], ["GBS", "DISEASE", 148, 151], ["SARS-CoV-2 infection", "DISEASE", 168, 188], ["patient", "ORGANISM", 61, 68], ["lower extremities", "ORGANISM_SUBDIVISION", 107, 124], ["CoV-2", "ORGANISM", 173, 178], ["patient", "SPECIES", 61, 68], ["COVID", "TEST", 36, 41], ["motor weakness of the lower extremities", "PROBLEM", 85, 124], ["COVID-19 symptoms", "PROBLEM", 129, 146], ["GBS", "PROBLEM", 148, 151], ["SARS", "PROBLEM", 168, 172], ["CoV", "PROBLEM", 173, 176], ["2 infection", "PROBLEM", 177, 188], ["motor weakness", "OBSERVATION", 85, 99], ["lower extremities", "ANATOMY", 107, 124], ["infection", "OBSERVATION", 179, 188]]], ["An increase in proteins (124 mg/dl) but not in cells was found in the CSF, while at neurophysiological examination increased distal latencies and F-waves absence was detected, suggesting a severe and diffuse peripheral nerve demyelination.", [["cells", "ANATOMY", 47, 52], ["peripheral nerve", "ANATOMY", 208, 224], ["peripheral nerve demyelination", "DISEASE", 208, 238], ["cells", "CELL", 47, 52], ["CSF", "GENE_OR_GENE_PRODUCT", 70, 73], ["peripheral nerve", "MULTI-TISSUE_STRUCTURE", 208, 224], ["An increase in proteins", "PROBLEM", 0, 23], ["the CSF", "TEST", 66, 73], ["neurophysiological examination", "TEST", 84, 114], ["increased distal latencies and F-waves absence", "PROBLEM", 115, 161], ["a severe and diffuse peripheral nerve demyelination", "PROBLEM", 187, 238], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["CSF", "ANATOMY", 70, 73], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["distal", "OBSERVATION_MODIFIER", 125, 131], ["latencies", "OBSERVATION_MODIFIER", 132, 141], ["severe", "OBSERVATION_MODIFIER", 189, 195], ["diffuse", "OBSERVATION_MODIFIER", 200, 207], ["peripheral", "ANATOMY_MODIFIER", 208, 218], ["nerve", "ANATOMY", 219, 224], ["demyelination", "OBSERVATION", 225, 238]]], ["Although the authors reported that the patient was infected by SARS-CoV-2 at the onset of GBS symptoms (because the patient had lymphopenia and thrombocytopenia), it cannot be excluded that COVID-19 and GBS presented coincidentally [76], and therefore further evidence is needed.4.8.", [["SARS", "DISEASE", 63, 67], ["GBS symptoms", "DISEASE", 90, 102], ["lymphopenia", "DISEASE", 128, 139], ["thrombocytopenia", "DISEASE", 144, 160], ["GBS", "DISEASE", 203, 206], ["patient", "ORGANISM", 39, 46], ["SARS-CoV-2", "ORGANISM", 63, 73], ["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 39, 46], ["patient", "SPECIES", 116, 123], ["SARS-CoV", "SPECIES", 63, 71], ["SARS", "PROBLEM", 63, 67], ["CoV", "TEST", 68, 71], ["GBS symptoms", "PROBLEM", 90, 102], ["lymphopenia", "PROBLEM", 128, 139], ["thrombocytopenia", "PROBLEM", 144, 160], ["COVID", "TEST", 190, 195], ["GBS", "TEST", 203, 206], ["GBS", "OBSERVATION", 90, 93], ["lymphopenia", "OBSERVATION", 128, 139], ["thrombocytopenia", "OBSERVATION", 144, 160]]], ["Non-Specific Neurological Symptoms ::: 4.", [["Non-Specific Neurological Symptoms", "PROBLEM", 0, 34]]], ["Main Neurological Manifestations of COVID-19Some of the most frequently described non-specific symptoms are myalgia, unsteadiness, and fatigue.", [["myalgia", "DISEASE", 108, 115], ["unsteadiness", "DISEASE", 117, 129], ["fatigue", "DISEASE", 135, 142], ["COVID", "TEST", 36, 41], ["non-specific symptoms", "PROBLEM", 82, 103], ["myalgia", "PROBLEM", 108, 115], ["unsteadiness", "PROBLEM", 117, 129], ["fatigue", "PROBLEM", 135, 142], ["myalgia", "OBSERVATION", 108, 115]]], ["Of note, 36.4% of 214 patients with COVID-19 admitted in a Wuhan hospital exhibited neurological manifestations [68], which were categorized as \u201cCNS involvement\u201d (24.8%), \u201cperipheral involvement\u201d (10.7%), and \u201cmuscular-skeletal involvement\u201d (10.7%).", [["neurological", "ANATOMY", 84, 96], ["CNS", "ANATOMY", 145, 148], ["muscular", "ANATOMY", 210, 218], ["skeletal", "ANATOMY", 219, 227], ["muscular-skeletal involvement\u201d", "DISEASE", 210, 240], ["patients", "ORGANISM", 22, 30], ["skeletal", "ORGAN", 219, 227], ["patients", "SPECIES", 22, 30], ["COVID", "TEST", 36, 41], ["neurological manifestations", "PROBLEM", 84, 111], ["peripheral involvement\u201d", "TEST", 172, 195], ["\u201cmuscular-skeletal involvement", "PROBLEM", 209, 239], ["peripheral", "ANATOMY_MODIFIER", 172, 182], ["involvement", "OBSERVATION", 183, 194], ["muscular", "ANATOMY", 210, 218], ["skeletal", "ANATOMY", 219, 227]]], ["Among the latter, 15% of the non-severe patients reported myalgia, while 13.7% had elevated levels of creatine kinase.", [["myalgia", "DISEASE", 58, 65], ["creatine", "CHEMICAL", 102, 110], ["creatine", "CHEMICAL", 102, 110], ["patients", "ORGANISM", 40, 48], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 102, 117], ["creatine kinase", "PROTEIN", 102, 117], ["patients", "SPECIES", 40, 48], ["myalgia", "PROBLEM", 58, 65], ["elevated levels of creatine kinase", "PROBLEM", 83, 117]]], ["Two cases of rhabdomyolysis (0.2%) were also described [61].4.9.", [["rhabdomyolysis", "DISEASE", 13, 27], ["rhabdomyolysis", "PROBLEM", 13, 27], ["rhabdomyolysis", "OBSERVATION", 13, 27]]], ["Main Neurological Manifestations of COVID-19Apart from a general unspecific reaction to the awareness of infection, some psychiatric illnesses might directly result from exposure to human CoVs.", [["COVID-19Apart", "CHEMICAL", 36, 49], ["infection", "DISEASE", 105, 114], ["psychiatric illnesses", "DISEASE", 121, 142], ["human", "ORGANISM", 182, 187], ["CoVs", "GENE_OR_GENE_PRODUCT", 188, 192], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 182, 187], ["COVID", "TEST", 36, 41], ["a general unspecific reaction", "PROBLEM", 55, 84], ["infection", "PROBLEM", 105, 114], ["some psychiatric illnesses", "PROBLEM", 116, 142], ["human CoVs", "PROBLEM", 182, 192], ["infection", "OBSERVATION", 105, 114]]], ["In patients with psychotic symptoms compared to non-psychiatric controls, a higher prevalence of immune reactivity for HKU1 and NL63 CoVs was found [95], suggesting that viral exposure may represent a comorbid risk factor in neuropsychiatric disease.", [["psychotic symptoms", "DISEASE", 17, 35], ["neuropsychiatric disease", "DISEASE", 225, 249], ["patients", "ORGANISM", 3, 11], ["HKU1", "GENE_OR_GENE_PRODUCT", 119, 123], ["NL63 CoVs", "GENE_OR_GENE_PRODUCT", 128, 137], ["HKU1", "PROTEIN", 119, 123], ["NL63 CoVs", "PROTEIN", 128, 137], ["patients", "SPECIES", 3, 11], ["psychotic symptoms", "PROBLEM", 17, 35], ["immune reactivity", "PROBLEM", 97, 114], ["HKU1", "PROBLEM", 119, 123], ["NL63 CoVs", "PROBLEM", 128, 137], ["viral exposure", "PROBLEM", 170, 184], ["a comorbid risk factor", "PROBLEM", 199, 221], ["neuropsychiatric disease", "PROBLEM", 225, 249], ["viral exposure", "OBSERVATION", 170, 184], ["may represent", "UNCERTAINTY", 185, 198], ["neuropsychiatric disease", "OBSERVATION", 225, 249]]], ["However, the role that SARS-CoV-2 may play in the etiopathogenesis of psychiatric diseases needs to be explored.5.1.", [["psychiatric diseases", "DISEASE", 70, 90], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["psychiatric diseases", "PROBLEM", 70, 90]]], ["Lessons from SARS- and MERS-CoV Infections ::: 5.", [["SARS", "DISEASE", 13, 17], ["MERS-CoV", "ORGANISM", 23, 31], ["SARS", "PROBLEM", 13, 17], ["SARS", "OBSERVATION", 13, 17]]], ["Proposed Neuropathogenic MechanismsSARS-CoV entry into the human host cell seems to be mediated primarily by cellular receptors ACE2, which are expressed in the lung, kidney, vascular endothelia, small intestine, and human airway epithelia [96,97,98].", [["cell", "ANATOMY", 70, 74], ["cellular", "ANATOMY", 109, 117], ["lung", "ANATOMY", 161, 165], ["kidney", "ANATOMY", 167, 173], ["vascular endothelia", "ANATOMY", 175, 194], ["small intestine", "ANATOMY", 196, 211], ["airway epithelia", "ANATOMY", 223, 239], ["human", "ORGANISM", 59, 64], ["host cell", "CELL", 65, 74], ["cellular", "CELL", 109, 117], ["ACE2", "GENE_OR_GENE_PRODUCT", 128, 132], ["lung", "ORGAN", 161, 165], ["kidney", "ORGAN", 167, 173], ["vascular endothelia", "TISSUE", 175, 194], ["small intestine", "ORGAN", 196, 211], ["human", "ORGANISM", 217, 222], ["airway epithelia", "TISSUE", 223, 239], ["human host cell", "CELL_TYPE", 59, 74], ["cellular receptors", "PROTEIN", 109, 127], ["ACE2", "PROTEIN", 128, 132], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 217, 222], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 217, 222], ["Proposed Neuropathogenic MechanismsSARS", "PROBLEM", 0, 39], ["small intestine", "PROBLEM", 196, 211], ["human airway epithelia", "PROBLEM", 217, 239], ["host cell", "OBSERVATION", 65, 74], ["lung", "ANATOMY", 161, 165], ["kidney", "ANATOMY", 167, 173], ["vascular endothelia", "ANATOMY", 175, 194], ["small intestine", "ANATOMY", 196, 211], ["airway epithelia", "OBSERVATION", 223, 239]]], ["Conversely, MERS-CoV may enter human host cells primarily through the dipeptidyl peptidase-4 (DPP4) protein located in the membrane of cells of the immune system, liver, small intestine, and lower respiratory tract [99,100].", [["cells", "ANATOMY", 42, 47], ["membrane", "ANATOMY", 123, 131], ["cells", "ANATOMY", 135, 140], ["immune system", "ANATOMY", 148, 161], ["liver", "ANATOMY", 163, 168], ["small intestine", "ANATOMY", 170, 185], ["lower respiratory tract", "ANATOMY", 191, 214], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 12, 20], ["human", "ORGANISM", 31, 36], ["host cells", "CELL", 37, 47], ["dipeptidyl peptidase-4", "GENE_OR_GENE_PRODUCT", 70, 92], ["DPP4", "GENE_OR_GENE_PRODUCT", 94, 98], ["membrane", "CELLULAR_COMPONENT", 123, 131], ["cells", "CELL", 135, 140], ["immune system", "ANATOMICAL_SYSTEM", 148, 161], ["liver", "ORGAN", 163, 168], ["small intestine", "ORGAN", 170, 185], ["lower respiratory", "ORGANISM_SUBDIVISION", 191, 208], ["tract", "ORGANISM_SUBDIVISION", 209, 214], ["MERS", "PROTEIN", 12, 16], ["human host cells", "CELL_TYPE", 31, 47], ["dipeptidyl peptidase-4 (DPP4) protein", "PROTEIN", 70, 107], ["human", "SPECIES", 31, 36], ["MERS-CoV", "SPECIES", 12, 20], ["human", "SPECIES", 31, 36], ["the dipeptidyl peptidase", "TEST", 66, 90], ["DPP4) protein", "TEST", 94, 107], ["lower respiratory tract", "PROBLEM", 191, 214], ["membrane", "ANATOMY_MODIFIER", 123, 131], ["immune system", "ANATOMY", 148, 161], ["liver", "ANATOMY", 163, 168], ["small intestine", "ANATOMY", 170, 185], ["lower", "ANATOMY_MODIFIER", 191, 196], ["respiratory tract", "ANATOMY", 197, 214]]], ["However, ACE2 or DPP4 alone are not enough to make the host cell susceptible to infections.", [["cell", "ANATOMY", 60, 64], ["infections", "DISEASE", 80, 90], ["ACE2", "GENE_OR_GENE_PRODUCT", 9, 13], ["DPP4", "GENE_OR_GENE_PRODUCT", 17, 21], ["host cell", "CELL", 55, 64], ["ACE2", "PROTEIN", 9, 13], ["DPP4", "PROTEIN", 17, 21], ["ACE2", "TEST", 9, 13], ["DPP4", "TEST", 17, 21], ["host cell", "OBSERVATION_MODIFIER", 55, 64], ["infections", "OBSERVATION", 80, 90]]], ["This is particularly true when considering that SARS or MERS infections were also reported in the CNS, where ACE2 or DDP4 expression level is low under normal conditions [101].5.1.", [["CNS", "ANATOMY", 98, 101], ["SARS", "DISEASE", 48, 52], ["infections", "DISEASE", 61, 71], ["CNS", "ANATOMICAL_SYSTEM", 98, 101], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["DDP4", "GENE_OR_GENE_PRODUCT", 117, 121], ["ACE2", "PROTEIN", 109, 113], ["DDP4", "PROTEIN", 117, 121], ["SARS", "PROBLEM", 48, 52], ["MERS infections", "PROBLEM", 56, 71], ["ACE2", "TEST", 109, 113], ["DDP4 expression level", "TEST", 117, 138]]], ["Lessons from SARS- and MERS-CoV Infections ::: 5.", [["SARS", "DISEASE", 13, 17], ["MERS-CoV", "ORGANISM", 23, 31], ["SARS", "PROBLEM", 13, 17], ["SARS", "OBSERVATION", 13, 17]]], ["Proposed Neuropathogenic MechanismsThe exact route through which SARS and MERS CoVs enter the CNS is still not clear, although the glymphatic or a pure hematogenous path seems to be unlikely, particularly in the initial infection stage, during which no virus particle is detected in the brain [49,102,103].", [["CNS", "ANATOMY", 94, 97], ["brain", "ANATOMY", 287, 292], ["SARS", "DISEASE", 65, 69], ["infection", "DISEASE", 220, 229], ["MERS CoVs", "GENE_OR_GENE_PRODUCT", 74, 83], ["CNS", "ANATOMICAL_SYSTEM", 94, 97], ["brain", "ORGAN", 287, 292], ["SARS", "PROBLEM", 65, 69], ["MERS CoVs", "PROBLEM", 74, 83], ["a pure hematogenous path", "PROBLEM", 145, 169], ["the initial infection stage", "PROBLEM", 208, 235], ["virus particle", "PROBLEM", 253, 267], ["CNS", "ANATOMY", 94, 97], ["clear", "OBSERVATION", 111, 116], ["pure", "OBSERVATION_MODIFIER", 147, 151], ["hematogenous", "OBSERVATION", 152, 164], ["seems to be unlikely", "UNCERTAINTY", 170, 190], ["infection", "OBSERVATION", 220, 229], ["no", "UNCERTAINTY", 250, 252], ["virus particle", "OBSERVATION", 253, 267], ["brain", "ANATOMY", 287, 292]]], ["However, some evidence indicates that CoVs might initially invade peripheral nerve terminals, and later the CNS through a synapse-connected route [104,105,106,107].", [["peripheral nerve terminals", "ANATOMY", 66, 92], ["CNS", "ANATOMY", 108, 111], ["synapse", "ANATOMY", 122, 129], ["CoVs", "GENE_OR_GENE_PRODUCT", 38, 42], ["peripheral nerve terminals", "MULTI-TISSUE_STRUCTURE", 66, 92], ["CNS", "ANATOMICAL_SYSTEM", 108, 111], ["CoVs", "PROTEIN", 38, 42], ["CoVs", "PROBLEM", 38, 42], ["CoVs", "OBSERVATION", 38, 42], ["peripheral", "ANATOMY_MODIFIER", 66, 76], ["nerve", "ANATOMY", 77, 82]]], ["Coherently, the SARS infection seems to be able to cause significant neuronal damage without substantial inflammatory infiltration [43].5.1.", [["neuronal", "ANATOMY", 69, 77], ["SARS infection", "DISEASE", 16, 30], ["neuronal damage", "DISEASE", 69, 84], ["neuronal", "CELL", 69, 77], ["the SARS infection", "PROBLEM", 12, 30], ["significant neuronal damage", "PROBLEM", 57, 84], ["substantial inflammatory infiltration", "PROBLEM", 93, 130], ["infection", "OBSERVATION", 21, 30], ["damage", "OBSERVATION", 78, 84], ["without", "UNCERTAINTY", 85, 92], ["substantial", "OBSERVATION_MODIFIER", 93, 104], ["inflammatory", "OBSERVATION_MODIFIER", 105, 117], ["infiltration", "OBSERVATION", 118, 130]]], ["Lessons from SARS- and MERS-CoV Infections ::: 5.", [["SARS", "DISEASE", 13, 17], ["MERS-CoV", "ORGANISM", 23, 31], ["SARS", "PROBLEM", 13, 17], ["SARS", "OBSERVATION", 13, 17]]], ["Proposed Neuropathogenic MechanismsEarlier studies have shown the presence of viral particles in the brain of patients with SARS, located exclusively in the neurons [102,103].", [["brain", "ANATOMY", 101, 106], ["neurons", "ANATOMY", 157, 164], ["SARS", "DISEASE", 124, 128], ["brain", "ORGAN", 101, 106], ["patients", "ORGANISM", 110, 118], ["neurons", "CELL", 157, 164], ["patients", "SPECIES", 110, 118], ["Proposed Neuropathogenic MechanismsEarlier studies", "TEST", 0, 50], ["viral particles in the brain", "PROBLEM", 78, 106], ["SARS", "PROBLEM", 124, 128], ["viral particles", "OBSERVATION", 78, 93], ["brain", "ANATOMY", 101, 106], ["neurons", "ANATOMY", 157, 164]]], ["In vivo experiments using transgenic mice showed that, when SARS or MERS CoVs are given intranasally, they can enter the brain via the olfactory nerve, and quickly spread to specific brain regions, such as the brainstem and the thalamus [43,108].", [["brain", "ANATOMY", 121, 126], ["olfactory nerve", "ANATOMY", 135, 150], ["brain", "ANATOMY", 183, 188], ["brainstem", "ANATOMY", 210, 219], ["thalamus", "ANATOMY", 228, 236], ["SARS", "DISEASE", 60, 64], ["mice", "ORGANISM", 37, 41], ["MERS CoVs", "GENE_OR_GENE_PRODUCT", 68, 77], ["brain", "ORGAN", 121, 126], ["olfactory nerve", "MULTI-TISSUE_STRUCTURE", 135, 150], ["brain", "ORGAN", 183, 188], ["brainstem", "ORGAN", 210, 219], ["MERS CoVs", "PROTEIN", 68, 77], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["SARS", "PROBLEM", 60, 64], ["MERS CoVs", "PROBLEM", 68, 77], ["brain", "ANATOMY", 121, 126], ["olfactory nerve", "ANATOMY", 135, 150], ["brain", "ANATOMY", 183, 188], ["regions", "ANATOMY_MODIFIER", 189, 196], ["brainstem", "ANATOMY", 210, 219], ["thalamus", "ANATOMY", 228, 236]]], ["In these cases, the brain expresses ACE2 receptors, that have been detected in neurons and glial cells, making them a potential target for COVID-19.5.1.", [["brain", "ANATOMY", 20, 25], ["neurons", "ANATOMY", 79, 86], ["glial cells", "ANATOMY", 91, 102], ["brain", "ORGAN", 20, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["neurons", "CELL", 79, 86], ["glial cells", "CELL", 91, 102], ["ACE2 receptors", "PROTEIN", 36, 50], ["neurons", "CELL_TYPE", 79, 86], ["glial cells", "CELL_TYPE", 91, 102], ["ACE2 receptors", "TEST", 36, 50], ["COVID", "TEST", 139, 144], ["brain", "ANATOMY", 20, 25], ["glial cells", "OBSERVATION", 91, 102]]], ["Lessons from SARS- and MERS-CoV Infections ::: 5.", [["SARS", "DISEASE", 13, 17], ["MERS-CoV", "ORGANISM", 23, 31], ["SARS", "PROBLEM", 13, 17], ["SARS", "OBSERVATION", 13, 17]]], ["Proposed Neuropathogenic MechanismsAnother important observation is that in mice infected with MERS-CoV with low inoculum doses, virus particles are not detected in the lung but only in the brain, which indicates that the CNS infection is relevant for the high mortality of the disease [108].", [["lung", "ANATOMY", 169, 173], ["brain", "ANATOMY", 190, 195], ["CNS", "ANATOMY", 222, 225], ["infection", "DISEASE", 226, 235], ["mice", "ORGANISM", 76, 80], ["MERS-CoV", "ORGANISM", 95, 103], ["lung", "ORGAN", 169, 173], ["brain", "ORGAN", 190, 195], ["CNS", "ANATOMICAL_SYSTEM", 222, 225], ["mice", "SPECIES", 76, 80], ["mice", "SPECIES", 76, 80], ["MERS-CoV", "SPECIES", 95, 103], ["MERS", "PROBLEM", 95, 99], ["low inoculum doses", "TREATMENT", 109, 127], ["virus particles", "PROBLEM", 129, 144], ["the CNS infection", "PROBLEM", 218, 235], ["the disease", "PROBLEM", 274, 285], ["lung", "ANATOMY", 169, 173], ["brain", "ANATOMY", 190, 195], ["CNS", "ANATOMY", 222, 225], ["infection", "OBSERVATION", 226, 235]]], ["However, although murine models develop CNS infection, MERS-CoV has never been detected in the human CNS, thus suggesting a different disease model [109].5.2.", [["CNS", "ANATOMY", 40, 43], ["CNS", "ANATOMY", 101, 104], ["CNS infection", "DISEASE", 40, 53], ["murine", "ORGANISM", 18, 24], ["CNS", "ANATOMICAL_SYSTEM", 40, 43], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 55, 63], ["human", "ORGANISM", 95, 100], ["CNS", "ANATOMICAL_SYSTEM", 101, 104], ["MERS-CoV", "PROTEIN", 55, 63], ["murine", "SPECIES", 18, 24], ["human", "SPECIES", 95, 100], ["MERS-CoV", "SPECIES", 55, 63], ["human", "SPECIES", 95, 100], ["CNS infection", "PROBLEM", 40, 53], ["MERS-CoV", "PROBLEM", 55, 63], ["a different disease model", "PROBLEM", 122, 147], ["CNS", "ANATOMY", 40, 43], ["infection", "OBSERVATION", 44, 53]]], ["Proposed Neuropathogenic MechanismsViruses are present in the brain of patients with SARS-CoVs [49].", [["brain", "ANATOMY", 62, 67], ["SARS-CoVs", "DISEASE", 85, 94], ["brain", "ORGAN", 62, 67], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["Proposed Neuropathogenic MechanismsViruses", "PROBLEM", 0, 42], ["SARS", "PROBLEM", 85, 89], ["Neuropathogenic", "OBSERVATION_MODIFIER", 9, 24], ["MechanismsViruses", "OBSERVATION", 25, 42], ["brain", "ANATOMY", 62, 67]]], ["Baig et al. [24] have recently suggested a putative transcribral SARS-CoV-2 route to the brain and the presence of its RNA in the CSF would be the conclusive evidence to support the COVID-19 neurovirulence.", [["brain", "ANATOMY", 89, 94], ["CoV-2", "GENE_OR_GENE_PRODUCT", 70, 75], ["brain", "ORGAN", 89, 94], ["CSF", "GENE_OR_GENE_PRODUCT", 130, 133], ["CSF", "PROTEIN", 130, 133], ["a putative transcribral SARS", "TEST", 41, 69], ["CoV", "TEST", 70, 73], ["its RNA in the CSF", "PROBLEM", 115, 133], ["the COVID", "TEST", 178, 187], ["neurovirulence", "PROBLEM", 191, 205], ["brain", "ANATOMY", 89, 94], ["RNA", "OBSERVATION", 119, 122]]], ["However, the pathomechanisms underlying the CNS invasion seem to be more complex.5.2.", [["CNS", "ANATOMY", 44, 47], ["CNS", "ANATOMICAL_SYSTEM", 44, 47], ["the pathomechanisms", "PROBLEM", 9, 28], ["the CNS invasion", "PROBLEM", 40, 56], ["CNS", "ANATOMY", 44, 47], ["invasion", "OBSERVATION", 48, 56]]], ["Proposed Neuropathogenic MechanismsA CNS invasion can occur in both the initial and late phases of SARS-CoV-2 infection [24].", [["CNS", "ANATOMY", 37, 40], ["SARS", "DISEASE", 99, 103], ["infection", "DISEASE", 110, 119], ["SARS-CoV-2", "ORGANISM", 99, 109], ["SARS-CoV-2", "SPECIES", 99, 109], ["Proposed Neuropathogenic MechanismsA CNS invasion", "PROBLEM", 0, 49], ["SARS", "PROBLEM", 99, 103], ["CoV-2 infection", "PROBLEM", 104, 119], ["CNS", "ANATOMY", 37, 40], ["invasion", "OBSERVATION", 41, 49]]], ["However, research is yet to determine the exact route for the entrance of the virus into the brain.", [["brain", "ANATOMY", 93, 98], ["brain", "ORGAN", 93, 98], ["virus", "OBSERVATION", 78, 83], ["brain", "ANATOMY", 93, 98]]], ["A direct entry along the olfactory nerve can be considered among the potential mechanisms.", [["olfactory nerve", "ANATOMY", 25, 40], ["olfactory nerve", "MULTI-TISSUE_STRUCTURE", 25, 40], ["olfactory nerve", "ANATOMY", 25, 40]]], ["In particular, the nasal olfactory epithelium is the probable site of enhanced binding of SARS-CoV-2.", [["nasal olfactory epithelium", "ANATOMY", 19, 45], ["SARS", "DISEASE", 90, 94], ["nasal olfactory epithelium", "TISSUE", 19, 45], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 90, 100], ["nasal olfactory epithelium", "ANATOMY", 19, 45], ["probable", "UNCERTAINTY", 53, 61], ["enhanced binding", "OBSERVATION", 70, 86], ["SARS", "OBSERVATION", 90, 94]]], ["Multiple non-neuronal cell types within the olfactory epithelium express two host receptors, ACE2 and transmembrane protease serine 2 (TMPRSS2), that facilitate SARS-CoV-2 binding, replication, and accumulation.", [["non-neuronal cell", "ANATOMY", 9, 26], ["olfactory epithelium", "ANATOMY", 44, 64], ["serine", "CHEMICAL", 125, 131], ["non-neuronal cell", "CELL", 9, 26], ["olfactory epithelium", "TISSUE", 44, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 102, 133], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 135, 142], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 161, 171], ["non-neuronal cell types", "CELL_TYPE", 9, 32], ["host receptors", "PROTEIN", 77, 91], ["ACE2", "PROTEIN", 93, 97], ["transmembrane protease serine 2", "PROTEIN", 102, 133], ["TMPRSS2", "PROTEIN", 135, 142], ["Multiple non-neuronal cell types", "PROBLEM", 0, 32], ["ACE2", "TEST", 93, 97], ["transmembrane protease serine", "TREATMENT", 102, 131], ["TMPRSS2", "TEST", 135, 142], ["non-neuronal cell types", "OBSERVATION", 9, 32], ["olfactory", "ANATOMY_MODIFIER", 44, 53], ["epithelium", "ANATOMY_MODIFIER", 54, 64]]], ["Moreover, a subsequent brain infection beginning from the olfactory neurons might be considered, as well as the possibility that ORNs may initiate a rapid immune response at the early stages of the disease [110].", [["brain", "ANATOMY", 23, 28], ["olfactory neurons", "ANATOMY", 58, 75], ["ORNs", "ANATOMY", 129, 133], ["brain infection", "DISEASE", 23, 38], ["brain", "ORGAN", 23, 28], ["olfactory neurons", "CELL", 58, 75], ["ORNs", "CELL", 129, 133], ["olfactory neurons", "CELL_TYPE", 58, 75], ["a subsequent brain infection", "PROBLEM", 10, 38], ["a rapid immune response", "PROBLEM", 147, 170], ["the disease", "PROBLEM", 194, 205], ["brain", "ANATOMY", 23, 28], ["infection", "OBSERVATION", 29, 38]]], ["Using a mouse model, Bilinska et al. [111] determined whether cells in the olfactory epithelium expressed the receptors allowing the entry of the SARS-CoV-2 virus.", [["cells", "ANATOMY", 62, 67], ["olfactory epithelium", "ANATOMY", 75, 95], ["mouse", "ORGANISM", 8, 13], ["cells", "CELL", 62, 67], ["olfactory epithelium", "TISSUE", 75, 95], ["SARS-CoV-2 virus", "ORGANISM", 146, 162], ["mouse", "SPECIES", 8, 13], ["CoV-2 virus", "SPECIES", 151, 162], ["mouse", "SPECIES", 8, 13], ["SARS-CoV-2 virus", "SPECIES", 146, 162], ["a mouse model", "TREATMENT", 6, 19], ["the SARS", "PROBLEM", 142, 150], ["CoV", "TEST", 151, 154], ["olfactory epithelium", "ANATOMY", 75, 95]]], ["They showed that ACE2 and TMPRSS2 were expressed in the SUSs of the olfactory epithelium but not, or much less, in most olfactory receptor neurons, suggesting that SUSs are involved in SARS-CoV-2 virus entry and smell impairment.", [["SUSs", "ANATOMY", 56, 60], ["olfactory epithelium", "ANATOMY", 68, 88], ["olfactory receptor neurons", "ANATOMY", 120, 146], ["SUSs", "ANATOMY", 164, 168], ["smell impairment", "DISEASE", 212, 228], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 26, 33], ["SUSs", "CANCER", 56, 60], ["olfactory epithelium", "TISSUE", 68, 88], ["olfactory receptor neurons", "CELL", 120, 146], ["SUSs", "GENE_OR_GENE_PRODUCT", 164, 168], ["SARS-CoV-2 virus", "ORGANISM", 185, 201], ["ACE2", "PROTEIN", 17, 21], ["TMPRSS2", "PROTEIN", 26, 33], ["olfactory receptor neurons", "CELL_TYPE", 120, 146], ["SUSs", "PROTEIN", 164, 168], ["SARS-CoV-2 virus", "SPECIES", 185, 201], ["ACE2", "TEST", 17, 21], ["TMPRSS2", "TEST", 26, 33], ["SUSs", "TEST", 164, 168], ["SARS", "PROBLEM", 185, 189], ["CoV", "TEST", 190, 193], ["smell impairment", "PROBLEM", 212, 228], ["olfactory epithelium", "ANATOMY", 68, 88], ["smell impairment", "OBSERVATION", 212, 228]]], ["Moreover, the expression of the entry proteins increased in older animals, thus possibly explaining, if verified also in humans, why older individuals are more susceptible to SARS-CoV-2 infection [111].5.2.", [["SARS", "DISEASE", 175, 179], ["infection", "DISEASE", 186, 195], ["humans", "ORGANISM", 121, 127], ["individuals", "ORGANISM", 139, 150], ["SARS-CoV-2", "ORGANISM", 175, 185], ["entry proteins", "PROTEIN", 32, 46], ["humans", "SPECIES", 121, 127], ["humans", "SPECIES", 121, 127], ["SARS-CoV", "SPECIES", 175, 183], ["the entry proteins", "PROBLEM", 28, 46], ["SARS", "PROBLEM", 175, 179], ["CoV-2 infection", "PROBLEM", 180, 195], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["possibly explaining", "UNCERTAINTY", 80, 99]]], ["Proposed Neuropathogenic MechanismsTranslationally, these preliminary findings suggest that damage to the olfactory epithelium may not only underlie clinical anosmia but also represent a preferential gate to the brain.", [["olfactory epithelium", "ANATOMY", 106, 126], ["brain", "ANATOMY", 212, 217], ["anosmia", "DISEASE", 158, 165], ["olfactory epithelium", "TISSUE", 106, 126], ["brain", "ORGAN", 212, 217], ["damage to the olfactory epithelium", "PROBLEM", 92, 126], ["clinical anosmia", "PROBLEM", 149, 165], ["a preferential gate to the brain", "PROBLEM", 185, 217], ["olfactory epithelium", "ANATOMY", 106, 126], ["may not only", "UNCERTAINTY", 127, 139], ["preferential gate", "OBSERVATION", 187, 204], ["brain", "ANATOMY", 212, 217]]], ["Namely, SARS-CoV-2 might spread via the transcribral route from the olfactory epithelium along the olfactory nerve to the olfactory bulb within the CNS or spread retrogradely via transsynaptic transfer using an endocytosis or exocytosis mechanism and a fast axonal transport mechanism of vesicle transport moving the virus along microtubules back to neuronal cell bodies [78].", [["olfactory epithelium", "ANATOMY", 68, 88], ["olfactory nerve", "ANATOMY", 99, 114], ["olfactory bulb", "ANATOMY", 122, 136], ["CNS", "ANATOMY", 148, 151], ["axonal", "ANATOMY", 258, 264], ["vesicle", "ANATOMY", 288, 295], ["microtubules", "ANATOMY", 329, 341], ["neuronal cell bodies", "ANATOMY", 350, 370], ["SARS", "DISEASE", 8, 12], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 8, 18], ["olfactory epithelium", "TISSUE", 68, 88], ["olfactory nerve", "MULTI-TISSUE_STRUCTURE", 99, 114], ["olfactory bulb", "ORGAN", 122, 136], ["CNS", "ANATOMICAL_SYSTEM", 148, 151], ["retrogradely", "IMMATERIAL_ANATOMICAL_ENTITY", 162, 174], ["vesicle", "CELLULAR_COMPONENT", 288, 295], ["microtubules", "CELLULAR_COMPONENT", 329, 341], ["neuronal cell bodies", "CELLULAR_COMPONENT", 350, 370], ["SARS-CoV", "SPECIES", 8, 16], ["SARS", "TEST", 8, 12], ["an endocytosis", "PROBLEM", 208, 222], ["exocytosis mechanism", "PROBLEM", 226, 246], ["vesicle transport", "PROBLEM", 288, 305], ["the virus", "PROBLEM", 313, 322], ["olfactory", "ANATOMY_MODIFIER", 68, 77], ["epithelium", "ANATOMY_MODIFIER", 78, 88], ["olfactory nerve", "ANATOMY", 99, 114], ["olfactory bulb", "ANATOMY", 122, 136], ["CNS", "ANATOMY", 148, 151], ["virus", "OBSERVATION", 317, 322], ["neuronal cell", "OBSERVATION", 350, 363], ["bodies", "ANATOMY_MODIFIER", 364, 370]]], ["Additionally, another possible transsynaptic route from the nasal respiratory epithelium to the brain via the trigeminal nerve branch has recently been hypothesized, although replication of the findings is needed [112].5.2.", [["nasal respiratory epithelium", "ANATOMY", 60, 88], ["brain", "ANATOMY", 96, 101], ["trigeminal nerve branch", "ANATOMY", 110, 133], ["nasal respiratory epithelium", "TISSUE", 60, 88], ["brain", "ORGAN", 96, 101], ["trigeminal nerve", "MULTI-TISSUE_STRUCTURE", 110, 126], ["nasal", "ANATOMY", 60, 65], ["respiratory epithelium", "OBSERVATION", 66, 88], ["brain", "ANATOMY", 96, 101], ["trigeminal nerve", "ANATOMY", 110, 126], ["branch", "ANATOMY_MODIFIER", 127, 133]]], ["Proposed Neuropathogenic MechanismsThe biological plausibility of the retrograde transsynaptic pathway from the peripheral nerve endings is based on the evidence that some CoVs appear to be capable of penetrating the CNS through the cribriform plate of the ethmoid bone, even if the olfactory bulb is efficient enough to control viral invasion [113].", [["peripheral nerve endings", "ANATOMY", 112, 136], ["CNS", "ANATOMY", 217, 220], ["cribriform plate", "ANATOMY", 233, 249], ["ethmoid bone", "ANATOMY", 257, 269], ["olfactory bulb", "ANATOMY", 283, 297], ["peripheral nerve endings", "MULTI-TISSUE_STRUCTURE", 112, 136], ["CoVs", "GENE_OR_GENE_PRODUCT", 172, 176], ["CNS", "ANATOMICAL_SYSTEM", 217, 220], ["cribriform plate", "TISSUE", 233, 249], ["ethmoid bone", "MULTI-TISSUE_STRUCTURE", 257, 269], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 283, 297], ["CoVs", "PROTEIN", 172, 176], ["the peripheral nerve endings", "PROBLEM", 108, 136], ["some CoVs", "PROBLEM", 167, 176], ["the olfactory bulb", "PROBLEM", 279, 297], ["viral invasion", "PROBLEM", 329, 343], ["peripheral", "ANATOMY_MODIFIER", 112, 122], ["nerve", "ANATOMY", 123, 128], ["penetrating", "OBSERVATION", 201, 212], ["CNS", "ANATOMY", 217, 220], ["cribriform", "ANATOMY_MODIFIER", 233, 243], ["plate", "ANATOMY_MODIFIER", 244, 249], ["ethmoid bone", "ANATOMY", 257, 269], ["olfactory bulb", "ANATOMY", 283, 297]]], ["According to Li et al. [113], mechanoreceptors and chemoreceptors in the lung and respiratory tract can act as a possible retrograde pathway for SARS-CoV-2, as the nucleus of the solitary tract receives sensory information from these anatomical structures.", [["lung", "ANATOMY", 73, 77], ["respiratory tract", "ANATOMY", 82, 99], ["nucleus", "ANATOMY", 164, 171], ["solitary tract", "ANATOMY", 179, 193], ["Li", "CHEMICAL", 13, 15], ["lung", "ORGAN", 73, 77], ["respiratory tract", "ORGANISM_SUBDIVISION", 82, 99], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 145, 155], ["nucleus", "CELLULAR_COMPONENT", 164, 171], ["solitary tract", "ORGAN", 179, 193], ["anatomical structures", "MULTI-TISSUE_STRUCTURE", 234, 255], ["mechanoreceptors and chemoreceptors in the lung and respiratory tract", "PROBLEM", 30, 99], ["SARS", "PROBLEM", 145, 149], ["CoV", "TEST", 150, 153], ["lung", "ANATOMY", 73, 77], ["respiratory tract", "ANATOMY", 82, 99], ["nucleus", "ANATOMY_MODIFIER", 164, 171], ["solitary tract", "ANATOMY", 179, 193]]], ["Indeed, a dysfunction of the cardiac-respiratory control centers in the medulla oblongata would aggravate the symptoms till death [113].5.2.", [["cardiac", "ANATOMY", 29, 36], ["medulla oblongata", "ANATOMY", 72, 89], ["death", "DISEASE", 124, 129], ["cardiac", "ORGAN", 29, 36], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 72, 89], ["a dysfunction of the cardiac-respiratory control centers in the medulla oblongata", "PROBLEM", 8, 89], ["the symptoms", "PROBLEM", 106, 118], ["dysfunction", "OBSERVATION", 10, 21], ["cardiac", "ANATOMY", 29, 36], ["respiratory control", "OBSERVATION", 37, 56], ["medulla oblongata", "ANATOMY", 72, 89]]], ["Proposed Neuropathogenic MechanismsHowever, the neurogenic hypothesis of respiratory failure is not supported by other researchers [114], as they argue that patients with COVID-19 pneumonia do develop hypoxia and low CO2 levels accompanied by increased respiratory rate.", [["respiratory", "ANATOMY", 73, 84], ["respiratory", "ANATOMY", 253, 264], ["respiratory failure", "DISEASE", 73, 92], ["pneumonia", "DISEASE", 180, 189], ["hypoxia", "DISEASE", 201, 208], ["CO2", "CHEMICAL", 217, 220], ["CO2", "CHEMICAL", 217, 220], ["patients", "ORGANISM", 157, 165], ["CO2", "SIMPLE_CHEMICAL", 217, 220], ["patients", "SPECIES", 157, 165], ["the neurogenic hypothesis", "PROBLEM", 44, 69], ["respiratory failure", "PROBLEM", 73, 92], ["COVID-19 pneumonia", "PROBLEM", 171, 189], ["hypoxia", "PROBLEM", 201, 208], ["low CO2 levels", "PROBLEM", 213, 227], ["increased respiratory rate", "PROBLEM", 243, 269], ["respiratory failure", "OBSERVATION", 73, 92], ["pneumonia", "OBSERVATION", 180, 189], ["hypoxia", "OBSERVATION", 201, 208], ["low CO2", "OBSERVATION", 213, 220], ["increased", "OBSERVATION_MODIFIER", 243, 252], ["respiratory rate", "OBSERVATION", 253, 269]]], ["While these patients can breathe spontaneously, they do it with great effort; thus, a respiratory failure resulting from a neurological origin would be characterized by a reduced respiratory rate, low oxygen levels, and high CO2 levels [114].", [["respiratory", "ANATOMY", 86, 97], ["neurological", "ANATOMY", 123, 135], ["respiratory", "ANATOMY", 179, 190], ["respiratory failure", "DISEASE", 86, 105], ["oxygen", "CHEMICAL", 201, 207], ["CO2", "CHEMICAL", 225, 228], ["oxygen", "CHEMICAL", 201, 207], ["CO2", "CHEMICAL", 225, 228], ["patients", "ORGANISM", 12, 20], ["oxygen", "SIMPLE_CHEMICAL", 201, 207], ["CO2", "SIMPLE_CHEMICAL", 225, 228], ["patients", "SPECIES", 12, 20], ["a respiratory failure", "PROBLEM", 84, 105], ["a reduced respiratory rate", "PROBLEM", 169, 195], ["low oxygen levels", "PROBLEM", 197, 214], ["high CO2 levels", "PROBLEM", 220, 235], ["respiratory failure", "OBSERVATION", 86, 105], ["reduced", "OBSERVATION_MODIFIER", 171, 178], ["respiratory rate", "OBSERVATION", 179, 195]]], ["Further virologic, histopathological, and immunohistochemical studies are necessary to demonstrate a specific neurotropism of SARS-CoV-2 for the brain respiratory control centers.5.2.", [["brain", "ANATOMY", 145, 150], ["SARS", "DISEASE", 126, 130], ["SARS-CoV-2", "ORGANISM", 126, 136], ["brain", "ORGAN", 145, 150], ["Further virologic", "TEST", 0, 17], ["immunohistochemical studies", "TEST", 42, 69], ["CoV", "TEST", 131, 134], ["the brain respiratory control centers", "TREATMENT", 141, 178], ["brain", "ANATOMY", 145, 150], ["respiratory control", "OBSERVATION", 151, 170]]], ["Proposed Neuropathogenic MechanismsThe hypotheses behind SARS-CoV-2 transsynaptic propagation are further corroborated by other studies demonstrating that the virus may use a transsynaptic route for infecting the CNS.", [["CNS", "ANATOMY", 213, 216], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["CNS", "ANATOMICAL_SYSTEM", 213, 216], ["SARS", "PROBLEM", 57, 61], ["CoV", "PROBLEM", 62, 65], ["2 transsynaptic propagation", "PROBLEM", 66, 93], ["other studies", "TEST", 122, 135], ["the virus", "PROBLEM", 155, 164], ["a transsynaptic route", "TREATMENT", 173, 194], ["CNS", "ANATOMY", 213, 216]]], ["One of the first pieces of evidence was provided in 1986 by Gosztonyi [115], who described the axonal transport of viral nucleic acid of some neurotropic viruses.", [["axonal", "ANATOMY", 95, 101], ["nucleic acid", "CHEMICAL", 121, 133], ["neurotropic viruses", "ORGANISM", 142, 161], ["viral nucleic acid", "PROBLEM", 115, 133], ["some neurotropic viruses", "PROBLEM", 137, 161], ["viral nucleic acid", "OBSERVATION", 115, 133], ["neurotropic viruses", "OBSERVATION", 142, 161]]], ["In particular, he described that the rabies virus (RV) could be transmitted to other neurons by transsynaptic passage, without involving the complete virus replication, thus reaching various brain areas.", [["neurons", "ANATOMY", 85, 92], ["brain areas", "ANATOMY", 191, 202], ["rabies virus", "ORGANISM", 37, 49], ["neurons", "CELL", 85, 92], ["brain", "ORGAN", 191, 196], ["rabies virus", "SPECIES", 37, 49], ["rabies virus", "SPECIES", 37, 49], ["RV", "SPECIES", 51, 53], ["the rabies virus", "PROBLEM", 33, 49], ["the complete virus replication", "PROBLEM", 137, 167], ["virus", "OBSERVATION", 150, 155], ["brain", "ANATOMY", 191, 196]]], ["Li et al. [105] demonstrated that HEV was able to propagate into CNS via transsynaptic routes.", [["CNS", "ANATOMY", 65, 68], ["HEV", "ORGANISM", 34, 37], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["HEV", "SPECIES", 34, 37]]], ["Namely, the peripheral inoculation of HEV in both piglets and rodents results in encephalomyelitis via the primary motor cortex, where membranous-coating-mediated endo-/exocytosis events favor the HEV transsynaptic transfer.", [["primary motor cortex", "ANATOMY", 107, 127], ["encephalomyelitis", "DISEASE", 81, 98], ["HEV", "ORGANISM", 38, 41], ["piglets", "ORGANISM", 50, 57], ["motor cortex", "CANCER", 115, 127], ["HEV", "ORGANISM", 197, 200], ["piglets", "SPECIES", 50, 57], ["HEV", "SPECIES", 38, 41], ["HEV", "SPECIES", 197, 200], ["HEV", "PROBLEM", 38, 41], ["encephalomyelitis", "PROBLEM", 81, 98], ["exocytosis events", "PROBLEM", 169, 186], ["the HEV transsynaptic transfer", "TREATMENT", 193, 223], ["peripheral", "ANATOMY_MODIFIER", 12, 22], ["inoculation", "OBSERVATION", 23, 34], ["HEV", "OBSERVATION", 38, 41], ["encephalomyelitis", "OBSERVATION", 81, 98], ["motor cortex", "ANATOMY", 115, 127]]], ["In a recent review, Taylor and Enquist [116] deeply described the axonal route of propagation of several neuroinvasive viruses, including herpes simplex, varicella-zoster, pseudorabies, Rhabdoviridae (including RV), Flaviviridae, vesicular stomatitis (VSV), and Theiler\u2019s murine encephalitis virus (belonging to the Picornaviridae).", [["axonal", "ANATOMY", 66, 72], ["vesicular", "ANATOMY", 230, 239], ["herpes simplex", "DISEASE", 138, 152], ["varicella-zoster, pseudorabies, Rhabdoviridae (including RV), Flaviviridae", "DISEASE", 154, 228], ["vesicular stomatitis", "DISEASE", 230, 250], ["Theiler\u2019s murine encephalitis", "DISEASE", 262, 291], ["herpes simplex", "ORGANISM", 138, 152], ["varicella-zoster", "ORGANISM", 154, 170], ["pseudorabies", "ORGANISM", 172, 184], ["Rhabdoviridae", "CANCER", 186, 199], ["vesicular stomatitis", "ORGANISM", 230, 250], ["VSV", "ORGANISM", 252, 255], ["Theiler\u2019s murine encephalitis virus", "ORGANISM", 262, 297], ["herpes simplex", "SPECIES", 138, 152], ["varicella-zoster", "SPECIES", 154, 170], ["pseudorabies", "SPECIES", 172, 184], ["Theiler\u2019s", "SPECIES", 262, 271], ["murine encephalitis virus", "SPECIES", 272, 297], ["pseudorabies", "SPECIES", 172, 184], ["RV", "SPECIES", 211, 213], ["VSV", "SPECIES", 252, 255], ["Theiler\u2019s murine encephalitis virus", "SPECIES", 262, 297], ["several neuroinvasive viruses", "PROBLEM", 97, 126], ["herpes simplex", "PROBLEM", 138, 152], ["varicella", "PROBLEM", 154, 163], ["zoster", "PROBLEM", 164, 170], ["pseudorabies", "PROBLEM", 172, 184], ["Rhabdoviridae", "TREATMENT", 186, 199], ["RV)", "TREATMENT", 211, 214], ["Flaviviridae", "TREATMENT", 216, 228], ["vesicular stomatitis", "PROBLEM", 230, 250], ["Theiler\u2019s murine encephalitis virus", "TREATMENT", 262, 297], ["neuroinvasive viruses", "OBSERVATION", 105, 126], ["vesicular stomatitis", "OBSERVATION", 230, 250]]], ["They also described the mechanisms by which viruses were able to move in and out axons, both anterogradely or retrogradely, thanks to coupled or separate transports (mediated by vesicles or not, respectively) [116].5.2.", [["axons", "ANATOMY", 81, 86], ["vesicles", "ANATOMY", 178, 186], ["axons", "MULTI-TISSUE_STRUCTURE", 81, 86], ["vesicles", "CELLULAR_COMPONENT", 178, 186]]], ["Proposed Neuropathogenic MechanismsThe anterograde and retrograde transsynaptic propagation lead researchers to adopt this viral feature for mapping the axon transports of neuronal impulses, viruses, and other factors.", [["axon", "ANATOMY", 153, 157], ["neuronal", "ANATOMY", 172, 180], ["axon", "MULTI-TISSUE_STRUCTURE", 153, 157], ["neuronal", "CELL", 172, 180], ["neuronal impulses", "PROBLEM", 172, 189], ["viruses", "PROBLEM", 191, 198], ["neuronal impulses", "OBSERVATION", 172, 189]]], ["In this context, the transsynaptic transport of VSV has been used for tracing and mapping neuronal circuits by using specific virus-labeling techniques [117,118].", [["neuronal", "ANATOMY", 90, 98], ["VSV", "ORGANISM", 48, 51], ["neuronal", "CELL", 90, 98], ["VSV", "SPECIES", 48, 51], ["VSV", "TREATMENT", 48, 51], ["tracing", "TEST", 70, 77], ["mapping neuronal circuits", "TREATMENT", 82, 107]]], ["Of note, transsynaptic propagation is not a prerogative of CNS viruses.", [["CNS", "ANATOMY", 59, 62], ["CNS viruses", "ORGANISM", 59, 70], ["transsynaptic propagation", "PROBLEM", 9, 34], ["CNS viruses", "PROBLEM", 59, 70], ["CNS", "ANATOMY", 59, 62], ["viruses", "OBSERVATION", 63, 70]]], ["For instance, the measles virus (MV) can reach the CNS and cause subacute sclerosing panencephalitis, which is often fatal.", [["CNS", "ANATOMY", 51, 54], ["panencephalitis", "DISEASE", 85, 100], ["measles virus", "ORGANISM", 18, 31], ["CNS", "ANATOMICAL_SYSTEM", 51, 54], ["measles virus", "SPECIES", 18, 31], ["measles virus", "SPECIES", 18, 31], ["MV", "SPECIES", 33, 35], ["the measles virus", "PROBLEM", 14, 31], ["subacute sclerosing panencephalitis", "PROBLEM", 65, 100], ["CNS", "ANATOMY", 51, 54], ["subacute", "OBSERVATION_MODIFIER", 65, 73], ["sclerosing", "OBSERVATION_MODIFIER", 74, 84], ["panencephalitis", "OBSERVATION", 85, 100]]], ["The CNS complications of MV infection are known to be the results of transsynaptic viral propagation thanks to the binding between MV envelope F protein and several host proteins, including hemagglutinin and neurokinin-1 [119].5.2.", [["CNS", "ANATOMY", 4, 7], ["MV infection", "DISEASE", 25, 37], ["CNS", "ANATOMICAL_SYSTEM", 4, 7], ["MV envelope F", "GENE_OR_GENE_PRODUCT", 131, 144], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 190, 203], ["neurokinin-1", "GENE_OR_GENE_PRODUCT", 208, 220], ["MV envelope F protein", "PROTEIN", 131, 152], ["host proteins", "PROTEIN", 165, 178], ["hemagglutinin", "PROTEIN", 190, 203], ["neurokinin-1 [119].5.2", "PROTEIN", 208, 230], ["MV", "SPECIES", 25, 27], ["MV", "SPECIES", 131, 133], ["MV infection", "PROBLEM", 25, 37], ["transsynaptic viral propagation", "PROBLEM", 69, 100], ["MV envelope F protein", "TEST", 131, 152], ["several host proteins", "PROBLEM", 157, 178], ["hemagglutinin", "TEST", 190, 203], ["neurokinin-", "TEST", 208, 219], ["CNS", "ANATOMY", 4, 7], ["complications", "OBSERVATION", 8, 21], ["MV infection", "OBSERVATION", 25, 37]]], ["Proposed Neuropathogenic MechanismsTaken together, these observations support the concept that some viruses, including respiratory viruses like the SARS-CoV-2, may propagate through the CNS via a transsynaptic transport.5.3.", [["CNS", "ANATOMY", 186, 189], ["respiratory viruses", "DISEASE", 119, 138], ["respiratory viruses", "ORGANISM", 119, 138], ["SARS-CoV-2", "ORGANISM", 148, 158], ["CNS", "ANATOMICAL_SYSTEM", 186, 189], ["SARS-CoV", "SPECIES", 148, 156], ["some viruses", "PROBLEM", 95, 107], ["respiratory viruses", "PROBLEM", 119, 138], ["a transsynaptic transport", "TREATMENT", 194, 219], ["viruses", "OBSERVATION", 100, 107]]], ["The Role of Angiotensin II Converting Enzyme Receptor ::: 5.", [["Angiotensin II", "CHEMICAL", 12, 26], ["Angiotensin II Converting Enzyme Receptor", "GENE_OR_GENE_PRODUCT", 12, 53], ["Angiotensin II Converting Enzyme Receptor", "PROTEIN", 12, 53]]], ["Proposed Neuropathogenic MechanismsThe cell invasion of SARS-CoV-2 and its rapid replication seem to be supported by the ACE2 receptor [120].", [["cell", "ANATOMY", 39, 43], ["SARS", "DISEASE", 56, 60], ["cell", "CELL", 39, 43], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 56, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 121, 125], ["ACE2 receptor", "PROTEIN", 121, 134], ["SARS-CoV", "SPECIES", 56, 64], ["SARS", "PROBLEM", 56, 60], ["CoV", "TEST", 61, 64], ["its rapid replication", "TREATMENT", 71, 92], ["cell", "OBSERVATION_MODIFIER", 39, 43], ["invasion", "OBSERVATION_MODIFIER", 44, 52]]], ["The damaging effects of angiotensin II may be enhanced because of the depletion of the ACE2 receptor on the cell membrane, which leads to an acute deterioration in lung function.", [["cell membrane", "ANATOMY", 108, 121], ["lung", "ANATOMY", 164, 168], ["angiotensin II", "CHEMICAL", 24, 38], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 24, 38], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 87, 100], ["cell membrane", "CELLULAR_COMPONENT", 108, 121], ["lung", "ORGAN", 164, 168], ["angiotensin II", "PROTEIN", 24, 38], ["ACE2 receptor", "PROTEIN", 87, 100], ["angiotensin II", "PROBLEM", 24, 38], ["an acute deterioration in lung function", "PROBLEM", 138, 177], ["angiotensin", "OBSERVATION", 24, 35], ["depletion", "OBSERVATION", 70, 79], ["cell membrane", "OBSERVATION", 108, 121], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["deterioration", "OBSERVATION", 147, 160], ["lung", "ANATOMY", 164, 168], ["function", "OBSERVATION", 169, 177]]], ["Therefore, the down-regulation of the ACE2 receptor could put the hypertensive and diabetic population at higher risk for COVID-19 due to the increase in angiotensin II.", [["hypertensive", "DISEASE", 66, 78], ["diabetic", "DISEASE", 83, 91], ["angiotensin II", "CHEMICAL", 154, 168], ["COVID-19", "CHEMICAL", 122, 130], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 38, 51], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 154, 168], ["ACE2 receptor", "PROTEIN", 38, 51], ["angiotensin II", "PROTEIN", 154, 168], ["the ACE2 receptor", "TREATMENT", 34, 51], ["the hypertensive and diabetic population", "PROBLEM", 62, 102], ["COVID", "TEST", 122, 127], ["the increase in angiotensin II", "PROBLEM", 138, 168], ["hypertensive", "OBSERVATION_MODIFIER", 66, 78], ["diabetic", "OBSERVATION", 83, 91], ["increase", "OBSERVATION_MODIFIER", 142, 150], ["angiotensin II", "OBSERVATION", 154, 168]]], ["A hypothesis related to this issue is that ACE inhibitors, when used in patients with COVID-19, can lead to an increased expression of ACE2, thus probably making the cells more vulnerable to SARS-CoV-2 infection [120].", [["cells", "ANATOMY", 166, 171], ["COVID-19", "CHEMICAL", 86, 94], ["SARS", "DISEASE", 191, 195], ["infection", "DISEASE", 202, 211], ["COVID-19", "CHEMICAL", 86, 94], ["ACE", "GENE_OR_GENE_PRODUCT", 43, 46], ["patients", "ORGANISM", 72, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["cells", "CELL", 166, 171], ["SARS-CoV-2", "ORGANISM", 191, 201], ["ACE2", "PROTEIN", 135, 139], ["patients", "SPECIES", 72, 80], ["A hypothesis", "PROBLEM", 0, 12], ["ACE inhibitors", "TREATMENT", 43, 57], ["COVID", "TEST", 86, 91], ["an increased expression of ACE2", "PROBLEM", 108, 139], ["the cells", "PROBLEM", 162, 171], ["SARS", "PROBLEM", 191, 195], ["CoV-2 infection", "PROBLEM", 196, 211]]], ["A study examining the risk factors for mortality in patients with COVID-19 found that 40% of the deceased people presented single or multiple comorbidities, with high blood pressure being the most common (30%) [121].5.3.", [["blood", "ANATOMY", 167, 172], ["patients", "ORGANISM", 52, 60], ["people", "ORGANISM", 106, 112], ["blood", "ORGANISM_SUBSTANCE", 167, 172], ["patients", "SPECIES", 52, 60], ["people", "SPECIES", 106, 112], ["A study", "TEST", 0, 7], ["COVID", "TEST", 66, 71], ["multiple comorbidities", "PROBLEM", 133, 155], ["high blood pressure", "PROBLEM", 162, 181], ["multiple", "OBSERVATION_MODIFIER", 133, 141], ["comorbidities", "OBSERVATION", 142, 155]]], ["The Role of Angiotensin II Converting Enzyme Receptor ::: 5.", [["Angiotensin II", "CHEMICAL", 12, 26], ["Angiotensin II Converting Enzyme Receptor", "GENE_OR_GENE_PRODUCT", 12, 53], ["Angiotensin II Converting Enzyme Receptor", "PROTEIN", 12, 53]]], ["Proposed Neuropathogenic MechanismsThe neurovirulence of SARS-CoV-2 could be related to the degree of expression of the ACE receptor in the CNS, although this receptor is expressed in endothelial cells, so it is necessary to further investigate its role in the etiopathogenesis of some neurological complications, such as stroke [23].", [["CNS", "ANATOMY", 140, 143], ["endothelial cells", "ANATOMY", 184, 201], ["neurological", "ANATOMY", 286, 298], ["SARS", "DISEASE", 57, 61], ["neurological complications", "DISEASE", 286, 312], ["stroke", "DISEASE", 322, 328], ["SARS-CoV-2", "ORGANISM", 57, 67], ["ACE receptor", "GENE_OR_GENE_PRODUCT", 120, 132], ["CNS", "ANATOMICAL_SYSTEM", 140, 143], ["endothelial cells", "CELL", 184, 201], ["ACE receptor", "PROTEIN", 120, 132], ["endothelial cells", "CELL_TYPE", 184, 201], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "PROBLEM", 57, 61], ["the ACE receptor", "TREATMENT", 116, 132], ["some neurological complications", "PROBLEM", 281, 312], ["stroke", "PROBLEM", 322, 328], ["neurovirulence", "OBSERVATION_MODIFIER", 39, 53], ["SARS", "OBSERVATION", 57, 61], ["CNS", "ANATOMY", 140, 143], ["endothelial cells", "OBSERVATION", 184, 201], ["some", "OBSERVATION_MODIFIER", 281, 285], ["neurological", "OBSERVATION_MODIFIER", 286, 298], ["complications", "OBSERVATION", 299, 312]]], ["The viral S protein might allow the virus interaction in brain microcirculation with ACE2 receptors expressed in the capillary endothelium, possibly leading to endothelial cells infection and subsequent spreading to the neurons after that the endothelial damage has occurred [24].5.4.", [["brain", "ANATOMY", 57, 62], ["capillary endothelium", "ANATOMY", 117, 138], ["endothelial cells", "ANATOMY", 160, 177], ["neurons", "ANATOMY", 220, 227], ["endothelial", "ANATOMY", 243, 254], ["infection", "DISEASE", 178, 187], ["endothelial damage", "DISEASE", 243, 261], ["brain", "ORGAN", 57, 62], ["ACE2 receptors", "GENE_OR_GENE_PRODUCT", 85, 99], ["capillary endothelium", "TISSUE", 117, 138], ["endothelial cells", "CELL", 160, 177], ["neurons", "CELL", 220, 227], ["endothelial", "CELL", 243, 254], ["viral S protein", "PROTEIN", 4, 19], ["ACE2 receptors", "PROTEIN", 85, 99], ["endothelial cells", "CELL_TYPE", 160, 177], ["The viral S protein", "TEST", 0, 19], ["the virus interaction", "PROBLEM", 32, 53], ["ACE2 receptors", "TREATMENT", 85, 99], ["endothelial cells infection", "PROBLEM", 160, 187], ["the endothelial damage", "PROBLEM", 239, 261], ["viral", "OBSERVATION", 4, 9], ["capillary endothelium", "ANATOMY", 117, 138], ["possibly leading to", "UNCERTAINTY", 140, 159], ["endothelial cells infection", "OBSERVATION", 160, 187], ["endothelial", "ANATOMY", 243, 254], ["damage", "OBSERVATION", 255, 261]]], ["Hematogenous Propagation and the Role of the Blood-Brain Barrier ::: 5.", [["Hematogenous Propagation", "PROBLEM", 0, 24], ["Brain", "ANATOMY", 51, 56]]], ["Proposed Neuropathogenic MechanismsDamage of the epithelial barrier by CoVs may occur, thus allowing the virus to reach the bloodstream or the lymphatic system and to spread to other tissues, including the brain.", [["epithelial barrier", "ANATOMY", 49, 67], ["bloodstream", "ANATOMY", 124, 135], ["lymphatic system", "ANATOMY", 143, 159], ["tissues", "ANATOMY", 183, 190], ["brain", "ANATOMY", 206, 211], ["epithelial barrier", "TISSUE", 49, 67], ["CoVs", "GENE_OR_GENE_PRODUCT", 71, 75], ["lymphatic system", "ANATOMICAL_SYSTEM", 143, 159], ["tissues", "TISSUE", 183, 190], ["brain", "ORGAN", 206, 211], ["CoVs", "PROBLEM", 71, 75], ["the virus", "PROBLEM", 101, 110], ["Neuropathogenic", "OBSERVATION_MODIFIER", 9, 24], ["MechanismsDamage", "OBSERVATION", 25, 41], ["epithelial", "ANATOMY_MODIFIER", 49, 59], ["bloodstream", "ANATOMY", 124, 135], ["lymphatic system", "ANATOMY", 143, 159], ["brain", "ANATOMY", 206, 211]]], ["In this scenario, however, it is important to distinguish between the nasal olfactory epithelium and the nasal respiratory epithelium.", [["nasal olfactory epithelium", "ANATOMY", 70, 96], ["nasal respiratory epithelium", "ANATOMY", 105, 133], ["nasal olfactory epithelium", "TISSUE", 70, 96], ["nasal respiratory epithelium", "TISSUE", 105, 133], ["the nasal respiratory epithelium", "PROBLEM", 101, 133], ["nasal olfactory", "ANATOMY", 70, 85], ["epithelium", "ANATOMY_MODIFIER", 86, 96], ["nasal", "ANATOMY", 105, 110], ["respiratory epithelium", "OBSERVATION", 111, 133]]], ["While the former has been indicated as the main route for the trans-synaptic propagation of CoVs, the latter seems to be involved in the hematogenous propagation [78].", [["CoVs", "GENE_OR_GENE_PRODUCT", 92, 96], ["CoVs", "PROTEIN", 92, 96], ["CoVs", "PROBLEM", 92, 96], ["hematogenous", "OBSERVATION", 137, 149]]], ["Nevertheless, it is not well clearly understood how this could take place, although the BBB seems to be involved.5.4.", [["BBB", "MULTI-TISSUE_STRUCTURE", 88, 91]]], ["Hematogenous Propagation and the Role of the Blood-Brain Barrier ::: 5.", [["Hematogenous Propagation", "PROBLEM", 0, 24], ["Brain", "ANATOMY", 51, 56]]], ["Proposed Neuropathogenic MechanismsTwo hypotheses have been proposed for the crossing of the BBB by SARS-CoV-2.", [["BBB", "ANATOMY", 93, 96], ["BBB", "MULTI-TISSUE_STRUCTURE", 93, 96], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 100, 110], ["SARS-CoV", "SPECIES", 100, 108]]], ["The first mechanisms would involve the infection and transport across vascular endothelial cells, which express ACE2 and, as such, are at risk for SARS-CoV-2 infection [78].", [["vascular endothelial cells", "ANATOMY", 70, 96], ["infection", "DISEASE", 39, 48], ["SARS-CoV-2 infection", "DISEASE", 147, 167], ["vascular endothelial cells", "CELL", 70, 96], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["SARS-CoV-2", "ORGANISM", 147, 157], ["vascular endothelial cells", "CELL_TYPE", 70, 96], ["ACE2", "PROTEIN", 112, 116], ["SARS-CoV", "SPECIES", 147, 155], ["the infection", "PROBLEM", 35, 48], ["transport across vascular endothelial cells", "PROBLEM", 53, 96], ["ACE2", "TEST", 112, 116], ["SARS", "PROBLEM", 147, 151], ["CoV-2 infection", "PROBLEM", 152, 167], ["infection", "OBSERVATION", 39, 48], ["vascular endothelial cells", "OBSERVATION", 70, 96]]], ["SARS-CoV-2 particles have been found in capillary endothelia and neurons of a frontal lobe specimen from an autopsy case study [122].", [["capillary endothelia", "ANATOMY", 40, 60], ["neurons", "ANATOMY", 65, 72], ["frontal lobe specimen", "ANATOMY", 78, 99], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["capillary endothelia", "TISSUE", 40, 60], ["neurons", "CELL", 65, 72], ["frontal lobe specimen", "CANCER", 78, 99], ["SARS-CoV-2 particles", "TEST", 0, 20], ["an autopsy case study", "TEST", 105, 126], ["capillary endothelia", "ANATOMY", 40, 60], ["neurons", "ANATOMY", 65, 72], ["frontal lobe", "ANATOMY", 78, 90]]], ["In particular, viral particles were packaged in intraneuronal dilated vesicles, and endocytosis or exocytosis of viral particles across endothelial cells were detected by electron microscopic imaging [78].", [["vesicles", "ANATOMY", 70, 78], ["endothelial cells", "ANATOMY", 136, 153], ["vesicles", "CELLULAR_COMPONENT", 70, 78], ["endothelial cells", "CELL", 136, 153], ["endothelial cells", "CELL_TYPE", 136, 153], ["viral particles", "PROBLEM", 15, 30], ["intraneuronal dilated vesicles", "PROBLEM", 48, 78], ["endocytosis", "PROBLEM", 84, 95], ["exocytosis of viral particles across endothelial cells", "PROBLEM", 99, 153], ["electron microscopic imaging", "TEST", 171, 199], ["viral particles", "OBSERVATION", 15, 30], ["intraneuronal", "OBSERVATION_MODIFIER", 48, 61], ["dilated vesicles", "OBSERVATION", 62, 78], ["viral particles", "OBSERVATION", 113, 128], ["endothelial cells", "OBSERVATION", 136, 153]]], ["As soon as the virus enters vascular and neuronal cells, it might interact with ACE2 on neurons, glia, and vessels, and then begin a cycle of viral budding, thus further damaging both vascular and neuronal tissue [24].5.4.", [["vascular", "ANATOMY", 28, 36], ["neuronal cells", "ANATOMY", 41, 55], ["neurons", "ANATOMY", 88, 95], ["glia", "ANATOMY", 97, 101], ["vessels", "ANATOMY", 107, 114], ["vascular", "ANATOMY", 184, 192], ["neuronal tissue", "ANATOMY", 197, 212], ["vascular", "CELL", 28, 36], ["neuronal cells", "CELL", 41, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 80, 84], ["neurons", "CELL", 88, 95], ["glia", "CELL", 97, 101], ["vessels", "MULTI-TISSUE_STRUCTURE", 107, 114], ["vascular", "MULTI-TISSUE_STRUCTURE", 184, 192], ["neuronal tissue", "TISSUE", 197, 212], ["vascular and neuronal cells", "CELL_TYPE", 28, 55], ["ACE2", "PROTEIN", 80, 84], ["neurons", "CELL_TYPE", 88, 95], ["glia", "CELL_TYPE", 97, 101], ["the virus enters vascular and neuronal cells", "PROBLEM", 11, 55], ["viral budding", "PROBLEM", 142, 155], ["vascular", "ANATOMY", 28, 36], ["neuronal cells", "OBSERVATION", 41, 55], ["glia", "ANATOMY", 97, 101], ["vessels", "ANATOMY", 107, 114], ["vascular", "ANATOMY", 184, 192]]], ["Hematogenous Propagation and the Role of the Blood-Brain Barrier ::: 5.", [["Hematogenous Propagation", "PROBLEM", 0, 24], ["Brain", "ANATOMY", 51, 56]]], ["Proposed Neuropathogenic MechanismsThe second hypothesis is based on the so-called \u201cTrojan horse mechanism,\u201d through the infection of leukocytes that pass the BBB [35].", [["leukocytes", "ANATOMY", 134, 144], ["BBB", "ANATOMY", 159, 162], ["infection", "DISEASE", 121, 130], ["horse", "ORGANISM_SUBDIVISION", 91, 96], ["leukocytes", "CELL", 134, 144], ["leukocytes", "CELL_TYPE", 134, 144], ["horse", "SPECIES", 91, 96], ["the infection of leukocytes", "PROBLEM", 117, 144], ["infection", "OBSERVATION", 121, 130]]], ["As lymphocytes, granulocytes, and monocytes all express ACE2, the SARS-CoV might able to infect them [49,123,124,125], and it is likely that SARS-CoV-2 too may act in the same manner.", [["lymphocytes", "ANATOMY", 3, 14], ["granulocytes", "ANATOMY", 16, 28], ["monocytes", "ANATOMY", 34, 43], ["lymphocytes", "CELL", 3, 14], ["granulocytes", "CELL", 16, 28], ["monocytes", "CELL", 34, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["SARS-CoV", "ORGANISM", 66, 74], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 141, 151], ["lymphocytes", "CELL_TYPE", 3, 14], ["granulocytes", "CELL_TYPE", 16, 28], ["monocytes", "CELL_TYPE", 34, 43], ["ACE2", "PROTEIN", 56, 60], ["SARS-CoV", "SPECIES", 66, 74], ["SARS-CoV", "SPECIES", 141, 149], ["lymphocytes", "TEST", 3, 14], ["granulocytes", "TEST", 16, 28], ["monocytes", "TEST", 34, 43], ["ACE2", "TEST", 56, 60], ["the SARS", "TEST", 62, 70], ["SARS", "PROBLEM", 141, 145], ["CoV", "TEST", 146, 149], ["granulocytes", "OBSERVATION", 16, 28], ["is likely", "UNCERTAINTY", 126, 135]]], ["Moreover, the COVID-19-related systemic inflammation would increase the BBB permeability, thus facilitating the invasion of the CNS by the infected immune cells [126].5.5.", [["BBB", "ANATOMY", 72, 75], ["CNS", "ANATOMY", 128, 131], ["immune cells", "ANATOMY", 148, 160], ["inflammation", "DISEASE", 40, 52], ["BBB", "MULTI-TISSUE_STRUCTURE", 72, 75], ["CNS", "ANATOMICAL_SYSTEM", 128, 131], ["immune cells", "CELL", 148, 160], ["infected immune cells", "CELL_TYPE", 139, 160], ["the COVID", "TEST", 10, 19], ["systemic inflammation", "PROBLEM", 31, 52], ["the BBB permeability", "PROBLEM", 68, 88], ["the invasion of the CNS", "PROBLEM", 108, 131], ["the infected immune cells", "PROBLEM", 135, 160], ["systemic", "OBSERVATION_MODIFIER", 31, 39], ["inflammation", "OBSERVATION", 40, 52], ["BBB permeability", "OBSERVATION", 72, 88], ["CNS", "ANATOMY", 128, 131], ["infected", "OBSERVATION_MODIFIER", 139, 147], ["immune cells", "OBSERVATION", 148, 160]]], ["Proposed Neuropathogenic MechanismsCOVID-19-related hypoxia may be responsible for indirect neuronal damage as it induces anaerobic metabolism in the CNS cells, ischemia, interstitial edema, and vasodilatation in the cerebral circulation, which eventually causes stroke, syncope, and anoxic crisis [127].5.5.", [["neuronal", "ANATOMY", 92, 100], ["CNS cells", "ANATOMY", 150, 159], ["interstitial edema", "ANATOMY", 171, 189], ["cerebral", "ANATOMY", 217, 225], ["MechanismsCOVID-19", "CHEMICAL", 25, 43], ["hypoxia", "DISEASE", 52, 59], ["neuronal damage", "DISEASE", 92, 107], ["ischemia", "DISEASE", 161, 169], ["interstitial edema", "DISEASE", 171, 189], ["stroke", "DISEASE", 263, 269], ["syncope", "DISEASE", 271, 278], ["neuronal", "CELL", 92, 100], ["CNS cells", "CELL", 150, 159], ["interstitial edema", "PATHOLOGICAL_FORMATION", 171, 189], ["cerebral", "ORGAN", 217, 225], ["CNS cells", "CELL_TYPE", 150, 159], ["Proposed Neuropathogenic MechanismsCOVID", "TEST", 0, 40], ["hypoxia", "PROBLEM", 52, 59], ["indirect neuronal damage", "PROBLEM", 83, 107], ["anaerobic metabolism in the CNS cells", "PROBLEM", 122, 159], ["ischemia", "PROBLEM", 161, 169], ["interstitial edema", "PROBLEM", 171, 189], ["vasodilatation in the cerebral circulation", "PROBLEM", 195, 237], ["stroke", "PROBLEM", 263, 269], ["syncope", "PROBLEM", 271, 278], ["anoxic crisis", "PROBLEM", 284, 297], ["may be responsible for", "UNCERTAINTY", 60, 82], ["anaerobic metabolism", "OBSERVATION", 122, 142], ["CNS cells", "ANATOMY", 150, 159], ["ischemia", "OBSERVATION", 161, 169], ["interstitial", "ANATOMY_MODIFIER", 171, 183], ["edema", "OBSERVATION", 184, 189], ["vasodilatation", "OBSERVATION", 195, 209], ["cerebral circulation", "ANATOMY", 217, 237], ["stroke", "OBSERVATION", 263, 269], ["anoxic crisis", "OBSERVATION", 284, 297]]], ["Proposed Neuropathogenic MechanismsThe fact that CoVs can infect macrophages, astroglia, and microglia makes it possible for the host\u2019s immune-mediated response to playing a role.", [["macrophages", "ANATOMY", 65, 76], ["astroglia", "ANATOMY", 78, 87], ["microglia", "ANATOMY", 93, 102], ["CoVs", "GENE_OR_GENE_PRODUCT", 49, 53], ["macrophages", "CELL", 65, 76], ["astroglia", "CELL", 78, 87], ["microglia", "CELL", 93, 102], ["CoVs", "PROTEIN", 49, 53], ["macrophages", "CELL_TYPE", 65, 76], ["astroglia", "CELL_TYPE", 78, 87], ["microglia", "CELL_TYPE", 93, 102], ["CoVs can infect macrophages", "PROBLEM", 49, 76], ["astroglia", "PROBLEM", 78, 87], ["microglia", "PROBLEM", 93, 102]]], ["In some patients who died because of COVID-19, a multiple organ failure and a hyperinflammatory syndrome (the \u201ccytokine storm\u201d) were hypothesized as possible underlying causes [81].", [["organ", "ANATOMY", 58, 63], ["organ failure", "DISEASE", 58, 71], ["hyperinflammatory syndrome", "DISEASE", 78, 104], ["patients", "ORGANISM", 8, 16], ["organ", "ORGAN", 58, 63], ["cytokine", "PROTEIN", 111, 119], ["patients", "SPECIES", 8, 16], ["COVID", "TEST", 37, 42], ["a multiple organ failure", "PROBLEM", 47, 71], ["a hyperinflammatory syndrome", "PROBLEM", 76, 104], ["multiple", "OBSERVATION_MODIFIER", 49, 57], ["organ", "ANATOMY", 58, 63], ["failure", "OBSERVATION", 64, 71], ["hyperinflammatory syndrome", "OBSERVATION", 78, 104]]], ["In this context, a previous study in mice showed T-lymphocyte infiltration into the CNS and significantly increased levels of the proinflammatory cytokine IL-6 and the chemokine monocyte chemoattractant protein-1 after CoV exposure [128].5.5.", [["T-lymphocyte", "ANATOMY", 49, 61], ["CNS", "ANATOMY", 84, 87], ["mice", "ORGANISM", 37, 41], ["T-lymphocyte", "CELL", 49, 61], ["CNS", "ANATOMICAL_SYSTEM", 84, 87], ["IL-6", "GENE_OR_GENE_PRODUCT", 155, 159], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 178, 212], ["CoV", "ORGANISM", 219, 222], ["proinflammatory cytokine IL-6", "PROTEIN", 130, 159], ["chemokine monocyte chemoattractant protein-1", "PROTEIN", 168, 212], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["a previous study", "TEST", 17, 33], ["T-lymphocyte infiltration into the CNS", "PROBLEM", 49, 87], ["the proinflammatory cytokine IL", "TEST", 126, 157], ["the chemokine monocyte chemoattractant protein", "TEST", 164, 210], ["CoV exposure", "TEST", 219, 231], ["lymphocyte infiltration", "OBSERVATION", 51, 74], ["CNS", "ANATOMY", 84, 87], ["significantly", "OBSERVATION_MODIFIER", 92, 105], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["proinflammatory", "OBSERVATION_MODIFIER", 130, 145]]], ["Proposed Neuropathogenic MechanismsFinally, in genetically predisposed individuals, the persistence of CoVs in some CNS resident cells cannot be excluded, where they would act as a cofactor of clinical exacerbations.", [["CNS resident cells", "ANATOMY", 116, 134], ["CoVs", "GENE_OR_GENE_PRODUCT", 103, 107], ["CNS resident cells", "CELL", 116, 134], ["CoVs", "PROTEIN", 103, 107], ["CNS resident cells", "CELL_TYPE", 116, 134], ["CoVs", "PROBLEM", 103, 107], ["clinical exacerbations", "PROBLEM", 193, 215], ["CoVs", "OBSERVATION", 103, 107]]], ["Serological techniques have identified CoVs in various neurological diseases, such as Parkinson\u2019s disease, MS, and optic neuritis [129,130,131,132].", [["neurological", "ANATOMY", 55, 67], ["neurological diseases", "DISEASE", 55, 76], ["Parkinson\u2019s disease", "DISEASE", 86, 105], ["MS", "DISEASE", 107, 109], ["optic neuritis", "DISEASE", 115, 129], ["CoVs", "GENE_OR_GENE_PRODUCT", 39, 43], ["CoVs", "PROTEIN", 39, 43], ["Serological techniques", "TEST", 0, 22], ["CoVs in various neurological diseases", "PROBLEM", 39, 76], ["Parkinson\u2019s disease", "PROBLEM", 86, 105], ["MS", "PROBLEM", 107, 109], ["optic neuritis", "PROBLEM", 115, 129], ["CoVs", "OBSERVATION_MODIFIER", 39, 43], ["various", "OBSERVATION_MODIFIER", 47, 54], ["neurological diseases", "OBSERVATION", 55, 76], ["optic neuritis", "OBSERVATION", 115, 129]]], ["Therefore, it was proposed that a persistent CoV infection might be a pathogenic factor in the development and course of some neurological diseases.", [["neurological", "ANATOMY", 126, 138], ["CoV infection", "DISEASE", 45, 58], ["neurological diseases", "DISEASE", 126, 147], ["CoV", "ORGANISM", 45, 48], ["CoV", "SPECIES", 45, 48], ["a persistent CoV infection", "PROBLEM", 32, 58], ["a pathogenic factor", "PROBLEM", 68, 87], ["some neurological diseases", "PROBLEM", 121, 147], ["persistent", "OBSERVATION_MODIFIER", 34, 44], ["CoV", "OBSERVATION_MODIFIER", 45, 48], ["infection", "OBSERVATION", 49, 58], ["pathogenic", "OBSERVATION_MODIFIER", 70, 80], ["neurological diseases", "OBSERVATION", 126, 147]]], ["For instance, infectious agents may play a triggering role in MS, with viruses being the most likely culprit in genetically predisposed individuals [133].5.5.", [["MS", "DISEASE", 62, 64], ["infectious agents", "TREATMENT", 14, 31], ["viruses", "PROBLEM", 71, 78], ["infectious", "OBSERVATION", 14, 24], ["most likely", "UNCERTAINTY", 89, 100]]], ["Proposed Neuropathogenic MechanismsTaken together, all the mechanisms discussed here might, at least in part, explain why and how SARS-CoV-2 could be moved in or within the CNS despite the low expression of ACE2 receptor in the brain.", [["CNS", "ANATOMY", 173, 176], ["brain", "ANATOMY", 228, 233], ["SARS", "DISEASE", 130, 134], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 130, 140], ["CNS", "ANATOMICAL_SYSTEM", 173, 176], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 207, 220], ["brain", "ORGAN", 228, 233], ["ACE2 receptor", "PROTEIN", 207, 220], ["brain", "ANATOMY", 228, 233]]], ["Further studies are needed to better understand these pivotal aspects of neuroinfection.6.", [["neuroinfection", "DISEASE", 73, 87], ["Further studies", "TEST", 0, 15], ["neuroinfection", "PROBLEM", 73, 87], ["neuroinfection", "OBSERVATION", 73, 87]]], ["Unmet Needs and Conclusive RemarksThe research on the neurological manifestations of COVID-19 has recently made significant progress, although the exact neuropathogenic mechanisms of SARS-CoV-2 are not yet completely clear.", [["neurological", "ANATOMY", 54, 66], ["COVID-19", "CHEMICAL", 85, 93], ["SARS", "DISEASE", 183, 187], ["COVID-19", "CHEMICAL", 85, 93], ["COVID-19", "CELL", 85, 93], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 183, 193], ["SARS", "PROBLEM", 183, 187], ["CoV", "TEST", 188, 191], ["clear", "OBSERVATION", 217, 222]]], ["Essential questions are emerging with the identification of people with COVID-19 and CNS involvement.", [["CNS", "ANATOMY", 85, 88], ["people", "ORGANISM", 60, 66], ["CNS", "ANATOMICAL_SYSTEM", 85, 88], ["people", "SPECIES", 60, 66], ["COVID", "TEST", 72, 77]]], ["Although these patients may exhibit a wide range of neurological complications, it remains to be determined whether these can be an indirect and unspecific consequence of the pulmonary disease, hypoxia, or generalized inflammatory state on the CNS, or if they may rather reflect a direct viral-related neuronal damage.", [["neurological", "ANATOMY", 52, 64], ["pulmonary", "ANATOMY", 175, 184], ["CNS", "ANATOMY", 244, 247], ["neuronal", "ANATOMY", 302, 310], ["neurological complications", "DISEASE", 52, 78], ["pulmonary disease", "DISEASE", 175, 192], ["hypoxia", "DISEASE", 194, 201], ["neuronal damage", "DISEASE", 302, 317], ["patients", "ORGANISM", 15, 23], ["pulmonary", "ORGAN", 175, 184], ["CNS", "ANATOMICAL_SYSTEM", 244, 247], ["neuronal", "CELL", 302, 310], ["patients", "SPECIES", 15, 23], ["neurological complications", "PROBLEM", 52, 78], ["the pulmonary disease", "PROBLEM", 171, 192], ["hypoxia", "PROBLEM", 194, 201], ["generalized inflammatory state", "PROBLEM", 206, 236], ["a direct viral-related neuronal damage", "PROBLEM", 279, 317], ["pulmonary", "ANATOMY", 175, 184], ["disease", "OBSERVATION", 185, 192], ["hypoxia", "OBSERVATION", 194, 201], ["generalized", "OBSERVATION_MODIFIER", 206, 217], ["inflammatory", "OBSERVATION", 218, 230], ["viral", "OBSERVATION", 288, 293], ["neuronal damage", "OBSERVATION", 302, 317]]], ["Some symptoms, such as headache and unsteadiness, are non-specific manifestations of several viral infections but, in some cases, they might accompany more severe diseases, such as meningitis, encephalitis, and stroke.6.", [["headache", "DISEASE", 23, 31], ["unsteadiness", "DISEASE", 36, 48], ["viral infections", "DISEASE", 93, 109], ["meningitis", "DISEASE", 181, 191], ["encephalitis", "DISEASE", 193, 205], ["stroke", "DISEASE", 211, 217], ["Some symptoms", "PROBLEM", 0, 13], ["headache", "PROBLEM", 23, 31], ["unsteadiness", "PROBLEM", 36, 48], ["non-specific manifestations", "PROBLEM", 54, 81], ["several viral infections", "PROBLEM", 85, 109], ["more severe diseases", "PROBLEM", 151, 171], ["meningitis", "PROBLEM", 181, 191], ["encephalitis", "PROBLEM", 193, 205], ["stroke", "PROBLEM", 211, 217], ["several", "OBSERVATION_MODIFIER", 85, 92], ["viral", "OBSERVATION_MODIFIER", 93, 98], ["infections", "OBSERVATION", 99, 109], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["diseases", "OBSERVATION", 163, 171], ["meningitis", "OBSERVATION", 181, 191], ["encephalitis", "OBSERVATION", 193, 205], ["stroke", "OBSERVATION", 211, 217]]], ["Unmet Needs and Conclusive RemarksA hematogenous versus a transsynaptic propagation is still debated, as well as the role of the ACE2 receptor, the impact of hyperimmune response, and the viral persistence within some CNS cells.", [["CNS cells", "ANATOMY", 218, 227], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 129, 142], ["hyperimmune", "ORGANISM", 158, 169], ["CNS cells", "CELL", 218, 227], ["ACE2 receptor", "PROTEIN", 129, 142], ["CNS cells", "CELL_TYPE", 218, 227], ["Conclusive RemarksA hematogenous", "PROBLEM", 16, 48], ["a transsynaptic propagation", "PROBLEM", 56, 83], ["the ACE2 receptor", "TREATMENT", 125, 142], ["hyperimmune response", "PROBLEM", 158, 178], ["the viral persistence", "PROBLEM", 184, 205], ["hematogenous", "OBSERVATION", 36, 48], ["hyperimmune response", "OBSERVATION", 158, 178], ["viral persistence", "OBSERVATION", 188, 205], ["CNS cells", "OBSERVATION", 218, 227]]], ["The different levels and severity of human neurotropism and neurovirulence in patients with COVID-19 might be explained by a combination of viral and host factors and their interaction.", [["neurovirulence", "DISEASE", 60, 74], ["COVID-19", "CHEMICAL", 92, 100], ["human", "ORGANISM", 37, 42], ["patients", "ORGANISM", 78, 86], ["viral and host factors", "PROTEIN", 140, 162], ["human", "SPECIES", 37, 42], ["patients", "SPECIES", 78, 86], ["human", "SPECIES", 37, 42], ["The different levels", "TEST", 0, 20], ["human neurotropism", "PROBLEM", 37, 55], ["neurovirulence", "PROBLEM", 60, 74], ["COVID", "TEST", 92, 97], ["viral and host factors", "PROBLEM", 140, 162], ["human neurotropism", "OBSERVATION", 37, 55]]], ["Although researchers are yet to elucidate the real degree of neurovirulence of SARS-CoV-2, there is a demonstration of its presence in the CSF or tissue samples at autopsy.", [["CSF", "ANATOMY", 139, 142], ["tissue samples", "ANATOMY", 146, 160], ["SARS", "DISEASE", 79, 83], ["SARS-CoV-2", "ORGANISM", 79, 89], ["CSF", "GENE_OR_GENE_PRODUCT", 139, 142], ["tissue samples", "TISSUE", 146, 160], ["SARS-CoV", "SPECIES", 79, 87], ["SARS", "PROBLEM", 79, 83], ["autopsy", "TEST", 164, 171], ["CSF", "ANATOMY", 139, 142]]], ["However, in the current epidemic, some difficulties may occur in performing MRI or a lumbar puncture, especially in severely affected patients and in those admitted in intensive care units.", [["lumbar", "ANATOMY", 85, 91], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["MRI", "TEST", 76, 79], ["a lumbar puncture", "TEST", 83, 100], ["lumbar", "ANATOMY", 85, 91]]], ["Nevertheless, it remains of pivotal importance for all patients with altered consciousness or any unexplained neurological manifestation to receive an accurate neurological exam and appropriate instrumental investigations (i.e., neuroimaging, EEG, evoked potentials, CSF), when necessary [134].6.", [["neurological", "ANATOMY", 110, 122], ["neurological", "ANATOMY", 160, 172], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["altered consciousness", "PROBLEM", 69, 90], ["any unexplained neurological manifestation", "PROBLEM", 94, 136], ["an accurate neurological exam", "TEST", 148, 177], ["appropriate instrumental investigations", "TEST", 182, 221], ["neuroimaging", "TEST", 229, 241], ["EEG", "TEST", 243, 246]]], ["Unmet Needs and Conclusive RemarksAnother warning related to this topic is that lymphopenia in immunosuppressed patients with COVID-19 can be a serious risk factor; these are not only patients with cancer or with systemic autoimmune diseases but also patients with neurological disorders.", [["cancer", "ANATOMY", 198, 204], ["neurological", "ANATOMY", 265, 277], ["lymphopenia", "DISEASE", 80, 91], ["immunosuppressed", "DISEASE", 95, 111], ["COVID-19", "CHEMICAL", 126, 134], ["cancer", "DISEASE", 198, 204], ["systemic autoimmune diseases", "DISEASE", 213, 241], ["neurological disorders", "DISEASE", 265, 287], ["COVID-19", "CHEMICAL", 126, 134], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 184, 192], ["cancer", "CANCER", 198, 204], ["patients", "ORGANISM", 251, 259], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 184, 192], ["patients", "SPECIES", 251, 259], ["lymphopenia", "PROBLEM", 80, 91], ["COVID", "TREATMENT", 126, 131], ["a serious risk factor", "PROBLEM", 142, 163], ["cancer", "PROBLEM", 198, 204], ["systemic autoimmune diseases", "PROBLEM", 213, 241], ["neurological disorders", "PROBLEM", 265, 287], ["lymphopenia", "OBSERVATION", 80, 91], ["cancer", "OBSERVATION", 198, 204], ["systemic", "OBSERVATION_MODIFIER", 213, 221], ["autoimmune", "OBSERVATION", 222, 232]]], ["Indeed, taking high-dose corticosteroids or immunosuppressive/biological treatments is relevant for diseases like cerebral vasculitis, neuromyelitis optica, neurosarcoidosis, polymyositis, myasthenia gravis, or MS, and the scientific community should rapidly develop ad hoc guidelines for the management (especially in terms of reevaluation of dosages and treatment cycles) of these diseases during the COVID-19 era.6.", [["cerebral", "ANATOMY", 114, 122], ["cerebral vasculitis", "DISEASE", 114, 133], ["neuromyelitis optica", "DISEASE", 135, 155], ["neurosarcoidosis", "DISEASE", 157, 173], ["polymyositis", "DISEASE", 175, 187], ["myasthenia gravis", "DISEASE", 189, 206], ["MS", "DISEASE", 211, 213], ["corticosteroids", "CHEMICAL", 25, 40], ["cerebral", "ORGAN", 114, 122], ["high-dose corticosteroids", "TREATMENT", 15, 40], ["immunosuppressive/biological treatments", "TREATMENT", 44, 83], ["diseases", "PROBLEM", 100, 108], ["cerebral vasculitis", "PROBLEM", 114, 133], ["neuromyelitis optica", "PROBLEM", 135, 155], ["neurosarcoidosis", "PROBLEM", 157, 173], ["polymyositis", "PROBLEM", 175, 187], ["myasthenia gravis", "PROBLEM", 189, 206], ["MS", "PROBLEM", 211, 213], ["the management", "TREATMENT", 289, 303], ["dosages", "TREATMENT", 344, 351], ["treatment cycles", "TREATMENT", 356, 372], ["these diseases", "PROBLEM", 377, 391], ["the COVID", "TEST", 399, 408], ["cerebral", "ANATOMY", 114, 122], ["vasculitis", "OBSERVATION", 123, 133], ["polymyositis", "OBSERVATION", 175, 187]]], ["Unmet Needs and Conclusive RemarksAnother relevant consideration concerns the possibility of developing anti-COVID-19 drugs to cross the BBB and to selectively target the SARS-CoV-2 inside the brain.", [["BBB", "ANATOMY", 137, 140], ["brain", "ANATOMY", 193, 198], ["anti-COVID-19 drugs", "SIMPLE_CHEMICAL", 104, 123], ["BBB", "MULTI-TISSUE_STRUCTURE", 137, 140], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 171, 181], ["brain", "ORGAN", 193, 198], ["anti-COVID-19 drugs", "TREATMENT", 104, 123], ["the SARS", "TEST", 167, 175], ["CoV", "TEST", 176, 179], ["SARS", "OBSERVATION", 171, 175], ["brain", "ANATOMY", 193, 198]]], ["The role of the BBB needs to be further explored in patients with COVID-19.", [["BBB", "ANATOMY", 16, 19], ["BBB", "MULTI-TISSUE_STRUCTURE", 16, 19], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["COVID", "TEST", 66, 71]]], ["Hence, the possible neuroinvasion may be a significant mechanism to take into account for treating and preventing COVID-19.", [["neuroinvasion", "DISEASE", 20, 33], ["COVID-19", "CHEMICAL", 114, 122], ["neuroinvasion", "PROBLEM", 20, 33], ["COVID", "TEST", 114, 119], ["possible", "UNCERTAINTY", 11, 19], ["neuroinvasion", "OBSERVATION", 20, 33]]], ["In this context, the design of safe and effective brain penetrating drugs would be very helpful in preventing and possibly treating the neurological complications of COVID-19, although the studies on this \u201ccutting-edge topic\u201d are still at their beginning [135].6.", [["brain", "ANATOMY", 50, 55], ["neurological", "ANATOMY", 136, 148], ["COVID", "DISEASE", 166, 171], ["COVID-19", "CHEMICAL", 166, 174], ["brain", "ORGAN", 50, 55], ["safe and effective brain penetrating drugs", "TREATMENT", 31, 73], ["the neurological complications", "PROBLEM", 132, 162], ["COVID", "TEST", 166, 171], ["the studies", "TEST", 185, 196]]], ["Unmet Needs and Conclusive RemarksThe differences in the sequence of spike proteins between SARS-CoV and SARS-CoV-2 will enable scientists to identify epitopes in COVID-19 patients for the development of monoclonal antibodies against this virus.", [["SARS-CoV", "ORGANISM", 92, 100], ["SARS-CoV-2", "ORGANISM", 105, 115], ["patients", "ORGANISM", 172, 180], ["spike proteins", "PROTEIN", 69, 83], ["epitopes", "PROTEIN", 151, 159], ["monoclonal antibodies", "PROTEIN", 204, 225], ["patients", "SPECIES", 172, 180], ["SARS-CoV", "SPECIES", 92, 100], ["SARS-CoV", "SPECIES", 105, 113], ["spike proteins", "PROBLEM", 69, 83], ["SARS", "TEST", 92, 96], ["SARS", "PROBLEM", 105, 109], ["COVID", "TEST", 163, 168], ["monoclonal antibodies", "PROBLEM", 204, 225], ["this virus", "PROBLEM", 234, 244]]], ["Basic research studies on SARS-CoV-2 and host interactions are the key to several unanswered questions in the prevention and control of the disease, including the challenging question of why not all patients with COVID-19 show neuroinvasion and why, among those experiencing neuroinvasion, not all show neurotropism or neurovirulence [136].", [["SARS", "DISEASE", 26, 30], ["neuroinvasion", "DISEASE", 227, 240], ["neuroinvasion", "DISEASE", 275, 288], ["SARS-CoV-2", "ORGANISM", 26, 36], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207], ["SARS-CoV", "SPECIES", 26, 34], ["Basic research studies", "TEST", 0, 22], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["the disease", "PROBLEM", 136, 147], ["COVID", "TEST", 213, 218], ["neuroinvasion", "PROBLEM", 227, 240], ["neuroinvasion", "PROBLEM", 275, 288], ["neurovirulence", "PROBLEM", 319, 333], ["disease", "OBSERVATION", 140, 147]]], ["Moreover, the difference in terms of neurological involvement and pathomechanisms between the current pandemic and the SARS and MERS infections needs to be further studied.6.", [["neurological", "ANATOMY", 37, 49], ["SARS", "DISEASE", 119, 123], ["infections", "DISEASE", 133, 143], ["neurological involvement", "PROBLEM", 37, 61], ["pathomechanisms", "PROBLEM", 66, 81], ["the SARS", "PROBLEM", 115, 123], ["MERS infections", "PROBLEM", 128, 143]]], ["Unmet Needs and Conclusive RemarksLastly, longitudinal neurological assessments of patients after their recovery will be crucial in the understanding of the natural history of COVID-19 in the CNS and for monitoring potential neurological sequelae.", [["neurological", "ANATOMY", 55, 67], ["CNS", "ANATOMY", 192, 195], ["neurological", "ANATOMY", 225, 237], ["neurological sequelae", "DISEASE", 225, 246], ["patients", "ORGANISM", 83, 91], ["CNS", "ANATOMICAL_SYSTEM", 192, 195], ["patients", "SPECIES", 83, 91], ["longitudinal neurological assessments", "TEST", 42, 79], ["COVID", "TEST", 176, 181], ["potential neurological sequelae", "PROBLEM", 215, 246], ["CNS", "ANATOMY", 192, 195]]], ["Reaching a more global vision of COVID-19 neuroinfection is also crucial, for instance how SARS-CoV-2 may affect the clinical expression of other infections or co-infectious diseases within the CNS (i.e., the human immunodeficiency virus).6.", [["CNS", "ANATOMY", 194, 197], ["SARS", "DISEASE", 91, 95], ["infections", "DISEASE", 146, 156], ["human immunodeficiency virus", "DISEASE", 209, 237], ["SARS-CoV-2", "ORGANISM", 91, 101], ["CNS", "ANATOMICAL_SYSTEM", 194, 197], ["human immunodeficiency virus", "ORGANISM", 209, 237], ["human", "SPECIES", 209, 214], ["immunodeficiency virus", "SPECIES", 215, 237], ["human immunodeficiency virus", "SPECIES", 209, 237], ["COVID", "TEST", 33, 38], ["other infections", "PROBLEM", 140, 156], ["co-infectious diseases", "PROBLEM", 160, 182], ["the CNS", "PROBLEM", 190, 197], ["the human immunodeficiency virus", "PROBLEM", 205, 237], ["infections", "OBSERVATION", 146, 156], ["CNS", "ANATOMY", 194, 197]]], ["Unmet Needs and Conclusive RemarksFurther studies on clinical features of patients and pathogenetic mechanisms will provide guidance to deal with this pandemic infection, which seems to go well beyond pneumonia and whose multifaceted aspects warrant an urgent need for multidisciplinary and multidimensional research.", [["infection", "DISEASE", 160, 169], ["pneumonia", "DISEASE", 201, 210], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Conclusive RemarksFurther studies", "TEST", 16, 49], ["pathogenetic mechanisms", "PROBLEM", 87, 110], ["this pandemic infection", "PROBLEM", 146, 169], ["pneumonia", "PROBLEM", 201, 210], ["infection", "OBSERVATION", 160, 169], ["pneumonia", "OBSERVATION", 201, 210]]]], "PMC7107829": [["Another Novel Viral Respiratory Pathogen?Gaynor AM, Nissen MD, Whiley DM, et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections.", [["respiratory tract", "ANATOMY", 145, 162], ["polyomavirus", "DISEASE", 107, 119], ["acute respiratory tract infections", "DISEASE", 139, 173], ["polyomavirus", "ORGANISM", 107, 119], ["patients", "ORGANISM", 125, 133], ["tract", "ORGANISM_SUBDIVISION", 157, 162], ["patients", "SPECIES", 125, 133], ["Another Novel Viral Respiratory Pathogen", "PROBLEM", 0, 40], ["DM", "PROBLEM", 70, 72], ["a novel polyomavirus", "PROBLEM", 99, 119], ["acute respiratory tract infections", "PROBLEM", 139, 173], ["Viral", "OBSERVATION_MODIFIER", 14, 19], ["Respiratory Pathogen", "OBSERVATION", 20, 40], ["Nissen", "OBSERVATION", 52, 58], ["polyomavirus", "OBSERVATION", 107, 119], ["acute", "OBSERVATION_MODIFIER", 139, 144], ["respiratory tract", "ANATOMY", 145, 162], ["infections", "OBSERVATION", 163, 173]]], ["PLoS Pathogens 2007; 3:595\u2013603.Another Novel Viral Respiratory Pathogen?After failing to detect nucleic acid of known respiratory viruses in a nasopharyngeal aspirate specimen obtained from a 3-year-old child who had been hospitalized in Brisbane, Australia, with pneumonia, Gaynor and colleagues, in a search for novel viral pathogens, randomly amplified and cloned total nucleic acid from the specimen.", [["nasopharyngeal aspirate specimen", "ANATOMY", 143, 175], ["specimen", "ANATOMY", 395, 403], ["nucleic acid", "CHEMICAL", 96, 108], ["respiratory viruses", "DISEASE", 118, 137], ["pneumonia", "DISEASE", 264, 273], ["nucleic acid", "CHEMICAL", 373, 385], ["nasopharyngeal aspirate specimen", "CANCER", 143, 175], ["child", "ORGANISM", 203, 208], ["Another Novel Viral Respiratory Pathogen", "PROBLEM", 31, 71], ["nucleic acid of known respiratory viruses", "PROBLEM", 96, 137], ["a nasopharyngeal aspirate specimen", "TEST", 141, 175], ["pneumonia", "PROBLEM", 264, 273], ["novel viral pathogens", "PROBLEM", 314, 335], ["total nucleic acid", "TEST", 367, 385], ["Viral", "OBSERVATION_MODIFIER", 45, 50], ["Respiratory Pathogen", "OBSERVATION", 51, 71], ["respiratory viruses", "OBSERVATION", 118, 137], ["nasopharyngeal", "ANATOMY", 143, 157], ["pneumonia", "OBSERVATION", 264, 273]]], ["They then sequenced a 384-well plate of clones using a universal primer.", [["a universal primer", "TREATMENT", 53, 71]]], ["This yielded multiple reads, 6 of which were of sequences of a single virus.", [["a single virus", "PROBLEM", 61, 75]]], ["Further evaluation of these sequences demonstrated homology (albeit limited) to known polyomaviruses, with the closest relationship being to KI, a polyomavirus that had recently been recovered from respiratory tract samples from individuals with respiratory symptoms [1].", [["respiratory tract samples", "ANATOMY", 198, 223], ["respiratory", "ANATOMY", 246, 257], ["respiratory symptoms", "DISEASE", 246, 266], ["polyomaviruses", "ORGANISM", 86, 100], ["polyomavirus", "ORGANISM", 147, 159], ["Further evaluation", "TEST", 0, 18], ["these sequences", "TEST", 22, 37], ["known polyomaviruses", "PROBLEM", 80, 100], ["a polyomavirus", "PROBLEM", 145, 159], ["respiratory tract samples", "PROBLEM", 198, 223], ["respiratory symptoms", "PROBLEM", 246, 266], ["polyomaviruses", "OBSERVATION", 86, 100], ["polyomavirus", "OBSERVATION", 147, 159], ["respiratory tract", "ANATOMY", 198, 215]]], ["The newly discovered virus was designated WU, in keeping with the practice of naming polyomaviruses with 2-letter designations (e.g., KI, JC, and BK).", [["polyomaviruses", "ORGANISM", 85, 99], ["The newly discovered virus", "PROBLEM", 0, 26], ["naming polyomaviruses", "PROBLEM", 78, 99], ["KI", "TEST", 134, 136], ["virus", "OBSERVATION", 21, 26]]], ["Phylogenetic analysis demonstrated that WU and KI are divergent from other known polyomaviruses and define a novel branch within this family.Another Novel Viral Respiratory Pathogen?WU was detected by PCR in 37 (3.0%) of 1245 respiratory specimens collected in Brisbane in 2003 and in 5 (1.2%) of 410 upper respiratory samples collected in St. Louis, Missouri, as well as in 1 of 480 bronchoalveolar lavage samples obtained mostly from adults, also in St. Louis.", [["respiratory specimens", "ANATOMY", 226, 247], ["upper respiratory samples", "ANATOMY", 301, 326], ["bronchoalveolar lavage samples", "ANATOMY", 384, 414], ["polyomaviruses", "ORGANISM", 81, 95], ["St. Louis", "ORGANISM", 340, 349], ["bronchoalveolar lavage samples", "ORGANISM_SUBSTANCE", 384, 414], ["St. Louis", "ORGANISM", 452, 461], ["Phylogenetic analysis", "TEST", 0, 21], ["other known polyomaviruses", "PROBLEM", 69, 95], ["Another Novel Viral Respiratory Pathogen", "PROBLEM", 141, 181], ["PCR", "TEST", 201, 204], ["respiratory specimens", "TEST", 226, 247], ["upper respiratory samples", "TEST", 301, 326], ["bronchoalveolar lavage samples", "TEST", 384, 414], ["polyomaviruses", "OBSERVATION", 81, 95], ["branch", "OBSERVATION_MODIFIER", 115, 121], ["Viral", "OBSERVATION_MODIFIER", 155, 160], ["Respiratory Pathogen", "OBSERVATION", 161, 181], ["upper", "ANATOMY_MODIFIER", 301, 306], ["respiratory", "ANATOMY", 307, 318]]], ["In Brisbane, the samples yielding WU were obtained from individuals aged from 4 months to 53 years, although 33 of the 37 specimens were obtained from persons aged \u2a7d3 years.", [["samples", "ANATOMY", 17, 24], ["specimens", "ANATOMY", 122, 131], ["specimens", "CANCER", 122, 131], ["persons", "ORGANISM", 151, 158], ["persons", "SPECIES", 151, 158]]], ["At least 3 of the 4 adults in whom WU was detected were significantly immunocompromised, and the fourth had cirrhosis and was undergoing mechanically ventilation.Another Novel Viral Respiratory Pathogen?WU was the only virus recovered from 12 patients, whereas at least 1 additional virus was detected in the other 25 patients; these included rhinovirus (in 15 patients) and human bocavirus (in 10 patients).", [["cirrhosis", "DISEASE", 108, 117], ["rhinovirus", "DISEASE", 343, 353], ["human bocavirus", "DISEASE", 375, 390], ["adults", "ORGANISM", 20, 26], ["patients", "ORGANISM", 243, 251], ["patients", "ORGANISM", 318, 326], ["rhinovirus", "ORGANISM", 343, 353], ["patients", "ORGANISM", 361, 369], ["human", "ORGANISM", 375, 380], ["bocavirus", "CANCER", 381, 390], ["patients", "ORGANISM", 398, 406], ["patients", "SPECIES", 243, 251], ["patients", "SPECIES", 318, 326], ["patients", "SPECIES", 361, 369], ["human", "SPECIES", 375, 380], ["patients", "SPECIES", 398, 406], ["human", "SPECIES", 375, 380], ["significantly immunocompromised", "PROBLEM", 56, 87], ["cirrhosis", "PROBLEM", 108, 117], ["mechanically ventilation", "TREATMENT", 137, 161], ["Another Novel Viral Respiratory Pathogen", "PROBLEM", 162, 202], ["virus", "PROBLEM", 219, 224], ["1 additional virus", "PROBLEM", 270, 288], ["rhinovirus", "PROBLEM", 343, 353], ["human bocavirus", "PROBLEM", 375, 390], ["significantly", "OBSERVATION_MODIFIER", 56, 69], ["immunocompromised", "OBSERVATION", 70, 87], ["cirrhosis", "OBSERVATION", 108, 117], ["mechanically ventilation", "OBSERVATION", 137, 161], ["Viral", "OBSERVATION_MODIFIER", 176, 181], ["Respiratory Pathogen", "OBSERVATION", 182, 202], ["virus", "OBSERVATION", 283, 288]]], ["Three viruses were detected in 6 samples, and 1 sample contained 4 viruses (WU, bocavirus, rhinovirus, and adenovirus).", [["samples", "ANATOMY", 33, 40], ["sample", "ANATOMY", 48, 54], ["bocavirus", "GENE_OR_GENE_PRODUCT", 80, 89], ["rhinovirus", "ORGANISM", 91, 101], ["adenovirus", "ORGANISM", 107, 117], ["Three viruses", "PROBLEM", 0, 13], ["4 viruses", "PROBLEM", 65, 74], ["bocavirus", "PROBLEM", 80, 89], ["rhinovirus", "PROBLEM", 91, 101], ["adenovirus", "PROBLEM", 107, 117], ["viruses", "OBSERVATION", 6, 13]]], ["All 6 samples from St. Louis that contained WU yielded evidence of the presence of an additional virus.", [["samples", "ANATOMY", 6, 13], ["St. Louis", "ORGANISM", 19, 28], ["an additional virus", "PROBLEM", 83, 102], ["virus", "OBSERVATION", 97, 102]]], ["Overall, 72% of the samples that contained WU had evidence of coinfection with \u2a7e1 additional virus.", [["samples", "ANATOMY", 20, 27], ["coinfection", "DISEASE", 62, 73], ["samples", "CANCER", 20, 27], ["the samples", "TEST", 16, 27], ["coinfection", "PROBLEM", 62, 73], ["\u2a7e1 additional virus", "PROBLEM", 79, 98], ["evidence of", "UNCERTAINTY", 50, 61], ["coinfection", "OBSERVATION", 62, 73]]], ["Because the BK and JC polyomaviruses are commonly found in urine specimens, 501 urine samples obtained from renal transplant recipients in St. Louis and 226 samples obtained from patients in Brisbane were screened by PCR; none contained WU.Another Novel Viral Respiratory Pathogen?These findings suggest\u2014but do not prove\u2014that this novel polyomavirus has a role in respiratory tract infection.", [["urine specimens", "ANATOMY", 59, 74], ["urine samples", "ANATOMY", 80, 93], ["renal", "ANATOMY", 108, 113], ["samples", "ANATOMY", 157, 164], ["respiratory tract", "ANATOMY", 364, 381], ["respiratory tract infection", "DISEASE", 364, 391], ["BK", "GENE_OR_GENE_PRODUCT", 12, 14], ["JC polyomaviruses", "ORGANISM", 19, 36], ["urine specimens", "ORGANISM_SUBSTANCE", 59, 74], ["urine samples", "ORGANISM_SUBSTANCE", 80, 93], ["renal", "ORGAN", 108, 113], ["St. Louis", "ORGANISM", 139, 148], ["patients", "ORGANISM", 179, 187], ["polyomavirus", "ORGANISM", 337, 349], ["respiratory tract", "ORGANISM_SUBDIVISION", 364, 381], ["patients", "SPECIES", 179, 187], ["JC polyomaviruses", "SPECIES", 19, 36], ["the BK and JC polyomaviruses", "PROBLEM", 8, 36], ["urine specimens", "TEST", 59, 74], ["urine samples", "TEST", 80, 93], ["Another Novel Viral Respiratory Pathogen", "PROBLEM", 240, 280], ["this novel polyomavirus", "PROBLEM", 326, 349], ["respiratory tract infection", "PROBLEM", 364, 391], ["JC polyomaviruses", "OBSERVATION", 19, 36], ["renal", "ANATOMY", 108, 113], ["transplant", "OBSERVATION", 114, 124], ["Viral", "OBSERVATION_MODIFIER", 254, 259], ["Respiratory Pathogen", "OBSERVATION", 260, 280], ["respiratory tract", "ANATOMY", 364, 381], ["infection", "OBSERVATION", 382, 391]]], ["The very high frequency of detection of additional viruses, which were detected in almost three-fourths of the patients, complicates the analysis.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["additional viruses", "PROBLEM", 40, 58], ["the analysis", "TEST", 133, 145], ["very", "OBSERVATION_MODIFIER", 4, 8], ["high", "OBSERVATION_MODIFIER", 9, 13], ["viruses", "OBSERVATION", 51, 58]]], ["Nonetheless, the frequency of its detection in individuals (especially young children with respiratory symptoms) in 2 geographically distinct areas highly suggests that it is a cause of human disease.", [["respiratory", "ANATOMY", 91, 102], ["respiratory symptoms", "DISEASE", 91, 111], ["children", "ORGANISM", 77, 85], ["human", "ORGANISM", 186, 191], ["children", "SPECIES", 77, 85], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 186, 191], ["respiratory symptoms", "PROBLEM", 91, 111], ["human disease", "PROBLEM", 186, 199]]], ["In the meantime, we can expect the continued identification of additional novel viruses as candidate human respiratory pathogens and can add WU, along with the recently identified rhinovirus HRV-QPM [2], to the list of viruses identified in respiratory tract specimens since 2001: human metapneumovirus, severe acute respiratory syndrome coronavirus, coronaviruses NL63 and HKU1, human bocavirus, KI polyomavirus, and now HRV-QPM (rhinovirus) and WU polyomavirus.Antibiotic Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa) Skin and Soft-Tissue Infections (Sstis)Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections.", [["respiratory tract specimens", "ANATOMY", 241, 268], ["Skin", "ANATOMY", 557, 561], ["oral", "ANATOMY", 634, 638], ["skin", "ANATOMY", 734, 738], ["soft-tissue", "ANATOMY", 743, 754], ["respiratory pathogens", "DISEASE", 107, 128], ["human metapneumovirus", "DISEASE", 281, 302], ["acute respiratory syndrome coronavirus", "DISEASE", 311, 349], ["Methicillin", "CHEMICAL", 506, 517], ["Staphylococcus Aureus", "CHEMICAL", 528, 549], ["Soft-Tissue Infections", "DISEASE", 566, 588], ["Tetracyclines", "CHEMICAL", 614, 627], ["methicillin", "CHEMICAL", 690, 701], ["Staphylococcus aureus", "DISEASE", 712, 733], ["soft-tissue infections", "DISEASE", 743, 765], ["Methicillin", "CHEMICAL", 506, 517], ["methicillin", "CHEMICAL", 690, 701], ["human", "ORGANISM", 101, 106], ["rhinovirus", "ORGANISM", 180, 190], ["human metapneumovirus", "ORGANISM", 281, 302], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 304, 349], ["coronaviruses", "ORGANISM", 351, 364], ["HKU1", "GENE_OR_GENE_PRODUCT", 374, 378], ["human", "ORGANISM", 380, 385], ["bocavirus", "ORGANISM", 386, 395], ["KI polyomavirus", "ORGANISM", 397, 412], ["HRV-QPM", "ORGANISM", 422, 429], ["rhinovirus", "ORGANISM", 431, 441], ["WU polyomavirus", "ORGANISM", 447, 462], ["Staphylococcus Aureus", "ORGANISM", 528, 549], ["Mrsa", "ORGANISM", 551, 555], ["Skin", "ORGAN", 557, 561], ["oral", "ORGANISM_SUBDIVISION", 634, 638], ["patients", "ORGANISM", 660, 668], ["Staphylococcus aureus", "ORGANISM", 712, 733], ["skin", "ORGAN", 734, 738], ["soft-tissue", "TISSUE", 743, 754], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 281, 286], ["metapneumovirus", "SPECIES", 287, 302], ["human", "SPECIES", 380, 385], ["Staphylococcus Aureus", "SPECIES", 528, 549], ["patients", "SPECIES", 660, 668], ["Staphylococcus aureus", "SPECIES", 712, 733], ["human", "SPECIES", 101, 106], ["human metapneumovirus", "SPECIES", 281, 302], ["severe acute respiratory syndrome coronavirus", "SPECIES", 304, 349], ["human", "SPECIES", 380, 385], ["WU polyomavirus", "SPECIES", 447, 462], ["Staphylococcus Aureus", "SPECIES", 528, 549], ["Staphylococcus aureus", "SPECIES", 712, 733], ["additional novel viruses", "PROBLEM", 63, 87], ["human respiratory pathogens", "PROBLEM", 101, 128], ["rhinovirus HRV", "TEST", 180, 194], ["viruses", "PROBLEM", 219, 226], ["respiratory tract specimens", "TEST", 241, 268], ["human metapneumovirus", "PROBLEM", 281, 302], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 304, 349], ["coronaviruses", "PROBLEM", 351, 364], ["HKU1", "PROBLEM", 374, 378], ["human bocavirus", "PROBLEM", 380, 395], ["KI polyomavirus", "PROBLEM", 397, 412], ["HRV", "TEST", 422, 425], ["rhinovirus", "PROBLEM", 431, 441], ["WU polyomavirus", "PROBLEM", 447, 462], ["Antibiotic Treatment", "TREATMENT", 463, 483], ["Community", "TEST", 487, 496], ["Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa)", "PROBLEM", 497, 556], ["Soft-Tissue Infections (Sstis)", "PROBLEM", 566, 596], ["Menon A. Tetracyclines", "TREATMENT", 605, 627], ["an oral treatment option", "TREATMENT", 631, 655], ["methicillin-resistant Staphylococcus aureus skin", "PROBLEM", 690, 738], ["soft-tissue infections", "PROBLEM", 743, 765], ["viruses", "OBSERVATION", 219, 226], ["respiratory tract", "ANATOMY", 241, 258], ["metapneumovirus", "OBSERVATION", 287, 302], ["severe", "OBSERVATION_MODIFIER", 304, 310], ["acute", "OBSERVATION_MODIFIER", 311, 316], ["respiratory syndrome coronavirus", "OBSERVATION", 317, 349], ["polyomavirus", "OBSERVATION", 450, 462], ["Staphylococcus Aureus", "OBSERVATION", 528, 549], ["Skin", "ANATOMY", 557, 561], ["Soft-Tissue", "OBSERVATION_MODIFIER", 566, 577], ["Infections", "OBSERVATION", 578, 588], ["JJ", "ANATOMY", 601, 603], ["Staphylococcus aureus", "OBSERVATION", 712, 733], ["skin", "ANATOMY", 734, 738], ["soft-tissue", "OBSERVATION_MODIFIER", 743, 754], ["infections", "OBSERVATION", 755, 765]]], ["Antimicrob Agents Chemother 2007; 51:3298\u2013303.Antibiotic Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa) Skin and Soft-Tissue Infections (Sstis)The role of antibiotics in the treatment of uncomplicated SSTI due to community-acquired MRSA has been a matter of dispute.", [["Skin", "ANATOMY", 140, 144], ["Methicillin", "CHEMICAL", 89, 100], ["Staphylococcus Aureus", "CHEMICAL", 111, 132], ["Soft-Tissue Infections", "DISEASE", 149, 171], ["SSTI", "DISEASE", 237, 241], ["MRSA", "DISEASE", 268, 272], ["Methicillin", "CHEMICAL", 89, 100], ["Staphylococcus Aureus", "ORGANISM", 111, 132], ["Skin", "ORGAN", 140, 144], ["Tissue", "TISSUE", 154, 160], ["Staphylococcus Aureus", "SPECIES", 111, 132], ["MRSA", "SPECIES", 268, 272], ["Staphylococcus Aureus", "SPECIES", 111, 132], ["Antibiotic Treatment", "TREATMENT", 46, 66], ["Community", "TEST", 70, 79], ["Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa)", "PROBLEM", 80, 139], ["Soft-Tissue Infections", "PROBLEM", 149, 171], ["antibiotics", "TREATMENT", 191, 202], ["the treatment", "TREATMENT", 206, 219], ["uncomplicated SSTI", "PROBLEM", 223, 241], ["community-acquired MRSA", "PROBLEM", 249, 272], ["Staphylococcus Aureus", "OBSERVATION", 111, 132], ["Skin", "ANATOMY", 140, 144], ["Soft-Tissue", "OBSERVATION_MODIFIER", 149, 160], ["Infections", "OBSERVATION", 161, 171], ["uncomplicated", "OBSERVATION_MODIFIER", 223, 236], ["SSTI", "OBSERVATION", 237, 241], ["MRSA", "OBSERVATION", 268, 272]]], ["Early reports suggested that incision and drainage of cutaneous abscesses due to community-acquired MRSA was sufficient, at least for abscesses of relatively small size.", [["cutaneous abscesses", "ANATOMY", 54, 73], ["abscesses", "ANATOMY", 134, 143], ["abscesses", "DISEASE", 64, 73], ["MRSA", "DISEASE", 100, 104], ["abscesses", "DISEASE", 134, 143], ["cutaneous abscesses", "PATHOLOGICAL_FORMATION", 54, 73], ["abscesses", "PATHOLOGICAL_FORMATION", 134, 143], ["MRSA", "SPECIES", 100, 104], ["incision", "TREATMENT", 29, 37], ["drainage", "TREATMENT", 42, 50], ["cutaneous abscesses", "PROBLEM", 54, 73], ["community-acquired MRSA", "PROBLEM", 81, 104], ["abscesses", "PROBLEM", 134, 143], ["relatively small size", "PROBLEM", 147, 168], ["incision", "OBSERVATION", 29, 37], ["drainage", "OBSERVATION_MODIFIER", 42, 50], ["cutaneous", "ANATOMY", 54, 63], ["abscesses", "OBSERVATION", 64, 73], ["MRSA", "OBSERVATION", 100, 104], ["abscesses", "OBSERVATION", 134, 143], ["relatively", "OBSERVATION_MODIFIER", 147, 157], ["small", "OBSERVATION_MODIFIER", 158, 163], ["size", "OBSERVATION_MODIFIER", 164, 168]]], ["Newer, more convincing evidence, however, appears to indicate that antibiotic treatment does matter.Antibiotic Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa) Skin and Soft-Tissue Infections (Sstis)Ruhe and colleagues retrospectively examined the records of 282 patients with 282 episodes of SSTI due to MRSA who presented either to the emergency department or to the outpatient clinic at 2 medical centers during the period 2002\u20132007.", [["Skin", "ANATOMY", 194, 198], ["Methicillin", "CHEMICAL", 143, 154], ["Staphylococcus Aureus", "CHEMICAL", 165, 186], ["SSTI", "DISEASE", 327, 331], ["MRSA", "DISEASE", 339, 343], ["Methicillin", "CHEMICAL", 143, 154], ["Staphylococcus Aureus", "ORGANISM", 165, 186], ["Skin", "ORGAN", 194, 198], ["patients", "ORGANISM", 297, 305], ["Staphylococcus Aureus", "SPECIES", 165, 186], ["patients", "SPECIES", 297, 305], ["MRSA", "SPECIES", 339, 343], ["Staphylococcus Aureus", "SPECIES", 165, 186], ["MRSA", "SPECIES", 339, 343], ["antibiotic treatment", "TREATMENT", 67, 87], ["Antibiotic Treatment", "TREATMENT", 100, 120], ["Community", "TEST", 124, 133], ["Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa)", "PROBLEM", 134, 193], ["SSTI", "PROBLEM", 327, 331], ["MRSA", "PROBLEM", 339, 343], ["Staphylococcus Aureus", "OBSERVATION", 165, 186], ["Skin", "ANATOMY", 194, 198], ["Soft-Tissue", "OBSERVATION_MODIFIER", 203, 214], ["Infections", "OBSERVATION", 215, 225], ["SSTI", "OBSERVATION", 327, 331], ["MRSA", "OBSERVATION", 339, 343]]], ["Three-fourths of patients had abscesses, 13% had furuncles or carbuncles, and 12% had cellulitis with a purulent focus.", [["abscesses", "ANATOMY", 30, 39], ["furuncles", "ANATOMY", 49, 58], ["carbuncles", "ANATOMY", 62, 72], ["abscesses", "DISEASE", 30, 39], ["furuncles", "DISEASE", 49, 58], ["carbuncles", "DISEASE", 62, 72], ["cellulitis", "DISEASE", 86, 96], ["patients", "ORGANISM", 17, 25], ["abscesses", "PATHOLOGICAL_FORMATION", 30, 39], ["carbuncles", "CANCER", 62, 72], ["patients", "SPECIES", 17, 25], ["abscesses", "PROBLEM", 30, 39], ["furuncles or carbuncles", "PROBLEM", 49, 72], ["cellulitis", "PROBLEM", 86, 96], ["a purulent focus", "PROBLEM", 102, 118], ["abscesses", "OBSERVATION", 30, 39], ["cellulitis", "OBSERVATION", 86, 96], ["purulent", "OBSERVATION_MODIFIER", 104, 112], ["focus", "OBSERVATION", 113, 118]]], ["The median lesion maximum diameter was 4 cm (range, 3\u20135 cm).", [["lesion", "ANATOMY", 11, 17], ["median", "OBSERVATION_MODIFIER", 4, 10], ["lesion", "OBSERVATION", 11, 17], ["maximum", "OBSERVATION_MODIFIER", 18, 25], ["diameter", "OBSERVATION_MODIFIER", 26, 34], ["4 cm", "OBSERVATION_MODIFIER", 39, 43], ["3\u20135 cm", "OBSERVATION_MODIFIER", 52, 58]]], ["Incision and drainage procedures were performed for 91% of episodes with abscess, furuncles, or carbuncles and for 66% of the other episodes.", [["abscess", "ANATOMY", 73, 80], ["furuncles", "ANATOMY", 82, 91], ["carbuncles", "ANATOMY", 96, 106], ["abscess", "DISEASE", 73, 80], ["furuncles", "DISEASE", 82, 91], ["carbuncles", "DISEASE", 96, 106], ["abscess", "PATHOLOGICAL_FORMATION", 73, 80], ["Incision", "TREATMENT", 0, 8], ["drainage procedures", "TREATMENT", 13, 32], ["episodes", "PROBLEM", 59, 67], ["abscess", "PROBLEM", 73, 80], ["carbuncles", "TREATMENT", 96, 106], ["the other episodes", "PROBLEM", 122, 140], ["drainage", "OBSERVATION", 13, 21], ["abscess", "OBSERVATION", 73, 80]]], ["For 90 episodes (32%), patients received doxycycline (n = 87) or minocycline (n = 3), whereas a \u03b2-lactam antibiotic was provided for the remaining episodes.", [["doxycycline", "CHEMICAL", 41, 52], ["minocycline", "CHEMICAL", 65, 76], ["\u03b2-lactam", "CHEMICAL", 96, 104], ["doxycycline", "CHEMICAL", 41, 52], ["minocycline", "CHEMICAL", 65, 76], ["\u03b2-lactam", "CHEMICAL", 96, 104], ["patients", "ORGANISM", 23, 31], ["doxycycline", "SIMPLE_CHEMICAL", 41, 52], ["minocycline", "SIMPLE_CHEMICAL", 65, 76], ["\u03b2-lactam", "SIMPLE_CHEMICAL", 96, 104], ["patients", "SPECIES", 23, 31], ["doxycycline (n", "TREATMENT", 41, 55], ["minocycline", "TREATMENT", 65, 76], ["a \u03b2-lactam antibiotic", "TREATMENT", 94, 115], ["the remaining episodes", "PROBLEM", 133, 155]]], ["During the years of the study, 94%\u201396% of isolates were found to be susceptible to tetracycline.Antibiotic Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa) Skin and Soft-Tissue Infections (Sstis)Ten percent of patients experienced treatment failure, with 23 requiring a second incision and drainage procedure and 5 requiring hospital admission.", [["Skin", "ANATOMY", 190, 194], ["tetracycline", "CHEMICAL", 83, 95], ["Methicillin", "CHEMICAL", 139, 150], ["Soft-Tissue Infections", "DISEASE", 199, 221], ["tetracycline", "CHEMICAL", 83, 95], ["Methicillin", "CHEMICAL", 139, 150], ["tetracycline", "SIMPLE_CHEMICAL", 83, 95], ["Staphylococcus Aureus", "ORGANISM", 161, 182], ["Skin", "ORGAN", 190, 194], ["Tissue", "TISSUE", 204, 210], ["patients", "ORGANISM", 244, 252], ["Staphylococcus Aureus", "SPECIES", 161, 182], ["patients", "SPECIES", 244, 252], ["Staphylococcus Aureus", "SPECIES", 161, 182], ["the study", "TEST", 20, 29], ["isolates", "TEST", 42, 50], ["tetracycline", "TREATMENT", 83, 95], ["Antibiotic Treatment", "TREATMENT", 96, 116], ["Community", "TEST", 120, 129], ["Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa)", "PROBLEM", 130, 189], ["Soft-Tissue Infections", "PROBLEM", 199, 221], ["treatment failure", "PROBLEM", 265, 282], ["a second incision", "TREATMENT", 302, 319], ["drainage procedure", "TREATMENT", 324, 342], ["Staphylococcus Aureus", "OBSERVATION", 161, 182], ["Skin", "ANATOMY", 190, 194], ["Soft-Tissue", "OBSERVATION_MODIFIER", 199, 210], ["Infections", "OBSERVATION", 211, 221], ["incision", "OBSERVATION", 311, 319], ["drainage", "OBSERVATION", 324, 332]]], ["In contrast to previous reports, the size of the lesion was not associated with outcome.", [["lesion", "ANATOMY", 49, 55], ["lesion", "CANCER", 49, 55], ["the lesion", "PROBLEM", 45, 55], ["size", "OBSERVATION_MODIFIER", 37, 41], ["lesion", "OBSERVATION", 49, 55], ["not associated with", "UNCERTAINTY", 60, 79]]], ["Logistic regression analysis identified receipt of a \u03b2-lactam antibiotic as the only clinical predictor of treatment failure (adjusted OR, 3.94; 95% CI, 1.28\u201312.15).", [["\u03b2-lactam", "CHEMICAL", 53, 61], ["\u03b2-lactam", "CHEMICAL", 53, 61], ["\u03b2-lactam", "SIMPLE_CHEMICAL", 53, 61], ["Logistic regression analysis", "TEST", 0, 28], ["a \u03b2-lactam antibiotic", "TREATMENT", 51, 72], ["treatment failure", "PROBLEM", 107, 124], ["CI", "TEST", 149, 151]]], ["Subgroup analysis that included only the 225 episodes in which incision and drainage were performed at presentation confirmed that \u03b2-lactam antibiotic therapy was significantly associated with treatment failure.Antibiotic Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa) Skin and Soft-Tissue Infections (Sstis)These results are consistent with those of several other recent studies that have found that administration of an antibiotic that inhibits the growth of MRSA improves outcomes, even in patients who have undergone incision and drainage.", [["Skin", "ANATOMY", 305, 309], ["\u03b2-lactam", "CHEMICAL", 131, 139], ["Methicillin", "CHEMICAL", 254, 265], ["Staphylococcus Aureus", "CHEMICAL", 276, 297], ["Infections", "DISEASE", 326, 336], ["MRSA", "DISEASE", 497, 501], ["Methicillin", "CHEMICAL", 254, 265], ["\u03b2-lactam", "SIMPLE_CHEMICAL", 131, 139], ["Staphylococcus Aureus", "ORGANISM", 276, 297], ["Skin", "ORGAN", 305, 309], ["MRSA", "CANCER", 497, 501], ["patients", "ORGANISM", 529, 537], ["Staphylococcus Aureus", "SPECIES", 276, 297], ["MRSA", "SPECIES", 497, 501], ["patients", "SPECIES", 529, 537], ["Staphylococcus Aureus", "SPECIES", 276, 297], ["MRSA", "SPECIES", 497, 501], ["Subgroup analysis", "TEST", 0, 17], ["the 225 episodes in which incision", "PROBLEM", 37, 71], ["drainage", "TREATMENT", 76, 84], ["\u03b2-lactam antibiotic therapy", "TREATMENT", 131, 158], ["treatment failure", "PROBLEM", 193, 210], ["Antibiotic Treatment", "TREATMENT", 211, 231], ["Community", "TEST", 235, 244], ["Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa)", "PROBLEM", 245, 304], ["Soft-Tissue Infections (Sstis", "PROBLEM", 314, 343], ["an antibiotic", "TREATMENT", 455, 468], ["MRSA", "PROBLEM", 497, 501], ["incision", "TREATMENT", 557, 565], ["drainage", "TREATMENT", 570, 578], ["incision", "OBSERVATION", 63, 71], ["drainage", "OBSERVATION", 76, 84], ["Staphylococcus Aureus", "OBSERVATION", 276, 297], ["Skin", "ANATOMY", 305, 309], ["Soft-Tissue", "OBSERVATION_MODIFIER", 314, 325], ["Infections", "OBSERVATION", 326, 336], ["consistent with", "UNCERTAINTY", 362, 377], ["growth", "OBSERVATION_MODIFIER", 487, 493], ["MRSA", "OBSERVATION", 497, 501], ["incision", "OBSERVATION", 557, 565], ["drainage", "OBSERVATION", 570, 578]]], ["For example, in a similar retrospective study of 531 episodes of community-acquired MRSA SSTI, most of which were treated with incision and drainage, Ruhe et al. [1] found treatment failure rates of 5% among patients who received an antibiotic active against the pathogen and 13% among those who received an antibiotic without activity (P = .01).", [["SSTI", "DISEASE", 89, 93], ["patients", "ORGANISM", 208, 216], ["MRSA", "SPECIES", 84, 88], ["patients", "SPECIES", 208, 216], ["MRSA", "SPECIES", 84, 88], ["a similar retrospective study", "TEST", 16, 45], ["community-acquired MRSA SSTI", "PROBLEM", 65, 93], ["incision", "TREATMENT", 127, 135], ["drainage", "TREATMENT", 140, 148], ["treatment failure rates", "TREATMENT", 172, 195], ["an antibiotic", "TREATMENT", 230, 243], ["the pathogen", "PROBLEM", 259, 271], ["an antibiotic", "TREATMENT", 305, 318], ["MRSA SSTI", "OBSERVATION", 84, 93], ["incision", "OBSERVATION", 127, 135], ["drainage", "OBSERVATION", 140, 148]]], ["There has been little study of which antibiotic with activity against MRSA is optimum.Antibiotic Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa) Skin and Soft-Tissue Infections (Sstis)Although Ruhe and colleagues provide evidence of the benefit of doxycyline for the treatment of SSTI due to antibiotic-susceptible MRSA, alternative antibiotic choices may be considered.", [["Skin", "ANATOMY", 180, 184], ["MRSA", "DISEASE", 70, 74], ["Methicillin", "CHEMICAL", 129, 140], ["Staphylococcus Aureus", "CHEMICAL", 151, 172], ["Soft-Tissue Infections", "DISEASE", 189, 211], ["doxycyline", "CHEMICAL", 283, 293], ["SSTI", "DISEASE", 315, 319], ["MRSA", "DISEASE", 350, 354], ["Methicillin", "CHEMICAL", 129, 140], ["doxycyline", "CHEMICAL", 283, 293], ["Staphylococcus Aureus", "ORGANISM", 151, 172], ["Skin", "ORGAN", 180, 184], ["doxycyline", "SIMPLE_CHEMICAL", 283, 293], ["MRSA", "SPECIES", 70, 74], ["Staphylococcus Aureus", "SPECIES", 151, 172], ["MRSA", "SPECIES", 350, 354], ["MRSA", "SPECIES", 70, 74], ["Staphylococcus Aureus", "SPECIES", 151, 172], ["MRSA", "SPECIES", 350, 354], ["little study", "TEST", 15, 27], ["antibiotic", "TREATMENT", 37, 47], ["MRSA", "PROBLEM", 70, 74], ["Antibiotic Treatment", "TREATMENT", 86, 106], ["Community", "TEST", 110, 119], ["Acquired Methicillin-Resistant Staphylococcus Aureus (Mrsa)", "PROBLEM", 120, 179], ["Soft-Tissue Infections (Sstis", "PROBLEM", 189, 218], ["doxycyline", "TREATMENT", 283, 293], ["SSTI", "PROBLEM", 315, 319], ["antibiotic", "TREATMENT", 327, 337], ["susceptible MRSA", "PROBLEM", 338, 354], ["alternative antibiotic choices", "TREATMENT", 356, 386], ["Staphylococcus Aureus", "OBSERVATION", 151, 172], ["Skin", "ANATOMY", 180, 184], ["Soft-Tissue", "OBSERVATION_MODIFIER", 189, 200], ["Infections", "OBSERVATION", 201, 211], ["MRSA", "OBSERVATION", 350, 354]]], ["In a small, prospective, open-label trial, outpatients with SSTI were randomized to receive treatment with either trimethoprim-sulfamethoxazole (160 mg/800 mg) or doxycycline (100 mg), each given twice daily for 7 days [2].", [["SSTI", "DISEASE", 60, 64], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 114, 143], ["doxycycline", "CHEMICAL", 163, 174], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 114, 143], ["doxycycline", "CHEMICAL", 163, 174], ["outpatients", "ORGANISM", 43, 54], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 114, 143], ["doxycycline", "SIMPLE_CHEMICAL", 163, 174], ["outpatients", "SPECIES", 43, 54], ["SSTI", "TREATMENT", 60, 64], ["treatment", "TREATMENT", 92, 101], ["trimethoprim", "TREATMENT", 114, 126], ["sulfamethoxazole", "TREATMENT", 127, 143], ["doxycycline", "TREATMENT", 163, 174], ["small", "OBSERVATION_MODIFIER", 5, 10]]], ["Although there was not a statistically significant difference in outcome, all 3 treatment failures occurred among the 14 patients who received trimethoprim-sulfamethoxazole, for a treatment failure rate of 21%.", [["trimethoprim-sulfamethoxazole", "CHEMICAL", 143, 172], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 143, 172], ["patients", "ORGANISM", 121, 129], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 143, 172], ["patients", "SPECIES", 121, 129], ["all 3 treatment failures", "PROBLEM", 74, 98], ["trimethoprim", "TREATMENT", 143, 155], ["sulfamethoxazole", "TREATMENT", 156, 172], ["a treatment failure rate", "TEST", 178, 202], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["difference", "OBSERVATION_MODIFIER", 51, 61]]], ["The optimal antibiotic choice thus awaits results of future clinical trials with sample sizes sufficient to allow for definitive answers.", [["The optimal antibiotic choice", "TREATMENT", 0, 29], ["sample sizes", "TREATMENT", 81, 93]]], ["One problem, however, is that community-acquired MRSA is a moving target, and that, in some geographical areas, it has acquired additional antibiotic-resistance determinants.", [["MRSA", "DISEASE", 49, 53], ["MRSA", "SPECIES", 49, 53], ["acquired MRSA", "PROBLEM", 40, 53], ["antibiotic-resistance determinants", "TREATMENT", 139, 173], ["MRSA", "OBSERVATION", 49, 53]]], ["An additional factor that must be considered in future trials is the potential benefit of effective antibiotic therapy on the prevention or delay of recurrences of infection.Gonorrhea and Chlamydia in the United StatesDatta SD, Sternberg M, Johnson RE, Berman S. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002.", [["infection", "DISEASE", 164, 173], ["Gonorrhea", "DISEASE", 174, 183], ["Chlamydia", "DISEASE", 188, 197], ["Gonorrhea and chlamydia", "DISEASE", 263, 286], ["persons", "ORGANISM", 314, 321], ["persons", "SPECIES", 314, 321], ["effective antibiotic therapy", "TREATMENT", 90, 118], ["the prevention", "TREATMENT", 122, 136], ["recurrences", "PROBLEM", 149, 160], ["infection", "PROBLEM", 164, 173], ["Gonorrhea", "PROBLEM", 174, 183], ["Chlamydia", "PROBLEM", 188, 197], ["Gonorrhea", "PROBLEM", 263, 272], ["chlamydia", "PROBLEM", 277, 286], ["infection", "OBSERVATION", 164, 173], ["Chlamydia", "OBSERVATION", 188, 197], ["Gonorrhea", "OBSERVATION", 263, 272], ["chlamydia", "OBSERVATION", 277, 286]]], ["Ann Intern Med 2007; 147:89\u201396.Gonorrhea and Chlamydia in the United StatesThe most frequently reported notifiable disease in the United States is infection with Chlamydia trachomatis, with Neisseria gonorrhoeae infection placing second.", [["Gonorrhea", "DISEASE", 31, 40], ["Chlamydia", "DISEASE", 45, 54], ["infection", "DISEASE", 147, 156], ["Chlamydia trachomatis", "DISEASE", 162, 183], ["Neisseria gonorrhoeae infection", "DISEASE", 190, 221], ["Chlamydia trachomatis", "ORGANISM", 162, 183], ["Neisseria gonorrhoeae", "ORGANISM", 190, 211], ["Chlamydia trachomatis", "SPECIES", 162, 183], ["Neisseria gonorrhoeae", "SPECIES", 190, 211], ["Chlamydia trachomatis", "SPECIES", 162, 183], ["Neisseria gonorrhoeae", "SPECIES", 190, 211], ["Gonorrhea", "PROBLEM", 31, 40], ["Chlamydia", "PROBLEM", 45, 54], ["infection", "PROBLEM", 147, 156], ["Chlamydia trachomatis", "PROBLEM", 162, 183], ["Neisseria gonorrhoeae infection", "PROBLEM", 190, 221], ["Med", "ANATOMY", 11, 14], ["Chlamydia", "OBSERVATION", 45, 54], ["infection", "OBSERVATION", 147, 156], ["Chlamydia", "OBSERVATION", 162, 171]]], ["Urine specimens were obtained from 6632 participants (age, 14\u201339 years) during the period 1999\u20132002 in the National Health and Examination Survey; ligase chain reaction detected a prevalence of chlamydial infection of 2.2% (95% CI, 1.8%\u20132.8%) and a prevalence of gonorrheal infection of 0.24% (95% CI, 0.16%\u20130.38%).", [["Urine specimens", "ANATOMY", 0, 15], ["chlamydial infection", "DISEASE", 194, 214], ["gonorrheal infection", "DISEASE", 263, 283], ["Urine specimens", "ORGANISM_SUBSTANCE", 0, 15], ["participants", "SPECIES", 40, 52], ["Urine specimens", "TEST", 0, 15], ["Examination Survey", "TEST", 127, 145], ["ligase chain reaction", "PROBLEM", 147, 168], ["chlamydial infection", "PROBLEM", 194, 214], ["CI", "TEST", 228, 230], ["gonorrheal infection", "PROBLEM", 263, 283], ["CI", "TEST", 298, 300], ["chlamydial", "OBSERVATION_MODIFIER", 194, 204], ["infection", "OBSERVATION", 205, 214], ["infection", "OBSERVATION", 274, 283]]], ["The prevalence of chlamydial infection was similar in male and female subjects but peaked at the ages of 14\u201319 years in female subjects and 14\u201329 years in male subjects.", [["chlamydial infection", "DISEASE", 18, 38], ["chlamydial infection", "PROBLEM", 18, 38], ["chlamydial", "OBSERVATION_MODIFIER", 18, 28], ["infection", "OBSERVATION", 29, 38]]], ["The prevalence was higher among non-Hispanic black subjects (6.4%) than among non-Hispanic white subjects (1.5%).", [["non-Hispanic white subjects", "PROBLEM", 78, 105], ["higher", "OBSERVATION_MODIFIER", 19, 25]]], ["The prevalence of gonorrheal infection was also higher in non-Hispanic blacks (1.2% vs. 0.07%).", [["gonorrheal infection", "DISEASE", 18, 38], ["gonorrheal infection", "PROBLEM", 18, 38], ["gonorrheal", "OBSERVATION_MODIFIER", 18, 28], ["infection", "OBSERVATION", 29, 38], ["higher", "OBSERVATION_MODIFIER", 48, 54]]], ["Forty-six percent of individuals with gonorrheal infection were coinfected with C. trachomatis.", [["gonorrheal infection", "DISEASE", 38, 58], ["C. trachomatis", "DISEASE", 80, 94], ["individuals", "ORGANISM", 21, 32], ["C. trachomatis", "ORGANISM", 80, 94], ["C. trachomatis", "SPECIES", 80, 94], ["C. trachomatis", "SPECIES", 80, 94], ["gonorrheal infection", "PROBLEM", 38, 58], ["C. trachomatis", "PROBLEM", 80, 94], ["gonorrheal", "OBSERVATION_MODIFIER", 38, 48], ["infection", "OBSERVATION", 49, 58]]], ["It should be noted that the test used in this survey targets a portion of a cryptic plasmid in C. trachomatis that has been lost by some isolates in Sweden, leading to false-negative results [1].", [["plasmid", "ANATOMY", 84, 91], ["C. trachomatis", "DISEASE", 95, 109], ["C. trachomatis", "ORGANISM", 95, 109], ["cryptic plasmid", "DNA", 76, 91], ["C. trachomatis", "SPECIES", 95, 109], ["C. trachomatis", "SPECIES", 95, 109], ["the test", "TEST", 24, 32], ["a cryptic plasmid", "TREATMENT", 74, 91], ["C. trachomatis", "PROBLEM", 95, 109]]], ["Although this is not likely to have affected the results of this study, it is an issue that may have to addressed in the future.Gonorrhea and Chlamydia in the United StatesThe authors point out that these data support current recommendations for screening sexually active females aged \u2a7d25 years for chlamydial infection and for coadministration of treatment for C. trachomatis infection in patients with gonorrheal infection, unless the former has been ruled out [2].", [["Gonorrhea", "DISEASE", 128, 137], ["Chlamydia", "DISEASE", 142, 151], ["chlamydial infection", "DISEASE", 299, 319], ["C. trachomatis infection", "DISEASE", 362, 386], ["gonorrheal infection", "DISEASE", 404, 424], ["C. trachomatis", "ORGANISM", 362, 376], ["patients", "ORGANISM", 390, 398], ["C. trachomatis", "SPECIES", 362, 376], ["patients", "SPECIES", 390, 398], ["C. trachomatis", "SPECIES", 362, 376], ["this study", "TEST", 60, 70], ["Gonorrhea", "PROBLEM", 128, 137], ["Chlamydia", "PROBLEM", 142, 151], ["chlamydial infection", "PROBLEM", 299, 319], ["coadministration", "TREATMENT", 328, 344], ["treatment", "TREATMENT", 348, 357], ["C. trachomatis infection", "PROBLEM", 362, 386], ["gonorrheal infection", "PROBLEM", 404, 424], ["not likely", "UNCERTAINTY", 17, 27], ["Chlamydia", "OBSERVATION", 142, 151], ["infection", "OBSERVATION", 310, 319], ["infection", "OBSERVATION", 415, 424]]], ["The following is a summary of current recommendations for screening [2]:Gonorrhea and Chlamydia in the United States\u2022 Screen for chlamydial infection in all sexually active, nonpregnant, young women (age, \u2a7d24 years) and in older, nonpregnant women who are at increased risk.Gonorrhea and Chlamydia in the United States\u2022 Screen for chlamydial infection in all pregnant women aged \u2a7d24 years and in older, pregnant women who are at increased risk.Gonorrhea and Chlamydia in the United States\u2022 Do not routinely screen for chlamydial infection in women aged \u2a7e25 years, regardless of whether they are pregnant, if they are not at increased risk.Gonorrhea and Chlamydia in the United States\u2022 Current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydial infection in men.", [["Gonorrhea", "DISEASE", 72, 81], ["Chlamydia", "DISEASE", 86, 95], ["chlamydial infection", "DISEASE", 129, 149], ["Gonorrhea", "DISEASE", 274, 283], ["Chlamydia", "DISEASE", 288, 297], ["chlamydial infection", "DISEASE", 331, 351], ["Gonorrhea", "DISEASE", 444, 453], ["Chlamydia", "DISEASE", 458, 467], ["chlamydial infection", "DISEASE", 518, 538], ["Gonorrhea", "DISEASE", 639, 648], ["Chlamydia", "DISEASE", 653, 662], ["chlamydial infection", "DISEASE", 779, 799], ["women", "ORGANISM", 193, 198], ["women", "ORGANISM", 242, 247], ["women", "ORGANISM", 368, 373], ["women", "ORGANISM", 412, 417], ["women", "ORGANISM", 542, 547], ["men", "ORGANISM", 803, 806], ["women", "SPECIES", 193, 198], ["women", "SPECIES", 242, 247], ["women", "SPECIES", 368, 373], ["women", "SPECIES", 412, 417], ["women", "SPECIES", 542, 547], ["men", "SPECIES", 803, 806], ["Gonorrhea", "PROBLEM", 72, 81], ["Chlamydia", "PROBLEM", 86, 95], ["chlamydial infection", "PROBLEM", 129, 149], ["Gonorrhea", "PROBLEM", 274, 283], ["Chlamydia", "PROBLEM", 288, 297], ["chlamydial infection", "PROBLEM", 331, 351], ["Gonorrhea", "PROBLEM", 444, 453], ["Chlamydia", "PROBLEM", 458, 467], ["chlamydial infection", "PROBLEM", 518, 538], ["Gonorrhea", "PROBLEM", 639, 648], ["Chlamydia", "PROBLEM", 653, 662], ["screening", "TEST", 765, 774], ["chlamydial infection", "PROBLEM", 779, 799], ["Chlamydia", "OBSERVATION", 86, 95], ["infection", "OBSERVATION", 140, 149], ["Chlamydia", "OBSERVATION", 288, 297], ["infection", "OBSERVATION", 342, 351], ["Chlamydia", "OBSERVATION", 458, 467], ["infection", "OBSERVATION", 529, 538], ["Chlamydia", "OBSERVATION", 653, 662], ["infection", "OBSERVATION", 790, 799]]]]}